acetaminophen has been researched along with Fever in 704 studies
Acetaminophen: Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.
paracetamol : A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.
Fever: An abnormal elevation of body temperature, usually as a result of a pathologic process.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fever after removal of tube drainage is caused by a normal inflammatory response, and a small dose of acetaminophen could significantly reduce the possibility of fever." | 9.69 | A Randomized Study on the Prophylactic Use of Acetaminophen to Prevent Fever after the Removal of Drainage Tubes for Lumbar Surgery. ( Li, Y; Liu, K; Tian, Y; Xing, Y; Ye, K; Zhang, Y; Zhou, F, 2023) |
| "This study aims to evaluate the efficacy and safety of multiple or single-dosage intravenous ibuprofen (IVIB) in managing postoperative pain and fever in adults who are unable to take oral medications." | 9.41 | Intravenous ibuprofen in postoperative pain and fever management in adults: A systematic review and meta-analysis of randomized controlled trials. ( Chen, L; He, L; Tian, S; Wang, E; Zhai, S; Zhou, P, 2023) |
| "Our primary objective was to assess the effectiveness of paracetamol (acetaminophen) or NSAIDs, alone or combined, compared with placebo or no treatment in relieving pain in children with AOM." | 9.41 | Paracetamol (acetaminophen) or non-steroidal anti-inflammatory drugs, alone or combined, for pain relief in acute otitis media in children. ( Damoiseaux, RA; de Sévaux, JLH; Hay, AD; Little, P; Lutje, V; Schilder, AG; van de Pol, AC; Venekamp, RP, 2023) |
| "Intravenous acetaminophen did not demonstrate a higher efficacy than oral acetaminophen in treating intrapartum maternal fever." | 9.41 | Randomized control trial of intravenous acetaminophen for reduction of intrapartum maternal fever. ( Cabbad, M; Kanninen, T; Lakhi, N; Mehraban, S; Mehraban, SS; Moretti, M; Nematian, S; Parnas, Z; Petrucci, S; Shats, L; Tricorico, G, 2021) |
| "In adult age group patients admitted to the emergency department with high fever, the IV forms of 1000 mg paracetamol and 400 mg ibuprofen effectively and equally reduce complaints, such as fever and accompanying pain." | 9.41 | Comparison of intravenous ibuprofen and paracetamol in the treatment of fever: A randomized double-blind study. ( Can, Ö; Kıyan, GS; Yalçınlı, S, 2021) |
| "the overall result showed that ibuprofen had a better fever reducing effect compared to paracetamol." | 9.34 | Ibuprofen versus paracetamol for treating fever in preschool children in Nigeria: a randomized clinical trial of effectiveness and safety. ( Akande, PA; Alaje, EO; Meremikwu, MM; Odey, FA; Udoh, EE, 2020) |
| "This observational single-dose study was conducted at Department of Pedriatrics, Army Hospital (Research and Referral), a multispecialty tertiary care center in New Delhi in fever patients to assess the antipyretic efficacy of IV acetaminophen 15 mg/kg/dose vs." | 9.27 | Comparison of Antipyretic Efficacy of Intravenous (IV) Acetaminophen versus Oral (PO) Acetaminophen in the Management of Fever in Children. ( Roy, S; Simalti, AK, 2018) |
| "No evidence can be found in the medical literature about the efficacy of alternating acetaminophen and ibuprofen treatment in children with refractory fever." | 9.24 | Alternating Acetaminophen and Ibuprofen versus Monotherapies in Improvements of Distress and Reducing Refractory Fever in Febrile Children: A Randomized Controlled Trial. ( Guo, Q; Luo, Q; Luo, S; Ran, M; Shu, M; Wan, C; Xie, X; Zhang, C; Zhu, Y, 2017) |
| "001); in a greater reduction in change from baseline temperature compared to treatment with acetaminophen, and it reduced fever throughout a 24 h dosing period." | 9.24 | A multicenter, randomized, open-label, active-comparator trial to determine the efficacy, safety, and pharmacokinetics of intravenous ibuprofen for treatment of fever in hospitalized pediatric patients. ( Chumpitazi, CE; Hahn, BJ; Kaelin, BA; Khalil, SN; Macias, CG; Rock, AD, 2017) |
| "PAIS 2 (Paracetamol [Acetaminophen] in Stroke 2) was a multicenter, randomized, double-blind, placebo-controlled clinical trial." | 9.24 | PAIS 2 (Paracetamol [Acetaminophen] in Stroke 2): Results of a Randomized, Double-Blind Placebo-Controlled Clinical Trial. ( Algra, A; de Ridder, IR; den Hertog, HM; Dippel, DW; Jansen, BP; Kappelle, LJ; Koudstaal, PJ; Maasland, EL; Ruitenberg, A; Saxena, R; Schreuder, AH; Van den Berg-Vos, RM; van der Worp, HB; van Gemert, HM; van Tuijl, JH; Vermeij, F, 2017) |
| "To evaluate ibuprofen and acetaminophen in the treatment of infectious fever in children." | 9.22 | Comparison between Ibuprofen and Acetaminophen in the Treatment of Infectious Fever in Children: A Meta-Analysis. ( Guo, H; Liu, Y; Yin, F, 2022) |
| "Studies have suggested an association between frequent acetaminophen use and asthma-related complications among children, leading some physicians to recommend that acetaminophen be avoided in children with asthma; however, appropriately designed trials evaluating this association in children are lacking." | 9.22 | Acetaminophen versus Ibuprofen in Young Children with Mild Persistent Asthma. ( Bacharier, LB; Baxi, SN; Beigelman, A; Benson, M; Blake, K; Boehmer, SJ; Cabana, MD; Chmiel, JF; Covar, R; Daines, CL; Daines, MO; Fitzpatrick, AM; Gaffin, JM; Gentile, DA; Gower, WA; Holguin, F; Israel, E; Jackson, DJ; Kumar, HV; Lang, JE; Lazarus, SC; Lemanske, RF; Lima, JJ; Ly, N; Marbin, J; Martinez, FD; Mauger, DT; Morgan, WJ; Moy, JN; Myers, RE; Olin, JT; Paul, IM; Peters, SP; Phipatanakul, W; Pongracic, JA; Raissy, HH; Robison, RG; Ross, K; Sheehan, WJ; Sorkness, CA; Szefler, SJ; Thyne, SM; Wechsler, ME, 2016) |
| "The Paracetamol (Acetaminophen) In Stroke 2 trial is a multicenter, randomized, double-blind, placebo-controlled clinical trial." | 9.20 | Paracetamol (Acetaminophen) in stroke 2 (PAIS 2): protocol for a randomized, placebo-controlled, double-blind clinical trial to assess the effect of high-dose paracetamol on functional outcome in patients with acute stroke and a body temperature of 36.5 ° ( Algra, A; de Jong, FJ; de Ridder, IR; den Hertog, HM; Dippel, DW; Kappelle, LJ; Koudstaal, PJ; Lingsma, HF; Maasland, EL; Oomes, P; Ruitenberg, A; Saxena, R; Schreuder, AH; van der Worp, HB; van Gemert, HM; van Tuijl, J, 2015) |
| "Acetaminophen is a common therapy for fever in patients in the intensive care unit (ICU) who have probable infection, but its effects are unknown." | 9.20 | Acetaminophen for Fever in Critically Ill Patients with Suspected Infection. ( Beasley, R; Bellomo, R; Freebairn, R; Hammond, N; Henderson, S; Holliday, M; Mackle, D; McArthur, C; McGuinness, S; Myburgh, J; Saxena, M; van Haren, F; Weatherall, M; Webb, S; Young, P, 2015) |
| "The combination of dabrafenib and trametinib (CombiDT) is an effective treatment for BRAF-mutant metastatic melanoma; however, over 70% of patients develop drug-related pyrexia, and little is known about this toxicity." | 9.19 | Features and management of pyrexia with combined dabrafenib and trametinib in metastatic melanoma. ( Azer, M; Clements, A; Haydu, LE; Kefford, RF; Lee, CI; Long, GV; Menzies, AM, 2014) |
| "The purpose of this study was to assess the safety and dynamics of the onset of antipyretic efficacy of intravenous (IV) acetaminophen versus oral (PO) acetaminophen in the treatment of endotoxin-induced fever." | 9.15 | A randomized study of the efficacy and safety of intravenous acetaminophen compared to oral acetaminophen for the treatment of fever. ( Breitmeyer, JB; Pan, C; Peacock, WF; Royal, MA; Smith, WB, 2011) |
| ") acetaminophen using an endotoxin-induced fever model." | 9.15 | A randomized study of the efficacy and safety of intravenous acetaminophen vs. intravenous placebo for the treatment of fever. ( Ang, R; Breitmeyer, JB; Kett, DH; Royal, MA, 2011) |
| "The results of this relatively small trial suggest that acetaminophen may reduce the risk of post-vaccination fever and fussiness." | 9.15 | A randomized placebo-controlled trial of acetaminophen for prevention of post-vaccination fever in infants. ( Benoit, J; Benson, P; Carste, B; Dominguez-Islas, CP; Dunn, J; Dunstan, M; Hambidge, SJ; Jackson, LA; Nelson, JC; Peterson, D; Starkovich, P; Yu, O, 2011) |
| "Routine prophylactic acetaminophen after DPT vaccination was effective in reducing the frequency of fever and irritability in the initial 6 hours." | 9.15 | Immediate versus as-needed acetaminophen for post-immunisation pyrexia. ( Dhingra, B; Mishra, D, 2011) |
| "To establish the relative clinical effectiveness and cost-effectiveness of paracetamol plus ibuprofen compared with paracetamol and ibuprofen separately for time without fever, and the relief of fever-associated discomfort in young children who can be managed at home." | 9.14 | Paracetamol and ibuprofen for the treatment of fever in children: the PITCH randomised controlled trial. ( Costelloe, C; Fletcher, M; Hay, AD; Hollinghurst, S; Montgomery, AA; Peters, TJ; Redmond, NM, 2009) |
| "To compare three dose levels of ketoprofen with paracetamol (acetaminophen) in the management of fever in children." | 9.14 | Dose-finding studies of ketoprofen in the management of fever in children: report on two randomized, single-blind, comparator-controlled, single-dose, multicentre, phase II studies. ( Kokki, H; Kokki, M, 2010) |
| "Acetaminophen and diphenhydramine are commonly used as pretransfusion medications to prevent transfusion reactions." | 9.13 | A prospective, randomized, double-blind controlled trial of acetaminophen and diphenhydramine pretransfusion medication versus placebo for the prevention of transfusion reactions. ( Case, LD; Cruz, JM; Hurd, DD; Kennedy, LD; Pomper, GJ, 2008) |
| "To investigate whether paracetamol (acetaminophen) plus ibuprofen are superior to either drug alone for increasing time without fever and the relief of fever associated discomfort in febrile children managed at home." | 9.13 | Paracetamol plus ibuprofen for the treatment of fever in children (PITCH): randomised controlled trial. ( Costelloe, C; Fletcher, M; Hay, AD; Hollinghurst, S; Montgomery, AA; Peters, TJ; Redmond, NM, 2008) |
| "The Paracetamol (Acetaminophen) In Stroke (PAIS) study is a phase III multicenter, double blind, randomized, placebo-controlled clinical trial of high-dose acetaminophen in patients with acute stroke." | 9.13 | Correction: PAIS: paracetamol (acetaminophen) in stroke; protocol for a randomized, double blind clinical trial. [ISCRTN74418480]. ( Algra, A; den Hertog, HM; Dippel, DW; Kappelle, LJ; Koudstaal, PJ; van der Worp, HB; van Gemert, HM; van Gijn, J, 2008) |
| "According to this study: In children younger than age two, treatment with ibuprofen was associated with reduced fever and less pain within the first 24 hours compared with acetaminophen." | 9.12 | Ibuprofen Better than Acetaminophen for Reducing Fever, Pain in Young Children. ( Rosenberg, K, 2021) |
| "5 mg/kg per dose) and ibuprofen (5 mg/kg per dose) every 4 hours for 3 days, regardless of the initial loading medication, is more effective than monotherapy in lowering fever in infants and children." | 9.12 | Antipyretic treatment in young children with fever: acetaminophen, ibuprofen, or both alternating in a randomized, double-blind study. ( Cohen, HA; Sarrell, EM; Wielunsky, E, 2006) |
| "A randomised open label study of the combined use of paracetamol and ibuprofen to rapidly reduce fever is reported." | 9.12 | Randomised controlled trial of combined paracetamol and ibuprofen for fever. ( Benger, JR; Chinnick, PJ; Coppens, K; Davies, P; Erlewyn-Lajeunesse, MD; Higginson, IM; Hunt, LP, 2006) |
| "An intravenous formulation of paracetamol and an intravenous formulation of propacetamol (prodrug of paracetamol) were compared in children with acute fever due to infection in order to determine the antipyretic efficacy and safety during the 6-hour period after administration." | 9.12 | Antipyretic efficacy and safety of a single intravenous administration of 15 mg/kg paracetamol versus 30 mg/kg propacetamol in children with acute fever due to infection. ( Dalphin, ML; Duhamel, JF; Le Gall, E; Payen-Champenois, C, 2007) |
| "Children from the age of 3 months to 12 years with a fever of non-serious origin were randomized to receive either ibuprofen or paracetamol." | 9.12 | Ibuprofen versus paracetamol in pediatric fever: objective and subjective findings from a randomized, blinded study. ( Autret-Leca, E; Gibb, IA; Goulder, MA, 2007) |
| "In the majority of patients with acute ischemic stroke, ASA and acetaminophen are insufficient for reducing an elevated BT to a state of normothermia." | 9.11 | Acetylsalicylic acid and acetaminophen to combat elevated body temperature in acute ischemic stroke. ( De Keyser, J; Elting, JW; Luijckx, GJ; Luyckx, GJ; Maurits, N; Sulter, G, 2004) |
| "Acetaminophen prophylaxis prevented neither maternal hyperthermia nor fever secondary to epidural analgesia, suggesting that the mechanism underlying fever does not include centrally mediated perturbations of maternal thermoregulation." | 9.11 | Prophylactic acetaminophen does not prevent epidural fever in nulliparous women: a double-blind placebo-controlled trial. ( Citron, DR; Evans, T; Goetzl, L; Lieberman, E; Richardson, BE; Rivers, J; Suresh, MS, 2004) |
| "Aspirin (acetylsalicylic acid) and acetaminophen (paracetamol) are frequently used to treat fever and other symptoms of upper respiratory tract infection (URTI)." | 9.11 | Aspirin compared with acetaminophen in the treatment of fever and other symptoms of upper respiratory tract infection in adults: a multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group, single-dose, 6-hour dose-ranging st ( Bachert, C; Chuchalin, AG; Eisebitt, R; Netayzhenko, VZ; Voelker, M, 2005) |
| " In a previous randomized trial we observed that treatment with high-dose acetaminophen (paracetamol) led to a reduction of body temperature in patients with acute ischemic stroke, even when they had no fever." | 9.10 | Effect of paracetamol (acetaminophen) and ibuprofen on body temperature in acute ischemic stroke PISA, a phase II double-blind, randomized, placebo-controlled trial [ISRCTN98608690]. ( Dippel, DW; Kappelle, LJ; Koudstaal, PJ; Meijer, RJ; van Breda, EJ; van der Worp, HB; van Gemert, HM, 2003) |
| "Early administration of acetaminophen (3900 mg/d) to afebrile patients with acute stroke may result in a small reduction in CBT." | 9.10 | Acetaminophen for altering body temperature in acute stroke: a randomized clinical trial. ( Chalela, JA; Grotta, JC; Kasner, SE; Kimmel, SE; Krieger, DW; Morgenstern, LB; Piriyawat, P; Villar-Cordova, CE; Wein, T, 2002) |
| "Rather than supporting the hypothesis that ibuprofen increases asthma morbidity among children who are not known to be sensitive to aspirin or other nonsteroidal antiinflammatory drugs, these data suggest that compared with acetaminophen, ibuprofen may reduce such risks." | 9.10 | Asthma morbidity after the short-term use of ibuprofen in children. ( Lesko, SM; Louik, C; Mitchell, AA; Vezina, RM, 2002) |
| "Acetaminophen was the superior antipyretic drug in endotoxemia compared with aspirin." | 9.09 | Acetaminophen has greater antipyretic efficacy than aspirin in endotoxemia: a randomized, double-blind, placebo-controlled trial. ( Bieglmayer, C; Eichler, HG; Jilma, B; Kapiotis, S; Pernerstorfer, T; Schmid, R, 1999) |
| "The purpose of this preliminary study was to compare acetaminophen to ketorolac for treating patients with fever in the emergency department (ED)." | 9.09 | Ketorolac versus acetaminophen for treatment of acute fever in the emergency department. ( Ernst, A; Houry, D; Ledbetter, M; Weiss, S, 1999) |
| "The aim of this study was to assess and compare the efficacy and tolerability of paracetamol, ibuprofen and nimesulide in children with upper respiratory tract infections (URTIs)." | 9.09 | Assessment of the efficacy and safety of paracetamol, ibuprofen and nimesulide in children with upper respiratory tract infections. ( Cin, S; Köksal, Y; Ulukol, B, 1999) |
| "The objectives of this prospective non-concurrent cohort study were to confirm the efficacy of vaginal misoprostol for early pregnancy termination and to determine whether the incidence of side effects is lower with prophylactic loperamide and acetaminophen." | 9.09 | Early pregnancy termination with vaginal misoprostol combined with loperamide and acetaminophen prophylaxis. ( Harwood, B; Jain, JK; Meckstroth, KR; Mishell, DR, 2001) |
| "Seventy-five patients with acute ischemic stroke confined to the anterior circulation were randomized to treatment with either 500 mg (low dose) or 1000 mg (high dose) acetaminophen or with placebo, administered as suppositories 6 times daily during 5 days." | 9.09 | Effect of paracetamol (acetaminophen) on body temperature in acute ischemic stroke: a double-blind, randomized phase II clinical trial. ( Dippel, DW; Kappelle, LJ; Koudstaal, PJ; Meijer, RJ; van Breda, EJ; van der Worp, HB; van Gemert, HM, 2001) |
| "5 mg/kg per dose), aspirin (10 mg/kg/dose) and paracetamol (10 mg/kg per dose) on children with fever aged 6-24 months in an open, randomised study with three parallel groups." | 9.08 | Evaluation of ibuprofen versus aspirin and paracetamol on efficacy and comfort in children with fever. ( Autret, E; Courcier, S; Goehrs, JM; Henry-Launois, B; Laborde, C; Languillat, G; Launois, R; Reboul-Marty, J, 1997) |
| "The efficacy and tolerability of nimesulide were compared with those of paracetamol in a nonblind randomised study that recruited 110 children (64 males, 46 females; aged 3 to 6 years) with inflammation of the upper respiratory tract and fever." | 9.07 | A comparison of nimesulide and paracetamol in the treatment of fever due to inflammatory diseases of the upper respiratory tract in children. ( Comito, A; Pieragostini, P; Polidori, G; Scaricabarozzi, I; Titti, G, 1993) |
| "The authors studied the antipyretic effect of three intramuscular doses of ketorolac (15, 30, and 60 mg), acetaminophen 650 mg PO, and placebo in healthy male volunteers using an endotoxin-induced fever model." | 9.07 | Evaluation of the antipyretic effect of ketorolac, acetaminophen, and placebo in endotoxin-induced fever. ( Bynum, L; Maneatis, T; McMahon, FG; Peterson, C; Vargas, R, 1994) |
| "kg-1 acetaminophen syrup (n = 77) in 154 children (6 months to 5 years) with fever (> or = 38 degrees C) associated with infectious diseases and treated with antibiotic therapy." | 9.07 | Comparative efficacy and tolerance of ibuprofen syrup and acetaminophen syrup in children with pyrexia associated with infectious diseases and treated with antibiotics. ( Autret, E; Breart, G; Courcier, S; Goehrs, JM; Jonville, AP; Lassale, C, 1994) |
| "The effect of acetaminophen on fever in bacterial vs." | 9.06 | Fever response to acetaminophen in viral vs. bacterial infections. ( Brien, JH; Miller, G; Weisse, ME, 1987) |
| "Acetaminophen (paracetamol) and ibuprofen are the most widely prescribed and available over-the-counter medications for management of fever and pain in children." | 9.05 | Comparison of Acetaminophen (Paracetamol) With Ibuprofen for Treatment of Fever or Pain in Children Younger Than 2 Years: A Systematic Review and Meta-analysis. ( Braithwaite, I; Dalziel, SR; McKinlay, CJD; Tan, E, 2020) |
| "The present randomized single-blind trial was performed to study antipyretic effect and tolerability of alpha-methyl-4-(2-thienylcarbonyl)-phenyl acetic acid (suprofen, Suprol) suppositories versus paracetamol (acetaminophen) suppositories in pediatric patients with fever of various etiology." | 9.05 | Clinical experience and results of treatment with suprofen in pediatrics. 2nd communication: Use of suprofen suppositories as an antipyretic in children with fever due to acute infections/A single-blind controlled study of suprofen versus paracetamol. ( Michos, N; Stocker, H; Sundal, EJ; Weippl, G, 1985) |
| "Our primary objective was to assess the effectiveness of paracetamol (acetaminophen) or NSAIDs, alone or combined, compared with placebo or no treatment in relieving pain in children with AOM." | 8.93 | Paracetamol (acetaminophen) or non-steroidal anti-inflammatory drugs, alone or combined, for pain relief in acute otitis media in children. ( Damoiseaux, RA; Hay, AD; Little, P; Schilder, AG; Sjoukes, A; van de Pol, AC; Venekamp, RP, 2016) |
| "Combination treatment with ibuprofen and acetaminophen is beneficial over either agent alone for sustained fever reduction in children older than 6 months." | 8.89 | Does combination treatment with ibuprofen and acetaminophen improve fever control? ( Malya, RR, 2013) |
| "To analyse major sources of evidence-based information on the efficacy and gastrointestinal tolerability of aspirin, used short-term, in over-the-counter (OTC) doses, to relieve acute pain and cold symptoms, including associated feverishness." | 8.88 | Efficacy and gastrointestinal risk of aspirin used for the treatment of pain and cold. ( McCarthy, DM, 2012) |
| "Acetylsalicylic acid (ASA [aspirin]) is a commonly used over-the-counter drug for the treatment of pain, fever, or colds, but data on the safety of this use are very limited." | 8.87 | Short-term acetylsalicylic acid (aspirin) use for pain, fever, or colds - gastrointestinal adverse effects: a meta-analysis of randomized clinical trials. ( Baron, JA; Brueckner, A; Lanas, A; McCarthy, D; Senn, S; Voelker, M, 2011) |
| "Paracetamol and ibuprofen are safe and effective medications for reducing a fever in children and young people and they are often administered together with a view to reducing a temperature quickly." | 8.86 | Fever management: evaluating the use of ibuprofen and paracetamol. ( Crook, J, 2010) |
| "Schultz et al (2008) raised the question whether regression into autism is triggered, not by the measles-mumps-rubella (MMR) vaccine, but by acetaminophen (Tylenol) given for its fever and pain." | 8.85 | Did acetaminophen provoke the autism epidemic? ( Good, P, 2009) |
| "To characterize clozapine-induced fever and suggest clinically relevant management recommendations." | 8.84 | Characterization and clinical management of clozapine-induced fever. ( Grube, RR; Lowe, CM; Scates, AC, 2007) |
| "Although many studies have investigated the safety and tolerability of ibuprofen or acetaminophen (paracetamol) use in children, few have specifically examined the association of ibuprofen or acetaminophen and the occurrence of asthma in pediatric populations." | 8.84 | A review of ibuprofen and acetaminophen use in febrile children and the occurrence of asthma-related symptoms. ( Dale, S; Kanabar, D; Rawat, M, 2007) |
| "To summarize studies testing the efficacy and safety of single-dose acetaminophen and ibuprofen for treating children's pain or fever." | 8.82 | Efficacy and safety of acetaminophen vs ibuprofen for treating children's pain or fever: a meta-analysis. ( Champion, GD; Goodenough, B; Perrott, DA; Piira, T, 2004) |
| "This study was undertaken to evaluate the efficacy, safety, and economic impact of diazepam suppositories with as-needed acetaminophen in comparison with as-needed acetaminophen alone for prevention of seizure recurrence during the same fever episode in suspected pediatric simple febrile seizures (SFS)." | 8.12 | Efficacy, safety, and economic impact of diazepam suppositories with as-needed acetaminophen for prevention of seizure recurrence during the same fever episode in children with suspected simple febrile seizures. ( Fujita, S; Hataya, H; Kishibe, S; Miyama, S; Morikawa, EK; Morikawa, Y; Narita, K; Sammori, H; Suzuki, S; Takehira, K; Tanaka, M; Tsukamoto, J; Wang, Q; Yano, M, 2022) |
| "The pharmacological specificities of the rectal formulation of acetaminophen led to a debate on its appropriateness for managing fever in children, but few data are available on the formulation's current use and determinants of use." | 7.83 | Enduring large use of acetaminophen suppositories for fever management in children: a national survey of French parents and healthcare professionals' practices. ( Bertille, N; Chalumeau, M; Fournier-Charrière, E; Khoshnood, B; Pons, G, 2016) |
| "Acetaminophen is a commonly used medication to manage fever and pain in children and the drug is generally considered to be safe when used at appropriate therapeutic dosages." | 7.81 | Severe intrinsic acute kidney injury associated with therapeutic doses of acetaminophen. ( Aizawa, T; Hirono, K; Ito, E; Ito, T; Joh, K; Tanaka, H; Tsuruga, K; Watanabe, S, 2015) |
| "Acetaminophen is one of the world's most commonly used drugs to treat fever and pain, yet its mechanism of action has remained unclear." | 7.79 | Acetaminophen reduces lipopolysaccharide-induced fever by inhibiting cyclooxygenase-2. ( Blomqvist, A; Elander, L; Engblom, D; Engström Ruud, L; Eskilsson, A; Vasilache, AM; Wilhelms, DB, 2013) |
| "Children who have unresolved pain despite the use of either ibuprofen or acetaminophen should have their medication regimen reviewed to ensure they are receiving the medication at an adequate dose and interval." | 7.78 | Alternating acetaminophen and ibuprofen for pain in children. ( Goldman, RD; Smith, C, 2012) |
| "Acetaminophen use in children has been associated with increased autism risk." | 7.76 | Can autism be triggered by acetaminophen activation of the endocannabinoid system? ( Schultz, ST, 2010) |
| "Paracetamol (Acetaminophen) In Stroke (PAIS) is a randomized, double-blind clinical trial, comparing high-dose acetaminophen with placebo in 2500 patients." | 7.73 | PAIS: paracetamol (acetaminophen) in stroke; protocol for a randomized, double blind clinical trial [ISCRTN 74418480]. ( Algra, A; Dippel, DW; Kappelle, LJ; Koudstaal, PJ; van Breda, EJ; van der Worp, HB; van Gemert, HM; van Gijn, J, 2005) |
| "Children frequently suffer infections accompanied by fever, which is commonly treated with acetaminophen (paracetamol), a use not devoid of risk." | 7.73 | The effects of a complex homeopathic medicine compared with acetaminophen in the symptomatic treatment of acute febrile infections in children: an observational study. ( Derasse, M; Klein, P; Weiser, M, 2005) |
| "The present study was designed to determine whether the inhibition of glutamate release in organum vasculosum laminae terminalis (OVLT) of rabbit brain by acetaminophen might be protective in a whole-animal model of staphylococcal enterotoxin A (SEA) fever." | 7.72 | Antipyretic effect of acetaminophen by inhibition of glutamate release after staphylococcal enterotoxin A fever in rabbits. ( Huang, WT; Lin, MT; Wang, JJ, 2004) |
| "Seventy-five (3 x 25) patients with acute ischaemic stroke confined to the anterior circulation will be randomised to treatment with either: 400 mg ibuprofen, 1000 mg acetaminophen, or with placebo 6 times daily during 5 days." | 7.71 | PISA. The effect of paracetamol (acetaminophen) and ibuprofen on body temperature in acute stroke: protocol for a phase II double-blind randomised placebo-controlled trial [ISRCTN98608690]. ( Dippel, DW; Kappelle, J; Koudstaal, PJ; Meijer, R; van Breda, EJ; van der Worp, B; van Gemert, M, 2002) |
| "A cohort of 484 febrile children were examined to (1) assess the utility of temperature response to acetaminophen as a diagnostic test for occult bacteremia (OB) and (2) compare it with the white blood cell (WBC) count." | 7.69 | Diagnostic tests for occult bacteremia: temperature response to acetaminophen versus WBC count. ( Kozinetz, CA; Mazur, LJ, 1994) |
| "We have investigated the effect of malaria infection with the rodent parasite Plasmodium berghei and fever induced by Escherichia coli endotoxin on the metabolism of phenacetin to paracetamol by rat liver microsomes from young (4 weeks old) male Wistar rats (N = 5 in control and fever groups; N = 10 in malaria-infected group)." | 7.68 | Effect of malaria infection and endotoxin-induced fever on phenacetin O-deethylation by rat liver microsomes. ( Breckenridge, AM; Edwards, G; Glazier, AP; Kokwaro, GO; Ward, SA, 1993) |
| "Fever is a common symptom in children and one of the major concerns of parents of younger and preschool-age children." | 6.75 | Ketoprofen versus paracetamol (acetaminophen) or ibuprofen in the management of fever: results of two randomized, double-blind, double-dummy, parallel-group, repeated-dose, multicentre, phase III studies in children. ( Kokki, H; Kokki, M, 2010) |
| "At physician-directed dosing (acetaminophen 15 mg/kg vs ibuprofen 10 mg/kg), no significant differences in antipyretic effects from 0‒6 h and between 0‒6, ‒12, ‒24, or ‒48 h, with single or multiple-doses, respectively, were observed." | 6.72 | Acetaminophen and ibuprofen in the treatment of pediatric fever: a narrative review. ( Paul, IM; Walson, PD, 2021) |
| "Ibuprofen, paracetamol and placebo have similar tolerability and safety profiles in terms of gastrointestinal symptoms, asthma and renal adverse effects." | 6.45 | Systematic review and meta-analysis of the clinical safety and tolerability of ibuprofen compared with paracetamol in paediatric pain and fever. ( Kleijnen, J; Soares-Weiser, K; Southey, ER, 2009) |
| " In summary, all methodologically sound studies available indicate that therapeutic dosing of paracetamol to the alcoholic patient is not associated with hepatic injury." | 6.41 | Treatment of pain or fever with paracetamol (acetaminophen) in the alcoholic patient: a systematic review. ( Dart, RC; Kuffner, EK; Rumack, BH, 2000) |
| "Fever after removal of tube drainage is caused by a normal inflammatory response, and a small dose of acetaminophen could significantly reduce the possibility of fever." | 5.69 | A Randomized Study on the Prophylactic Use of Acetaminophen to Prevent Fever after the Removal of Drainage Tubes for Lumbar Surgery. ( Li, Y; Liu, K; Tian, Y; Xing, Y; Ye, K; Zhang, Y; Zhou, F, 2023) |
| "Fever has been reported as a common symptom occurring in COVID-19 illness." | 5.56 | The use of ibuprofen to treat fever in COVID-19: A possible indirect association with worse outcome? ( Haryadi, TH; Jamerson, BD, 2020) |
| " The Paracetamol and Ibuprofen in the Primary Prevention of Asthma in Tamariki (PIPPA Tamariki) trial is an open-label, randomised controlled trial aiming to determine whether paracetamol treatment, compared with ibuprofen treatment, as required for fever and pain in the first year of life, increases the risk of asthma at age six years." | 5.51 | Panic or peace - prioritising infant welfare when medicating feverish infants: a grounded theory study of adherence in a paediatric clinical trial. ( Braithwaite, I; Dalziel, SR; Fernando, K; Haskell, L; Hoare, K; McKinlay, CJ; Riley, J; Tan, E, 2022) |
| " Eligible children will receive treatment allocation randomization either to standard of care for fever management or to prophylactic, scheduled treatment every 6 hours for 72 hours with dual antipyretic therapies using acetaminophen and ibuprofen." | 5.51 | Aggressive antipyretics in central nervous system malaria: Study protocol of a randomized-controlled trial assessing antipyretic efficacy and parasite clearance effects (Malaria FEVER study). ( Birbeck, GL; Chilombe, MB; Mathews, M; McDermott, MP; Mwenechanya, M; Seydel, KB, 2022) |
| " Intravenous acetaminophen, with its increased bioavailability and more rapid onset of action, may have benefit in the intrapartum setting by reducing adverse neonatal and maternal outcomes associated with febrile morbidity." | 5.46 | Intravenous acetaminophen for the treatment of intrapartum fever and resolution of fetal tachycardia: a novel use for an old medication. ( Burgess, APH; Lakhi, N; Moretti, M; Ope-Adenuga, S; Reilly, JG, 2017) |
| "This study aims to evaluate the efficacy and safety of multiple or single-dosage intravenous ibuprofen (IVIB) in managing postoperative pain and fever in adults who are unable to take oral medications." | 5.41 | Intravenous ibuprofen in postoperative pain and fever management in adults: A systematic review and meta-analysis of randomized controlled trials. ( Chen, L; He, L; Tian, S; Wang, E; Zhai, S; Zhou, P, 2023) |
| "Our primary objective was to assess the effectiveness of paracetamol (acetaminophen) or NSAIDs, alone or combined, compared with placebo or no treatment in relieving pain in children with AOM." | 5.41 | Paracetamol (acetaminophen) or non-steroidal anti-inflammatory drugs, alone or combined, for pain relief in acute otitis media in children. ( Damoiseaux, RA; de Sévaux, JLH; Hay, AD; Little, P; Lutje, V; Schilder, AG; van de Pol, AC; Venekamp, RP, 2023) |
| "Intravenous acetaminophen did not demonstrate a higher efficacy than oral acetaminophen in treating intrapartum maternal fever." | 5.41 | Randomized control trial of intravenous acetaminophen for reduction of intrapartum maternal fever. ( Cabbad, M; Kanninen, T; Lakhi, N; Mehraban, S; Mehraban, SS; Moretti, M; Nematian, S; Parnas, Z; Petrucci, S; Shats, L; Tricorico, G, 2021) |
| "In adult age group patients admitted to the emergency department with high fever, the IV forms of 1000 mg paracetamol and 400 mg ibuprofen effectively and equally reduce complaints, such as fever and accompanying pain." | 5.41 | Comparison of intravenous ibuprofen and paracetamol in the treatment of fever: A randomized double-blind study. ( Can, Ö; Kıyan, GS; Yalçınlı, S, 2021) |
| "(1) Renal colic is an acute syndrome involving unilateral flank pain, linked to an obstruction in the upper urinary tract." | 5.35 | Renal colic in adults: NSAIDs and morphine are effective for pain relief. ( , 2009) |
| "the overall result showed that ibuprofen had a better fever reducing effect compared to paracetamol." | 5.34 | Ibuprofen versus paracetamol for treating fever in preschool children in Nigeria: a randomized clinical trial of effectiveness and safety. ( Akande, PA; Alaje, EO; Meremikwu, MM; Odey, FA; Udoh, EE, 2020) |
| "He had an upper respiratory tract infection in which a vaso-occlusive crisis was precipitated." | 5.34 | Tramadol infusion for the pain management in sickle cell disease: a case report. ( Aydinok, Y; Balkan, C; Erhan, E; Inal, MT; Yegul, I, 2007) |
| "This observational single-dose study was conducted at Department of Pedriatrics, Army Hospital (Research and Referral), a multispecialty tertiary care center in New Delhi in fever patients to assess the antipyretic efficacy of IV acetaminophen 15 mg/kg/dose vs." | 5.27 | Comparison of Antipyretic Efficacy of Intravenous (IV) Acetaminophen versus Oral (PO) Acetaminophen in the Management of Fever in Children. ( Roy, S; Simalti, AK, 2018) |
| "We aimed to compare the antipyretic efficacy, safety, and tolerability between oral dexibuprofen and intravenous propacetamol in children with upper respiratory tract infection (URTI) presenting with fever." | 5.27 | The antipyretic efficacy and safety of propacetamol compared with dexibuprofen in febrile children: a multicenter, randomized, double-blind, comparative, phase 3 clinical trial. ( Choi, SJ; Choi, UY; Chun, YH; Jeong, DC; Kim, HM; Lee, J; Lee, JH; Moon, S; Rhim, JW, 2018) |
| "Acetaminophen (15 mg/kg) was administered to each child and repeat temperatures were taken one and two hours later." | 5.27 | Childhood fever: correlation of diagnosis with temperature response to acetaminophen. ( Baker, MD; Carpenter, RO; Fosarelli, PD, 1987) |
| "No evidence can be found in the medical literature about the efficacy of alternating acetaminophen and ibuprofen treatment in children with refractory fever." | 5.24 | Alternating Acetaminophen and Ibuprofen versus Monotherapies in Improvements of Distress and Reducing Refractory Fever in Febrile Children: A Randomized Controlled Trial. ( Guo, Q; Luo, Q; Luo, S; Ran, M; Shu, M; Wan, C; Xie, X; Zhang, C; Zhu, Y, 2017) |
| "No randomized study has been conducted to investigate the use of intravenous paracetamol (acetaminophen, APAP) for the management of fever due to infection." | 5.24 | Randomized, controlled, multicentre clinical trial of the antipyretic effect of intravenous paracetamol in patients admitted to hospital with infection. ( Akinosoglou, K; Giamarellos-Bourboulis, EJ; Gogos, C; Karagiannis, A; Koupetori, M; Pyrpasopoulou, A; Soumelas, GS; Sympardi, S; Tsaganos, T; Tseti, IK; Tsokos, N; Tziolos, N, 2017) |
| "Two blinded single-dose studies randomized children 6 months to 11 years old with fever to receive ibuprofen (IBU) pediatric suspension 7." | 5.24 | Antipyretic Efficacy and Safety of Ibuprofen Versus Acetaminophen Suspension in Febrile Children: Results of 2 Randomized, Double-Blind, Single-Dose Studies. ( Jayawardena, S; Kellstein, D, 2017) |
| "001); in a greater reduction in change from baseline temperature compared to treatment with acetaminophen, and it reduced fever throughout a 24 h dosing period." | 5.24 | A multicenter, randomized, open-label, active-comparator trial to determine the efficacy, safety, and pharmacokinetics of intravenous ibuprofen for treatment of fever in hospitalized pediatric patients. ( Chumpitazi, CE; Hahn, BJ; Kaelin, BA; Khalil, SN; Macias, CG; Rock, AD, 2017) |
| "PAIS 2 (Paracetamol [Acetaminophen] in Stroke 2) was a multicenter, randomized, double-blind, placebo-controlled clinical trial." | 5.24 | PAIS 2 (Paracetamol [Acetaminophen] in Stroke 2): Results of a Randomized, Double-Blind Placebo-Controlled Clinical Trial. ( Algra, A; de Ridder, IR; den Hertog, HM; Dippel, DW; Jansen, BP; Kappelle, LJ; Koudstaal, PJ; Maasland, EL; Ruitenberg, A; Saxena, R; Schreuder, AH; Van den Berg-Vos, RM; van der Worp, HB; van Gemert, HM; van Tuijl, JH; Vermeij, F, 2017) |
| "To evaluate ibuprofen and acetaminophen in the treatment of infectious fever in children." | 5.22 | Comparison between Ibuprofen and Acetaminophen in the Treatment of Infectious Fever in Children: A Meta-Analysis. ( Guo, H; Liu, Y; Yin, F, 2022) |
| "In May and June 2020, an open-date literature search of English publications indexed in ProQuest, PubMed, and EBSCO was conducted with the search terms 'acetaminophen' and 'hypotension' and related search combinations ('paracetamol', 'propacetamol', 'low blood pressure', 'fever', 'sepsis', and 'shock') to identify peer-reviewed publications of blood pressure changes after paracetamol administration in humans." | 5.22 | A narrative review of paracetamol-induced hypotension: Keeping the patient safe. ( Young, TL, 2022) |
| "Studies have suggested an association between frequent acetaminophen use and asthma-related complications among children, leading some physicians to recommend that acetaminophen be avoided in children with asthma; however, appropriately designed trials evaluating this association in children are lacking." | 5.22 | Acetaminophen versus Ibuprofen in Young Children with Mild Persistent Asthma. ( Bacharier, LB; Baxi, SN; Beigelman, A; Benson, M; Blake, K; Boehmer, SJ; Cabana, MD; Chmiel, JF; Covar, R; Daines, CL; Daines, MO; Fitzpatrick, AM; Gaffin, JM; Gentile, DA; Gower, WA; Holguin, F; Israel, E; Jackson, DJ; Kumar, HV; Lang, JE; Lazarus, SC; Lemanske, RF; Lima, JJ; Ly, N; Marbin, J; Martinez, FD; Mauger, DT; Morgan, WJ; Moy, JN; Myers, RE; Olin, JT; Paul, IM; Peters, SP; Phipatanakul, W; Pongracic, JA; Raissy, HH; Robison, RG; Ross, K; Sheehan, WJ; Sorkness, CA; Szefler, SJ; Thyne, SM; Wechsler, ME, 2016) |
| "The Paracetamol (Acetaminophen) In Stroke 2 trial is a multicenter, randomized, double-blind, placebo-controlled clinical trial." | 5.20 | Paracetamol (Acetaminophen) in stroke 2 (PAIS 2): protocol for a randomized, placebo-controlled, double-blind clinical trial to assess the effect of high-dose paracetamol on functional outcome in patients with acute stroke and a body temperature of 36.5 ° ( Algra, A; de Jong, FJ; de Ridder, IR; den Hertog, HM; Dippel, DW; Kappelle, LJ; Koudstaal, PJ; Lingsma, HF; Maasland, EL; Oomes, P; Ruitenberg, A; Saxena, R; Schreuder, AH; van der Worp, HB; van Gemert, HM; van Tuijl, J, 2015) |
| "Acetaminophen is a common therapy for fever in patients in the intensive care unit (ICU) who have probable infection, but its effects are unknown." | 5.20 | Acetaminophen for Fever in Critically Ill Patients with Suspected Infection. ( Beasley, R; Bellomo, R; Freebairn, R; Hammond, N; Henderson, S; Holliday, M; Mackle, D; McArthur, C; McGuinness, S; Myburgh, J; Saxena, M; van Haren, F; Weatherall, M; Webb, S; Young, P, 2015) |
| "The combination of dabrafenib and trametinib (CombiDT) is an effective treatment for BRAF-mutant metastatic melanoma; however, over 70% of patients develop drug-related pyrexia, and little is known about this toxicity." | 5.19 | Features and management of pyrexia with combined dabrafenib and trametinib in metastatic melanoma. ( Azer, M; Clements, A; Haydu, LE; Kefford, RF; Lee, CI; Long, GV; Menzies, AM, 2014) |
| "316 patients (6 months-12 years) with fever were randomly assigned to receive a single dose of acetaminophen or ketoprofen orally." | 5.16 | Comparison of acetaminophen and ketoprofen in febrile children: a single dose randomized clinical trial. ( Erkek, N; Karacan, CD; Senel, S, 2012) |
| "The purpose of this study was to assess the safety and dynamics of the onset of antipyretic efficacy of intravenous (IV) acetaminophen versus oral (PO) acetaminophen in the treatment of endotoxin-induced fever." | 5.15 | A randomized study of the efficacy and safety of intravenous acetaminophen compared to oral acetaminophen for the treatment of fever. ( Breitmeyer, JB; Pan, C; Peacock, WF; Royal, MA; Smith, WB, 2011) |
| ") acetaminophen using an endotoxin-induced fever model." | 5.15 | A randomized study of the efficacy and safety of intravenous acetaminophen vs. intravenous placebo for the treatment of fever. ( Ang, R; Breitmeyer, JB; Kett, DH; Royal, MA, 2011) |
| "The results of this relatively small trial suggest that acetaminophen may reduce the risk of post-vaccination fever and fussiness." | 5.15 | A randomized placebo-controlled trial of acetaminophen for prevention of post-vaccination fever in infants. ( Benoit, J; Benson, P; Carste, B; Dominguez-Islas, CP; Dunn, J; Dunstan, M; Hambidge, SJ; Jackson, LA; Nelson, JC; Peterson, D; Starkovich, P; Yu, O, 2011) |
| "Routine prophylactic acetaminophen after DPT vaccination was effective in reducing the frequency of fever and irritability in the initial 6 hours." | 5.15 | Immediate versus as-needed acetaminophen for post-immunisation pyrexia. ( Dhingra, B; Mishra, D, 2011) |
| "To establish the relative clinical effectiveness and cost-effectiveness of paracetamol plus ibuprofen compared with paracetamol and ibuprofen separately for time without fever, and the relief of fever-associated discomfort in young children who can be managed at home." | 5.14 | Paracetamol and ibuprofen for the treatment of fever in children: the PITCH randomised controlled trial. ( Costelloe, C; Fletcher, M; Hay, AD; Hollinghurst, S; Montgomery, AA; Peters, TJ; Redmond, NM, 2009) |
| "To compare three dose levels of ketoprofen with paracetamol (acetaminophen) in the management of fever in children." | 5.14 | Dose-finding studies of ketoprofen in the management of fever in children: report on two randomized, single-blind, comparator-controlled, single-dose, multicentre, phase II studies. ( Kokki, H; Kokki, M, 2010) |
| "Subjects were randomized (3:3:1) to receive IV acetaminophen (1,000mg q6h or 650mg q4h) or standard-of-care treatment for pain or fever." | 5.14 | Safety of multiple-dose intravenous acetaminophen in adult inpatients. ( Bergese, SD; Candiotti, KA; Royal, MA; Singla, NK; Singla, SK; Viscusi, ER, 2010) |
| "Many pediatricians recommend, and many parents administer, alternating or combined doses of ibuprofen and acetaminophen for fever." | 5.14 | Efficacy of standard doses of Ibuprofen alone, alternating, and combined with acetaminophen for the treatment of febrile children. ( Berlin, CM; Engle, L; Paul, IM; Sturgis, SA; Watts, H; Yang, C, 2010) |
| "Methods A prospective, randomized double-blind placebo control study comparing the efficacy of acetaminophen to acetaminophen alternated with ibuprofen in 38 healthy outpatient children 6 months to 6 years presenting to the outpatient clinic with fever >38 degrees C was conducted." | 5.13 | Alternating antipyretics: antipyretic efficacy of acetaminophen versus acetaminophen alternated with ibuprofen in children. ( Fairchok, MP; Harper, DP; Kramer, LC; Richards, PA; Thompson, AM, 2008) |
| "Acetaminophen and diphenhydramine are commonly used as pretransfusion medications to prevent transfusion reactions." | 5.13 | A prospective, randomized, double-blind controlled trial of acetaminophen and diphenhydramine pretransfusion medication versus placebo for the prevention of transfusion reactions. ( Case, LD; Cruz, JM; Hurd, DD; Kennedy, LD; Pomper, GJ, 2008) |
| "To investigate whether paracetamol (acetaminophen) plus ibuprofen are superior to either drug alone for increasing time without fever and the relief of fever associated discomfort in febrile children managed at home." | 5.13 | Paracetamol plus ibuprofen for the treatment of fever in children (PITCH): randomised controlled trial. ( Costelloe, C; Fletcher, M; Hay, AD; Hollinghurst, S; Montgomery, AA; Peters, TJ; Redmond, NM, 2008) |
| "The Paracetamol (Acetaminophen) In Stroke (PAIS) study is a phase III multicenter, double blind, randomized, placebo-controlled clinical trial of high-dose acetaminophen in patients with acute stroke." | 5.13 | Correction: PAIS: paracetamol (acetaminophen) in stroke; protocol for a randomized, double blind clinical trial. [ISCRTN74418480]. ( Algra, A; den Hertog, HM; Dippel, DW; Kappelle, LJ; Koudstaal, PJ; van der Worp, HB; van Gemert, HM; van Gijn, J, 2008) |
| "According to this study: In children younger than age two, treatment with ibuprofen was associated with reduced fever and less pain within the first 24 hours compared with acetaminophen." | 5.12 | Ibuprofen Better than Acetaminophen for Reducing Fever, Pain in Young Children. ( Rosenberg, K, 2021) |
| "Paracetamol (acetaminophen) is one of the most popular and widely used drugs for the treatment of pain and fever." | 5.12 | Paracetamol: unconventional uses of a well-known drug. ( Bloukh, S; Matheson, C; Wazaify, M, 2021) |
| "5 mg/kg per dose) and ibuprofen (5 mg/kg per dose) every 4 hours for 3 days, regardless of the initial loading medication, is more effective than monotherapy in lowering fever in infants and children." | 5.12 | Antipyretic treatment in young children with fever: acetaminophen, ibuprofen, or both alternating in a randomized, double-blind study. ( Cohen, HA; Sarrell, EM; Wielunsky, E, 2006) |
| "A randomised open label study of the combined use of paracetamol and ibuprofen to rapidly reduce fever is reported." | 5.12 | Randomised controlled trial of combined paracetamol and ibuprofen for fever. ( Benger, JR; Chinnick, PJ; Coppens, K; Davies, P; Erlewyn-Lajeunesse, MD; Higginson, IM; Hunt, LP, 2006) |
| "Propacetamol is an acetaminophen prodrug that was available in Europe as an IV formu lation for the treatment of pain and fever for some time." | 5.12 | Antipyretic efficacy and tolerability of a single intravenous dose of the acetaminophen prodrug propacetamol in children: a randomized, double-blind, placebo-controlled trial. ( Chesney, R; Jones, J; Rodarte, A; Walson, PD, 2006) |
| "An intravenous formulation of paracetamol and an intravenous formulation of propacetamol (prodrug of paracetamol) were compared in children with acute fever due to infection in order to determine the antipyretic efficacy and safety during the 6-hour period after administration." | 5.12 | Antipyretic efficacy and safety of a single intravenous administration of 15 mg/kg paracetamol versus 30 mg/kg propacetamol in children with acute fever due to infection. ( Dalphin, ML; Duhamel, JF; Le Gall, E; Payen-Champenois, C, 2007) |
| "Children from the age of 3 months to 12 years with a fever of non-serious origin were randomized to receive either ibuprofen or paracetamol." | 5.12 | Ibuprofen versus paracetamol in pediatric fever: objective and subjective findings from a randomized, blinded study. ( Autret-Leca, E; Gibb, IA; Goulder, MA, 2007) |
| "In the majority of patients with acute ischemic stroke, ASA and acetaminophen are insufficient for reducing an elevated BT to a state of normothermia." | 5.11 | Acetylsalicylic acid and acetaminophen to combat elevated body temperature in acute ischemic stroke. ( De Keyser, J; Elting, JW; Luijckx, GJ; Luyckx, GJ; Maurits, N; Sulter, G, 2004) |
| "To determine whether evidence in the medical literature supports ibuprofen or acetaminophen for reducing fever in children." | 5.11 | The antipyretic effect of ibuprofen and acetaminophen in children. ( Wahba, H, 2004) |
| "Acetaminophen prophylaxis prevented neither maternal hyperthermia nor fever secondary to epidural analgesia, suggesting that the mechanism underlying fever does not include centrally mediated perturbations of maternal thermoregulation." | 5.11 | Prophylactic acetaminophen does not prevent epidural fever in nulliparous women: a double-blind placebo-controlled trial. ( Citron, DR; Evans, T; Goetzl, L; Lieberman, E; Richardson, BE; Rivers, J; Suresh, MS, 2004) |
| "Aspirin (acetylsalicylic acid) and acetaminophen (paracetamol) are frequently used to treat fever and other symptoms of upper respiratory tract infection (URTI)." | 5.11 | Aspirin compared with acetaminophen in the treatment of fever and other symptoms of upper respiratory tract infection in adults: a multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group, single-dose, 6-hour dose-ranging st ( Bachert, C; Chuchalin, AG; Eisebitt, R; Netayzhenko, VZ; Voelker, M, 2005) |
| "To compare the antipyretic and hemodynamic effects of metamizol and propacetamol in critically ill patients with fever." | 5.10 | [Metamizol versus propacetamol: comparative study of the hemodynamic and antipyretic effects in critically ill patients]. ( Cruz, P; Díaz, S; Fernández-Quero, L; Garutti, I, 2002) |
| " In a previous randomized trial we observed that treatment with high-dose acetaminophen (paracetamol) led to a reduction of body temperature in patients with acute ischemic stroke, even when they had no fever." | 5.10 | Effect of paracetamol (acetaminophen) and ibuprofen on body temperature in acute ischemic stroke PISA, a phase II double-blind, randomized, placebo-controlled trial [ISRCTN98608690]. ( Dippel, DW; Kappelle, LJ; Koudstaal, PJ; Meijer, RJ; van Breda, EJ; van der Worp, HB; van Gemert, HM, 2003) |
| "Early administration of acetaminophen (3900 mg/d) to afebrile patients with acute stroke may result in a small reduction in CBT." | 5.10 | Acetaminophen for altering body temperature in acute stroke: a randomized clinical trial. ( Chalela, JA; Grotta, JC; Kasner, SE; Kimmel, SE; Krieger, DW; Morgenstern, LB; Piriyawat, P; Villar-Cordova, CE; Wein, T, 2002) |
| "Rather than supporting the hypothesis that ibuprofen increases asthma morbidity among children who are not known to be sensitive to aspirin or other nonsteroidal antiinflammatory drugs, these data suggest that compared with acetaminophen, ibuprofen may reduce such risks." | 5.10 | Asthma morbidity after the short-term use of ibuprofen in children. ( Lesko, SM; Louik, C; Mitchell, AA; Vezina, RM, 2002) |
| "Acetaminophen was the superior antipyretic drug in endotoxemia compared with aspirin." | 5.09 | Acetaminophen has greater antipyretic efficacy than aspirin in endotoxemia: a randomized, double-blind, placebo-controlled trial. ( Bieglmayer, C; Eichler, HG; Jilma, B; Kapiotis, S; Pernerstorfer, T; Schmid, R, 1999) |
| "To compare the incidence of serious adverse clinical events among children <2 years old given ibuprofen and acetaminophen to control fever." | 5.09 | The safety of acetaminophen and ibuprofen among children younger than two years old. ( Lesko, SM; Mitchell, AA, 1999) |
| "The purpose of this preliminary study was to compare acetaminophen to ketorolac for treating patients with fever in the emergency department (ED)." | 5.09 | Ketorolac versus acetaminophen for treatment of acute fever in the emergency department. ( Ernst, A; Houry, D; Ledbetter, M; Weiss, S, 1999) |
| "The aim of this study was to assess and compare the efficacy and tolerability of paracetamol, ibuprofen and nimesulide in children with upper respiratory tract infections (URTIs)." | 5.09 | Assessment of the efficacy and safety of paracetamol, ibuprofen and nimesulide in children with upper respiratory tract infections. ( Cin, S; Köksal, Y; Ulukol, B, 1999) |
| "Current acetaminophen (APAP) formulations approved for antipyretic use in children require up to five doses/day, which compromise compliance and risk breakthrough fever over 4 hours after dosing." | 5.09 | Acetaminophen controlled-release sprinkles versus acetaminophen immediate-release elixir in febrile children. ( Brown, RD; Donahue, L; Helms, R; Pickering, BD; Wilson, JT, 2000) |
| "The objectives of this prospective non-concurrent cohort study were to confirm the efficacy of vaginal misoprostol for early pregnancy termination and to determine whether the incidence of side effects is lower with prophylactic loperamide and acetaminophen." | 5.09 | Early pregnancy termination with vaginal misoprostol combined with loperamide and acetaminophen prophylaxis. ( Harwood, B; Jain, JK; Meckstroth, KR; Mishell, DR, 2001) |
| "Seventy-five patients with acute ischemic stroke confined to the anterior circulation were randomized to treatment with either 500 mg (low dose) or 1000 mg (high dose) acetaminophen or with placebo, administered as suppositories 6 times daily during 5 days." | 5.09 | Effect of paracetamol (acetaminophen) on body temperature in acute ischemic stroke: a double-blind, randomized phase II clinical trial. ( Dippel, DW; Kappelle, LJ; Koudstaal, PJ; Meijer, RJ; van Breda, EJ; van der Worp, HB; van Gemert, HM, 2001) |
| "An initial 30-mg/kg acetaminophen loading dose seemed to be more effective in reducing fever than a 15-mg/kg maintenance dose." | 5.09 | Antipyretic efficacy of an initial 30-mg/kg loading dose of acetaminophen versus a 15-mg/kg maintenance dose. ( d'Athis, P; Jolivet-Landreau, I; Leclerc, B; Pons, G; Tonnelier, S; Tréluyer, JM, 2001) |
| "This study compared the antipyretic effectiveness of acetaminophen, ibuprofen, and dipyrone in young children with fever." | 5.09 | Antipyretic effects of dipyrone versus ibuprofen versus acetaminophen in children: results of a multinational, randomized, modified double-blind study. ( Barragán, S; Campos, S; De León González, M; Escobar, AM; Ferrero, F; Kesselring, GL; Plager, M; Santolaya, ME; Sibbald, A; Wong, A, 2001) |
| "Infusion-related adverse events (IRAEs) such as nausea, vomiting, fever, chills, and thrombophlebitis that are associated with amphotericin B therapy often lead clinicians to prescribe a number of adjunctive pretreatment medications in an attempt to reduce the incidence and severity of these events." | 5.08 | Pretreatment regimens for adverse events related to infusion of amphotericin B. ( Cleary, JD; Goodwin, SD; Grasela, TH; Taylor, JW; Walawander, CA, 1995) |
| "5 mg/kg per dose), aspirin (10 mg/kg/dose) and paracetamol (10 mg/kg per dose) on children with fever aged 6-24 months in an open, randomised study with three parallel groups." | 5.08 | Evaluation of ibuprofen versus aspirin and paracetamol on efficacy and comfort in children with fever. ( Autret, E; Courcier, S; Goehrs, JM; Henry-Launois, B; Laborde, C; Languillat, G; Launois, R; Reboul-Marty, J, 1997) |
| " Children with a febrile illness were enrolled from outpatient pediatric and family medicine practices and randomly assigned to receive either acetaminophen suspension or one of two dosages of ibuprofen suspension (5 mg/kg or 10 mg/kg) for fever control." | 5.08 | Renal function after short-term ibuprofen use in infants and children. ( Lesko, SM; Mitchell, AA, 1997) |
| "The efficacy and tolerability of nimesulide were compared with those of paracetamol in a nonblind randomised study that recruited 110 children (64 males, 46 females; aged 3 to 6 years) with inflammation of the upper respiratory tract and fever." | 5.07 | A comparison of nimesulide and paracetamol in the treatment of fever due to inflammatory diseases of the upper respiratory tract in children. ( Comito, A; Pieragostini, P; Polidori, G; Scaricabarozzi, I; Titti, G, 1993) |
| "This study defines what degree of respiratory rate (RR) elevation can be attributed to fever using a double blind randomized pre- and post-acetaminophen comparison of vital signs of febrile children presenting to an outpatient clinic." | 5.07 | Correcting respiratory rate for the presence of fever. ( Gadomski, AM; Permutt, T; Stanton, B, 1994) |
| "The objective of this study was to determine whether paracetamol (acetaminophen) affects the outcome of children with fever due to bacterial infectious disease." | 5.07 | Risks of antipyretics in young children with fever due to infectious disease. ( Asakuno, Y; Fujimoto, T; Hayakawa, H; Korematu, S; Maruoka, T; Motoyama, H; Sugimura, T, 1994) |
| "The authors studied the antipyretic effect of three intramuscular doses of ketorolac (15, 30, and 60 mg), acetaminophen 650 mg PO, and placebo in healthy male volunteers using an endotoxin-induced fever model." | 5.07 | Evaluation of the antipyretic effect of ketorolac, acetaminophen, and placebo in endotoxin-induced fever. ( Bynum, L; Maneatis, T; McMahon, FG; Peterson, C; Vargas, R, 1994) |
| " All patients had evaluations performed for fever reduction, use of acetaminophen for temperature > or = 38." | 5.07 | Efficacy and safety of aerosolized ribavirin in young children hospitalized with influenza: a double-blind, multicenter, placebo-controlled trial. ( Arrobio, J; Groothuis, JR; Hall, CB; Johnson, G; Rodriguez, WJ; Ryan, ME; Simoes, EA; Stutman, H; Van Dyke, R; Welliver, R, 1994) |
| "kg-1 acetaminophen syrup (n = 77) in 154 children (6 months to 5 years) with fever (> or = 38 degrees C) associated with infectious diseases and treated with antibiotic therapy." | 5.07 | Comparative efficacy and tolerance of ibuprofen syrup and acetaminophen syrup in children with pyrexia associated with infectious diseases and treated with antibiotics. ( Autret, E; Breart, G; Courcier, S; Goehrs, JM; Jonville, AP; Lassale, C, 1994) |
| "5-, 5-, or 10-mg/kg ibuprofen therapy via a liquid or 15-mg/kg acetaminophen therapy via an elixir every 6 hours for 24 to 48 hours show equivalent fever reduction or suffer adverse effects of the drug administered." | 5.07 | Comparison of multidose ibuprofen and acetaminophen therapy in febrile children. ( Braden, NJ; Chomilo, F; Galletta, G; Sawyer, LA; Scheinbaum, ML; Walson, PD, 1992) |
| "A double-blind, parallel-group, triple-dummy-designed, single-oral-dose study compared the efficacy, tolerability, safety, and dose-response of 5 mg/kg (n = 32) and 10 mg/kg (n = 28) ibuprofen suspension, 10 mg/kg acetaminophen elixir (n = 33), and placebo liquids (n = 34) in 127 children (2 to 11 years of age) with fever (101 degrees to 104 degrees F)." | 5.06 | Ibuprofen, acetaminophen, and placebo treatment of febrile children. ( Alexander, L; Braden, NJ; Galletta, G; Walson, PD, 1989) |
| "The effectiveness of acetaminophen in preventing post-vaccination fever was studied in a double-blind randomized manner." | 5.06 | Effect of prophylactic acetaminophen administration on reaction to DTP vaccination. ( Hietala, J; Uhari, M; Viljanen, MK, 1988) |
| "The effect of acetaminophen on fever in bacterial vs." | 5.06 | Fever response to acetaminophen in viral vs. bacterial infections. ( Brien, JH; Miller, G; Weisse, ME, 1987) |
| "Acetaminophen (paracetamol) and ibuprofen are the most widely prescribed and available over-the-counter medications for management of fever and pain in children." | 5.05 | Comparison of Acetaminophen (Paracetamol) With Ibuprofen for Treatment of Fever or Pain in Children Younger Than 2 Years: A Systematic Review and Meta-analysis. ( Braithwaite, I; Dalziel, SR; McKinlay, CJD; Tan, E, 2020) |
| "Acetaminophen serum concentrations were studied in 21 infants and children with fever." | 5.05 | Acetaminophen accumulation in pediatric patients after repeated therapeutic doses. ( Durrell, DE; Miller, MA; Nahata, MC; Powell, DA, 1984) |
| "The present randomized single-blind trial was performed to study antipyretic effect and tolerability of alpha-methyl-4-(2-thienylcarbonyl)-phenyl acetic acid (suprofen, Suprol) suppositories versus paracetamol (acetaminophen) suppositories in pediatric patients with fever of various etiology." | 5.05 | Clinical experience and results of treatment with suprofen in pediatrics. 2nd communication: Use of suprofen suppositories as an antipyretic in children with fever due to acute infections/A single-blind controlled study of suprofen versus paracetamol. ( Michos, N; Stocker, H; Sundal, EJ; Weippl, G, 1985) |
| "- Paracetamol or ibuprofen should only be given when there is a combination of fever and pain." | 4.95 | [Revision of the Dutch College of General Practitioners practice guideline 'Children with fever']. ( Eizenga, WE; Opstelten, W, 2017) |
| " Paracetamol and ibuprofen are the most commonly used interventions to manage fever in children; however, there have been no comparative analyses." | 4.95 | Effectiveness of paracetamol versus ibuprofen administration in febrile children: A systematic literature review. ( Cooper, S; Innes, K; Morphet, J; Narayan, K, 2017) |
| " The aim of this review is to determine if there are any clinically relevant differences in safety between ibuprofen and paracetamol that may recommend one agent over the other in the management of fever and discomfort in children older than 3 months of age." | 4.95 | A clinical and safety review of paracetamol and ibuprofen in children. ( Kanabar, DJ, 2017) |
| "Our primary objective was to assess the effectiveness of paracetamol (acetaminophen) or NSAIDs, alone or combined, compared with placebo or no treatment in relieving pain in children with AOM." | 4.93 | Paracetamol (acetaminophen) or non-steroidal anti-inflammatory drugs, alone or combined, for pain relief in acute otitis media in children. ( Damoiseaux, RA; Hay, AD; Little, P; Schilder, AG; Sjoukes, A; van de Pol, AC; Venekamp, RP, 2016) |
| "Paracetamol (acetaminophen) is one of the most popular and widely used drugs for the treatment of pain and fever in children." | 4.90 | Paracetamol: a focus for the general pediatrician. ( Barbi, E; Guarino, S; Marzuillo, P, 2014) |
| "Health professionals frequently recommend fever treatment regimens for children that either combine paracetamol and ibuprofen or alternate them." | 4.90 | Combined and alternating paracetamol and ibuprofen therapy for febrile children. ( Ganshorn, H; Hartling, L; Johnson, DW; Maconochie, IK; Stang, AS; Thomsen, AM; Wong, T, 2014) |
| "Combination treatment with ibuprofen and acetaminophen is beneficial over either agent alone for sustained fever reduction in children older than 6 months." | 4.89 | Does combination treatment with ibuprofen and acetaminophen improve fever control? ( Malya, RR, 2013) |
| "Health professionals frequently recommend fever treatment regimens for children that either combine paracetamol and ibuprofen or alternate them." | 4.89 | Combined and alternating paracetamol and ibuprofen therapy for febrile children. ( Ganshorn, H; Hartling, L; Johnson, DW; Maconochie, IK; Stang, AS; Thomsen, AM; Wong, T, 2013) |
| " In paediatric populations, ibuprofen and paracetamol (acetaminophen) are both commonly used over-the-counter medicines for the management of fever or mild-to-moderate pain associated with sore throat, otitis media, toothache, earache and headache." | 4.89 | Optimising the management of fever and pain in children. ( van den Anker, JN, 2013) |
| "To analyse major sources of evidence-based information on the efficacy and gastrointestinal tolerability of aspirin, used short-term, in over-the-counter (OTC) doses, to relieve acute pain and cold symptoms, including associated feverishness." | 4.88 | Efficacy and gastrointestinal risk of aspirin used for the treatment of pain and cold. ( McCarthy, DM, 2012) |
| "To evaluate the evidence surrounding the use of combinations of paracetamol and ibuprofen in the treatment of fever." | 4.87 | Systematic review of studies comparing combined treatment with paracetamol and ibuprofen, with either drug alone. ( Purssell, E, 2011) |
| "Acetylsalicylic acid (ASA [aspirin]) is a commonly used over-the-counter drug for the treatment of pain, fever, or colds, but data on the safety of this use are very limited." | 4.87 | Short-term acetylsalicylic acid (aspirin) use for pain, fever, or colds - gastrointestinal adverse effects: a meta-analysis of randomized clinical trials. ( Baron, JA; Brueckner, A; Lanas, A; McCarthy, D; Senn, S; Voelker, M, 2011) |
| "Ibuprofen is as or more efficacious than acetaminophen for the treatment of pain and fever in adult and pediatric populations and is equally safe." | 4.86 | Efficacy and safety of ibuprofen and acetaminophen in children and adults: a meta-analysis and qualitative review. ( Pierce, CA; Voss, B, 2010) |
| "Paracetamol and ibuprofen are safe and effective medications for reducing a fever in children and young people and they are often administered together with a view to reducing a temperature quickly." | 4.86 | Fever management: evaluating the use of ibuprofen and paracetamol. ( Crook, J, 2010) |
| "Intravenous paracetamol (rINN)/intravenous acetaminophen (USAN) is an analgesic and antipyretic agent, recommended worldwide as a first-line agent for the treatment of pain and fever in adults and children." | 4.85 | Intravenous paracetamol (acetaminophen). ( Duggan, ST; Scott, LJ, 2009) |
| "Schultz et al (2008) raised the question whether regression into autism is triggered, not by the measles-mumps-rubella (MMR) vaccine, but by acetaminophen (Tylenol) given for its fever and pain." | 4.85 | Did acetaminophen provoke the autism epidemic? ( Good, P, 2009) |
| "To determine, on the basis of published studies, the efficacy of rectal vs oral acetaminophen as treatment of fever and pain." | 4.84 | Effectiveness of oral vs rectal acetaminophen: a meta-analysis. ( Berkovitch, M; Berlin, M; Goldstein, LH; Kozer, E, 2008) |
| "To characterize clozapine-induced fever and suggest clinically relevant management recommendations." | 4.84 | Characterization and clinical management of clozapine-induced fever. ( Grube, RR; Lowe, CM; Scates, AC, 2007) |
| "Although many studies have investigated the safety and tolerability of ibuprofen or acetaminophen (paracetamol) use in children, few have specifically examined the association of ibuprofen or acetaminophen and the occurrence of asthma in pediatric populations." | 4.84 | A review of ibuprofen and acetaminophen use in febrile children and the occurrence of asthma-related symptoms. ( Dale, S; Kanabar, D; Rawat, M, 2007) |
| "This paper describes two studies in children with fever in which the safety of ibuprofen was compared with that of paracetamol." | 4.82 | The safety of ibuprofen suspension in children. ( Lesko, SM, 2003) |
| "Antipyretics, including acetaminophen (paracetamol), are prescribed commonly in children with pyrexia, despite minimal evidence of a clinical benefit." | 4.82 | Evidence on the use of paracetamol in febrile children. ( Curtis, N; Mulholland, K; Russell, FM; Shann, F, 2003) |
| "Ibuprofen was significantly more effective than acetaminophen in reducing fever after a single dose." | 4.82 | Antipyretic efficacy and safety of ibuprofen and acetaminophen in children. ( Goldman, RD; Ko, K; Linett, LJ; Scolnik, D, 2004) |
| "To summarize studies testing the efficacy and safety of single-dose acetaminophen and ibuprofen for treating children's pain or fever." | 4.82 | Efficacy and safety of acetaminophen vs ibuprofen for treating children's pain or fever: a meta-analysis. ( Champion, GD; Goodenough, B; Perrott, DA; Piira, T, 2004) |
| "Paracetamol (acetaminophen) is widely used for treating fever in children." | 4.81 | Paracetamol for treating fever in children. ( Meremikwu, M; Oyo-Ita, A, 2002) |
| "Paracetamol (acetaminophen) has a unique role in children because it is the first-line choice for the treatment of both fever and pain." | 4.80 | Paracetamol efficacy and safety in children: the first 40 years. ( Coghlan, D; Cranswick, N, 2000) |
| "Paracetamol (acetaminophen) is one of the most widely used of all drugs, with a wealth of experience clearly establishing it as the standard antipyretic and analgesic for mild to moderate pain states." | 4.80 | Paracetamol: past, present, and future. ( Prescott, LF, 2000) |
| "Paracetamol (acetaminophen) is recommended as a first-line drug in the management of pain and pyrexia in humans due to its minor gastrointestinal, renal and vascular side effects." | 4.31 | Current perceptions and use of paracetamol in dogs among veterinary surgeons working in the United Kingdom. ( Bello, AM; Dye, C, 2023) |
| "Paracetamol 1,000 mg represents the first choice for the treatment of fever in the ED, followed by Paracetamol/Ibuprofen 500/150 mg." | 4.31 | Treatment of fever and associated symptoms in the emergency department: which drug to choose? ( Candelli, M; Carnicelli, A; Covino, M; Franceschi, F; Lorusso, C; Novelli, A; Ojetti, V; Saviano, A, 2023) |
| "The use of intravenous (IV) acetaminophen (APAP) for fever has not been thoroughly studied in neurocritical care (NCC) patients, in whom a temperature of ≥38°C is associated with poor outcomes and treatment to normothermia is common practice." | 4.12 | Intravenous Versus Oral Acetaminophen Use in Febrile Neurocritical Care Patients. ( Brophy, GM; D'Eramo, RE; Nadpara, PA; Sandler, M; Taylor, PD, 2022) |
| "Intravenous propacetamol is commonly used to control fever and pain in neurocritically ill patients in whom oral administration is often difficult." | 4.12 | Risk Factors for Intravenous Propacetamol-Induced Blood Pressure Drop in the Neurointensive Care Unit: A Retrospective Observational Study. ( Han, MK; Jeon, S; Jeong, HG; Lee, E; Lee, J; Lee, JY; Song, YJ, 2022) |
| "This study was undertaken to evaluate the efficacy, safety, and economic impact of diazepam suppositories with as-needed acetaminophen in comparison with as-needed acetaminophen alone for prevention of seizure recurrence during the same fever episode in suspected pediatric simple febrile seizures (SFS)." | 4.12 | Efficacy, safety, and economic impact of diazepam suppositories with as-needed acetaminophen for prevention of seizure recurrence during the same fever episode in children with suspected simple febrile seizures. ( Fujita, S; Hataya, H; Kishibe, S; Miyama, S; Morikawa, EK; Morikawa, Y; Narita, K; Sammori, H; Suzuki, S; Takehira, K; Tanaka, M; Tsukamoto, J; Wang, Q; Yano, M, 2022) |
| "We describe a case of a 5-year-old female with stage III Wilms tumor who had recurrent VCR-associated fever that was controlled with prophylactic dexamethasone and acetaminophen." | 4.12 | Recurrent vincristine-associated fever in a child with Wilms tumor. ( Al-Antary, ET; Ramiz, S, 2022) |
| " One hundred and seventy-nine (44%) patients had fever, with 32% using paracetamol and 22% using ibuprofen, for symptom-relief." | 3.96 | Ibuprofen use and clinical outcomes in COVID-19 patients. ( Bar-Haim, A; Kozer, E; Rinott, E; Shapira, Y; Youngster, I, 2020) |
| "Paracetamol (acetaminophen) is widely used for management of mild-to-moderate pain and reduction of fever." | 3.91 | Efficacy and safety of modified-release paracetamol for acute and chronic pain: a systematic review protocol. ( Dosenovic, S; Margan Koletic, Z; Puljak, L, 2019) |
| "We retrospectively reviewed the medical records of the patients with laboratory-confirmed influenza A who received intravenous propacetamol for the control of fever in the ED during the 2015-16 influenza season." | 3.88 | Hemodynamic changes in patients with influenza A after propacetamol infusion in the emergency department. ( Durey, A; Han, SB; Kim, AJ; Lee, HJ; Suh, YJ, 2018) |
| "Clinical studies have indicated that transient hypotension can occur after propacetamol administration." | 3.88 | Hemodynamic changes after propacetamol administration in patients with febrile UTI in the ED. ( Durey, A; Kang, S; Kim, AJ; Suh, YJ, 2018) |
| "All children who received acetaminophen or had a fever (temperature ≥ 38°C) while on the ICU over a 40-month period (September 2012 to December 2015)." | 3.88 | The Effect of Acetaminophen on Temperature in Critically Ill Children: A Retrospective Analysis of Over 50,000 Doses. ( Brown, KL; Peters, MJ; Ray, S; Rogers, L, 2018) |
| " In 1980 s, the relevance of aspirin for Reye's syndrome became a problem, then acetaminophen came into use for various kinds of cases such as children, pregnant women and the elderly for pain management or alleviation of fever." | 3.83 | [Side Effects of Acetaminophen and their Management]. ( Saeki, S, 2016) |
| "Our study shows that preventive action should be taken regarding the use of acetaminophen as antipyretic drug in children in order to reduce the fever phobia and self-prescription, especially of caregivers with higher educational levels." | 3.83 | Acetaminophen administration in pediatric age: an observational prospective cross-sectional study. ( Bonci, M; Cecchetti, C; Di Ruzza, L; Falsaperla, R; Gentile, I; Lubrano, R; Matin, N; Paoli, S; Pavone, P; Vitaliti, G, 2016) |
| "The pharmacological specificities of the rectal formulation of acetaminophen led to a debate on its appropriateness for managing fever in children, but few data are available on the formulation's current use and determinants of use." | 3.83 | Enduring large use of acetaminophen suppositories for fever management in children: a national survey of French parents and healthcare professionals' practices. ( Bertille, N; Chalumeau, M; Fournier-Charrière, E; Khoshnood, B; Pons, G, 2016) |
| "Acetaminophen is a commonly used medication to manage fever and pain in children and the drug is generally considered to be safe when used at appropriate therapeutic dosages." | 3.81 | Severe intrinsic acute kidney injury associated with therapeutic doses of acetaminophen. ( Aizawa, T; Hirono, K; Ito, E; Ito, T; Joh, K; Tanaka, H; Tsuruga, K; Watanabe, S, 2015) |
| "The primary objective was to assess whether patients with a fever are treated with acetaminophen or ibuprofen more promptly than they are treated for pain." | 3.80 | Is fever treated more promptly than pain in the pediatric emergency department? ( Bair, J; Dvorkin, R; Glantz, S; Marguilies, J; Patel, H; Rosalia, A; Yens, DP, 2014) |
| "Treatment of pediatric fever is based on two main molecules, paracetamol and ibuprofen." | 3.80 | [How to treat pediatric fever in 2013 with little evidence-based?]. ( Gehri, M; Pauchard, JY, 2014) |
| "High anion gap metabolic acidosis due to pyroglutamic acid (5-oxoproline) is a rare complication of acetaminophen treatment (which depletes glutathione stores) and is often associated with clinically moderate to severe encephalopathy." | 3.80 | Pyroglutamic acid-induced metabolic acidosis: a case report. ( Dive, A; Galanti, L; Luyasu, S; Wamelink, MM, 2014) |
| "Health-care professionals frequently recommend fever treatment regimens for children who either combine paracetamol and ibuprofen or alternate them." | 3.80 | Cochrane in context: Combined and alternating paracetamol and ibuprofen therapy for febrile children. ( Ganshorn, H; Hartling, L; Johnson, DW; Maconochie, IK; Stang, AS; Thomsen, AM; Wong, T, 2014) |
| "Acetaminophen is one of the world's most commonly used drugs to treat fever and pain, yet its mechanism of action has remained unclear." | 3.79 | Acetaminophen reduces lipopolysaccharide-induced fever by inhibiting cyclooxygenase-2. ( Blomqvist, A; Elander, L; Engblom, D; Engström Ruud, L; Eskilsson, A; Vasilache, AM; Wilhelms, DB, 2013) |
| " Nevertheless, the anti-inflammatory activity was tested in carrageenan induced paw edema and histamine induced inflammatory tests." | 3.78 | Antipyretic, analgesic and anti-inflammatory activity of Viola betonicifolia whole plant. ( Khan, H; Muhammad, N; Saeed, M, 2012) |
| "Children who have unresolved pain despite the use of either ibuprofen or acetaminophen should have their medication regimen reviewed to ensure they are receiving the medication at an adequate dose and interval." | 3.78 | Alternating acetaminophen and ibuprofen for pain in children. ( Goldman, RD; Smith, C, 2012) |
| "This study aims to explore the knowledge of a randomly selected cohort of Iranian general practitioners (GPs) on the topic of acetaminophen dosing for fever in children." | 3.78 | Knowledge of Iranian general practitioners for acetaminophen dosing in children. ( Bagheri, M; Mirmoghtadaee, P; Sabzghabaee, AM; Soltani, R, 2012) |
| "We performed a retrospective study of medical intensive care unit and surgical intensive care unit patients with systemic inflammatory response syndrome and compared the resolution of fever in the presence and absence of acetaminophen treatment by comparing the absolute reduction in body temperature and the rate of cooling over comparable time frames in fevers that were untreated and those treated with acetaminophen." | 3.76 | Acetaminophen has limited antipyretic activity in critically ill patients. ( Chen, H; Greenberg, RS; Hasday, JD, 2010) |
| "Acetaminophen use in children has been associated with increased autism risk." | 3.76 | Can autism be triggered by acetaminophen activation of the endocannabinoid system? ( Schultz, ST, 2010) |
| "001) dose-dependent analgesic effect in the tail flick, hot plate, and tail clip (central) as well as in acetic acid-induced writhing (peripheral) nociceptive tests in mice, suggesting the involvement of both central and peripheral mechanisms in alleviating the pain response." | 3.76 | Analgesic and antipyretic activities of ethanol extract of Stereospermum suaveolens. ( Kumar, CT; Mpharm, TB, 2010) |
| "To investigate the effect of intravenous propacetamol, a parenteral bioprecursor of acetaminophen, on systemic blood pressure in critically ill patients with fever, and to establish the prevalence and clinical significance of this effect." | 3.74 | Effect of intravenous propacetamol on blood pressure in febrile critically ill patients. ( Hersch, M; Izbicki, G; Raveh, D, 2008) |
| "The inclusion criteria were age between 3 and 36 months, main complaint of fever and at least one dose of dipyrone or acetaminophen given to the child during the 24 hours preceding their arrival at the emergency department." | 3.74 | Dipyrone and acetaminophen: correct dosing by parents? ( Almeida, CD; Almeida, ND; Alves, JG; Cardoso Neto, FJ, 2007) |
| "To report Australian parents' medication (paracetamol, ibuprofen and homeopathic) use in childhood fever management." | 3.74 | Over-the-counter medication use for childhood fever: a cross-sectional study of Australian parents. ( Edwards, H; Fraser, J; Walsh, A, 2007) |
| " Two days prior to the incident, the twins had received the second dose of oral polio, DPT and the first dose of hepatitis B vaccines and they had fever on the first day of the vaccination and been given teaspoonful of acetaminophen." | 3.74 | Simultaneous sudden infant death syndrome. ( Balci, Y; Kocaturk, BK; Tok, M; Yenilmez, C; Yirulmaz, C, 2007) |
| "Acetaminophen is an effective mild analgesic and antipyretic agent." | 3.74 | Acetaminophen. ( Ameer, B; Greenblatt, DJ, 1977) |
| " However, due to its side effects, ibuprofen should be used only in high and badly tolerated fever that is not altered by a well conducted acetaminophen monotherapy." | 3.73 | [Familial use of ibuprofen in febrile children: a prospective study in the emergency room of an hospital in Lille]. ( Charkaluk, ML; El Kohen, R; Kalach, N; Kremp, O, 2005) |
| "Paracetamol (Acetaminophen) In Stroke (PAIS) is a randomized, double-blind clinical trial, comparing high-dose acetaminophen with placebo in 2500 patients." | 3.73 | PAIS: paracetamol (acetaminophen) in stroke; protocol for a randomized, double blind clinical trial [ISCRTN 74418480]. ( Algra, A; Dippel, DW; Kappelle, LJ; Koudstaal, PJ; van Breda, EJ; van der Worp, HB; van Gemert, HM; van Gijn, J, 2005) |
| "Children frequently suffer infections accompanied by fever, which is commonly treated with acetaminophen (paracetamol), a use not devoid of risk." | 3.73 | The effects of a complex homeopathic medicine compared with acetaminophen in the symptomatic treatment of acute febrile infections in children: an observational study. ( Derasse, M; Klein, P; Weiser, M, 2005) |
| "The results of this survey concerning antipyretic treatment of children by their Jewish and Bedouin Moslem caregivers suggest that lighter body weight and the use of acetaminophen rectal suppositories were associated with the administration of higher-than-recommended doses of acetaminophen." | 3.73 | Determinants of antipyretic misuse in children up to 5 years of age: a cross-sectional study. ( Bilenko, N; Gorodischer, R; Okbe, R; Press, J; Tessler, H, 2006) |
| "We have previously shown that both chloroquine and paracetamol (acetaminophen) have antipyretic activity during treatment of acute uncomplicated Plasmodium falciparum malaria in children 1-4 years old." | 3.73 | Relationship between antipyretic effects and cytokine levels in uncomplicated falciparum malaria during different treatment regimes. ( Björkman, A; Hugosson, E; Montgomery, SM; Premji, Z; Troye-Blomberg, M, 2006) |
| "The present study was designed to determine whether the inhibition of glutamate release in organum vasculosum laminae terminalis (OVLT) of rabbit brain by acetaminophen might be protective in a whole-animal model of staphylococcal enterotoxin A (SEA) fever." | 3.72 | Antipyretic effect of acetaminophen by inhibition of glutamate release after staphylococcal enterotoxin A fever in rabbits. ( Huang, WT; Lin, MT; Wang, JJ, 2004) |
| "A cross-sectional study including 248 caregivers of children who had a chief complaint of fever and had been given acetaminophen in the preceding 24 hours were interviewed." | 3.72 | Underdosing of acetaminophen by parents and emergency department utilization. ( Goldman, RD; Scolnik, D, 2004) |
| " Nonetheless, these data suggest that parents use ibuprofen or ibuprofen together with acetaminophen to treat high fever and severe illness, which seems to identify children at high risk for invasive GAS infection." | 3.71 | Invasive group A streptococcal infection and nonsteroidal antiinflammatory drug use among children with primary varicella. ( Lesko, SM; Mitchell, AA; O'Brien, KL; Schwartz, B; Vezina, R, 2001) |
| " Predictive factors of this practice among pediatricians are male sex, having relatively little experience, considering ibuprofen as the drug of choice and recommending the administration of new doses of antipyretic to control mild fever." | 3.71 | [Use of alternating antipyretics in the treatment of fever in Spain]. ( Ballester Sanz, A; Burgos Ramírez, A; Díez Domingo, J; Garrido García, J; Moreno Carretero, E, 2001) |
| "Seventy-five (3 x 25) patients with acute ischaemic stroke confined to the anterior circulation will be randomised to treatment with either: 400 mg ibuprofen, 1000 mg acetaminophen, or with placebo 6 times daily during 5 days." | 3.71 | PISA. The effect of paracetamol (acetaminophen) and ibuprofen on body temperature in acute stroke: protocol for a phase II double-blind randomised placebo-controlled trial [ISRCTN98608690]. ( Dippel, DW; Kappelle, J; Koudstaal, PJ; Meijer, R; van Breda, EJ; van der Worp, B; van Gemert, M, 2002) |
| " Fever always occurred before their admission and aspirin (n = 12) or acetaminophen (n = 7) was prescribed." | 3.71 | [Severe Reye syndrome: report of 14 cases managed in a pediatric intensive care unit over 11 years]. ( Brivet, M; Chevret, L; Debray, D; Devictor, D; Durand, P; Fabre, M; Thabet, F, 2002) |
| "A cohort of 484 febrile children were examined to (1) assess the utility of temperature response to acetaminophen as a diagnostic test for occult bacteremia (OB) and (2) compare it with the white blood cell (WBC) count." | 3.69 | Diagnostic tests for occult bacteremia: temperature response to acetaminophen versus WBC count. ( Kozinetz, CA; Mazur, LJ, 1994) |
| "We have investigated the effect of malaria infection with the rodent parasite Plasmodium berghei and fever induced by Escherichia coli endotoxin on the metabolism of phenacetin to paracetamol by rat liver microsomes from young (4 weeks old) male Wistar rats (N = 5 in control and fever groups; N = 10 in malaria-infected group)." | 3.68 | Effect of malaria infection and endotoxin-induced fever on phenacetin O-deethylation by rat liver microsomes. ( Breckenridge, AM; Edwards, G; Glazier, AP; Kokwaro, GO; Ward, SA, 1993) |
| "Orders for acetaminophen prn (as needed), without further explanation, were interpreted by the nursing staff as antipyretic orders; 78% of patients with such an order and fever received acetaminophen during the febrile episode." | 3.68 | Antipyretic orders in a university hospital. ( Axelrod, PI; Isaacs, SN; Lorber, B, 1990) |
| "Centrally administered alpha-melanocyte stimulating hormone is much more potent in reducing fever than the widely used antipyretic acetaminophen." | 3.66 | Antipyretic potency of centrally administered alpha-melanocyte stimulating hormone. ( Lipton, JM; Murphy, MT; Richards, DB, 1983) |
| "An animal model used yeast-fevered rats to measure the relative antipyretic effects of different commercially available acetaminophen-containing suppositories." | 3.66 | Antipyretic effect of acetaminophen suppositories in rats. ( Ayres, J; Eckman, BM; Lock, A, 1979) |
| "The capacity of N-(2,3-xylyl)anthranilic acid (mefenamic acid) to reduce fever in children was compared with that of acetylsalicylic acid, paracetamol and amino-phenazone." | 3.65 | Oral antipyretic therapy. Evaluation of mefenamic acid (short communication). ( Keinänen, S; Kouvalainen, K; Similä, S, 1977) |
| "The capacity of ibuprofen to reduce fever in children was compared with that of aspirin, paracetamol, aminophenazone and indomethacin." | 3.65 | Oral antipyretic therapy. ( Keinänen, S; Kouvalainen, K; Similä, S, 1976) |
| "Fever is the most common reason for children's visits to medical centers." | 3.11 | Comparing the effect of body wash with marshmallow plant and lukewarm water on reducing the temperature of febrile children: a randomized clinical trial. ( Delfan, B; Ebrahimzade, F; Ghasemi, F; Goodarzi, H; Seifosadat, SH; Taee, N; Valizadeh, F, 2022) |
| " Globally, the pharmacologic treatment of pain in pediatric patients is limited largely to nonopioid analgesics, and dosing must account for differences in age, weight, metabolism, and risk of adverse effects." | 3.01 | Common Selfcare Indications of Pain Medications in Children. ( Bell, J; Kachroo, P; Mossali, VM; Siddiqui, K; Zempsky, W, 2023) |
| "Fever is the most common reason for the presentation of children in the outpatient department." | 3.01 | Randomised comparative trial of the efficacy of paracetamol syrup and dispersible tablets for the treatment of fever in children. ( Bisi-Onyemaechi, A; Ibeleme, O; Okereke, B, 2021) |
| "Dengue is a common cause of acute liver failure in tropical countries." | 2.90 | Effect of standard dose paracetamol versus placebo as antipyretic therapy on liver injury in adult dengue infection: a multicentre randomised controlled trial. ( Changpradub, D; Chuerboonchai, W; Jitsiri, S; Lertliewtrakool, N; Niyasom, S; Rojdumrongrattana, T; Siriwiwattana, T; Thongtaeparak, W; Vasikasin, V, 2019) |
| "A clinical pharmacokinetic study in adult patients with TBI was performed as a sub-study to a prospective, phase 2B, randomized placebo-controlled study (PARITY)." | 2.87 | Population pharmacokinetics of intravenous paracetamol in critically ill patients with traumatic brain injury. ( Gowardman, J; Lipman, J; Myburgh, J; Parker, SL; Roberts, JA; Saxena, M, 2018) |
| "Low grade fever is a known adverse effect of vaccination." | 2.84 | Effect of prophylactic or therapeutic administration of paracetamol on immune response to DTwP-HepB-Hib combination vaccine in Indian infants. ( Bavdekar, SB; Chhatwal, J; D'Cor, NA; Dhaded, SM; Dhingra, MS; Dubey, AP; Dupuy, M; Gandhi, DJ; Gupta, M; Jayanth, MV; Kundu, R; Lalwani, SK; Mangarule, SA; Mathew, LG; Patnaik, BN; Ravi, MD; Ravinuthala, S; Reddy E, J; Rout, SP; Sharma, SD; Sil, A, 2017) |
| "To assess the safety and feasibility of treating critically ill adults with different fever control strategies." | 2.78 | Assessment of the safety and feasibility of administering antipyretic therapy in critically ill adults: a pilot randomized clinical trial. ( Kubes, P; Laupland, KB; Léger, C; Niven, DJ; Stelfox, HT, 2013) |
| "Pain, swelling, infection, trismus and temperature were recorded on days 3, 7 and 14 after surgery." | 2.75 | Antibiotic prophylaxis in third molar surgery: A randomized double-blind placebo-controlled clinical trial using split-mouth technique. ( Morkel, JA; Siddiqi, A; Zafar, S, 2010) |
| "Fever is a common symptom in children and one of the major concerns of parents of younger and preschool-age children." | 2.75 | Ketoprofen versus paracetamol (acetaminophen) or ibuprofen in the management of fever: results of two randomized, double-blind, double-dummy, parallel-group, repeated-dose, multicentre, phase III studies in children. ( Kokki, H; Kokki, M, 2010) |
| "Fever was measured with the aid of a tympanic thermometer (Braun Kronberg 6014) and followed for 4-6 hours." | 2.74 | Antipyretic effect of ketoprofen. ( Akgoz, S; Arisoy, ES; Aygun, D; Celebi, S; Citak Kurt, AN; Hacimustafaoglu, M; Karali, Y; Seringec, M, 2009) |
| "Although fever is part of the normal inflammatory process after immunisation, prophylactic antipyretic drugs are sometimes recommended to allay concerns of high fever and febrile convulsion." | 2.74 | Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials. ( Borys, D; Chlibek, R; Kaliskova, E; Lommel, P; Prymula, R; Schuerman, L; Siegrist, CA; Smetana, J; Vackova, M; Zemlickova, H, 2009) |
| " Our hypothesis was that common liver tests would be unaffected by administration of the maximum recommended daily dosage of acetaminophen for 3 consecutive days to newly-abstinent alcoholic subjects." | 2.73 | The effect of acetaminophen (four grams a day for three consecutive days) on hepatic tests in alcoholic patients--a multicenter randomized study. ( Bogdan, GM; Dart, RC; Green, JL; Heard, K; Knox, PC; Kuffner, EK; Palmer, RB; Slattery, JT, 2007) |
| "At physician-directed dosing (acetaminophen 15 mg/kg vs ibuprofen 10 mg/kg), no significant differences in antipyretic effects from 0‒6 h and between 0‒6, ‒12, ‒24, or ‒48 h, with single or multiple-doses, respectively, were observed." | 2.72 | Acetaminophen and ibuprofen in the treatment of pediatric fever: a narrative review. ( Paul, IM; Walson, PD, 2021) |
| " tables of normal and abnormal ranges of temperature, recommended temperature measurement techniques, dosage regimen of antipyretic drugs, guidelines to parents), justifying the implementation of a pharmaceutical follow-up." | 2.71 | When fever, paracetamol? Theory and practice in a paediatric outpatient clinic. ( Cotting, JQ; Di Paolo, ER; Djahnine, SR; Gehri, M; Guignard, E; Krahenbuhl, JD; Pannatier, A; Yersin, C, 2005) |
| "Aggressively treating fever in critically ill patients may lead to a higher mortality rate." | 2.71 | The effect of antipyretic therapy upon outcomes in critically ill patients: a randomized, prospective study. ( Alhaddad, A; Amortegui, J; Baracco, G; Cohn, SM; Dlugasch, L; Doherty, J; Dy, CJ; Elhaddad, A; Lasko, D; Li, P; Manning, RJ; Namias, N; Schulman, CI, 2005) |
| "Epidural fever is associated with maternal and fetal inflammation in the absence of neonatal infection." | 2.70 | Elevated maternal and fetal serum interleukin-6 levels are associated with epidural fever. ( Evans, T; Goetzl, L; Lieberman, E; Rivers, J; Suresh, MS, 2002) |
| "Although it is necessary to treat the cause of fever, if possible, symptomatic fever management is also important." | 2.70 | Symptomatic intravenous antipyretic therapy: efficacy of metamizol, diclofenac, and propacetamol. ( Korístek, Z; Mayer, J; Oborilová, A; Pospísil, Z, 2002) |
| "Severe infarcts and intracerebral hemorrhages caused temperature to rise, whereas initially increased temperature had no influence on stroke severity." | 2.70 | Stroke severity determines body temperature in acute stroke. ( Boysen, G; Christensen, H, 2001) |
| "Although fever is a host defense response that may benefit some critically ill patients, others may not tolerate the cardiovascular demands associated with fever." | 2.70 | Comparison of fever treatments in the critically ill: a pilot study. ( Henker, R; Kelso, L; Kerr, M; Kramer, DJ; Rogers, S; Sereika, S, 2001) |
| "Chronic hepatitis C was a frequent complication in patients treated for malignancy until the introduction of anti-HCV screening tests for blood donors." | 2.69 | Interferon treatment of chronic hepatitis C in patients cured of pediatric malignancies. ( Bortolotti, F; Brugiolo, A; Cesaro, S; Cusinato, R; Guido, M; Masiero, L; Petris, MG; Rossetti, F; Zanesco, L, 2000) |
| "falciparum malaria were treated with intravenous quinine and received either mechanical antipyresis alone (electric fanning, tepid sponging, and cool blankets) or in combination with paracetamol." | 2.68 | Effect of paracetamol on parasite clearance time in Plasmodium falciparum malaria. ( Brandts, CH; Graninger, W; Kremsner, PG; Ndjavé, M, 1997) |
| " The statistical analysis of the results confirmed that ibuprofen and paracetamol are equivalent with respect to the following criteria (1) time elapsed between dosing and the lowest temperature: 3." | 2.68 | Equivalent antipyretic activity of ibuprofen and paracetamol in febrile children. ( d'Athis, P; Debregeas, S; Olive, G; Pariente-Khayat, A; Pons, G; Vauzelle-Kervroëdan, F, 1997) |
| "Indomethacin was significantly quicker at clearing fever than acetaminophen (P < 0." | 2.67 | Antipyretic efficacy of indomethacin and acetaminophen in uncomplicated falciparum malaria. ( Looareesuwan, S; Wilairatana, P, 1994) |
| "At 2 months of age, 145 infants were randomized to receive either a two-component acellular pertussis vaccine [lymphocytosis-promoting factor (LPF)/filamentous hemagglutinin (FHA)] or standard whole-cell pertussis vaccine, each combined with diphtheria-tetanus toxoids, as their primary immunization series." | 2.67 | Primary immunization series for infants: comparison of two-component acellular and standard whole-cell pertussis vaccines combined with diphtheria-tetanus toxoids. ( Andrew, M; Feldman, S; Jones, L; Lamb, D; Meschievitz, C; Moffitt, JE; Perry, CS, 1993) |
| " Pharmacokinetic and pharmacodynamic analyses were performed with temperature as the effect parameter and mean acetaminophen, total ibuprofen, and ibuprofen stereoisomer concentrations over time." | 2.67 | Pharmacokinetics and pharmacodynamics of ibuprofen isomers and acetaminophen in febrile children. ( Cox, S; Edge, JH; Kelley, MT; Mortensen, ME; Walson, PD, 1992) |
| "Ibuprofen is a potent antipyretic agent and is a safe alternative for the selected febrile child who may benefit from antipyretic medication but who either cannot take or does not achieve satisfactory antipyresis with acetaminophen." | 2.67 | Antipyretic efficacy of ibuprofen vs acetaminophen. ( Kauffman, RE; Sawyer, LA; Scheinbaum, ML, 1992) |
| "Nimesulide was studied in comparison with paracetamol, according to a double-blind technique." | 2.67 | Pilot study of the antipyretic and analgesic activity of nimesulide paediatric suppositories. ( D'Apuzzo, V; Monti, T, 1992) |
| "Ibuprofen was evaluated as an antipyretic agent in 178 children (aged 3 months to 12 years) to compare dosage (5 vs 10 mg/kg), establish absolute efficacy (with a placebo control group), determine relative efficacy (ibuprofen vs acetaminophen), evaluate maximum efficacy, and identify potential confounding variables." | 2.67 | Single-dose, placebo-controlled comparative study of ibuprofen and acetaminophen antipyresis in children. ( Bertrand, KM; Brown, RD; Eichler, VF; Johnson, VA; Kearns, GL; Lowe, BA; Wilson, JT, 1991) |
| " Both plasma elimination half life and area under the plasma concentration time curve were significantly increased in neonates after suppository dosing compared with older children." | 2.67 | Pharmacokinetics of paracetamol after cardiac surgery. ( Booker, PD; Hopkins, CS; Underhill, S, 1990) |
| " A control of the actual rectal dosage scheme for repetitive applications is recommended and the combination of paracetamol with sedatives is to be discussed." | 2.64 | [On the antipyretic effect of paracetamol. Clinical investigation with two different forms of application (author's transl)]. ( Götte, R; Liedtke, R, 1978) |
| " The total amount of paracetamol and its metabolites excreted and the peak excretion rates were lower from the suppository bases than from the oral dosage forms." | 2.64 | Antipyretic therapy. Comparison of rectal and oral paracetamol. ( Hietula, M; Keinänen, S; Kouvalainen, K; Similä, S, 1977) |
| "Fever is a very common adaptive immune response in acute respiratory tract disorders during infancy." | 2.61 | Faster recovery and reduced paracetamol use - a meta-analysis of EPs 7630 in children with acute respiratory tract infections. ( Brandes-Schramm, J; Kamin, W; Lehmacher, W; Seifert, G; Zimmermann, A, 2019) |
| "Induction of fever is mediated by the release of pyrogenic cytokines (tumor necrosis factor α, interleukin 1, interleukin 6, and interferons)." | 2.55 | Paracetamol in fever in critically ill patients-an update. ( Chiumello, D; Gotti, M; Vergani, G, 2017) |
| "Acetaminophen is a commonly used pediatric medication that has recently been approved for intravenous use in the United States." | 2.52 | Intravenous acetaminophen use in pediatrics. ( Shastri, N, 2015) |
| "Fever is a common symptom of childhood infections that in itself does not require treatment." | 2.50 | A practical approach to the treatment of low-risk childhood fever. ( Kanabar, D, 2014) |
| "Dengue is a resurging mosquito-borne disease that is often contracted in U." | 2.49 | A review of dengue fever: a resurging tropical disease. ( Mangold, KA; Reynolds, SL, 2013) |
| "A standardized approach to dosing acetaminophen in pediatric populations was published in 1983." | 2.49 | Dosing and antipyretic efficacy of oral acetaminophen in children. ( Kuffner, EK; Temple, AR; Temple, BR, 2013) |
| "The selected studies showed great heterogeneity of participants, temperature for fever diagnosis, interventions (dose and dosing intervals) and assessed outcomes." | 2.48 | Alternating antipyretics in the treatment of fever in children: a systematic review of randomized clinical trials. ( Dagostini, JM; Pereira, GL; Pizzol, Tda S, 2012) |
| "Acetaminophen has unique analgesic and antipyretic properties." | 2.46 | Intravenous acetaminophen. ( Jahr, JS; Lee, VK, 2010) |
| "Ibuprofen, paracetamol and placebo have similar tolerability and safety profiles in terms of gastrointestinal symptoms, asthma and renal adverse effects." | 2.45 | Systematic review and meta-analysis of the clinical safety and tolerability of ibuprofen compared with paracetamol in paediatric pain and fever. ( Kleijnen, J; Soares-Weiser, K; Southey, ER, 2009) |
| "Fever is the most common problem in medical situations, but controversy still surrounds its benefit/ risk ratio for human beings." | 2.44 | [Using evidence-based nursing to explore the management of child fever]. ( Huang, MC; Wang, YM, 2008) |
| " The review establishes that aspirin, paracetamol and ibuprofen are safe in OTC doses and that there is no evidence for any difference between the medicines as regards efficacy and safety for treatment of colds and flu (except in certain cases such as the use of aspirin in feverish children)." | 2.43 | Efficacy and safety of over-the-counter analgesics in the treatment of common cold and flu. ( Eccles, R, 2006) |
| "Fever is frequently managed outside the purview of medical professionals, and antipyretic therapy, on the whole, is generally considered safe." | 2.41 | Toxicities of drugs used in the management of fever. ( Plaisance, KI, 2000) |
| " In summary, all methodologically sound studies available indicate that therapeutic dosing of paracetamol to the alcoholic patient is not associated with hepatic injury." | 2.41 | Treatment of pain or fever with paracetamol (acetaminophen) in the alcoholic patient: a systematic review. ( Dart, RC; Kuffner, EK; Rumack, BH, 2000) |
| "Fever is an important symptom of underlying disease condition and in general is considered harmful in pediatric age group as it may lead to febrile seizures, stupor, dehydration increase work of breathing, discomfort and tachycardia." | 2.41 | Antipyretics in children. ( Bhatnagar, SK; Chandra, J, 2002) |
| "The decision to treat fever therefore needs to be: individualised, based on knowledge of effectiveness, balanced against any risk of harm that might result from intervening." | 2.41 | Management of the child with fever. ( Robertson, J, 2002) |
| "Acetaminophen is a safe antipyretic therapy prescribed in children." | 2.39 | [Paracetamol and other antipyretic analgesics: optimal doses in pediatrics]. ( Stamm, D, 1994) |
| "Reasons for treating fever include patient discomfort, the potential for adverse sequelae, the possibility of seizures, and the possibility that fever could affect the pharmacokinetic profiles of drugs." | 2.38 | Antipyretic therapy in the febrile child. ( Drwal-Klein, LA; Phelps, SJ, 1992) |
| "Acetaminophen is an effective antipyretic and analgesic with few side effects that is toxic only in massive overdose." | 2.36 | Use of antipyretic analgesics in the pediatric patient. ( Gladtke, E, 1983) |
| "Fever is one of the most common medical complaints referred to physicians for diagnosis and therapy." | 2.36 | Review of comparative antipyretic activity in children. ( Temple, AR, 1983) |
| "Aspirin has some advantage over acetaminophen for analgesia." | 2.36 | Aspirin and acetaminophen: a comparative view of their antipyretic and analgesic activity. ( Lovejoy, FH, 1978) |
| " Due to the strong evidence of increased risk of fever after administration, surveillance of adverse events following immunization (AEFIs) is a priority for 4CMenB." | 1.91 | Adverse events following immunization (AEFIs) with anti-meningococcus type B vaccine (4CMenB): Data of post-marketing active surveillance program. Apulia Region (Italy), 2019-2023. ( Ancona, D; Di Lorenzo, A; Martinelli, A; Moscara, L; Stefanizzi, P; Stella, P; Tafuri, S, 2023) |
| "Its therapeutic effect in treating fever and its safety have not been studied in animal models." | 1.72 | Investigations of the antipyretic effect and safety of Prasachandaeng, a traditional remedy from Thailand national list of essential medicines. ( Davies, NM; Inprasit, J; Itharat, A; Löbenberg, R; Ooraikul, B; Prommee, N; Somayaji, V; Sukkasem, K; Tasanarong, A; Thisayakorn, K, 2022) |
| " We aimed in this study to assess parents' knowledge, attitudes, and practice regarding paracetamol dosing and toxicity, as well as their awareness regarding paracetamol-containing products." | 1.62 | An assessment of parents' knowledge and awareness regarding paracetamol use in children: a cross-sectional study from Palestine. ( Al-Jabi, SW; Al-Tawil, F; Daifallah, A; Elkourdi, M; Jabr, R; Koni, A; Salman, Z; Samara, A; Zyoud, SH, 2021) |
| "Evaluate the appropriateness of acetaminophen dosing by caregivers seeking care for their children/wards at the emergency department of a pediatric hospital." | 1.62 | Appropriateness of Acetaminophen Dosing by Caregivers of Pediatric Patients Presenting to the Emergency Department at the University Pediatric Hospital in Puerto Rico. ( Hernández-Muñoz, JJ; Ortiz-Vera, YA; Parambil, A; Rodríguez-Rodríguez, NJ; Vélez-Rivera, SM, 2021) |
| "Acetaminophen was the most commonly used single agent (60,929/152,017, 40." | 1.62 | Comparative Analysis of Single and Combined Antipyretics Using Patient-Generated Health Data: Retrospective Observational Study. ( Ahn, SH; Chang, S; Kim, H; Kim, M; Lee, JH; Park, JA; Park, YR; Shin, JW, 2021) |
| "Fever has been reported as a common symptom occurring in COVID-19 illness." | 1.56 | The use of ibuprofen to treat fever in COVID-19: A possible indirect association with worse outcome? ( Haryadi, TH; Jamerson, BD, 2020) |
| "Among first-line methods to treat fever, ice packs were the most frequently utilized physical method (n=90, [47%]), external nonautomated system was the most frequent utilized device (n=49, [25%]), and paracetamol was the most frequently utilized drug (n=135, [70%])." | 1.51 | A Survey on Fever Monitoring and Management in Patients With Acute Brain Injury: The SUMMA Study. ( Helbok, R; Oddo, M; Picetti, E; Prisco, L; Taccone, FS, 2019) |
| " No protocol-related adverse events occurred." | 1.51 | Feasibility and Safety of Transnasal High Flow Air to Reduce Core Body Temperature in Febrile Neurocritical Care Patients: A Pilot Study. ( Assis, FR; Geocadin, RG; Shah, D; Tandri, H; Ziai, WC, 2019) |
| " Because of the limited clinical experience with the four-component meningococcal B vaccine (4CMenB), active surveillance for adverse events following immunization (AEFI) was conducted." | 1.48 | Short-term safety of 4CMenB vaccine during a mass meningococcal B vaccination campaign in Quebec, Canada. ( Billard, MN; Boulianne, N; De Serres, G; Deceuninck, G; Gagné, H; Gariépy, MC; Gilca, V; Landry, M; Ouakki, M; Rouleau, I; Skowronski, DM; Toth, E, 2018) |
| "Pediatric acute-liver-failure due to acetaminophen (APAP) administration at therapeutic dosage is rare, while viral infections and metabolic defects are the prevalent causes." | 1.46 | NBAS mutations cause acute liver failure: when acetaminophen is not a culprit. ( Brunati, A; Calvo, PL; Haak, TB; Olio, DD; Pinon, M; Romagnoli, R; Spada, M; Tandoi, F, 2017) |
| " Intravenous acetaminophen, with its increased bioavailability and more rapid onset of action, may have benefit in the intrapartum setting by reducing adverse neonatal and maternal outcomes associated with febrile morbidity." | 1.46 | Intravenous acetaminophen for the treatment of intrapartum fever and resolution of fetal tachycardia: a novel use for an old medication. ( Burgess, APH; Lakhi, N; Moretti, M; Ope-Adenuga, S; Reilly, JG, 2017) |
| "Ibuprofen use was significantly lower in children diagnosed with wheezing (n = 22, 52." | 1.46 | Association of Acetaminophen and Ibuprofen Use With Wheezing in Children With Acute Febrile Illness. ( Elizur, A; Ganor, S; Kozer, E; Levine, H; Matok, I; Perlman, A, 2017) |
| "Acetaminophen was administered 2." | 1.46 | Parental Approach to the Prevention and Management of Fever and Pain Following Childhood Immunizations: A Survey Study. ( Moody, MA; Saleh, E; Swamy, GK; Walter, EB, 2017) |
| "Fever is a very common problem in pediatric age and is one of the most common reasons parents seek medical attention." | 1.46 | Parental beliefs and practices regarding childhood fever in Turkish primary care. ( Çakır, L; Cebeci, SE; Doğan, S; Gümüştakım, RŞ; Kırımlı, E; Yavuz, E; Yayla, E, 2017) |
| "The median reported threshold for treating fever in clinical practice was 38 °C (IQR 38-38." | 1.46 | Attitudes towards fever amongst UK paediatric intensive care staff. ( Agbeko, RS; Brick, T; Davies, P; Davis, PJ; Deep, A; Fortune, PM; Inwald, DP; Jones, A; Levin, R; Morris, KP; Pappachan, J; Peters, MJ; Ray, S; Tibby, SM; Tume, LN, 2017) |
| "Acetaminophen (APAP) elixir is a widely used pediatric antipyretic medication." | 1.43 | Are Recommended Doses of Acetaminophen Effective for Children Aged 2 to 3 Years? A Pharmacokinetic Modeling Answer. ( Abourbih, DA; Gosselin, S; Kazim, S; Villeneuve, E, 2016) |
| "Fever is frequently observed in conjunction with interleukin-2 (IL-2)-based immunotherapy." | 1.42 | Fever and the use of paracetamol during IL-2-based immunotherapy in metastatic melanoma. ( Bastholt, L; Christensen, IJ; Ellegaard, MB; Køstner, AH; Schmidt, H, 2015) |
| " This study aimed to assess the health literacy skills of parents and caregivers of preschool-aged children, using a progressive scenario describing a child with fever and presenting tasks relating to selection of a medicine and hypothetical dosing of their child." | 1.40 | Management of children's fever by parents and caregivers: Practical measurement of functional health literacy. ( Chaw, XY; Emmerton, L; Kairuz, T; Kelly, F; Marriott, J; Moles, R; Wheeler, A, 2014) |
| "Next day pyrexia was induced with lipopolysaccharide and paracetamol's (200 mg/kg, oral) antipyretic activity was assessed." | 1.40 | Arsenic reduces the antipyretic activity of paracetamol in rats: modulation of brain COX-2 activity and CB₁ receptor expression. ( Kannan, K; Kesavan, M; Sankar, P; Sarkar, SN; Suresh, S; Tandan, SK; Vijayakaran, K, 2014) |
| " No problems related to norepinephrine administration and/or increase in dosage were observed." | 1.40 | Intravenous paracetamol for fever control in acute brain injury patients: cerebral and hemodynamic effects. ( Antonini, MV; Caspani, ML; De Angelis, A; Picetti, E; Rossi, I; Servadei, F; Villani, F, 2014) |
| " Forty-six parents (32%) had an acetaminophen dosing error." | 1.39 | Parental language and dosing errors after discharge from the pediatric emergency department. ( Porter, SC; Samuels-Kalow, ME; Stack, AM, 2013) |
| "Although fever and hypothermia are common abnormal physical signs observed in patients admitted to intensive care units (ICU), little data exist on their optimal management." | 1.39 | Diagnosis and management of temperature abnormality in ICUs: a EUROBACT investigators' survey. ( de Waele, J; Dimopoulos, G; Koulenti, D; Laupland, KB; Niven, DJ; Rello, J; Tabah, A; Timsit, JF; Vesin, A, 2013) |
| "Fever is one of the most common problems about which primary caregivers seek medical advice for their children." | 1.38 | Knowledge of using acetaminophen syrup and comprehension of written medication instruction among caregivers with febrile children. ( Chang, MC; Chang, SC; Chen, YC; Smith, GD, 2012) |
| "Fever is one of the most commonly observed abnormal signs in patients with critical illness." | 1.38 | Assessment of the safety and feasibility of administering anti-pyretic therapy in critically ill adults: study protocol of a randomized trial. ( Kubes, P; Laupland, KB; Léger, C; Niven, DJ; Stelfox, HT, 2012) |
| "Dexketoprofen was the most effective antipyretic agent at the doses tested." | 1.38 | [Hemodynamic and antipyretic effects of paracetamol, metamizol and dexketoprofen in critical patients]. ( Betbesé, AJ; Gich, I; Mancebo, J; Vera, P; Zapata, L, 2012) |
| "In Denmark, the traditional choice for treating fever and pain in children is paracetamol." | 1.38 | [Ibuprofen is more effective than paracetamol in lowering the temperature in febrile children]. ( Lundstrøm, KE, 2012) |
| "Even though fever is a common symptom in childhood, it often worries parents and they may try to reduce discomfort by giving the child paracetamol, which is currently the most commonly sold over-the-counter medicine." | 1.38 | The majority of sick children receive paracetamol during the winter. ( Ertmann, RK; Møller, JJ; Reventlow, S; Siersma, V; Söderström, M; Waldorff, FB, 2012) |
| "We investigated acetaminophen use and identify factors contributing to supratherapeutic dosing of acetaminophen in hospitalized patients." | 1.38 | Supratherapeutic dosing of acetaminophen among hospitalized patients. ( Bates, DW; Boulware, LJ; Chang, F; Mahoney, LM; Maviglia, SM; Orav, EJ; Plasek, J; Rocha, RA; Zhou, L, 2012) |
| "Compared to conventional treatment, fever burden was significantly lower within the first 4 days after admission (p < 0." | 1.37 | Standardized antipyretic treatment in stroke: a pilot study. ( Beck, A; Breuer, L; Kallmünzer, B; Köhrmann, M; Kollmar, R; Krause, C; Pauli, E, 2011) |
| "Fever is an important mechanism of intrinsic resistance against infectious disease." | 1.37 | Fever and antipyresis in infection. ( Beasley, RW; Saxena, MK; Young, PJ, 2011) |
| "Danish parents regularly treat feverish children with paracetamol." | 1.36 | Paracetamol for feverish children: parental motives and experiences. ( Jensen, JF; Siersma, V; Söderström, M; Thorsen, H; Tønnesen, LL, 2010) |
| "Pallor was significantly more frequent after the first dose of whole cell pertussis than after acellulair pertussis vaccination (18." | 1.35 | Reactogenicity of infant whole cell pertussis combination vaccine compared with acellular pertussis vaccines with or without simultaneous pneumococcal vaccine in the Netherlands. ( David, S; van der Maas, NA; Vermeer-de Bondt, PE, 2008) |
| " Appropriate dosing and managing of these drugs do not likely lead to organ toxicity." | 1.35 | Acute non-oliguric kidney failure and cholestatic hepatitis induced by ibuprofen and acetaminophen: a case report. ( Angeli, S; Brugnara, M; Cuzzolin, L; Zaffanello, M, 2009) |
| "Twenty-one sequential case notes of Pfeiffer syndrome were retrospectively reviewed to collect 38 postoperative temperature courses." | 1.35 | Pyrexia after transcranial surgery for Pfeiffer syndrome. ( Anderson, PJ; David, DJ; Tamada, I, 2009) |
| "Acute renal failure is commonly seen in adults after treatment with analgesic agents." | 1.35 | Acute, reversible nonoliguric renal failure in two children associated with analgesic-antipyretic drugs. ( Baskin, E; Bayrakci, US; Cengiz, N; Erçoban, HS; Melek, E; Onay, OS, 2009) |
| "(1) Renal colic is an acute syndrome involving unilateral flank pain, linked to an obstruction in the upper urinary tract." | 1.35 | Renal colic in adults: NSAIDs and morphine are effective for pain relief. ( , 2009) |
| "Fever was most prominent in A/H3N2 and young children." | 1.34 | Natural course of fever during influenza virus infection in children. ( Ichihara, K; Johnson, AM; Suzuki, E, 2007) |
| "He had an upper respiratory tract infection in which a vaso-occlusive crisis was precipitated." | 1.34 | Tramadol infusion for the pain management in sickle cell disease: a case report. ( Aydinok, Y; Balkan, C; Erhan, E; Inal, MT; Yegul, I, 2007) |
| " There was a wide variability of the dosing interval." | 1.34 | Alternating antipyretics for fever reduction in children: an unfounded practice passed down to parents from pediatricians. ( Liebelt, EL; Wright, AD, 2007) |
| "Prazosin pretreatment eliminated the first T(c) rise but not the second; PGE(2) rose normally." | 1.34 | Preoptic norepinephrine mediates the febrile response of guinea pigs to lipopolysaccharide. ( Blatteis, CM; Feleder, C; Perlik, V, 2007) |
| "Conflicting attitudes toward febrile convulsions were highlighted by beliefs that antipyretic therapy prevents these and that antipyretics do not prevent initial febrile convulsions." | 1.33 | Fever management: paediatric nurses' knowledge, attitudes and influencing factors. ( Courtney, MD; Edwards, HE; Monaghan, SJ; Walsh, AM; Wilson, JE, 2005) |
| "To identify folk remedies used to treat fever, colic, and teething among black children in Detroit, Michigan." | 1.33 | The use of folk remedies among children in an urban black community: remedies for fever, colic, and teething. ( Janisse, J; Mathur, A; Smitherman, LC, 2005) |
| "In this clinically relevant septic shock model, the febrile response thus resulted in better respiratory function, lower blood lactate concentration, and prolonged survival time." | 1.33 | Fever control in septic shock: beneficial or harmful? ( Cai, Y; Nguyen, ND; Rogiers, P; Su, F; Vincent, JL; Wang, Z, 2005) |
| "Aspirin was used by 7." | 1.33 | Use and misuse of aspirin in rural Ethiopia. ( Aref-Adib, G; Britton, J; Davey, G; Duncan, P; Venn, A, 2006) |
| "To evaluate the risk of fulminant hepatic failure in relation to paracetamol overuse with therapeutic intent in febrile children." | 1.33 | Fulminant hepatic failure and paracetamol overuse with therapeutic intent in febrile children. ( Fernandopulle, BM; Fernandopulle, M; Lamabadusuriya, SP; Ranganathan, SS; Sathiadas, MG; Sumanasena, S, 2006) |
| "Fever was considered a definite sign of illness, almost congruent with the disease itself." | 1.32 | Childhood illnesses and the use of paracetamol (acetaminophen): a qualitative study of parents' management of common childhood illnesses. ( Helseth, S; Holager, T; Lagerløv, P, 2003) |
| "Febrile nonhemolytic transfusion reactions (FNHTRs) cause unwelcome interruptions during the course of blood product transfusions and necessitate measures to verify the nature of the reaction and to exclude certain dangerous reactions, such as hemolytic and septic phenomena." | 1.32 | Febrile nonhemolytic transfusion reactions. Management by premedication and cost implications in adult patients. ( Ezidiegwu, CN; Henry, JB; Kelly, KC; Lauenstein, KJ; Rosales, LG, 2004) |
| "To report a case of toxic epidermal necrolysis (TEN) associated with acetaminophen ingestion." | 1.31 | Toxic epidermal necrolysis associated with acetaminophen ingestion. ( Ben-Amitai, D; Garty, BZ; Halevi, A, 2000) |
| "Fever is a common symptom of childhood illness, and much time and effort is spent in the pursuit of reducing high temperature." | 1.31 | Physical treatment of fever. ( Purssell, E, 2000) |
| "Subjects from the six influenza A studies were challenged intranasally." | 1.31 | Effect of antipyretic therapy on the duration of illness in experimental influenza A, Shigella sonnei, and Rickettsia rickettsii infections. ( Kudaravalli, S; Levine, MM; Mackowiak, PA; Plaisance, KI; Wasserman, SS, 2000) |
| " We explore the toxicities of OTC cough and cold medications, discuss mechanisms of dosing errors, and suggest why physicians should be more vigilant in specifically inquiring about OTCs when evaluating an ill child." | 1.31 | Toxicity of over-the-counter cough and cold medications. ( Gunn, VL; Liebelt, EL; Serwint, JR; Taha, SH, 2001) |
| " Tablets "Paravit" have mark, which allows exact dosing for children of different age." | 1.30 | [The physiological properties of the action of a new analgesic and antipyretic preparation]. ( Chernykh, VP; Shapovalova, VO, 1997) |
| "To evaluate caregiver (parent or guardian) use of over-the-counter medications (OTCs) as related to the accuracy and correctness of dosing for children seen at a pediatric emergency department with nonemergent concerns." | 1.30 | Over-the-counter medications. Do parents give what they intend to give? ( Simon, HK; Weinkle, DA, 1997) |
| "A pharmacokinetic dynamic simulation model was used to predict rectal paracetamol dosing schedules which would maintain steady state plasma concentrations of 10-20 mg." | 1.30 | Rectal paracetamol dosing regimens: determination by computer simulation. ( Anderson, BJ; Holford, NH, 1997) |
| "Amphetamine treatment caused an acute rise in core body temperature to 40 degrees C for at least 1 hr and increased hsp25 and hsp70i levels, as measured by Western blotting, at 6, 24, 48, and 72 hr with no apparent induction of other hsps (hsp60, hsc70, or hsp90)." | 1.30 | Protection against hepatotoxicity by a single dose of amphetamine: the potential role of heat shock protein induction. ( Roberts, SM; Salminen, WF; Voellmy, R, 1997) |
| "Acetaminophen was the treatment of choice for 96% and dipyrone for 4%." | 1.30 | Parental knowledge of the treatment of fever in children. ( Barzilai, A; Davidovitch, N; Eisen, I; Kaplan, G; Linder, N; Sirota, L; Snapir, A, 1999) |
| "Sixty-nine children with first febrile seizures and no history of previous unprovoked seizures were matched for age (+/- 6 months), site of routine pediatric care, and date of visit (+/- 2 weeks) with 1 or 2 febrile controls who had no history of previous febrile or unprovoked seizures." | 1.29 | Risk factors for a first febrile seizure: a matched case-control study. ( Berg, AT; Crain, EF; Hauser, WA; Salomon, ME; Shapiro, ED; Shinnar, S, 1995) |
| "When post-ischemic seizures ensued in hyperglycemic subjects, temperature was 39." | 1.29 | Preischemic hyperglycemia leads to delayed postischemic hyperthermia. ( Lundgren, J; Siesjö, BK; Smith, ML; Uchino, H, 1994) |
| "For acetaminophen, the tlag was less than ibuprofen, Ka was more than ibuprofen, and beta was less than ibuprofen." | 1.28 | Single-dose pharmacokinetics of ibuprofen and acetaminophen in febrile children. ( Bertrand, KM; Brown, RD; Eichler, VF; Johnson, VA; Kearns, GL; Wilson, JT, 1992) |
| "Fever was induced by intraperitoneal injection of pyrogen (10 micrograms/kg)." | 1.28 | [Antipyretic action of aniline derivatives in rats during different parts of the day]. ( Rachtan, R; Starek, A, 1990) |
| "Cases of Reye's syndrome declined both in numbers (from a peak of 79 in 1983/4 to 19 in 1988/9) and in median age." | 1.28 | Trends in the incidence of Reye's syndrome and the use of aspirin. ( Banks, JH; Glasgow, JF; Hall, SM; Porter, JD; Robinson, PH, 1990) |
| "The reasons given for treating fever were to make the child comfortable (99%), to prevent seizures (63%), and to satisfy parents (44%)." | 1.27 | House officer management of the febrile child. A survey. ( Herskowitz, L; Weiss, J, 1983) |
| " Based on available clinical and pharmacokinetic data, acetaminophen should be dosed with single doses in the range of 10-15 mg/kg at 4-hour intervals." | 1.27 | Pediatric dosing of acetaminophen. ( Temple, AR, 1983) |
| "Acetaminophen is an effective analgesic and antipyretic agent with few adverse effects when used in recommended dosages." | 1.27 | Acetaminophen: a practical pharmacologic overview. ( Cornett, JW; Jackson, CH; MacDonald, NC, 1984) |
| "Fever is a part of the acute phase response, a generalized reaction to infection or inflammation initiated by interleukin-1 (IL-1)." | 1.27 | Fever. What to do and what not to do. ( Rosenthal, TC; Silverstein, DA, 1988) |
| " FS 205-397 will offer potent analgesic and antipyretic therapy in man based on an innovative biochemical principle which eliminates the undesirable toxic effects associated with most other non-narcotic analgesics." | 1.27 | FS 205-397: a new antipyretic analgesic with a paracetamol-like profile of activity but lack of acute hepatotoxicity in mice. ( Achini, R; Foote, RW; Römer, D, 1988) |
| "The parents of 106 children who had had Reye's syndrome and those of 185 comparison children who had febrile illnesses were interviewed in order to compare preadmission medication exposure rates in the two groups." | 1.27 | Preadmission antipyretics in Reye's syndrome. ( Glasgow, JF; Hall, SM; Hancock, P; Plaster, PA, 1988) |
| "Acetaminophen (15 mg/kg) was administered to each child and repeat temperatures were taken one and two hours later." | 1.27 | Childhood fever: correlation of diagnosis with temperature response to acetaminophen. ( Baker, MD; Carpenter, RO; Fosarelli, PD, 1987) |
| "The incidence of Reye syndrome has been decreasing in Michigan, perhaps as a result of decreased aspirin use among children." | 1.27 | Decreasing trends in Reye syndrome and aspirin use in Michigan, 1979 to 1984. ( Hall, WN; McGee, H; Monto, AS; Remington, PL; Rowley, D, 1986) |
| "Fever was measured with a thermometer in 114 ill children, 103 of whom had at least one measured temperature of 37." | 1.27 | Antipyretic use among children during the 1983 influenza season. ( Brandenburg, N; Glezen, WP; Gustafson, TL; Johnson, CC; Taylor, JP, 1985) |
| " Thus a pharmacokinetic interaction between CAP and APAP was not demonstrated in acutely ill febrile children during concomitant therapy." | 1.27 | Absence of a pharmacokinetic interaction between chloramphenicol and acetaminophen in children. ( Bocchini, JA; Brown, RD; Cotter, DL; Kearns, GL; Wilson, JT, 1985) |
| "Aspirin prescriptions were consistent over the entire study period among inpatients, but preadmission use decreased substantially." | 1.26 | Acetaminophen and aspirin. Prescription, use, and accidental ingestion among children. ( Lovejoy, FH; Mitchell, AA; Shapiro, S; Slone, D, 1982) |
| " Acetaminophen and diazepam seemed to be well absorbed from the rectal suppositories, the maximal plasma concentration of diazepam after a rectal dose of 0." | 1.26 | Antipyretic effect and plasma concentrations of rectal acetaminophen and diazepam in children. ( Kangas, L; Keinänen-Kiukaanniemi, S; Luoma, P; Saukkonen, AL; Similä, S, 1979) |
| " With the same dosage serum concentrations are lower after rectal application than after oral." | 1.26 | [Investigations concerning temperature and serum concentrations of paracetamol in febrile infants following rectal application of paracetamol (author's transl)]. ( Windofer, A, 1978) |
| " The children were divided into 3 groups on the basis of dosage (5, 10 and 20 mg/kg body weight)." | 1.26 | [Investigations concerning serum concentration and temperature following oral application of a new paracetamol preparation (author's transl)]. ( Vogel, C; Windorfer, A, 1976) |
| "Short-term fever is usually a viral infection but may be a bacterial infection." | 1.26 | Fever in childhood. ( Shrand, H, 1976) |
| "Marked cyanosis was observed in experimental cats within 4 hours after administration of one 325-mg tablet." | 1.25 | Acetaminophen toxicosis in the cat. ( Duncan, JR; Finco, DC; Prasse, KW; Schall, WD, 1975) |
| "Indomethacin was more potent than paracetamol and both were more potent than injected I." | 1.25 | Prostaglandins, endotoxin and lipid A on body temperature in rats. ( Feldberg, W; Saxena, PN, 1975) |
| "Fever was produced by injection of the bacterial pyrogen of Shigella dysenteriae either into the third ventricle, cisterna magna or I." | 1.25 | Effect of pyrogen and antipyretics on prostaglandin acitvity in cisternal c.s.f. of unanaesthetized cats. ( Feldberg, W; Gupta, KP; Milton, AS; Wendlandt, S, 1973) |
| "The characteristics, circumstances, and treatment of 450 pyrexial reactions occurring in 468 patient-months over a period of two and a half years, using a warm single-pass Kiil system, were studied." | 1.25 | Pyrexial reactions during haemodialysis. ( Robinson, PJ; Rosen, SM, 1971) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 132 (18.75) | 18.7374 |
| 1990's | 117 (16.62) | 18.2507 |
| 2000's | 199 (28.27) | 29.6817 |
| 2010's | 204 (28.98) | 24.3611 |
| 2020's | 52 (7.39) | 2.80 |
| Authors | Studies |
|---|---|
| Friesen, RW | 1 |
| Mancini, JA | 1 |
| Eissa, AA | 1 |
| Farag, NA | 1 |
| Soliman, GA | 1 |
| Tripathi, P | 1 |
| Tripathi, AC | 1 |
| Chawla, V | 1 |
| Saraf, SK | 1 |
| Das, M | 1 |
| Bhattacharjee, S | 1 |
| Fronczek, FR | 1 |
| Bazan, NG | 1 |
| Trudell, ML | 1 |
| Gautry, P | 1 |
| Bussereau, M | 2 |
| D'Eramo, RE | 1 |
| Nadpara, PA | 1 |
| Sandler, M | 1 |
| Taylor, PD | 1 |
| Brophy, GM | 1 |
| Saifuddin, A | 1 |
| Koesnoe, S | 1 |
| Kurniati, N | 1 |
| Sirait, S | 1 |
| Arisanty, R | 1 |
| Yunihastuti, E | 1 |
| Kokawa, T | 1 |
| Yamamoto, H | 1 |
| Itoh, M | 1 |
| Shimane, A | 1 |
| Kawai, H | 1 |
| Takaya, T | 1 |
| Kazama, I | 1 |
| Senzaki, M | 1 |
| Lee, E | 3 |
| Song, YJ | 1 |
| Jeon, S | 1 |
| Lee, J | 2 |
| Lee, JY | 1 |
| Han, MK | 1 |
| Jeong, HG | 1 |
| Prommee, N | 1 |
| Itharat, A | 1 |
| Thisayakorn, K | 1 |
| Sukkasem, K | 1 |
| Inprasit, J | 1 |
| Tasanarong, A | 1 |
| Löbenberg, R | 1 |
| Somayaji, V | 1 |
| Davies, NM | 1 |
| Ooraikul, B | 1 |
| Yin, F | 1 |
| Liu, Y | 1 |
| Guo, H | 1 |
| Tan, E | 2 |
| Hoare, K | 1 |
| Riley, J | 1 |
| Fernando, K | 1 |
| Haskell, L | 1 |
| McKinlay, CJ | 1 |
| Dalziel, SR | 2 |
| Braithwaite, I | 2 |
| Tanaka, M | 1 |
| Wang, Q | 1 |
| Morikawa, Y | 1 |
| Tsukamoto, J | 1 |
| Sammori, H | 1 |
| Takehira, K | 1 |
| Yano, M | 1 |
| Miyama, S | 1 |
| Fujita, S | 1 |
| Narita, K | 1 |
| Kishibe, S | 1 |
| Morikawa, EK | 1 |
| Suzuki, S | 1 |
| Hataya, H | 1 |
| Tantivit, N | 1 |
| Thangjui, S | 1 |
| Trongtorsak, A | 1 |
| Al-Antary, ET | 1 |
| Ramiz, S | 1 |
| Simon Junior, H | 1 |
| Pedreira, MC | 1 |
| Barbosa, SMM | 1 |
| Fernandes, TF | 1 |
| Escobar, AMU | 1 |
| Chulapornsiri, C | 2 |
| Pradermdussadeeporn, E | 1 |
| Pongpittayut, S | 1 |
| Sutthithumthaworn, A | 1 |
| Aninlabon, W | 1 |
| Wisassittichok, M | 1 |
| Maitongngam, K | 1 |
| Subchartanan, J | 1 |
| Suteerojntrakool, O | 1 |
| Tempark, T | 1 |
| Bongsebandhu-Phubhakdi, C | 1 |
| Chilombe, MB | 1 |
| McDermott, MP | 1 |
| Seydel, KB | 1 |
| Mathews, M | 1 |
| Mwenechanya, M | 1 |
| Birbeck, GL | 1 |
| Goodarzi, H | 1 |
| Valizadeh, F | 1 |
| Ghasemi, F | 1 |
| Ebrahimzade, F | 1 |
| Seifosadat, SH | 1 |
| Delfan, B | 1 |
| Taee, N | 1 |
| Ye, K | 3 |
| Li, Y | 3 |
| Xing, Y | 3 |
| Liu, K | 3 |
| Zhou, F | 3 |
| Tian, Y | 3 |
| Zhang, Y | 3 |
| Baker, AH | 2 |
| Monuteaux, MC | 2 |
| Michelson, KA | 2 |
| Neuman, MI | 2 |
| Bello, AM | 1 |
| Dye, C | 1 |
| Zempsky, W | 1 |
| Bell, J | 1 |
| Mossali, VM | 1 |
| Kachroo, P | 1 |
| Siddiqui, K | 1 |
| Roy, R | 1 |
| Roy, J | 1 |
| Liya, IJ | 1 |
| Basher, MA | 1 |
| Miah, MY | 1 |
| Verd, S | 1 |
| Rodríguez-Trabal, C | 1 |
| Mambié, M | 1 |
| Milani, GP | 3 |
| Corsello, A | 1 |
| Schulz, PJ | 1 |
| Fadda, M | 1 |
| Giannì, ML | 1 |
| Alberti, I | 1 |
| Comotti, A | 1 |
| Marchisio, P | 1 |
| Chiappini, E | 4 |
| Peroni, D | 1 |
| Zhou, P | 1 |
| Chen, L | 1 |
| Wang, E | 1 |
| He, L | 1 |
| Tian, S | 1 |
| Zhai, S | 1 |
| de Sévaux, JLH | 1 |
| Damoiseaux, RA | 2 |
| van de Pol, AC | 2 |
| Lutje, V | 1 |
| Hay, AD | 6 |
| Little, P | 2 |
| Schilder, AG | 2 |
| Venekamp, RP | 2 |
| Franceschi, F | 1 |
| Saviano, A | 1 |
| Carnicelli, A | 1 |
| Lorusso, C | 1 |
| Novelli, A | 1 |
| Candelli, M | 1 |
| Ojetti, V | 1 |
| Covino, M | 1 |
| Abitbol, V | 1 |
| Sohn, WY | 1 |
| Horn, M | 1 |
| Safadi, MAP | 1 |
| Stefanizzi, P | 1 |
| Di Lorenzo, A | 1 |
| Martinelli, A | 1 |
| Moscara, L | 1 |
| Stella, P | 1 |
| Ancona, D | 1 |
| Tafuri, S | 1 |
| Moffett, BS | 1 |
| Gutierrez, K | 1 |
| Davis, K | 1 |
| Sigdel, B | 1 |
| Strobel, N | 1 |
| Girard, P | 1 |
| Cantet, C | 1 |
| Rolland, Y | 1 |
| Young, PJ | 5 |
| Bailey, MJ | 1 |
| Bass, F | 1 |
| Beasley, RW | 4 |
| Freebairn, RC | 3 |
| Hammond, NE | 5 |
| van Haren, FMP | 1 |
| Harward, ML | 1 |
| Henderson, SJ | 3 |
| Mackle, DM | 1 |
| McArthur, CJ | 3 |
| McGuinness, SP | 3 |
| Myburgh, JA | 4 |
| Saxena, MK | 7 |
| Turner, AM | 1 |
| Webb, SAR | 1 |
| Bellomo, R | 6 |
| Margan Koletic, Z | 1 |
| Dosenovic, S | 1 |
| Puljak, L | 1 |
| Dubus, M | 1 |
| Ladhani, S | 1 |
| Vasu, V | 1 |
| Hervella, P | 1 |
| Rodríguez-Yáñez, M | 1 |
| Pumar, JM | 1 |
| Ávila-Gómez, P | 1 |
| da Silva-Candal, A | 1 |
| López-Loureiro, I | 1 |
| Rodríguez-Maqueda, E | 1 |
| Correa-Paz, C | 1 |
| Castillo, J | 1 |
| Sobrino, T | 1 |
| Campos, F | 1 |
| Iglesias-Rey, R | 1 |
| Veteikis, D | 1 |
| Elgamasy, S | 1 |
| Kamel, MG | 1 |
| Ghozy, S | 1 |
| Khalil, A | 1 |
| Morra, ME | 1 |
| Islam, SMS | 1 |
| Della-Torre, E | 1 |
| Della-Torre, F | 1 |
| Kusanovic, M | 1 |
| Scotti, R | 1 |
| Ramirez, GA | 1 |
| Dagna, L | 1 |
| Tresoldi, M | 1 |
| Jamerson, BD | 1 |
| Haryadi, TH | 1 |
| Rinott, E | 1 |
| Kozer, E | 6 |
| Shapira, Y | 1 |
| Bar-Haim, A | 1 |
| Youngster, I | 1 |
| Badjatia, N | 2 |
| Gupta, N | 1 |
| Sanchez, S | 1 |
| Haymore, J | 1 |
| Tripathi, H | 1 |
| Shah, R | 1 |
| Hannan, C | 1 |
| Tandri, H | 2 |
| Liu, JB | 1 |
| Hao, D | 1 |
| McKinlay, CJD | 1 |
| Alaje, EO | 1 |
| Udoh, EE | 1 |
| Akande, PA | 1 |
| Odey, FA | 1 |
| Meremikwu, MM | 1 |
| Mehraban, S | 1 |
| Nematian, S | 1 |
| Mehraban, SS | 1 |
| Petrucci, S | 1 |
| Tricorico, G | 1 |
| Parnas, Z | 1 |
| Shats, L | 1 |
| Kanninen, T | 1 |
| Moretti, M | 2 |
| Cabbad, M | 1 |
| Lakhi, N | 2 |
| Rosenberg, K | 1 |
| Daifallah, A | 1 |
| Jabr, R | 1 |
| Al-Tawil, F | 1 |
| Elkourdi, M | 1 |
| Salman, Z | 1 |
| Koni, A | 1 |
| Samara, A | 1 |
| Al-Jabi, SW | 1 |
| Zyoud, SH | 1 |
| Okereke, B | 1 |
| Ibeleme, O | 1 |
| Bisi-Onyemaechi, A | 1 |
| Can, Ö | 1 |
| Kıyan, GS | 1 |
| Yalçınlı, S | 1 |
| Vélez-Rivera, SM | 1 |
| Rodríguez-Rodríguez, NJ | 1 |
| Ortiz-Vera, YA | 1 |
| Parambil, A | 1 |
| Hernández-Muñoz, JJ | 1 |
| Long, B | 1 |
| Gottlieb, M | 1 |
| Paul, IM | 3 |
| Walson, PD | 7 |
| Kloeden, B | 1 |
| Tham, D | 1 |
| Oakley, E | 1 |
| Cheek, J | 1 |
| Park, YR | 1 |
| Kim, H | 1 |
| Park, JA | 1 |
| Ahn, SH | 1 |
| Chang, S | 1 |
| Shin, JW | 1 |
| Kim, M | 1 |
| Lee, JH | 3 |
| Young, TL | 1 |
| King, H | 1 |
| Deshpande, S | 1 |
| Woodbridge, T | 1 |
| Hilliard, T | 1 |
| Standing, J | 1 |
| Lewis, M | 1 |
| Ward, L | 1 |
| Finn, A | 1 |
| Roderick, M | 1 |
| Bloukh, S | 1 |
| Wazaify, M | 1 |
| Matheson, C | 1 |
| Schell-Chaple, HM | 1 |
| Liu, KD | 1 |
| Matthay, MA | 1 |
| Sessler, DI | 1 |
| Puntillo, KA | 1 |
| Eizenga, WE | 1 |
| Opstelten, W | 1 |
| Simon, A | 1 |
| Leffler, A | 1 |
| Hoag, SD | 1 |
| Chung, K | 1 |
| Ray, S | 3 |
| Brick, T | 2 |
| Raman, S | 1 |
| Birrell, PJ | 1 |
| Klein, NJ | 1 |
| Peters, MJ | 3 |
| Narayan, K | 1 |
| Cooper, S | 1 |
| Morphet, J | 1 |
| Innes, K | 1 |
| Sil, A | 1 |
| Ravi, MD | 1 |
| Patnaik, BN | 1 |
| Dhingra, MS | 1 |
| Dupuy, M | 1 |
| Gandhi, DJ | 1 |
| Dhaded, SM | 1 |
| Dubey, AP | 1 |
| Kundu, R | 1 |
| Lalwani, SK | 1 |
| Chhatwal, J | 1 |
| Mathew, LG | 1 |
| Gupta, M | 1 |
| Sharma, SD | 1 |
| Bavdekar, SB | 1 |
| Rout, SP | 1 |
| Jayanth, MV | 1 |
| D'Cor, NA | 1 |
| Mangarule, SA | 1 |
| Ravinuthala, S | 1 |
| Reddy E, J | 1 |
| Jackson, C | 1 |
| Yarwood, J | 1 |
| Saliba, V | 2 |
| Bedford, H | 1 |
| Luo, S | 1 |
| Ran, M | 1 |
| Luo, Q | 1 |
| Shu, M | 1 |
| Guo, Q | 1 |
| Zhu, Y | 1 |
| Xie, X | 1 |
| Zhang, C | 1 |
| Wan, C | 1 |
| Khan, MS | 1 |
| Hamid, A | 1 |
| Akram, M | 2 |
| Mustafa, SB | 1 |
| Sami, A | 1 |
| Shah, SMA | 2 |
| Usmanghani, K | 1 |
| Lee, HJ | 1 |
| Suh, YJ | 2 |
| Kim, AJ | 2 |
| Han, SB | 1 |
| Durey, A | 2 |
| Roy, S | 1 |
| Simalti, AK | 1 |
| Ocan, M | 1 |
| Aono, M | 1 |
| Bukirwa, C | 1 |
| Luyinda, E | 1 |
| Ochwo, C | 1 |
| Nsambu, E | 1 |
| Namugonza, S | 1 |
| Makoba, J | 1 |
| Kandaruku, E | 1 |
| Muyende, H | 1 |
| Nakawunde, A | 1 |
| Calvo, PL | 1 |
| Tandoi, F | 1 |
| Haak, TB | 1 |
| Brunati, A | 1 |
| Pinon, M | 1 |
| Olio, DD | 1 |
| Romagnoli, R | 1 |
| Spada, M | 1 |
| Rakowsky, S | 1 |
| Spiller, HA | 1 |
| Casavant, MJ | 1 |
| Chounthirath, T | 1 |
| Hodges, NL | 1 |
| Kim, EH | 1 |
| Smith, GA | 1 |
| Walter, EB | 2 |
| Hornik, CP | 1 |
| Grohskopf, L | 1 |
| McGee, CE | 1 |
| Todd, CA | 1 |
| Museru, OI | 1 |
| Harrington, L | 1 |
| Broder, KR | 1 |
| Kang, S | 1 |
| Rogers, L | 1 |
| Brown, KL | 1 |
| Saeedan, AS | 1 |
| Singh, I | 1 |
| Ansari, MN | 1 |
| Singh, M | 1 |
| Rawat, JK | 1 |
| Devi, U | 1 |
| Gautam, S | 1 |
| Yadav, RK | 1 |
| Kaithwas, G | 1 |
| Safari, L | 1 |
| Patrick, JD | 1 |
| Ope-Adenuga, S | 1 |
| Burgess, APH | 1 |
| Reilly, JG | 1 |
| Parker, SL | 1 |
| Saxena, M | 4 |
| Gowardman, J | 2 |
| Lipman, J | 2 |
| Myburgh, J | 4 |
| Roberts, JA | 2 |
| Choi, SJ | 1 |
| Moon, S | 1 |
| Choi, UY | 1 |
| Chun, YH | 1 |
| Rhim, JW | 1 |
| Kim, HM | 1 |
| Jeong, DC | 1 |
| Heinzl, S | 1 |
| Pigazzani, F | 1 |
| Mackenzie, I | 1 |
| MacDonald, TM | 1 |
| Picetti, E | 2 |
| Oddo, M | 1 |
| Prisco, L | 1 |
| Helbok, R | 1 |
| Taccone, FS | 1 |
| Saeki, S | 1 |
| De Serres, G | 1 |
| Billard, MN | 1 |
| Gariépy, MC | 1 |
| Rouleau, I | 1 |
| Toth, E | 1 |
| Landry, M | 1 |
| Boulianne, N | 1 |
| Gagné, H | 1 |
| Gilca, V | 1 |
| Deceuninck, G | 1 |
| Ouakki, M | 1 |
| Skowronski, DM | 1 |
| Islam, MT | 1 |
| Wang, MH | 1 |
| Hu, A | 1 |
| Lee, YS | 2 |
| Lai, CC | 1 |
| Ziai, WC | 1 |
| Shah, D | 2 |
| Assis, FR | 1 |
| Geocadin, RG | 1 |
| Deen, J | 1 |
| von Seidlein, L | 1 |
| Vasikasin, V | 1 |
| Rojdumrongrattana, T | 1 |
| Chuerboonchai, W | 1 |
| Siriwiwattana, T | 1 |
| Thongtaeparak, W | 1 |
| Niyasom, S | 1 |
| Lertliewtrakool, N | 1 |
| Jitsiri, S | 1 |
| Changpradub, D | 1 |
| Seifert, G | 1 |
| Brandes-Schramm, J | 1 |
| Zimmermann, A | 1 |
| Lehmacher, W | 1 |
| Kamin, W | 1 |
| Ajaz, M | 1 |
| Asif, HM | 1 |
| Hussain, A | 1 |
| Tahir, IM | 1 |
| Daniyal, M | 1 |
| Khan, FS | 1 |
| Gustavson, K | 1 |
| Ask, H | 1 |
| Ystrom, E | 1 |
| Stoltenberg, C | 1 |
| Lipkin, WI | 1 |
| Surén, P | 1 |
| Håberg, SE | 1 |
| Magnus, P | 1 |
| Knudsen, GP | 1 |
| Eilertsen, E | 1 |
| Bresnahan, M | 1 |
| Aase, H | 1 |
| Mjaaland, S | 1 |
| Susser, ES | 1 |
| Hornig, M | 1 |
| Reichborn-Kjennerud, T | 1 |
| Kose, D | 1 |
| Cadirci, E | 1 |
| Halici, Z | 1 |
| Sirin, B | 1 |
| Dincer, B | 1 |
| Ettinger, WH | 1 |
| Frank, B | 1 |
| Fulton, RL | 1 |
| Weimar, C | 1 |
| Lees, KR | 1 |
| Sanders, RD | 1 |
| Malya, RR | 1 |
| Engström Ruud, L | 1 |
| Wilhelms, DB | 1 |
| Eskilsson, A | 1 |
| Vasilache, AM | 1 |
| Elander, L | 1 |
| Engblom, D | 1 |
| Blomqvist, A | 1 |
| Mangold, KA | 1 |
| Reynolds, SL | 1 |
| de Ridder, IR | 3 |
| de Jong, FJ | 1 |
| den Hertog, HM | 6 |
| Lingsma, HF | 1 |
| van Gemert, HM | 12 |
| Schreuder, AH | 3 |
| Ruitenberg, A | 3 |
| Maasland, EL | 3 |
| Saxena, R | 3 |
| Oomes, P | 1 |
| van Tuijl, J | 1 |
| Koudstaal, PJ | 10 |
| Kappelle, LJ | 8 |
| Algra, A | 6 |
| van der Worp, HB | 12 |
| Dippel, DW | 13 |
| Charpiat, B | 1 |
| Zhou, L | 2 |
| Maviglia, SM | 2 |
| Rocha, RA | 2 |
| Weinkove, R | 1 |
| Clay, J | 1 |
| Wood, C | 1 |
| King, D | 1 |
| Emmerton, L | 1 |
| Chaw, XY | 1 |
| Kelly, F | 1 |
| Kairuz, T | 1 |
| Marriott, J | 1 |
| Wheeler, A | 1 |
| Moles, R | 1 |
| Morrison, CL | 1 |
| Glenn, LL | 1 |
| Taylor, CB | 1 |
| Seppelt, IM | 1 |
| Glass, P | 1 |
| Temple, AR | 5 |
| Temple, BR | 1 |
| Kuffner, EK | 3 |
| Samuels-Kalow, ME | 1 |
| Stack, AM | 1 |
| Porter, SC | 1 |
| Lavesson, T | 2 |
| Källén, K | 2 |
| Olofsson, P | 2 |
| Wong, T | 3 |
| Stang, AS | 3 |
| Ganshorn, H | 3 |
| Hartling, L | 3 |
| Maconochie, IK | 3 |
| Thomsen, AM | 3 |
| Johnson, DW | 3 |
| Dvorkin, R | 1 |
| Bair, J | 1 |
| Patel, H | 3 |
| Glantz, S | 1 |
| Yens, DP | 1 |
| Rosalia, A | 1 |
| Marguilies, J | 1 |
| Drury, P | 1 |
| Levi, C | 1 |
| McInnes, E | 1 |
| Hardy, J | 1 |
| Ward, J | 1 |
| Grimshaw, JM | 1 |
| D' Este, C | 1 |
| Dale, S | 2 |
| McElduff, P | 1 |
| Cheung, NW | 1 |
| Quinn, C | 1 |
| Griffiths, R | 1 |
| Evans, M | 1 |
| Cadilhac, D | 1 |
| Middleton, S | 1 |
| Weatherall, M | 3 |
| Haren, FM | 1 |
| Mackle, D | 3 |
| Webb, SA | 2 |
| Niven, DJ | 3 |
| Laupland, KB | 3 |
| Tabah, A | 1 |
| Vesin, A | 1 |
| Rello, J | 1 |
| Koulenti, D | 1 |
| Dimopoulos, G | 1 |
| de Waele, J | 1 |
| Timsit, JF | 1 |
| D'Elios, S | 1 |
| Mazzantini, R | 1 |
| Becherucci, P | 3 |
| Pierattelli, M | 1 |
| Galli, L | 3 |
| de Martino, M | 3 |
| Marzuillo, P | 1 |
| Guarino, S | 1 |
| Barbi, E | 1 |
| de Bont, EG | 1 |
| Brand, PL | 1 |
| Dinant, GJ | 1 |
| van Well, GT | 1 |
| Cals, J | 1 |
| Vijayakaran, K | 1 |
| Kannan, K | 1 |
| Kesavan, M | 1 |
| Suresh, S | 1 |
| Sankar, P | 1 |
| Tandan, SK | 1 |
| Sarkar, SN | 1 |
| Giamarellos-Bourboulis, EJ | 2 |
| Spyridaki, A | 1 |
| Savva, A | 1 |
| Georgitsi, M | 1 |
| Tsaganos, T | 2 |
| Mouktaroudi, M | 1 |
| Raftogiannis, M | 1 |
| Antonopoulou, A | 1 |
| Papaziogas, V | 1 |
| Baziaka, F | 1 |
| Sereti, K | 1 |
| Christopoulos, P | 1 |
| Marioli, A | 1 |
| Kanni, T | 1 |
| Maravitsa, P | 1 |
| Pantelidou, I | 1 |
| Leventogiannis, K | 1 |
| Tsiaoussis, P | 1 |
| Lymberopoulou, K | 1 |
| Koutelidakis, IM | 1 |
| Pauchard, JY | 1 |
| Gehri, M | 2 |
| Biswal, S | 1 |
| Sahoo, SS | 1 |
| Luyasu, S | 1 |
| Wamelink, MM | 1 |
| Galanti, L | 1 |
| Dive, A | 1 |
| Ahmadimanesh, M | 1 |
| Shadnia, S | 1 |
| Ghazi-Khansari, M | 1 |
| Duran, J | 1 |
| Siddique, S | 1 |
| Cleary, M | 1 |
| De Angelis, A | 1 |
| Villani, F | 1 |
| Antonini, MV | 1 |
| Rossi, I | 1 |
| Servadei, F | 1 |
| Caspani, ML | 1 |
| Doedée, AM | 1 |
| Boland, GJ | 1 |
| Pennings, JL | 1 |
| de Klerk, A | 1 |
| Berbers, GA | 1 |
| van der Klis, FR | 1 |
| de Melker, HE | 1 |
| van Loveren, H | 1 |
| Janssen, R | 1 |
| Kanabar, D | 2 |
| Nazarko, L | 1 |
| Lee, CI | 1 |
| Menzies, AM | 1 |
| Haydu, LE | 1 |
| Azer, M | 1 |
| Clements, A | 1 |
| Kefford, RF | 1 |
| Long, GV | 1 |
| Quartuccio, L | 1 |
| Maset, M | 1 |
| Soardo, G | 1 |
| Avellini, C | 1 |
| De Vita, S | 1 |
| Køstner, AH | 1 |
| Ellegaard, MB | 1 |
| Christensen, IJ | 1 |
| Bastholt, L | 1 |
| Schmidt, H | 1 |
| Mayooran, N | 1 |
| O'Cathain, E | 1 |
| Bresnihan, MN | 1 |
| Patil, N | 1 |
| Knox, C | 1 |
| Selker, E | 1 |
| Ito, T | 1 |
| Watanabe, S | 1 |
| Tsuruga, K | 1 |
| Aizawa, T | 1 |
| Hirono, K | 1 |
| Ito, E | 1 |
| Joh, K | 1 |
| Tanaka, H | 1 |
| Shastri, N | 1 |
| Chatterjee, T | 1 |
| Bhattacharyya, S | 1 |
| Yeh, KT | 1 |
| Wu, WT | 1 |
| Subeq, YM | 1 |
| Niu, CC | 1 |
| Liao, KW | 1 |
| Chen, IH | 1 |
| Wang, JH | 1 |
| Lee, RP | 1 |
| Young, P | 4 |
| Freebairn, R | 1 |
| Hammond, N | 1 |
| van Haren, F | 1 |
| Holliday, M | 1 |
| Henderson, S | 1 |
| McArthur, C | 1 |
| McGuinness, S | 1 |
| Webb, S | 1 |
| Beasley, R | 5 |
| Braccio, S | 1 |
| Ramsay, M | 1 |
| Ladhani, SN | 1 |
| Findlow, J | 1 |
| Taylor, C | 2 |
| Billot, L | 1 |
| Bompoint, S | 1 |
| Abourbih, DA | 1 |
| Gosselin, S | 1 |
| Villeneuve, E | 1 |
| Kazim, S | 1 |
| Lubrano, R | 1 |
| Paoli, S | 1 |
| Bonci, M | 1 |
| Di Ruzza, L | 1 |
| Cecchetti, C | 1 |
| Falsaperla, R | 1 |
| Pavone, P | 1 |
| Matin, N | 1 |
| Vitaliti, G | 1 |
| Gentile, I | 1 |
| Patel, J | 2 |
| Arik, G | 1 |
| Şengül Ayçiçek, G | 1 |
| Ulger, Z | 1 |
| Leiner, S | 1 |
| Bae, JI | 1 |
| Ahn, S | 1 |
| Kim, WY | 1 |
| Oh, BJ | 1 |
| Lim, KS | 1 |
| Bertille, N | 1 |
| Fournier-Charrière, E | 1 |
| Pons, G | 3 |
| Khoshnood, B | 1 |
| Chalumeau, M | 1 |
| Moriarty, C | 1 |
| Carroll, W | 1 |
| Mısırlıoğlu, ED | 1 |
| Akman, AÖ | 1 |
| Vezir, E | 1 |
| Başaran, Ö | 1 |
| Çakar, N | 1 |
| Kocabaş, CN | 1 |
| Zhang, XC | 1 |
| Siket, M | 1 |
| Binder, W | 1 |
| Sheehan, WJ | 2 |
| Mauger, DT | 1 |
| Moy, JN | 1 |
| Boehmer, SJ | 1 |
| Szefler, SJ | 1 |
| Fitzpatrick, AM | 1 |
| Jackson, DJ | 1 |
| Bacharier, LB | 1 |
| Cabana, MD | 1 |
| Covar, R | 1 |
| Holguin, F | 1 |
| Lemanske, RF | 1 |
| Martinez, FD | 1 |
| Pongracic, JA | 1 |
| Beigelman, A | 1 |
| Baxi, SN | 1 |
| Benson, M | 1 |
| Blake, K | 1 |
| Chmiel, JF | 1 |
| Daines, CL | 1 |
| Daines, MO | 1 |
| Gaffin, JM | 1 |
| Gentile, DA | 1 |
| Gower, WA | 1 |
| Israel, E | 1 |
| Kumar, HV | 1 |
| Lang, JE | 1 |
| Lazarus, SC | 1 |
| Lima, JJ | 1 |
| Ly, N | 1 |
| Marbin, J | 1 |
| Morgan, WJ | 1 |
| Myers, RE | 1 |
| Olin, JT | 1 |
| Peters, SP | 1 |
| Raissy, HH | 1 |
| Robison, RG | 1 |
| Ross, K | 1 |
| Sorkness, CA | 1 |
| Thyne, SM | 1 |
| Wechsler, ME | 1 |
| Phipatanakul, W | 2 |
| Mayor, S | 1 |
| Falup-Pecurariu, O | 1 |
| Man, SC | 1 |
| Neamtu, ML | 1 |
| Chicin, G | 1 |
| Baciu, G | 1 |
| Pitic, C | 1 |
| Cara, AC | 1 |
| Neculau, AE | 1 |
| Burlea, M | 1 |
| Brinza, IL | 1 |
| Schnell, CN | 1 |
| Sas, V | 1 |
| Lupu, VV | 1 |
| François, N | 1 |
| Swinnen, K | 1 |
| Borys, D | 2 |
| Lava, SA | 2 |
| Santi, M | 1 |
| Bianchetti, MG | 2 |
| Simonetti, GD | 2 |
| Tseti, IK | 1 |
| Tziolos, N | 1 |
| Soumelas, GS | 1 |
| Koupetori, M | 1 |
| Pyrpasopoulou, A | 1 |
| Akinosoglou, K | 1 |
| Gogos, C | 1 |
| Tsokos, N | 1 |
| Karagiannis, A | 1 |
| Sympardi, S | 1 |
| Matok, I | 1 |
| Elizur, A | 1 |
| Perlman, A | 1 |
| Ganor, S | 1 |
| Levine, H | 1 |
| Saleh, E | 1 |
| Swamy, GK | 1 |
| Moody, MA | 1 |
| Jayawardena, S | 1 |
| Kellstein, D | 1 |
| Yavuz, E | 1 |
| Yayla, E | 1 |
| Cebeci, SE | 1 |
| Kırımlı, E | 1 |
| Gümüştakım, RŞ | 1 |
| Çakır, L | 1 |
| Doğan, S | 1 |
| Uzoigwe, CE | 1 |
| Ali, OH | 1 |
| Sjoukes, A | 1 |
| Chiumello, D | 1 |
| Gotti, M | 1 |
| Vergani, G | 1 |
| Kanabar, DJ | 1 |
| Agbeko, RS | 1 |
| Davies, P | 2 |
| Davis, PJ | 1 |
| Deep, A | 1 |
| Fortune, PM | 1 |
| Inwald, DP | 1 |
| Jones, A | 1 |
| Levin, R | 1 |
| Morris, KP | 1 |
| Pappachan, J | 1 |
| Tibby, SM | 1 |
| Tume, LN | 1 |
| Khalil, SN | 1 |
| Hahn, BJ | 1 |
| Chumpitazi, CE | 1 |
| Rock, AD | 1 |
| Kaelin, BA | 1 |
| Macias, CG | 1 |
| Helbling, R | 1 |
| Conficconi, E | 1 |
| Wyttenbach, M | 1 |
| Benetti, C | 1 |
| Hamitaga, F | 1 |
| Fossali, EF | 1 |
| Wysocki, J | 1 |
| Center, KJ | 1 |
| Brzostek, J | 1 |
| Majda-Stanislawska, E | 1 |
| Szymanski, H | 1 |
| Szenborn, L | 1 |
| Czajka, H | 1 |
| Hasiec, B | 1 |
| Dziduch, J | 1 |
| Jackowska, T | 1 |
| Witor, A | 1 |
| Kopińska, E | 1 |
| Konior, R | 1 |
| Giardina, PC | 1 |
| Sundaraiyer, V | 1 |
| Patterson, S | 1 |
| Gruber, WC | 1 |
| Scott, DA | 1 |
| Gurtman, A | 1 |
| van Tuijl, JH | 1 |
| Jansen, BP | 1 |
| Van den Berg-Vos, RM | 1 |
| Vermeij, F | 1 |
| Solzbach, U | 1 |
| Knöpfle, N | 1 |
| Haas, H | 1 |
| Kramer, LC | 1 |
| Richards, PA | 1 |
| Thompson, AM | 1 |
| Harper, DP | 1 |
| Fairchok, MP | 1 |
| Yalçin, SS | 1 |
| Gümüş, A | 1 |
| Yurdakök, K | 1 |
| Kennedy, LD | 1 |
| Case, LD | 1 |
| Hurd, DD | 1 |
| Cruz, JM | 1 |
| Pomper, GJ | 1 |
| Costelloe, C | 3 |
| Redmond, NM | 2 |
| Montgomery, AA | 2 |
| Fletcher, M | 4 |
| Hollinghurst, S | 3 |
| Peters, TJ | 3 |
| Harnden, A | 1 |
| David, S | 1 |
| Vermeer-de Bondt, PE | 1 |
| van der Maas, NA | 1 |
| Redmond, N | 2 |
| Montgomery, A | 1 |
| Purssell, E | 5 |
| Clayton, T | 1 |
| Crane, J | 1 |
| von Mutius, E | 1 |
| Lai, CK | 1 |
| Montefort, S | 1 |
| Stewart, A | 1 |
| Ospina, CA | 1 |
| Salcedo, A | 1 |
| Hersch, M | 1 |
| Raveh, D | 1 |
| Izbicki, G | 1 |
| Moore, ND | 1 |
| Goldstein, LH | 1 |
| Berlin, M | 1 |
| Berkovitch, M | 3 |
| van Gijn, J | 5 |
| Tobian, AA | 1 |
| King, KE | 1 |
| Ness, PM | 1 |
| Warwick, C | 1 |
| Guo, SX | 1 |
| Cheng, Y | 1 |
| Glatstein, M | 1 |
| Scolnik, D | 5 |
| Yam, MF | 1 |
| Ang, LF | 1 |
| Basir, R | 1 |
| Salman, IM | 1 |
| Ameer, OZ | 1 |
| Asmawi, MZ | 1 |
| Celebi, S | 1 |
| Hacimustafaoglu, M | 1 |
| Aygun, D | 1 |
| Arisoy, ES | 1 |
| Karali, Y | 1 |
| Akgoz, S | 1 |
| Citak Kurt, AN | 1 |
| Seringec, M | 1 |
| Licht-Strunk, E | 1 |
| Koch, W | 1 |
| Zaffanello, M | 1 |
| Brugnara, M | 1 |
| Angeli, S | 1 |
| Cuzzolin, L | 1 |
| Duggan, ST | 1 |
| Scott, LJ | 1 |
| Tamada, I | 1 |
| David, DJ | 1 |
| Anderson, PJ | 1 |
| Kanashiro, A | 1 |
| Pessini, AC | 1 |
| Machado, RR | 1 |
| Malvar, Ddo C | 1 |
| Aguiar, FA | 1 |
| Soares, DM | 1 |
| do Vale, ML | 1 |
| de Souza, GE | 1 |
| Chua, YA | 1 |
| Nurhaslina, H | 1 |
| Gan, SH | 1 |
| Onay, OS | 1 |
| Erçoban, HS | 1 |
| Bayrakci, US | 1 |
| Melek, E | 1 |
| Cengiz, N | 1 |
| Baskin, E | 1 |
| Cohee, LM | 1 |
| Crocetti, MT | 1 |
| Serwint, JR | 3 |
| Sabath, B | 1 |
| Kapoor, S | 1 |
| Southey, ER | 1 |
| Soares-Weiser, K | 1 |
| Kleijnen, J | 2 |
| Niazi, J | 1 |
| Singh, P | 1 |
| Bansal, Y | 1 |
| Goel, RK | 1 |
| Kedzia, A | 1 |
| Bołdys, A | 1 |
| Krysiak, R | 1 |
| Szkróbka, W | 1 |
| Okopień, B | 1 |
| Greenberg, RS | 1 |
| Chen, H | 1 |
| Hasday, JD | 1 |
| Nabulsi, M | 2 |
| Principi, N | 2 |
| Longhi, R | 2 |
| Tovo, PA | 2 |
| Bonsignori, F | 2 |
| Esposito, S | 3 |
| Festini, F | 2 |
| Lucchesi, B | 2 |
| Mugelli, A | 2 |
| Chen, RT | 1 |
| Clark, TA | 1 |
| Halperin, SA | 1 |
| Prymula, R | 1 |
| Siegrist, CA | 1 |
| Chlibek, R | 1 |
| Zemlickova, H | 1 |
| Vackova, M | 1 |
| Smetana, J | 1 |
| Lommel, P | 1 |
| Kaliskova, E | 1 |
| Schuerman, L | 1 |
| Good, P | 1 |
| Fowler, AW | 1 |
| Bareiss, D | 1 |
| Semela, D | 1 |
| Heim, M | 1 |
| Terracciano, L | 1 |
| Hunziker, S | 1 |
| Siddiqi, A | 1 |
| Morkel, JA | 1 |
| Zafar, S | 1 |
| Tapiainen, T | 1 |
| Dunder, T | 1 |
| Möttönen, M | 1 |
| Pokka, T | 1 |
| Uhari, M | 2 |
| Amabeoku, GJ | 1 |
| Erasmus, SJ | 1 |
| Ojewole, JA | 1 |
| Mukinda, JT | 1 |
| Pierce, CA | 1 |
| Voss, B | 1 |
| Kokki, H | 2 |
| Kokki, M | 2 |
| Crook, J | 1 |
| Jensen, JF | 1 |
| Tønnesen, LL | 1 |
| Söderström, M | 2 |
| Thorsen, H | 1 |
| Siersma, V | 2 |
| Miller, RJ | 1 |
| Bailey, J | 1 |
| Sullivan, K | 1 |
| Martí-Carvajal, AJ | 1 |
| Solà, I | 1 |
| González, LE | 1 |
| Leon de Gonzalez, G | 1 |
| Rodriguez-Malagon, N | 1 |
| Schultz, ST | 1 |
| Boyle, M | 1 |
| Nicholson, L | 1 |
| O'Brien, M | 1 |
| Flynn, GM | 1 |
| Collins, DW | 1 |
| Walsh, WR | 1 |
| Bihari, D | 1 |
| Allan, GM | 1 |
| Ivers, N | 1 |
| Shevchuk, Y | 1 |
| Schnabel, E | 1 |
| Heinrich, J | 1 |
| Thompson, HJ | 1 |
| Kagan, SH | 1 |
| Jahr, JS | 1 |
| Lee, VK | 1 |
| Dixson, M | 1 |
| Silverman, SL | 1 |
| Kriegman, A | 1 |
| Goncalves, J | 1 |
| Kianifard, F | 1 |
| Carlson, T | 1 |
| Leary, E | 1 |
| Candiotti, KA | 1 |
| Bergese, SD | 1 |
| Viscusi, ER | 1 |
| Singla, SK | 1 |
| Royal, MA | 3 |
| Singla, NK | 1 |
| Trainor, JL | 1 |
| Stamos, JK | 1 |
| Hopchet, L | 1 |
| Kulo, A | 1 |
| Rayyan, M | 1 |
| Verbesselt, R | 1 |
| Vanhole, C | 1 |
| de Hoon, JN | 1 |
| Allegaert, K | 1 |
| Kallmünzer, B | 1 |
| Krause, C | 1 |
| Pauli, E | 1 |
| Beck, A | 1 |
| Breuer, L | 1 |
| Köhrmann, M | 1 |
| Kollmar, R | 1 |
| Meisel, A | 1 |
| Andabaka, T | 1 |
| Globočnik, T | 1 |
| Vukelić, D | 1 |
| Baršić, B | 1 |
| Wark, JD | 1 |
| Bensen, W | 1 |
| Recknor, C | 1 |
| Ryabitseva, O | 1 |
| Chiodo, J | 1 |
| Mesenbrink, P | 1 |
| de Villiers, TJ | 1 |
| Sturgis, SA | 1 |
| Yang, C | 1 |
| Engle, L | 1 |
| Watts, H | 1 |
| Berlin, CM | 1 |
| Peacock, WF | 1 |
| Breitmeyer, JB | 2 |
| Pan, C | 1 |
| Smith, WB | 1 |
| Mullins, ME | 1 |
| Empey, M | 1 |
| Jaramillo, D | 1 |
| Sosa, S | 1 |
| Human, T | 1 |
| Diringer, MN | 1 |
| Ochi, H | 1 |
| Wada, K | 1 |
| Okada, H | 1 |
| Kohara, N | 1 |
| Fujita, T | 1 |
| Toda, K | 1 |
| Sakamoto, M | 1 |
| Seguchi, O | 1 |
| Murata, Y | 1 |
| Yanase, M | 1 |
| Nakatani, T | 1 |
| Kett, DH | 1 |
| Ang, R | 1 |
| Chang, MC | 1 |
| Chen, YC | 1 |
| Chang, SC | 1 |
| Smith, GD | 1 |
| Ziemann-Gimmel, P | 1 |
| Eastwood, GM | 1 |
| Kofoed, PE | 1 |
| Ursing, J | 1 |
| Rodrigues, A | 1 |
| Rombo, L | 1 |
| Salichs, M | 1 |
| Sabaté, D | 1 |
| Ciervo, O | 1 |
| Homedes, J | 1 |
| Jackson, LA | 1 |
| Peterson, D | 1 |
| Dunn, J | 1 |
| Hambidge, SJ | 1 |
| Dunstan, M | 1 |
| Starkovich, P | 1 |
| Yu, O | 1 |
| Benoit, J | 1 |
| Dominguez-Islas, CP | 1 |
| Carste, B | 1 |
| Benson, P | 1 |
| Nelson, JC | 1 |
| Senel, S | 1 |
| Erkek, N | 1 |
| Karacan, CD | 1 |
| Maesschalck, PJ | 1 |
| Oziegbe, EO | 1 |
| Esan, TA | 1 |
| Adekoya-Sofowora, CA | 1 |
| Folayan, MO | 1 |
| Lanas, A | 1 |
| McCarthy, D | 1 |
| Voelker, M | 2 |
| Brueckner, A | 1 |
| Senn, S | 1 |
| Baron, JA | 1 |
| Pickens, LA | 1 |
| Meinke, SM | 1 |
| Mohr, NM | 1 |
| Fuller, BM | 1 |
| Skrupky, LP | 1 |
| Moy, H | 2 |
| Alunday, R | 2 |
| Micek, ST | 1 |
| Fagley, RE | 1 |
| Eyers, S | 1 |
| Jefferies, S | 1 |
| Shirtcliffe, P | 1 |
| Perrin, K | 1 |
| Wrotek, SE | 1 |
| Kozak, WE | 1 |
| Hess, DC | 1 |
| Fagan, SC | 1 |
| Dhingra, B | 1 |
| Mishra, D | 1 |
| Reade, MC | 1 |
| Léger, C | 2 |
| Kubes, P | 2 |
| Stelfox, HT | 2 |
| Vera, P | 1 |
| Zapata, L | 1 |
| Gich, I | 1 |
| Mancebo, J | 1 |
| Betbesé, AJ | 1 |
| Mpharm, TB | 1 |
| Kumar, CT | 1 |
| Egi, M | 1 |
| Argentieri, J | 1 |
| Morrone, K | 1 |
| Pollack, Y | 1 |
| Hoover, L | 1 |
| McCarthy, DM | 1 |
| Thirstrup, S | 1 |
| Lundstrøm, KE | 1 |
| Muhammad, N | 1 |
| Saeed, M | 1 |
| Khan, H | 1 |
| Smith, C | 1 |
| Goldman, RD | 4 |
| Venturini, E | 1 |
| Mirmoghtadaee, P | 1 |
| Sabzghabaee, AM | 1 |
| Bagheri, M | 1 |
| Soltani, R | 1 |
| Obu, HA | 1 |
| Chinawa, JM | 1 |
| Ubesie, AC | 1 |
| Eke, CB | 1 |
| Ndu, IK | 1 |
| George, M | 1 |
| Phelps, MA | 1 |
| Kitzmiller, JP | 1 |
| Pereira, GL | 1 |
| Dagostini, JM | 1 |
| Pizzol, Tda S | 1 |
| Mohr, N | 1 |
| Skrupky, L | 1 |
| Fuller, B | 1 |
| Wallendorf, M | 1 |
| Micek, S | 1 |
| Fagley, R | 1 |
| van den Anker, JN | 1 |
| van Haren, FM | 1 |
| Oberoi, S | 1 |
| Trehan, A | 1 |
| Marwaha, RK | 1 |
| Bansal, D | 1 |
| Ertmann, RK | 1 |
| Møller, JJ | 1 |
| Waldorff, FB | 1 |
| Reventlow, S | 1 |
| Bardage, C | 1 |
| Westerlund, T | 1 |
| Barzi, S | 1 |
| Bernsten, C | 1 |
| Ghosh, S | 1 |
| Pandya, N | 1 |
| Naik, S | 1 |
| Åkerman, F | 1 |
| Mahoney, LM | 1 |
| Chang, F | 1 |
| Orav, EJ | 1 |
| Plasek, J | 1 |
| Boulware, LJ | 1 |
| Bates, DW | 1 |
| Nolent, P | 1 |
| Jacobson, S | 1 |
| Diamond, S | 1 |
| Young, NL | 1 |
| Takagi, K | 1 |
| Goetzl, L | 2 |
| Evans, T | 2 |
| Rivers, J | 2 |
| Suresh, MS | 2 |
| Lieberman, E | 2 |
| Cruz, P | 1 |
| Garutti, I | 1 |
| Díaz, S | 1 |
| Fernández-Quero, L | 1 |
| Locham, KK | 1 |
| Sodhi, M | 1 |
| Jindal, G | 1 |
| Mason, S | 1 |
| Thorp, S | 1 |
| Burke, D | 1 |
| Oborilová, A | 1 |
| Mayer, J | 1 |
| Pospísil, Z | 1 |
| Korístek, Z | 1 |
| Chattopadhyay, D | 1 |
| Arunachalam, G | 1 |
| Mandal, AB | 1 |
| Mandal, SC | 3 |
| Rao, RB | 1 |
| Anupama, K | 1 |
| Swaroop, KR | 1 |
| Murugesan, T | 1 |
| Pal, M | 1 |
| Watts, R | 1 |
| Robertson, J | 2 |
| Thomas, G | 1 |
| Amdekar, YK | 2 |
| Khubchandani, RP | 2 |
| van Breda, EJ | 6 |
| Meijer, RJ | 2 |
| Lesko, SM | 6 |
| Devi, BP | 1 |
| Boominathan, R | 1 |
| Meremikwu, M | 2 |
| Oyo-Ita, A | 2 |
| Moore, PK | 1 |
| Marshall, M | 1 |
| Russell, FM | 1 |
| Shann, F | 2 |
| Curtis, N | 1 |
| Mulholland, K | 1 |
| Giles, FJ | 1 |
| Cortes, JE | 1 |
| Halliburton, TA | 1 |
| Mallard, SJ | 1 |
| Estey, EH | 1 |
| Waddelow, TA | 1 |
| Lim, JT | 1 |
| GARCIAHERRERA, E | 1 |
| Havinga, W | 1 |
| Lagerløv, P | 4 |
| Helseth, S | 1 |
| Holager, T | 3 |
| Sulter, G | 1 |
| Elting, JW | 1 |
| Maurits, N | 1 |
| Luijckx, GJ | 1 |
| Luyckx, GJ | 1 |
| De Keyser, J | 1 |
| Gozzoli, V | 1 |
| Treggiari, MM | 1 |
| Kleger, GR | 1 |
| Roux-Lombard, P | 1 |
| Fathi, M | 1 |
| Pichard, C | 2 |
| Romand, JA | 2 |
| Huang, WT | 1 |
| Wang, JJ | 1 |
| Lin, MT | 1 |
| Ko, K | 1 |
| Linett, LJ | 1 |
| Wahba, H | 1 |
| Geffroy, A | 1 |
| Bronchard, R | 1 |
| Merckx, P | 1 |
| Seince, PF | 1 |
| Faillot, T | 1 |
| Albaladejo, P | 1 |
| Marty, J | 1 |
| Losek, JD | 1 |
| Citron, DR | 1 |
| Richardson, BE | 1 |
| Perrott, DA | 1 |
| Piira, T | 1 |
| Goodenough, B | 1 |
| Champion, GD | 1 |
| Westergren, T | 2 |
| Aamodt, G | 2 |
| Río, J | 3 |
| Nos, C | 1 |
| Bonaventura, I | 1 |
| Arroyo, R | 1 |
| Genis, D | 1 |
| Sureda, B | 1 |
| Ara, JR | 1 |
| Brieva, L | 1 |
| Martín, J | 1 |
| Saiz, A | 1 |
| Sánchez López, F | 1 |
| Prieto, JM | 1 |
| Roquer, J | 1 |
| Dorado, JF | 1 |
| Montalban, X | 3 |
| Ezidiegwu, CN | 1 |
| Lauenstein, KJ | 1 |
| Rosales, LG | 1 |
| Kelly, KC | 1 |
| Henry, JB | 1 |
| Mennick, F | 1 |
| Richardson, J | 1 |
| Sills, J | 1 |
| Carabaño Aguado, I | 1 |
| Jiménez López, I | 1 |
| López-Cerón Pinilla, M | 1 |
| Calvo García, I | 1 |
| Pello Lázaro, AM | 1 |
| Balugo Bengoechea, P | 1 |
| Baro Fernández, M | 1 |
| Ruiz Contreras, J | 1 |
| Walsh, AM | 1 |
| Edwards, HE | 1 |
| Courtney, MD | 1 |
| Wilson, JE | 1 |
| Monaghan, SJ | 1 |
| Smitherman, LC | 1 |
| Janisse, J | 1 |
| Mathur, A | 1 |
| Huang, X | 1 |
| Zhang, Z | 2 |
| Liu, W | 1 |
| Tang, S | 1 |
| Han, X | 1 |
| Su, F | 1 |
| Nguyen, ND | 1 |
| Wang, Z | 1 |
| Cai, Y | 1 |
| Rogiers, P | 1 |
| Vincent, JL | 1 |
| Zylicz, Z | 1 |
| Krajnik, M | 1 |
| Taéron, C | 1 |
| Reilly, DR | 1 |
| Oppenheimer, LW | 1 |
| Humphreys, BD | 1 |
| Forman, JP | 1 |
| Zandi-Nejad, K | 1 |
| Bazari, H | 1 |
| Seifter, J | 1 |
| Magee, CC | 1 |
| Charkaluk, ML | 1 |
| Kalach, N | 1 |
| El Kohen, R | 1 |
| Kremp, O | 1 |
| Guignard, E | 1 |
| Djahnine, SR | 1 |
| Cotting, JQ | 1 |
| Yersin, C | 1 |
| Di Paolo, ER | 1 |
| Krahenbuhl, JD | 1 |
| Pannatier, A | 1 |
| Sanders, RP | 1 |
| Maddirala, SD | 1 |
| Geiger, TL | 2 |
| Pounds, S | 1 |
| Sandlund, JT | 1 |
| Ribeiro, RC | 1 |
| Pui, CH | 1 |
| Howard, SC | 2 |
| Tamim, H | 2 |
| Sabra, R | 2 |
| Mahfoud, Z | 2 |
| Malaeb, S | 1 |
| Fakih, H | 1 |
| Mikati, M | 2 |
| Bachert, C | 1 |
| Chuchalin, AG | 1 |
| Eisebitt, R | 1 |
| Netayzhenko, VZ | 1 |
| Schulman, CI | 1 |
| Namias, N | 1 |
| Doherty, J | 1 |
| Manning, RJ | 1 |
| Li, P | 2 |
| Elhaddad, A | 1 |
| Alhaddad, A | 1 |
| Lasko, D | 1 |
| Amortegui, J | 1 |
| Dy, CJ | 1 |
| Dlugasch, L | 1 |
| Baracco, G | 1 |
| Cohn, SM | 1 |
| Sarrell, EM | 1 |
| Wielunsky, E | 1 |
| Cohen, HA | 1 |
| Erlewyn-Lajeunesse, MD | 1 |
| Coppens, K | 1 |
| Hunt, LP | 1 |
| Chinnick, PJ | 1 |
| Higginson, IM | 1 |
| Benger, JR | 1 |
| Okumura, A | 1 |
| Fukumoto, Y | 1 |
| Hayakawa, F | 1 |
| Nakano, T | 1 |
| Higuchi, K | 1 |
| Kamiya, H | 1 |
| Watanabe, K | 1 |
| Morishima, T | 1 |
| Nabulsi, MM | 1 |
| Itani, M | 1 |
| Chamseddine, F | 1 |
| Duncan, P | 1 |
| Aref-Adib, G | 1 |
| Venn, A | 1 |
| Britton, J | 1 |
| Davey, G | 1 |
| Rüster, M | 1 |
| Kiehntopf, M | 1 |
| Gröne, HJ | 1 |
| Wolf, G | 1 |
| Rodríguez Serna, A | 1 |
| Astobiza Beobide, E | 1 |
| González Balenciaga, M | 1 |
| Azkunaga Santibáñez, B | 1 |
| Benito Fernández, J | 1 |
| Mintegi Raso, S | 1 |
| Derasse, M | 1 |
| Klein, P | 1 |
| Weiser, M | 1 |
| Saphyakhajon, P | 1 |
| Greene, G | 1 |
| Schmitt, BD | 1 |
| Jones, J | 1 |
| Chesney, R | 1 |
| Rodarte, A | 1 |
| Bilenko, N | 1 |
| Tessler, H | 1 |
| Okbe, R | 1 |
| Press, J | 1 |
| Gorodischer, R | 1 |
| Eccles, R | 1 |
| Yadav, MR | 1 |
| Nimekar, DM | 1 |
| Ananthakrishnan, A | 1 |
| Brahmkshatriya, PS | 1 |
| Shirude, ST | 1 |
| Giridhar, R | 1 |
| Parmar, A | 1 |
| Balaraman, R | 1 |
| Hugosson, E | 1 |
| Montgomery, SM | 1 |
| Premji, Z | 1 |
| Troye-Blomberg, M | 1 |
| Björkman, A | 1 |
| Loeb, M | 1 |
| Slettevoll, J | 1 |
| Lingjaerde, OC | 1 |
| Fetveit, A | 1 |
| Ranganathan, SS | 1 |
| Sathiadas, MG | 1 |
| Sumanasena, S | 1 |
| Fernandopulle, M | 1 |
| Lamabadusuriya, SP | 1 |
| Fernandopulle, BM | 1 |
| Suzuki, E | 1 |
| Ichihara, K | 1 |
| Johnson, AM | 1 |
| Erhan, E | 1 |
| Inal, MT | 1 |
| Aydinok, Y | 1 |
| Balkan, C | 1 |
| Yegul, I | 1 |
| Fernandez, A | 1 |
| Schmidt, JM | 1 |
| Claassen, J | 1 |
| Pavlicova, M | 1 |
| Huddleston, D | 1 |
| Kreiter, KT | 1 |
| Ostapkovich, ND | 1 |
| Kowalski, RG | 1 |
| Parra, A | 1 |
| Connolly, ES | 1 |
| Mayer, SA | 1 |
| Wright, AD | 1 |
| Liebelt, EL | 2 |
| Duhamel, JF | 1 |
| Le Gall, E | 1 |
| Dalphin, ML | 1 |
| Payen-Champenois, C | 1 |
| Alves, JG | 1 |
| Cardoso Neto, FJ | 1 |
| Almeida, CD | 1 |
| Almeida, ND | 1 |
| Wong, AA | 1 |
| Davis, JP | 1 |
| Schluter, PJ | 1 |
| Henderson, RD | 1 |
| O'Sullivan, JD | 1 |
| Read, SJ | 2 |
| Green, JL | 1 |
| Bogdan, GM | 1 |
| Knox, PC | 1 |
| Palmer, RB | 1 |
| Heard, K | 1 |
| Slattery, JT | 1 |
| Dart, RC | 2 |
| Deligne, J | 1 |
| Grimaldi, L | 1 |
| Jonville-Béra, AP | 1 |
| Giraudeau, B | 1 |
| Blum-Boisgard, C | 1 |
| Autret-Leca, E | 2 |
| Feleder, C | 2 |
| Perlik, V | 2 |
| Blatteis, CM | 2 |
| Walsh, A | 1 |
| Edwards, H | 1 |
| Fraser, J | 1 |
| Balci, Y | 1 |
| Tok, M | 1 |
| Kocaturk, BK | 1 |
| Yenilmez, C | 1 |
| Yirulmaz, C | 1 |
| Warren, B | 1 |
| Gibb, IA | 1 |
| Goulder, MA | 1 |
| Miller, AA | 1 |
| Lowe, CM | 1 |
| Grube, RR | 1 |
| Scates, AC | 1 |
| Brown, JM | 1 |
| Udomphorn, Y | 1 |
| Suz, P | 1 |
| Vavilala, MS | 1 |
| Hata, JS | 1 |
| Shelsky, CR | 1 |
| Hindman, BJ | 1 |
| Smith, TC | 1 |
| Simmons, JS | 1 |
| Todd, MM | 1 |
| Hu, YJ | 1 |
| Sun, GM | 1 |
| Hahn, Y | 1 |
| Chaim, AB | 1 |
| Brandriss, N | 1 |
| Verjee, Z | 1 |
| Mor, A | 1 |
| Goldman, M | 1 |
| Gupta, H | 1 |
| Gupta, P | 1 |
| Sharma, KK | 1 |
| Rawat, M | 1 |
| Ahrenstorf, G | 1 |
| Burkhardt, O | 1 |
| Witte, T | 1 |
| Stoll, M | 1 |
| Schmidt, RE | 1 |
| Listernick, R | 1 |
| Alonso, E | 1 |
| Goodman, D | 1 |
| Adler, M | 1 |
| Katz, B | 1 |
| Wainwright, M | 1 |
| Nguyen, P | 1 |
| Wang, YM | 1 |
| Huang, MC | 1 |
| Petitpain, N | 1 |
| Goffinet, L | 1 |
| Cosserat, F | 1 |
| Trechot, P | 1 |
| Cuny, JF | 1 |
| Evron, S | 1 |
| Ezri, T | 1 |
| Protianov, M | 1 |
| Muzikant, G | 1 |
| Sadan, O | 1 |
| Herman, A | 1 |
| Szmuk, P | 1 |
| Eden, AN | 2 |
| Kaufman, A | 1 |
| Levy, RL | 1 |
| Chiarillo, S | 1 |
| Ames, JT | 1 |
| Hayden, GF | 1 |
| Campbell, RE | 1 |
| Lohr, JA | 1 |
| Bensaude, I | 1 |
| Modaï, I | 1 |
| Petrus, M | 1 |
| Done, AK | 2 |
| Gladtke, E | 1 |
| Addy, DP | 1 |
| Wilson, G | 1 |
| Guerra, AJ | 1 |
| Santos, NT | 1 |
| Nahata, MC | 1 |
| Powell, DA | 1 |
| Durrell, DE | 1 |
| Miller, MA | 1 |
| Sweet, L | 1 |
| Lewis, JM | 1 |
| Ghosh, JB | 1 |
| Chatterjee, A | 1 |
| Mahalanabis, D | 1 |
| Das, S | 1 |
| Murphy, MT | 1 |
| Richards, DB | 1 |
| Lipton, JM | 4 |
| Holý, J | 1 |
| Weiss, J | 1 |
| Herskowitz, L | 1 |
| Velásquez-Jones, L | 1 |
| Jean, R | 1 |
| Lesbros, D | 1 |
| Ariole, P | 1 |
| Jackson, CH | 1 |
| MacDonald, NC | 1 |
| Cornett, JW | 1 |
| de Paillerets, F | 1 |
| Furioli, J | 1 |
| Roscioni, C | 1 |
| De Ritis, G | 1 |
| Lotti, A | 1 |
| Pozzessere, C | 1 |
| De Rossi, P | 1 |
| Granato, C | 1 |
| Bruno, VF | 1 |
| Nola, P | 1 |
| Morabito, F | 1 |
| De Tommaso, G | 1 |
| Pesanti, E | 1 |
| Roberts, R | 1 |
| Wilson, JT | 5 |
| Brown, RD | 5 |
| Bocchini, JA | 2 |
| Kearns, GL | 4 |
| Yaffe, SJ | 1 |
| Dittmer, A | 1 |
| Mariani, L | 1 |
| Baratelli, M | 1 |
| Mitchell, AA | 6 |
| Lovejoy, FH | 2 |
| Slone, D | 1 |
| Shapiro, S | 1 |
| Brusquet, Y | 1 |
| Nezri, M | 1 |
| Liedtke, RK | 1 |
| MacKintosh, DA | 1 |
| Bowie, J | 1 |
| Baird-Lambert, J | 1 |
| Buchanan, N | 1 |
| Suma, V | 1 |
| Lupone, N | 1 |
| Beauregard, WG | 1 |
| Cunietti, E | 2 |
| Monti, M | 2 |
| Viganò, A | 2 |
| D'Aprile, E | 2 |
| Saligari, A | 2 |
| Scafuro, E | 2 |
| Scaricabarozzi, I | 3 |
| Polidori, G | 1 |
| Titti, G | 1 |
| Pieragostini, P | 1 |
| Comito, A | 1 |
| Berg, AT | 1 |
| Shinnar, S | 1 |
| Shapiro, ED | 1 |
| Salomon, ME | 1 |
| Crain, EF | 1 |
| Hauser, WA | 1 |
| Jákó, J | 1 |
| Arató, G | 1 |
| Cooney, K | 1 |
| Faschingbauer, C | 1 |
| Gadomski, AM | 1 |
| Permutt, T | 1 |
| Stanton, B | 1 |
| Stevens, T | 1 |
| Fitzsimmons, L | 1 |
| Goodwin, SD | 1 |
| Cleary, JD | 1 |
| Walawander, CA | 1 |
| Taylor, JW | 1 |
| Grasela, TH | 1 |
| Rothrock, SG | 1 |
| Green, SM | 1 |
| Sugimura, T | 1 |
| Fujimoto, T | 1 |
| Motoyama, H | 1 |
| Maruoka, T | 1 |
| Korematu, S | 1 |
| Asakuno, Y | 1 |
| Hayakawa, H | 1 |
| Vargas, R | 2 |
| Maneatis, T | 1 |
| Bynum, L | 1 |
| Peterson, C | 1 |
| McMahon, FG | 2 |
| Wilairatana, P | 1 |
| Looareesuwan, S | 1 |
| Stamm, D | 1 |
| Mahar, AF | 1 |
| Allen, SJ | 1 |
| Milligan, P | 2 |
| Suthumnirund, S | 1 |
| Chotpitayasunondh, T | 1 |
| Sabchareon, A | 1 |
| Coulter, JB | 1 |
| Regdon, G | 2 |
| Szikszay, M | 1 |
| Gebri, G | 1 |
| Rodriguez, WJ | 1 |
| Hall, CB | 1 |
| Welliver, R | 1 |
| Simoes, EA | 1 |
| Ryan, ME | 1 |
| Stutman, H | 1 |
| Johnson, G | 1 |
| Van Dyke, R | 1 |
| Groothuis, JR | 1 |
| Arrobio, J | 1 |
| Gerson, C | 1 |
| Mazur, LJ | 1 |
| Kozinetz, CA | 1 |
| Autret, E | 3 |
| Breart, G | 1 |
| Jonville, AP | 1 |
| Courcier, S | 2 |
| Lassale, C | 1 |
| Goehrs, JM | 2 |
| Uchino, H | 1 |
| Lundgren, J | 1 |
| Smith, ML | 1 |
| Siesjö, BK | 1 |
| Adam, D | 1 |
| Stankov, G | 1 |
| Bernal Ruiz, ML | 1 |
| Sinues Porta, B | 1 |
| Lanuza Giménez, J | 1 |
| Gracia Casanova, M | 1 |
| Mayayo Dehesa, E | 1 |
| Bartolomé Rodríguez, M | 1 |
| Schnaiderman, D | 1 |
| Lahat, E | 1 |
| Sheefer, T | 1 |
| Aladjem, M | 1 |
| Wilkinson, MF | 2 |
| Kasting, NW | 2 |
| Guignard, JP | 1 |
| Bonadio, WA | 1 |
| Bellomo, T | 1 |
| Brady, W | 1 |
| Smith, D | 1 |
| Feldman, S | 1 |
| Perry, CS | 1 |
| Andrew, M | 1 |
| Jones, L | 1 |
| Moffitt, JE | 1 |
| Lamb, D | 1 |
| Meschievitz, C | 1 |
| First, MR | 1 |
| Schroeder, TJ | 1 |
| Hariharan, S | 1 |
| Weiskittel, P | 1 |
| Kokwaro, GO | 1 |
| Glazier, AP | 1 |
| Ward, SA | 1 |
| Breckenridge, AM | 1 |
| Edwards, G | 1 |
| Penna, AC | 1 |
| Dawson, KP | 1 |
| Penna, CM | 1 |
| Alonso, EM | 1 |
| Sokol, RJ | 1 |
| Hart, J | 1 |
| Tyson, RW | 1 |
| Narkewicz, MR | 1 |
| Whitington, PF | 1 |
| McIntyre, J | 1 |
| Hull, D | 1 |
| Ghatikar, KN | 1 |
| Keny, S | 1 |
| Usgaonkar, NG | 1 |
| Dubey, NK | 1 |
| Jajoo, D | 1 |
| Gupta, A | 1 |
| Sharma, D | 2 |
| Reboul-Marty, J | 1 |
| Henry-Launois, B | 1 |
| Laborde, C | 1 |
| Languillat, G | 1 |
| Launois, R | 1 |
| Poblete, B | 1 |
| König, P | 1 |
| Suter, PM | 1 |
| Sharber, J | 1 |
| Aksoylar, S | 1 |
| Akşit, S | 1 |
| Cağlayan, S | 1 |
| Yaprak, I | 1 |
| Bakiler, R | 1 |
| Cetin, F | 1 |
| Gabriel, CM | 1 |
| Minor, JR | 1 |
| Vogel, S | 1 |
| Piscitelli, SC | 1 |
| Havinga, WH | 1 |
| Shapovalova, VO | 1 |
| Chernykh, VP | 1 |
| St Charles, CS | 1 |
| Matt, BH | 1 |
| Hamilton, MM | 1 |
| Katz, BP | 1 |
| Simon, HK | 1 |
| Weinkle, DA | 1 |
| Melis, R | 1 |
| Block, S | 1 |
| Brandts, CH | 1 |
| Ndjavé, M | 1 |
| Graninger, W | 1 |
| Kremsner, PG | 1 |
| Rajeshwari, K | 1 |
| Anderson, BJ | 2 |
| Holford, NH | 2 |
| Vauzelle-Kervroëdan, F | 1 |
| d'Athis, P | 2 |
| Pariente-Khayat, A | 1 |
| Debregeas, S | 1 |
| Olive, G | 1 |
| Zuev, VP | 2 |
| Minkin, LN | 2 |
| Evglevskaia, IuP | 2 |
| Agbolosu, NB | 1 |
| Cuevas, LE | 1 |
| Broadhead, RL | 1 |
| Brewster, D | 1 |
| Graham, SM | 1 |
| Salminen, WF | 1 |
| Voellmy, R | 1 |
| Roberts, SM | 1 |
| Kádas, I | 1 |
| Könczöl, F | 1 |
| Illés, T | 1 |
| Leary, PM | 1 |
| Walker, KG | 1 |
| van der Meulen, W | 1 |
| Monteleone, J | 1 |
| Martínez-Cáceres, EM | 1 |
| Barrau, M | 1 |
| Durán, I | 1 |
| Borrás, C | 1 |
| Tintoré, M | 1 |
| Mofenson, HC | 1 |
| McFee, R | 1 |
| Caraccio, T | 1 |
| Greensher, J | 1 |
| Hayward, J | 1 |
| Veale, B | 1 |
| Carley, S | 1 |
| Goyal, PK | 1 |
| Chandra, J | 3 |
| Unnikrishnan, G | 1 |
| Kumari, S | 1 |
| Passah, SM | 1 |
| Howell, TK | 1 |
| Pernerstorfer, T | 1 |
| Schmid, R | 1 |
| Bieglmayer, C | 1 |
| Eichler, HG | 1 |
| Kapiotis, S | 1 |
| Jilma, B | 1 |
| Stegelman, M | 1 |
| Houry, D | 1 |
| Ernst, A | 1 |
| Weiss, S | 1 |
| Ledbetter, M | 1 |
| Cesaro, S | 1 |
| Bortolotti, F | 1 |
| Petris, MG | 1 |
| Brugiolo, A | 1 |
| Cusinato, R | 1 |
| Guido, M | 1 |
| Rossetti, F | 1 |
| Masiero, L | 1 |
| Zanesco, L | 1 |
| Ulukol, B | 1 |
| Köksal, Y | 1 |
| Cin, S | 1 |
| Hochstein, HD | 1 |
| Halevi, A | 1 |
| Ben-Amitai, D | 1 |
| Garty, BZ | 1 |
| Linder, N | 1 |
| Sirota, L | 1 |
| Snapir, A | 1 |
| Eisen, I | 1 |
| Davidovitch, N | 1 |
| Kaplan, G | 1 |
| Barzilai, A | 1 |
| Helms, R | 1 |
| Pickering, BD | 1 |
| Donahue, L | 1 |
| Jacqz-Aigrain, E | 1 |
| Dally Gotfrid, C | 1 |
| Viner, Y | 1 |
| Luder, A | 1 |
| Simmons, DL | 1 |
| Wagner, D | 1 |
| Westover, K | 1 |
| Plaisance, KI | 2 |
| Kudaravalli, S | 1 |
| Wasserman, SS | 1 |
| Levine, MM | 1 |
| Mackowiak, PA | 1 |
| Boysen, G | 1 |
| Christensen, H | 1 |
| Lal, A | 1 |
| Gomber, S | 1 |
| Talukdar, B | 1 |
| Rumack, BH | 1 |
| Cranswick, N | 1 |
| Coghlan, D | 1 |
| Prescott, LF | 1 |
| O'Brien, KL | 1 |
| Schwartz, B | 1 |
| Vezina, R | 1 |
| Jain, JK | 1 |
| Harwood, B | 1 |
| Meckstroth, KR | 1 |
| Mishell, DR | 1 |
| Henker, R | 1 |
| Rogers, S | 1 |
| Kramer, DJ | 1 |
| Kelso, L | 1 |
| Kerr, M | 1 |
| Sereika, S | 1 |
| Gunn, VL | 1 |
| Taha, SH | 1 |
| Tréluyer, JM | 1 |
| Tonnelier, S | 1 |
| Leclerc, B | 1 |
| Jolivet-Landreau, I | 1 |
| Del Vecchio, MT | 1 |
| Sundel, ER | 1 |
| Díez Domingo, J | 1 |
| Burgos Ramírez, A | 1 |
| Garrido García, J | 1 |
| Ballester Sanz, A | 1 |
| Moreno Carretero, E | 1 |
| Legos, JJ | 1 |
| Mangoni, AA | 1 |
| Campbell, CA | 1 |
| Irving, EA | 1 |
| Roberts, J | 1 |
| Barone, FC | 1 |
| Parsons, AA | 1 |
| Kasner, SE | 1 |
| Wein, T | 1 |
| Piriyawat, P | 1 |
| Villar-Cordova, CE | 1 |
| Chalela, JA | 1 |
| Krieger, DW | 1 |
| Morgenstern, LB | 1 |
| Kimmel, SE | 1 |
| Grotta, JC | 1 |
| Koennecke, HC | 1 |
| Wong, A | 1 |
| Sibbald, A | 1 |
| Ferrero, F | 1 |
| Plager, M | 1 |
| Santolaya, ME | 1 |
| Escobar, AM | 1 |
| Campos, S | 1 |
| Barragán, S | 1 |
| De León González, M | 1 |
| Kesselring, GL | 1 |
| Louik, C | 1 |
| Vezina, RM | 1 |
| Ng, DK | 1 |
| Lam, JC | 1 |
| Chow, KW | 1 |
| Rosti, L | 1 |
| Bhatnagar, SK | 1 |
| van der Worp, B | 1 |
| van Gemert, M | 1 |
| Meijer, R | 1 |
| Kappelle, J | 1 |
| Barr, J | 1 |
| Bulkowstein, M | 1 |
| Avgil, M | 1 |
| Greenberg, R | 1 |
| Matias, A | 1 |
| Petrov, I | 1 |
| Bernath, VF | 1 |
| Anderson, JN | 1 |
| Silagy, CA | 1 |
| Reess, J | 1 |
| Haas, J | 1 |
| Gabriel, K | 1 |
| Fuhlrott, A | 1 |
| Fiola, M | 1 |
| O'Connor, S | 1 |
| Tse, SM | 1 |
| Silverman, ED | 1 |
| McCrindle, BW | 1 |
| Yeung, RS | 1 |
| Kapoor, SK | 1 |
| Sharma, J | 1 |
| Batra, B | 1 |
| Paul, E | 1 |
| Anand, K | 1 |
| Figueras Nadal, C | 1 |
| García de Miguel, MJ | 1 |
| Gómez Campderá, A | 1 |
| Pou Fernández, J | 1 |
| Alvarez Calatayud, G | 1 |
| Sánchez Bayle, M | 1 |
| Tarimo, DS | 1 |
| Minjas, JN | 1 |
| Bygbjerg, IC | 1 |
| Thabet, F | 1 |
| Durand, P | 1 |
| Chevret, L | 1 |
| Fabre, M | 1 |
| Debray, D | 1 |
| Brivet, M | 1 |
| Devictor, D | 1 |
| Similä, S | 6 |
| Keinänen, S | 4 |
| Kouvalainen, K | 4 |
| Reynolds, WW | 1 |
| Dinarello, CA | 1 |
| Kennedy, JI | 1 |
| Dascombe, MJ | 2 |
| Milton, AS | 6 |
| Philipp-Dormston, WK | 1 |
| Götte, R | 1 |
| Liedtke, R | 1 |
| Austin, TW | 1 |
| Truant, G | 1 |
| Lock, A | 1 |
| Eckman, BM | 1 |
| Ayres, J | 1 |
| Ameer, B | 1 |
| Greenblatt, DJ | 1 |
| Hietula, M | 1 |
| Dressler, F | 1 |
| Skjøtø, J | 1 |
| Reikvam, A | 1 |
| Vernon, S | 1 |
| Bacon, C | 1 |
| Weightman, D | 1 |
| Keinänen-Kiukaanniemi, S | 1 |
| Luoma, P | 1 |
| Kangas, L | 1 |
| Saukkonen, AL | 1 |
| Schuurmans, D | 1 |
| Vincent, JE | 1 |
| Bruinvels, J | 1 |
| Bonta, IL | 1 |
| Windofer, A | 1 |
| Hart, JL | 1 |
| Morg-Heimering, S | 1 |
| Nemec, A | 1 |
| Maron, JJ | 1 |
| Ickes, AC | 1 |
| Tomović, D | 1 |
| Hagmann, R | 1 |
| Clark, WG | 4 |
| Cumby, HR | 2 |
| Windorfer, A | 1 |
| Vogel, C | 1 |
| Finco, DC | 1 |
| Duncan, JR | 1 |
| Schall, WD | 1 |
| Prasse, KW | 1 |
| Feldberg, W | 5 |
| Saxena, PN | 1 |
| Shrand, H | 1 |
| Myers, RD | 1 |
| Drwal-Klein, LA | 1 |
| Phelps, SJ | 1 |
| Chevallier, B | 1 |
| Parat, S | 1 |
| Renaud, C | 1 |
| Gallet, JP | 1 |
| Choonara, I | 1 |
| Nunn, AJ | 1 |
| Barker, C | 1 |
| Kinmonth, AL | 1 |
| Fulton, Y | 1 |
| Campbell, MJ | 1 |
| Kelley, MT | 1 |
| Edge, JH | 1 |
| Cox, S | 1 |
| Mortensen, ME | 1 |
| Eichler, VF | 2 |
| Johnson, VA | 2 |
| Bertrand, KM | 2 |
| Kauffman, RE | 1 |
| Sawyer, LA | 2 |
| Scheinbaum, ML | 2 |
| Galletta, G | 2 |
| Chomilo, F | 1 |
| Braden, NJ | 2 |
| D'Apuzzo, V | 1 |
| Monti, T | 1 |
| Kramer, MS | 1 |
| Naimark, LE | 1 |
| Roberts-Bräuer, R | 1 |
| McDougall, A | 1 |
| Leduc, DG | 1 |
| Leung, AK | 1 |
| Robson, WL | 1 |
| Sunderland, R | 1 |
| Casteels-Van Daele, M | 1 |
| Liadkov, OV | 1 |
| Lysov, AG | 1 |
| Mariinskaia, ND | 1 |
| Kanter, MI | 1 |
| Bourrillon, A | 2 |
| Lowe, BA | 1 |
| Nicholas, SW | 1 |
| Sidler, J | 1 |
| Frey, B | 1 |
| Baerlocher, K | 1 |
| Hoza, J | 2 |
| Rachtan, R | 1 |
| Starek, A | 1 |
| Morgan, SP | 1 |
| Gramolini, C | 1 |
| Manini, G | 1 |
| Graham, NM | 1 |
| Burrell, CJ | 1 |
| Douglas, RM | 1 |
| Debelle, P | 1 |
| Davies, L | 1 |
| Hopkins, CS | 1 |
| Underhill, S | 1 |
| Booker, PD | 1 |
| Cervinka, L | 1 |
| Schaffer, SJ | 1 |
| Joshi, YM | 1 |
| Sovani, VB | 1 |
| Joshi, VV | 1 |
| Navrange, JR | 1 |
| Benakappa, DG | 1 |
| Shivananda, P | 1 |
| Sankaranarayanan, VS | 1 |
| Isaacs, SN | 1 |
| Axelrod, PI | 1 |
| Lorber, B | 1 |
| Guberman, D | 1 |
| Long, SS | 1 |
| Deforest, A | 1 |
| Smith, DG | 1 |
| Lazaro, C | 1 |
| Wassilak, GF | 1 |
| Friedman, AD | 2 |
| Barton, LL | 2 |
| Weston, HJ | 1 |
| Wallander, KA | 1 |
| Porter, JD | 1 |
| Robinson, PH | 1 |
| Glasgow, JF | 2 |
| Banks, JH | 1 |
| Hall, SM | 2 |
| Cedrato, AE | 1 |
| Passarelli, I | 1 |
| Cimollini, L | 1 |
| Maccarone, H | 1 |
| Deeter, LB | 1 |
| Martin, LW | 1 |
| Alexander, L | 1 |
| Blumenberg, D | 1 |
| Baker, RC | 1 |
| Tiller, T | 1 |
| Bausher, JC | 1 |
| Bellet, PS | 1 |
| Cotton, WH | 1 |
| Finley, AH | 1 |
| Lenane, AM | 1 |
| McHenry, C | 1 |
| Perez, KK | 1 |
| Shapiro, RA | 1 |
| Chitty, D | 1 |
| Cullen, S | 1 |
| Kenny, D | 1 |
| Ward, OC | 1 |
| Sabra, K | 1 |
| Hietala, J | 1 |
| Viljanen, MK | 1 |
| Rosenthal, TC | 1 |
| Silverstein, DA | 1 |
| Frank, OR | 1 |
| Coulthard, KP | 1 |
| Brauer, H | 1 |
| Foote, RW | 1 |
| Achini, R | 1 |
| Römer, D | 1 |
| Mitra, A | 1 |
| Ravikumar, VC | 1 |
| Bourn, WM | 1 |
| Bourcier, DR | 1 |
| Childs, C | 1 |
| Little, RA | 1 |
| Ipp, MM | 1 |
| Gold, R | 1 |
| Greenberg, S | 1 |
| Goldbach, M | 1 |
| Kupfert, BB | 1 |
| Lloyd, DD | 1 |
| Maresky, DC | 1 |
| Saunders, N | 1 |
| Wise, SA | 1 |
| Weisse, ME | 1 |
| Miller, G | 1 |
| Brien, JH | 1 |
| Plaster, PA | 1 |
| Hancock, P | 1 |
| Feng, J | 1 |
| Baker, MD | 1 |
| Fosarelli, PD | 1 |
| Carpenter, RO | 1 |
| Gribetz, B | 1 |
| Cronley, SA | 1 |
| Goulden, KJ | 1 |
| Banco, L | 1 |
| Torrey, SB | 1 |
| Henretig, F | 1 |
| Fleisher, G | 1 |
| Goldstein, RM | 1 |
| Ardire, A | 1 |
| Ludwig, S | 1 |
| Ruddy, R | 1 |
| Gray, JD | 1 |
| Blaschke, TF | 1 |
| Desai, RZ | 1 |
| Weippl, G | 1 |
| Michos, N | 1 |
| Sundal, EJ | 1 |
| Stocker, H | 1 |
| Kylmämaa, T | 1 |
| Remington, PL | 1 |
| Rowley, D | 1 |
| McGee, H | 1 |
| Hall, WN | 1 |
| Monto, AS | 1 |
| Koren, G | 1 |
| Lavi, S | 1 |
| Rose, V | 1 |
| Rowe, R | 1 |
| Newman, J | 1 |
| Taylor, JP | 1 |
| Gustafson, TL | 1 |
| Johnson, CC | 1 |
| Brandenburg, N | 1 |
| Glezen, WP | 1 |
| Beaufils, F | 1 |
| Cotter, DL | 1 |
| Noe, JM | 1 |
| Aber, RC | 1 |
| Dey, PK | 2 |
| Gupta, KP | 3 |
| Wendlandt, S | 5 |
| Davis, NE | 1 |
| Nachtigall, C | 1 |
| Fragen, CA | 1 |
| Tarlin, L | 1 |
| Landrigan, P | 1 |
| Babineau, R | 1 |
| Alpert, JJ | 1 |
| Vittadini, G | 1 |
| Hunter, J | 1 |
| Sutton, E | 1 |
| Soyka, LF | 1 |
| Horstmann, W | 1 |
| Brown, GL | 1 |
| Ghosh, SK | 1 |
| Reddy, TA | 1 |
| Vassena, E | 1 |
| Chierichetti, S | 1 |
| Brewer, EJ | 1 |
| Steele, RW | 2 |
| Young, FS | 1 |
| Bass, JW | 2 |
| Shirkey, HC | 1 |
| Alderdice, MT | 1 |
| Gellman, EF | 1 |
| Kobayashi, S | 1 |
| Takagi, H | 1 |
| Tanaka, PT | 1 |
| Lara, RP | 1 |
| Preidel, H | 1 |
| Robinson, PJ | 1 |
| Rosen, SM | 1 |
| Meloff, K | 1 |
| Cashin, CH | 1 |
| Heading, CE | 1 |
| Bour, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison of the Efficacy of Paracetamol and Ibuprofen in the Management of Fever in Sepsis Patients: A Randomized Double-Blind Controlled Study[NCT06061575] | Phase 4 | 84 participants (Anticipated) | Interventional | 2023-10-31 | Not yet recruiting | ||
| Randomized Control Trial of Intravenous Acetaminophen (OFIRMEV) for the Reduction of Intrapartum Maternal Fever and Fetal Tachycardia[NCT02625454] | Phase 2 | 168 participants (Anticipated) | Interventional | 2016-12-31 | Active, not recruiting | ||
| Efficacy of Bromocriptine to Reduce Body Temperature in Febrile Critically-ill Adults With Acute Neurologic Disease: an Open-label, Blinded Endpoint, Randomized Controlled Trial[NCT03496545] | Phase 1/Phase 2 | 47 participants (Actual) | Interventional | 2018-11-30 | Completed | ||
| [NCT02833584] | 123 participants (Actual) | Interventional | 2016-09-30 | Completed | |||
| Prospective Comparative Study of the Efficacy of Common Antipyretic Treatments in Febrile Children[NCT02294071] | Phase 4 | 120 participants (Anticipated) | Interventional | 2014-12-31 | Not yet recruiting | ||
| A Double-blind, Randomized, Placebo-controlled Phase IV Clinical Study of the Efficacy and Safety of a New Formulation of Paracetamol for the Management of Fever of Infectious Origin[NCT02283203] | Phase 4 | 80 participants (Actual) | Interventional | 2015-02-28 | Completed | ||
| "Do NSAIDS or Executing Exercise Decrease Local Erythema, Site Swelling & Pain After INoculation: the NEED LESS PAIN Study"[NCT02807623] | 300 participants (Actual) | Interventional | 2016-09-30 | Completed | |||
| Hypoalgesic Effect of Median Nerve Neural Mobilization in Cervicobrachial Pain Compared to a Controlled Group[NCT02596815] | 51 participants (Actual) | Interventional | 2015-07-31 | Completed | |||
| Hypoalgesic Effect of Neural Mobilization in Cervicobrachial Pain Compared to a Controlled Group[NCT02595294] | 52 participants (Actual) | Interventional | 2015-07-31 | Completed | |||
| Hypoalgesic Effect of Median Nerve Neural Mobilization Versus Ibuprofen Pharmacologic Treatment in Patients With Cervicobrachial Pain[NCT02593721] | Phase 2/Phase 3 | 50 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| Use of Intravenous Acetaminophen in Adolescents and Pediatrics Undergoing Spinal Fusion Surgery: Randomized Controlled Trial[NCT04959591] | Phase 3 | 99 participants (Actual) | Interventional | 2021-06-01 | Completed | ||
| Control of Fever in Septic Patients[NCT04227652] | 140 participants (Actual) | Interventional | 2013-09-03 | Completed | |||
| Acetaminophen vs. Ibuprofen in Children With Asthma[NCT01606319] | Phase 3 | 300 participants (Actual) | Interventional | 2013-02-28 | Completed | ||
| Impact of Immediate or Delayed Prophylactic Antipyretic Treatment on the Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline Biologicals' Pneumococcal Vaccine 1024850A and the Co-administered DTPa-combined Vaccines[NCT01235949] | Phase 4 | 850 participants (Actual) | Interventional | 2010-11-12 | Completed | ||
| A Multicenter, Randomized, Open-Label, Parallel, Active-Comparator Trial to Determine the Efficacy, Safety, and Pharmacokinetics of Ibuprofen Injection in Pediatric Patients[NCT01002573] | Phase 3 | 118 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| A Phase 4, Randomized, Open-Label Trial To Assess The Impact Of Prophylactic Antipyretic Medication On The Immunogenicity Of 13-Valent Pneumococcal Conjugate Vaccine Given With Routine Pediatric Vaccinations In Healthy Infants[NCT01392378] | Phase 4 | 908 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| Safety and Antipyretic Efficacy of Acetaminophen in the Febrile Intensive Care Unit Patient.[NCT02280239] | Phase 4 | 10 participants (Actual) | Interventional | 2015-05-31 | Terminated (stopped due to Only enrolled 10 participants over 9 months which is less then anticipated (75).) | ||
| Effects of Intravenous Acetaminophen on Body Temperature and Hemodynamic Responses in Febrile Critically Ill Adults: a Randomized Controlled Trial[NCT01869699] | Phase 4 | 41 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| A Prospective, Randomized, Double-blind Study Assessing the Efficacy of Intravenous (IV) Ibuprofen Versus IV Acetaminophen for the Treatment of Pain Following Orthopaedic Low Extremity Surgery[NCT03771755] | 62 participants (Actual) | Interventional | 2017-07-01 | Completed | |||
| Multicentre Study to Assess the Effect of Prophylactic Antipyretic Treatment on the Rate of Febrile Reactions Following Concomitant Administration of GSK Biologicals' 10-valent Pneumococcal Conjugate, Infanrix Hexa and Rotarix Vaccines[NCT00370318] | Phase 3 | 400 participants | Interventional | 2006-09-30 | Completed | ||
| Prophylactic Antipyretic Treatment in Children Receiving Booster Dose of Pneumococcal Vaccine GSK1024850A and DTPa-HBV-IPV/Hib Vaccine (Infanrix Hexa) and Assessment of Impact of Pneumococcal Vaccination on Nasopharyngeal Carriage[NCT00496015] | Phase 3 | 750 participants (Actual) | Interventional | 2007-07-02 | Completed | ||
| Effective Analgesia Using the 5 S's During Routine Immunizations at 2 and 4 Months[NCT01368861] | 230 participants (Actual) | Observational | 2010-06-30 | Completed | |||
| A Randomized Open Label Mechanistic Study in Atopic Dermatitis to Assess the Immunogenicity of Fluzone® Intradermal and Intramuscular Vaccines[NCT01737710] | 368 participants (Actual) | Interventional | 2012-10-31 | Completed | |||
| Oral Versus Intravenous Acetaminophen for Postoperative Pain Management After Oocyte Retrieval Procedure. A Double Blinded, Placebo Controlled, Randomized Clinical Trial[NCT04662567] | 42 participants (Actual) | Interventional | 2021-03-12 | Terminated (stopped due to It was determined that the study should not continue as the study drug, Acetaminophen, could only be mixed in a solvent that would not allow the patients to be NPO prior to procedure.) | |||
| Ibuprofen Alone and in Combination With Acetaminophen for Treatment of Fever[NCT00267293] | Phase 4 | 60 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| The Effect of Paracetamol in the Treatment of Non-severe Malaria in Children in Guinea-Bissau[NCT00137566] | Phase 4 | 0 participants | Interventional | 2004-05-31 | Active, not recruiting | ||
| A Randomized Placebo-controlled Trial of Acetaminophen for Prevention of Post-vaccination Fever in Infants[NCT00325819] | Phase 3 | 374 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| Assessment of the Safety of Anti-pyretic Therapy in Critically Ill Adults[NCT01173367] | Phase 2 | 26 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| Early Lactate-Directed Therapy on the ICU: A Randomized Controlled Trial[NCT00270673] | Phase 3 | 350 participants (Anticipated) | Interventional | 2006-02-28 | Completed | ||
| Randomized, Double-Blind, Placebo-Controlled Study of Effects of Combined Spinal Epidural Analgesia on Intrapartum Fever.[NCT00802646] | 0 participants (Actual) | Interventional | 2009-06-30 | Withdrawn (stopped due to study moved to alternate site) | |||
| A Trial of Prednisone and Acetaminophen Versus Acetaminophen Alone in Minimizing Flu-like Symptoms From Pegylated Interferon Beta-1a[NCT03424733] | Phase 4 | 50 participants (Anticipated) | Interventional | 2017-09-25 | Recruiting | ||
| An Open-label, Single-dose, Pharmacokinetic Study of Acetaminophen/Naproxen Sodium Fixed Combination Tablets in Adolescents 12 to <17 Years of Age With Orthodontic Pain[NCT05844995] | Phase 1 | 30 participants (Anticipated) | Interventional | 2023-09-13 | Recruiting | ||
| Postoperative Ibuprofen and the Risk of Bleeding After Tonsillectomy With or Without Adenoidectomy[NCT01605903] | Phase 2 | 741 participants (Actual) | Interventional | 2012-05-03 | Completed | ||
| Comparing Narcotics With Non-steroidal Anti-inflammatory Drugs (NSAIDS) Post-operatively in Pediatric Patients Undergoing Adenotonsillectomy[NCT02296840] | Phase 4 | 45 participants (Actual) | Interventional | 2014-11-30 | Terminated | ||
| Postoperative Ibuprofen Use and Risk of Bleeding in Pediatric Tonsillectomy[NCT03385057] | Phase 1 | 0 participants (Actual) | Interventional | 2018-09-30 | Withdrawn (stopped due to Study design flaws; research design needed to be reconfigured) | ||
| Randomised, Double-Blind, Placebo Controlled Study of the Antipyretic Effect of Ibuprofen in Children With Uncomplicated Malaria[NCT00167713] | Phase 4 | 50 participants | Interventional | 2003-04-30 | Completed | ||
| Comparison of Supportive Therapies for Symptom Relief From Pediatric Upper Respiratory Infections (URIs)[NCT01814293] | 0 participants (Actual) | Interventional | 2013-05-31 | Withdrawn (stopped due to loss of funding. No data was collected.) | |||
| A Full-Factorial, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Single-Dose Efficacy and Safety Study of an Acetaminophen/Naproxen Sodium Fixed Combination, Acetaminophen, and Naproxen Sodium in Postoperative Dental Pain[NCT05761574] | Phase 3 | 440 participants (Anticipated) | Interventional | 2023-05-22 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Mean total body temperature burden above 37°C over 48 hours during which patient receives either control or intervention medication. (NCT03496545)
Timeframe: over 48 hours
| Intervention | Temperature in degrees Celsius (Mean) |
|---|---|
| Acetaminophen | 37.8 |
| Bromocriptine and Acetaminophen | 37.7 |
Time in minutes where the temperature is ≥ 38.3ºC during the 48 hours of control versus intervention administration. (NCT03496545)
Timeframe: 48 hours
| Intervention | Minutes (Mean) |
|---|---|
| Acetaminophen | 216 |
| Bromocriptine and Acetaminophen | 300 |
Time in minutes it took after medication administration for the temperature to reach < 37.5ºC. (NCT03496545)
Timeframe: 48 hours
| Intervention | Minutes (Mean) |
|---|---|
| Acetaminophen | 253.5 |
| Bromocriptine and Acetaminophen | 556 |
Episodes of symptomatic hypotension, including decrease in supine systolic and diastolic pressures of greater than 20mm and 10mm Hg respectively with patient reported accompanying symptoms of light headedness or dizziness and incidence of nausea and headache. (NCT03496545)
Timeframe: Nursing assessment at every shift during 48 hour study period after first drug administration
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Decrease in blood pressure | Nausea | Headache | |
| Acetaminophen | 12 | 2 | 8 |
| Bromocriptine and Acetaminophen | 17 | 3 | 12 |
Swelling at vaccination site (NCT02807623)
Timeframe: baseline, 48-72 hours, and 21- 28 days (3 points)
| Intervention | Participants (Count of Participants) |
|---|---|
| Baseline | 0 |
| 48-72 Hours After Vaccination | 0 |
| 21-28 Days After Vaccination | 0 |
Reddening of the skin at vaccination site reported as the total number of participants with erythema over the duration of the study. (NCT02807623)
Timeframe: baseline, 48- 72 hours, 21-28 days (3 points)
| Intervention | Participants (Count of Participants) |
|---|---|
| Baseline | 0 |
| 48-72 Hours After Vaccination | 0 |
| 21-28 Days After Vaccination | 0 |
A Lactate meter was used to test the exercise group for lactate readings. Two lactate tests was performed for the exercise group at Visit 1, both pre and post Influenza vaccination. The first lactate reading was taken after the blood draw.The second lactate reading was obtained from a fingerstick from the hand opposite to the vaccination arm, ideally within 3-8 minutes after the study subject completes pushups. (NCT02807623)
Timeframe: Immediately prior to Influenza vaccine and 3-8 minutes after Influenza vaccine was administered and after push-ups were completed.
| Intervention | mmol/L (Mean) | |
|---|---|---|
| Lactate before pushups | Lactate after pushups | |
| Compound Exercise of Push-ups | 1.51 | 7.69 |
Level of Pain will be measured by validated pain scale, using a scale of 0 ( best, no pain) to 10 (worst, as bad as imaginable, completely interferes). (NCT02807623)
Timeframe: baseline, 48-72 hours and at 21-28 days ( 3 points )
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Visit 1 | Visit 2 | Visit 3 | |
| Compound Exercise of Push-ups | .14 | .19 | .13 |
| Ibuprofen | .39 | .56 | .28 |
| Placebo | .19 | .22 | .06 |
Baseline lab specimen (visit 1, day 0, before immunization) and repeated between 21-28 days (visit 3) after immunization to measure serologic response (NCT02807623)
Timeframe: Day 0 and between 21-28 days (2 points)
| Intervention | Titer (Mean) | |
|---|---|---|
| Baseline (day 0, visit 1) | Followup (between 21-28 days, visit 3) | |
| Compound Exercise of Push-ups | 214.80 | 345.09 |
| Ibuprofen | 171.00 | 239.25 |
| Placebo | 216.75 | 343.03 |
Baseline lab specimen (visit 1, day 0, before immunization) and repeated between 21-28 days (visit 3) after immunization to measure serologic response (NCT02807623)
Timeframe: Day 0 and between 21-28 days (2 points)
| Intervention | Titer (Mean) | |
|---|---|---|
| Baseline (day 0, visit 1) | Followup (between 21-28 days, visit 3) | |
| Compound Exercise of Push-ups | 149.22 | 232.58 |
| Ibuprofen | 177.78 | 243.13 |
| Placebo | 221.09 | 296.66 |
Baseline lab specimen (visit 1, day 0, before immunization) and repeated between 21-28 days (visit 3) after immunization to measure serologic response (NCT02807623)
Timeframe: Day 0 and between 21-28 days (2 points)
| Intervention | Titer (Mean) | |
|---|---|---|
| Baseline (day 0, visit 1) | Followup (between 21-28 days, visit 3) | |
| Compound Exercise of Push-ups | 26.00 | 41.02 |
| Ibuprofen | 17.41 | 25.47 |
| Placebo | 26.09 | 34.09 |
Baseline lab specimen (visit 1, day 0, before immunization) and repeated between 21-28 days (visit 3) after immunization to measure serologic response (NCT02807623)
Timeframe: Day 0 and between 21-28 days (2 points)
| Intervention | Titer (Mean) | |
|---|---|---|
| Baseline (day 0, visit 1) | Followup (between 21-28 days, visit 3) | |
| Compound Exercise of Push-ups | 32.89 | 49.07 |
| Ibuprofen | 40.16 | 47.34 |
| Placebo | 36.69 | 44.78 |
proportion of study days on which asthma was controlled, measured by electronic diary (NCT01606319)
Timeframe: last 46 weeks of 48 week treatment period
| Intervention | proportion of days (Mean) |
|---|---|
| Acetaminophen | .86 |
| Ibuprofen | .87 |
average albuterol rescue use per week, measured by electronic diary (NCT01606319)
Timeframe: last 46 weeks of 48 week treatment period
| Intervention | inhalations per week (Mean) |
|---|---|
| Acetaminophen | 2.8 |
| Ibuprofen | 3 |
the number of asthma exacerbations requiring systemic corticosteroids (NCT01606319)
Timeframe: last 46 weeks of 48 week treatment period
| Intervention | asthma exacerbations per 46 weeks (Mean) |
|---|---|
| Acetaminophen | 0.81 |
| Ibuprofen | .87 |
frequency of unscheduled physician visits, emergency department visits or hospitalizations for asthma (NCT01606319)
Timeframe: last 46 weeks of 48 week treatment period
| Intervention | unscheduled health visits per 46 weeks (Mean) |
|---|---|
| Acetaminophen | .75 |
| Ibuprofen | .76 |
Antibody concentrations assessed were presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL). The seroprotection cut-off for the assay was an antibody concentration ≥ 10 mIU/mL. (NCT01235949)
Timeframe: One month after primary immunization (Month 3)
| Intervention | mIU/mL (Geometric Mean) |
|---|---|
| IIBU Group | 911.85 |
| DIBU Group | 1139.1 |
| NIBU Group | 1245.07 |
| IPARA Group | 934.65 |
| DPARA Group | 674.25 |
| NPARA Group | 1027.79 |
Antibody concentrations assessed were presented as geometric mean concentrations (GMCs) and expressed in micrograms per milliliter (µg/mL). The seroprotection cut-off for the assay was an antibody concentration ≥ 0.15 µg/mL. (NCT01235949)
Timeframe: One month after primary immunization (Month 3)
| Intervention | µg/mL (Geometric Mean) |
|---|---|
| IIBU Group | 3.994 |
| DIBU Group | 3.66 |
| NIBU Group | 4.51 |
| IPARA Group | 3.29 |
| DPARA Group | 4.23 |
| NPARA Group | 5.007 |
Anti-PD antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in ELISA units (EL.U) per milliliter (EL.U/mL). The seropositivity cut-off of the assay was an antibody concentration ≥ 100 EL.U/mL. (NCT01235949)
Timeframe: One month after primary immunization (At Month 3)
| Intervention | EL.U/mL (Geometric Mean) |
|---|---|
| IIBU Group | 1461.3 |
| DIBU Group | 1353.1 |
| NIBU Group | 1557.7 |
| IPARA Group | 1109.6 |
| DPARA Group | 1348.6 |
| NPARA Group | 1667.9 |
SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity. (NCT01235949)
Timeframe: During the entire study period (Month 0 to 10)
| Intervention | Participants (Count of Participants) |
|---|---|
| IIBU Group | 4 |
| DIBU Group | 4 |
| NIBU Group | 2 |
| IPARA Group | 4 |
| DPARA Group | 1 |
| NPARA Group | 0 |
An unsolicited adverse event is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. (NCT01235949)
Timeframe: Within 31-days (Day 0-30) following booster vaccination
| Intervention | Subjects (Number) |
|---|---|
| IIBU-IIBU Group | 6 |
| IIBU-DIBU Group | 6 |
| IIBU-NIBU Group | 2 |
| DIBU-IIBU Group | 3 |
| DIBU-DIBU Group | 3 |
| DIBU-NIBU Group | 4 |
| NIBU-IIBU Group | 6 |
| NIBU-DIBU Group | 6 |
| NIBU-NIBU Group | 3 |
| IPARA-NPARA Group | 4 |
| DPARA-IPARA Group | 0 |
| NPARA-IPARA Group | 2 |
An unsolicited adverse event is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. (NCT01235949)
Timeframe: Within 31-days (Day 0-30) following each primary vaccination dose
| Intervention | Participants (Count of Participants) |
|---|---|
| IIBU Group | 28 |
| DIBU Group | 33 |
| NIBU Group | 35 |
| IPARA Group | 16 |
| DPARA Group | 4 |
| NPARA Group | 13 |
Anti-pneumococcal serotype 6A and 19A antibody concentrations have been assessed by 22F-inhibition ELISA, presented as geometric mean concentrations (GMCs) and expressed in micrograms per milliliter (μg/mL). The seropositivity cut-off for the assay was an antibody concentration ≥ 0.05 μg/mL. (NCT01235949)
Timeframe: One month after primary immunization (At Month 3)
| Intervention | μg/mL (Geometric Mean) | |
|---|---|---|
| Anti-6A | Anti-19A | |
| DIBU Group | 0.18 | 0.2 |
| DPARA Group | 0.12 | 0.17 |
| IIBU Group | 0.17 | 0.23 |
| IPARA Group | 0.11 | 0.15 |
| NIBU Group | 0.15 | 0.16 |
| NPARA Group | 0.19 | 0.25 |
Anti-D and anti-T antibody concentrations were presented as geometric mean concentrations (GMCs) and expressed in IU/mL. The seroprotection cut-off for the assay was an antibody concentration ≥ 0.1 IU/mL. (NCT01235949)
Timeframe: Prior to (Month 9) and one month after booster vaccination (Month 10)
| Intervention | IU/mL (Geometric Mean) | |||
|---|---|---|---|---|
| Anti-D, M9 | Anti-D, M10 | Anti-T, M9 | Anti-T, M10 | |
| DIBU-DIBU Group | 0.581 | 5.831 | 0.868 | 7.269 |
| DIBU-IIBU Group | 0.55 | 5.926 | 0.681 | 7.092 |
| DIBU-NIBU Group | 0.628 | 6.486 | 0.692 | 6.522 |
| DPARA-IPARA Group | 0.546 | 6.477 | 0.698 | 7.431 |
| IIBU-DIBU Group | 0.593 | 5.257 | 0.735 | 6.887 |
| IIBU-IIBU Group | 0.736 | 7.492 | 0.838 | 8.03 |
| IIBU-NIBU Group | 0.616 | 7.57 | 0.66 | 7.283 |
| IPARA-NPARA Group | 0.665 | 7.238 | 0.666 | 6.491 |
| NIBU-DIBU Group | 0.627 | 7.226 | 0.883 | 10.8 |
| NIBU-IIBU Group | 0.714 | 7.059 | 0.843 | 7.095 |
| NIBU-NIBU Group | 0.656 | 8.206 | 0.858 | 9.045 |
| NPARA-IPARA Group | 0.642 | 6.749 | 0.9 | 7.423 |
Anti-D and anti-T antibody concentrations were presented as geometric mean concentrations (GMCs) and expressed in international units per milliliter (IU/mL). The seroprotection cut-off for the assay was an antibody concentration ≥ 0.1 IU/mL. (NCT01235949)
Timeframe: One month after primary immunization (Month 3)
| Intervention | IU/mL (Geometric Mean) | |
|---|---|---|
| Anti-D | Anti-T | |
| DIBU Group | 2.938 | 3.373 |
| DPARA Group | 2.891 | 3.058 |
| IIBU Group | 3.326 | 3.746 |
| IPARA Group | 3.062 | 2.943 |
| NIBU Group | 3.132 | 3.961 |
| NPARA Group | 3.457 | 3.762 |
Antibody concentrations assessed were presented as geometric mean concentrations (GMCs) and expressed in mIU/mL. The seroprotection cut-off for the assay was an antibody concentration ≥ 10 mIU/mL. (NCT01235949)
Timeframe: Prior to (Month 9) and one month after booster vaccination (Month 10)
| Intervention | mIU/mL (Geometric Mean) | |
|---|---|---|
| Anti-HBs, M9 | Anti-HBs, M10 | |
| DIBU-DIBU Group | 225.01 | 2492.42 |
| DIBU-IIBU Group | 136.53 | 1685.87 |
| DIBU-NIBU Group | 194.51 | 2107.75 |
| DPARA-IPARA Group | 199.57 | 2003.09 |
| IIBU-DIBU Group | 210.32 | 1898.54 |
| IIBU-IIBU Group | 197.46 | 1949.42 |
| IIBU-NIBU Group | 164.33 | 1970.6 |
| IPARA-NPARA Group | 128.12 | 2078.63 |
| NIBU-DIBU Group | 244.52 | 2579.59 |
| NIBU-IIBU Group | 226.1 | 1851.22 |
| NIBU-NIBU Group | 159.79 | 3244.33 |
| NPARA-IPARA Group | 209.27 | 2218.23 |
Antibody concentrations assessed were presented as geometric mean concentrations (GMCs) and expressed in ELISA units per milliliter (EL.U/mL). The seropositivity cut-off for the assay was an antibody concentration ≥ 5 EL.U/mL. (NCT01235949)
Timeframe: One month after primary immunization (Month 3)
| Intervention | EL.U/mL (Geometric Mean) | ||
|---|---|---|---|
| Anti-PT | Anti-FHA | Anti-PRN | |
| DIBU Group | 64.2 | 171.6 | 114.3 |
| DPARA Group | 63.1 | 196.5 | 106.2 |
| IIBU Group | 59.1 | 163.1 | 103.9 |
| IPARA Group | 60.4 | 171 | 97.1 |
| NIBU Group | 65 | 191.1 | 118.1 |
| NPARA Group | 61.5 | 168.9 | 114 |
Antibody concentrations assessed were presented as geometric mean concentrations (GMCs) and expressed in ELISA units per milliliter (EL.U/mL). The seropositivity cut-off for the assay was an antibody concentration ≥ 5 EL.U/mL. (NCT01235949)
Timeframe: Prior to (Month 9) and one month after booster vaccination (Month 10)
| Intervention | EL.U/mL (Geometric Mean) | |||||
|---|---|---|---|---|---|---|
| Anti-PT, M9 | Anti-PT, M10 | Anti-FHA, M9 | Anti-FHA, M10 | Anti-PRN, M9 | Anti-PRN, M10 | |
| DIBU-DIBU Group | 14.2 | 75.5 | 59.3 | 322.9 | 25.1 | 246.2 |
| DIBU-IIBU Group | 14.7 | 72.3 | 53.8 | 359.8 | 22.4 | 262.9 |
| DIBU-NIBU Group | 13.6 | 74.8 | 57.7 | 332.7 | 16 | 184.3 |
| DPARA-IPARA Group | 10.8 | 66.8 | 48.5 | 332.9 | 19.7 | 214.2 |
| IIBU-DIBU Group | 12.8 | 64.4 | 42.6 | 252.7 | 16 | 173.5 |
| IIBU-IIBU Group | 13.3 | 73.8 | 46.1 | 308.8 | 15.7 | 218.6 |
| IIBU-NIBU Group | 10.5 | 56.6 | 42.6 | 327.2 | 18.3 | 225.9 |
| IPARA-NPARA Group | 13 | 59.4 | 50.8 | 321 | 20.1 | 205.1 |
| NIBU-DIBU Group | 12 | 74.9 | 45.7 | 338.6 | 18.8 | 255.7 |
| NIBU-IIBU Group | 12.8 | 63.4 | 57.9 | 312.3 | 19.4 | 226.7 |
| NIBU-NIBU Group | 15.2 | 97.6 | 59.1 | 442.8 | 27.3 | 330.4 |
| NPARA-IPARA Group | 14.2 | 57 | 52.9 | 294.2 | 20.3 | 213.6 |
Antibody concentrations assessed were presented as geometric mean concentrations (GMCs) and expressed in µg/mL. The seroprotection cut-off for the assay was an antibody concentration ≥ 0.15 µg/mL. (NCT01235949)
Timeframe: Prior to (Month 9) and one month after booster vaccination (Month 10)
| Intervention | µg/mL (Geometric Mean) | |
|---|---|---|
| Anti-PRP, M9 | Anti-PRP, M10 | |
| DIBU-DIBU Group | 0.847 | 18.987 |
| DIBU-IIBU Group | 0.824 | 20.28 |
| DIBU-NIBU Group | 0.763 | 17.544 |
| DPARA-IPARA Group | 0.651 | 21.602 |
| IIBU-DIBU Group | 0.684 | 17.484 |
| IIBU-IIBU Group | 0.878 | 21.964 |
| IIBU-NIBU Group | 0.678 | 21.277 |
| IPARA-NPARA Group | 0.696 | 16.682 |
| NIBU-DIBU Group | 0.72 | 33.45 |
| NIBU-IIBU Group | 0.798 | 20.659 |
| NIBU-NIBU Group | 1.013 | 22.083 |
| NPARA-IPARA Group | 0.953 | 23.277 |
Anti-PD antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in ELISA units per milliliter (EL.U//mL). The seroprotection cut-off for the assay was an antibody concentration ≥ 100 EL.U/mL. (NCT01235949)
Timeframe: Prior to (Month 9) and one month after booster vaccination (Month 10)
| Intervention | EL.U/mL (Geometric Mean) | |
|---|---|---|
| Anti-PD, M9 | Anti-PD M10 | |
| DIBU-DIBU Group | 590 | 1664.8 |
| DIBU-IIBU Group | 622.9 | 1888.7 |
| DIBU-NIBU Group | 502 | 1540.7 |
| DPARA-IPARA Group | 525.4 | 1517.3 |
| IIBU-DIBU Group | 660.4 | 1980.1 |
| IIBU-IIBU Group | 661.6 | 2069 |
| IIBU-NIBU Group | 588.3 | 1907.5 |
| IPARA-NPARA Group | 446.1 | 1482.7 |
| NIBU-DIBU Group | 555.1 | 1953.1 |
| NIBU-IIBU Group | 752.1 | 2319.7 |
| NIBU-NIBU Group | 777.2 | 2285.5 |
| NPARA-IPARA Group | 691.3 | 2082.5 |
Anti- pneumococcal serotypes 1, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F antibody concentrations have been assessed by 22F-inhibition ELISA, presented as geometric mean concentrations (GMCs) and expressed in micrograms per milliliter (μg/mL). The seropositivity cut-off for the assay was an antibody concentration greater than or equal to (≥) 0.05 μg/mL. (NCT01235949)
Timeframe: Prior to (Month 9) and one month after booster vaccination (Month 10)
| Intervention | μg/mL (Geometric Mean) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anti-1, M9 | Anti-1, M10 | Anti-4, M9 | Anti-4, M10 | Anti-5, M9 | Anti-5, M10 | Anti-6B, M9 | Anti-6B M10 | Anti-7F, M9 | Anti-7F M10 | Anti-9V, M9 | Anti-9V M10 | Anti-14, M9 | Anti-14 M10 | Anti-18C M9 | Anti-18C M10 | Anti-19F M9 | Anti-19F M10 | Anti-23F M9 | Anti-23F M10 | Anti-6A, M9 | Anti-6A M10 | Anti-19A M9 | Anti-19A M10 | |
| IIBU-NIBU Group | 0.27 | 2.39 | 0.55 | 3.22 | 0.76 | 4.11 | 0.54 | 2.43 | 0.89 | 4.2 | 0.83 | 3.94 | 1.06 | 5.16 | 0.96 | 7.78 | 1.72 | 6.91 | 0.41 | 2.59 | 0.25 | 1.14 | 0.22 | 1.05 |
| IPARA-NPARA Group | 0.31 | 1.76 | 0.52 | 3.27 | 0.59 | 2.62 | 0.43 | 1.74 | 0.84 | 3.89 | 0.74 | 3.11 | 1.18 | 4.72 | 0.91 | 6.18 | 1.56 | 5.94 | 0.47 | 2.5 | 0.19 | 0.81 | 0.21 | 0.74 |
| NIBU-DIBU Group | 0.38 | 3.04 | 0.73 | 4.08 | 0.84 | 3.92 | 0.58 | 2.32 | 1.31 | 5.55 | 0.92 | 3.88 | 1.93 | 6.56 | 1.39 | 11.29 | 1.7 | 7.26 | 0.69 | 3.17 | 0.28 | 0.99 | 0.2 | 0.93 |
| NIBU-IIBU Group | 0.44 | 2.84 | 0.72 | 4.04 | 0.83 | 4.21 | 0.56 | 2.16 | 1.07 | 5.43 | 1.09 | 4.07 | 1.6 | 6.03 | 1.12 | 7.15 | 1.25 | 5.24 | 0.61 | 3.12 | 0.26 | 1.03 | 0.15 | 0.67 |
| NIBU-NIBU Group | 0.43 | 2.84 | 0.62 | 4.07 | 0.96 | 4.48 | 0.67 | 2.51 | 1.11 | 4.93 | 1.09 | 4.05 | 1.95 | 6.3 | 1.23 | 8.68 | 1.9 | 7.34 | 0.58 | 3.33 | 0.34 | 1.4 | 0.28 | 0.97 |
| NPARA-IPARA Group | 0.45 | 2.84 | 0.84 | 4.28 | 0.85 | 4.33 | 0.61 | 2.29 | 0.97 | 4.52 | 0.97 | 3.9 | 1.86 | 5.62 | 1.31 | 8.17 | 1.72 | 6.66 | 0.52 | 3.15 | 0.24 | 0.98 | 0.24 | 1.11 |
| DIBU-DIBU Group | 0.42 | 2.44 | 0.72 | 3.63 | 0.76 | 3.33 | 0.62 | 2.18 | 1.1 | 4.36 | 1.03 | 3.16 | 1.7 | 5.08 | 1.1 | 7.16 | 1.54 | 5.27 | 0.5 | 2.16 | 0.32 | 1.09 | 0.2 | 0.66 |
| DIBU-IIBU Group | 0.38 | 2.69 | 0.63 | 4.05 | 0.78 | 3.42 | 0.55 | 2.13 | 1.08 | 4.96 | 1.03 | 3.47 | 1.31 | 4.54 | 1.08 | 8.23 | 1.58 | 5.35 | 0.55 | 2.93 | 0.26 | 0.89 | 0.24 | 0.75 |
| DIBU-NIBU Group | 0.34 | 1.87 | 0.64 | 3.41 | 0.7 | 3.37 | 0.6 | 1.52 | 1.09 | 3.93 | 0.93 | 3.07 | 1.73 | 4.61 | 1.03 | 7.1 | 1.38 | 5.57 | 0.65 | 2.74 | 0.32 | 0.74 | 0.24 | 0.95 |
| DPARA-IPARA Group | 0.3 | 2.14 | 0.6 | 3.31 | 0.72 | 3.58 | 0.43 | 1.84 | 0.98 | 4.63 | 0.93 | 3.49 | 1.53 | 5.52 | 1.14 | 8.66 | 1.51 | 5.54 | 0.43 | 2.53 | 0.22 | 0.87 | 0.19 | 0.63 |
| IIBU-DIBU Group | 0.36 | 2.23 | 0.63 | 3.65 | 0.83 | 3.9 | 0.44 | 1.97 | 0.96 | 4.2 | 0.83 | 3.3 | 1.74 | 5.62 | 1.03 | 8.06 | 1.66 | 6.64 | 0.64 | 3.08 | 0.18 | 0.86 | 0.23 | 1.1 |
| IIBU-IIBU Group | 0.41 | 2.87 | 0.71 | 4.09 | 0.98 | 4.5 | 0.63 | 2.75 | 1.33 | 5.75 | 1.07 | 4.46 | 1.76 | 6.02 | 1.13 | 9.35 | 1.94 | 6.9 | 0.65 | 3.72 | 0.31 | 1.36 | 0.28 | 1.11 |
Anti-pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F antibody concentrations have been assessed by 22F-inhibition ELISA, presented as geometric mean concentrations (GMCs) and expressed in micrograms per milliliter (μg/mL). The seropositivity cut-off for the assay was an antibody concentration ≥ 0.05 μg/mL. (NCT01235949)
Timeframe: One month after primary immunization (At Month 3)
| Intervention | µg/mL (Geometric Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Anti-1 | Anti-4 | Anti-5 | Anti-6B | Anti-7F | Anti-9V | Anti-14 | Anti-18C | Anti-19F | Anti-23F | |
| DIBU Group | 1.71 | 2.21 | 2.39 | 0.76 | 2.83 | 2.01 | 4.52 | 3.8 | 5.04 | 0.92 |
| DPARA Group | 1.38 | 1.95 | 2.36 | 0.42 | 2.45 | 1.82 | 4.12 | 4.08 | 5.2 | 0.74 |
| IIBU Group | 1.82 | 2.25 | 2.93 | 0.67 | 2.87 | 2.1 | 4.76 | 3.85 | 6.11 | 1.04 |
| IPARA Group | 1.32 | 1.57 | 1.95 | 0.49 | 2.18 | 1.67 | 3.44 | 3.08 | 4.95 | 0.77 |
| NIBU Group | 1.9 | 2.21 | 2.77 | 0.6 | 2.77 | 2.18 | 4.77 | 4.34 | 4.96 | 1.07 |
| NPARA Group | 1.95 | 2.59 | 3.05 | 0.72 | 2.95 | 2.4 | 5.17 | 4.96 | 6.98 | 1 |
Antibody titers assessed were presented as geometric mean titers (GMTs). The seroprotection cut-off for the assay was a titer ≥ the value of 8. (NCT01235949)
Timeframe: One month after primary immunization (Month 3)
| Intervention | Titers (Geometric Mean) | ||
|---|---|---|---|
| Anti-Polio 1 | Anti-Polio 2 | Anti-Polio 3 | |
| DIBU Group | 252.5 | 327.4 | 351.3 |
| DPARA Group | 166 | 394.8 | 394.8 |
| IIBU Group | 283.4 | 362 | 423.2 |
| IPARA Group | 225.6 | 240.7 | 284 |
| NIBU Group | 337 | 378 | 624.1 |
| NPARA Group | 449.3 | 335.2 | 438.6 |
Antibody titers assessed were presented as geometric mean titers (GMTs). The seroprotection cut-off for the assay was a titer ≥ the value of 8. (NCT01235949)
Timeframe: Prior to (Month 9) and one month after booster vaccination (Month 10)
| Intervention | Titers (Geometric Mean) | |||||
|---|---|---|---|---|---|---|
| Anti-Polio 1, M9 | Anti-Polio 1, M10 | Anti-Polio 2, M9 | Anti-Polio 2, M10 | Anti-Polio 3, M9 | Anti-Polio 3, M10 | |
| DIBU-DIBU Group | 45.4 | 388 | 41.7 | 512.5 | 45.3 | 588.1 |
| DIBU-IIBU Group | 145.7 | 1824.5 | 292.1 | 2151.9 | 205.4 | 3649.1 |
| DIBU-NIBU Group | 32.1 | 543.9 | 8 | 542.4 | 45.2 | 1152.5 |
| DPARA-IPARA Group | 128.3 | 1448.1 | 139.6 | 1625.4 | 108.1 | 1625.4 |
| IIBU-DIBU Group | 85.9 | 790.7 | 60.8 | 1217.7 | 86 | 1724.5 |
| IIBU-IIBU Group | 56 | 1378.2 | 120.8 | 1949 | 72 | 861 |
| IIBU-NIBU Group | 80.9 | 429.9 | 48.3 | 548.7 | 127.8 | 359.5 |
| IPARA-NPARA Group | 53.8 | 1290.1 | 29.7 | 2047.9 | 96.5 | 2195 |
| NIBU-DIBU Group | 53.7 | 4 | 119.6 | 434.1 | 139.6 | 724.1 |
| NIBU-IIBU Group | 67.1 | 1217.7 | 134.8 | 1217.7 | 70 | 558.3 |
| NIBU-NIBU Group | 141.2 | 1075.9 | 156.1 | 1393.4 | 128 | 2233.3 |
| NPARA-IPARA Group | 117.4 | 861.1 | 168.9 | 1116.6 | 69.7 | 2048 |
Antibodies against the vaccine pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (Anti-1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F) have been assessed by 22F-inhibition enzyme-linked immunosorbent assay (ELISA). The cut-off value of the assay was an antibody concentration greater than or equal to (≥) 0.2 micrograms per milliliter (μg/mL). (NCT01235949)
Timeframe: One month after primary immunization (At Month 3)
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Anti-1 | Anti-4 | Anti-5 | Anti-6B | Anti-7F | Anti-9V | Anti-14 | Anti-18C | Anti-19F | Anti-23F | |
| DIBU Group | 155 | 155 | 154 | 135 | 157 | 153 | 153 | 153 | 152 | 141 |
| DPARA Group | 50 | 51 | 50 | 37 | 55 | 50 | 50 | 50 | 50 | 43 |
| IIBU Group | 144 | 145 | 143 | 121 | 153 | 144 | 144 | 143 | 145 | 136 |
| IPARA Group | 52 | 53 | 53 | 42 | 55 | 53 | 53 | 52 | 53 | 47 |
| NIBU Group | 160 | 158 | 156 | 133 | 164 | 155 | 154 | 155 | 157 | 149 |
| NPARA Group | 55 | 56 | 54 | 48 | 56 | 53 | 53 | 54 | 54 | 50 |
Solicited local symptoms assessed were pain, redness and swelling. Any = incidence of any local symptom regardless of intensity grade. Grade 3 pain = cried when limb was moved/spontaneously painful. Grade 3 redness/swelling = redness/swelling above 30 millimeters (mm). (NCT01235949)
Timeframe: Within the 4-day (Days 0-3) period following booster vaccination
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| Any Pain | Grade 3 Pain | Any Redness | Grade 3 Redness | Any Swelling | Grade 3 Swelling | |
| DIBU-DIBU Group | 16 | 1 | 15 | 1 | 6 | 1 |
| DIBU-IIBU Group | 22 | 2 | 23 | 0 | 16 | 0 |
| DIBU-NIBU Group | 25 | 2 | 22 | 0 | 11 | 0 |
| DPARA-IPARA Group | 24 | 4 | 23 | 0 | 12 | 0 |
| IIBU-DIBU Group | 22 | 3 | 25 | 1 | 16 | 0 |
| IIBU-IIBU Group | 25 | 0 | 27 | 0 | 16 | 0 |
| IIBU-NIBU Group | 15 | 0 | 17 | 0 | 9 | 0 |
| IPARA-NPARA Group | 23 | 4 | 23 | 0 | 17 | 0 |
| NIBU-DIBU Group | 32 | 1 | 25 | 5 | 18 | 2 |
| NIBU-IIBU Group | 28 | 4 | 23 | 3 | 16 | 0 |
| NIBU-NIBU Group | 28 | 4 | 23 | 0 | 15 | 0 |
| NPARA-IPARA Group | 24 | 1 | 23 | 2 | 16 | 0 |
Solicited local symptoms assessed were pain, redness and swelling. Any = incidence of any local symptom regardless of intensity grade. Grade 3 pain = cried when limb was moved/spontaneously painful. Grade 3 redness/swelling = redness/swelling above 30 millimeters (mm). (NCT01235949)
Timeframe: Within the 4-day (Days 0-3) post-primary vaccination period following each dose and across doses
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any Pain, Dose 1 | Grade 3 Pain, Dose 1 | Any Redness, Dose 1 | Grade 3 Redness, Dose 1 | Any Swelling, Dose 1 | Grade 3 Swelling, Dose 1 | Any Pain, Dose 2 | Grade 3 Pain, Dose 2 | Any Redness, Dose 2 | Grade 3 Redness, Dose 2 | Any Swelling, Dose 2 | Grade 3 Swelling, Dose 2 | Any Pain, Dose 3 | Grade 3 Pain, Dose 3 | Any Redness, Dose 3 | Grade 3 Redness, Dose 3 | Any Swelling, Dose 3 | Grade 3 Swelling, Dose 3 | Any Pain, Across doses | Grade 3 Pain, Across doses | Any Redness, Across doses | Grade 3 Redness, Across doses | Any Swelling, Across doses | Grade 3 Swelling, Across doses | |
| DIBU Group | 48 | 2 | 52 | 0 | 22 | 0 | 49 | 2 | 59 | 0 | 33 | 0 | 48 | 3 | 63 | 0 | 32 | 0 | 76 | 7 | 89 | 0 | 51 | 0 |
| DPARA Group | 28 | 2 | 19 | 0 | 7 | 1 | 22 | 0 | 23 | 0 | 11 | 1 | 21 | 1 | 25 | 2 | 12 | 0 | 37 | 3 | 35 | 2 | 17 | 1 |
| IIBU Group | 44 | 3 | 74 | 1 | 29 | 1 | 60 | 1 | 73 | 1 | 31 | 1 | 50 | 2 | 70 | 2 | 36 | 1 | 92 | 5 | 108 | 4 | 61 | 3 |
| IPARA Group | 21 | 2 | 24 | 0 | 10 | 0 | 19 | 2 | 24 | 0 | 10 | 1 | 18 | 1 | 28 | 0 | 16 | 0 | 30 | 5 | 36 | 0 | 20 | 1 |
| NIBU Group | 78 | 8 | 77 | 1 | 28 | 0 | 67 | 6 | 72 | 0 | 31 | 0 | 52 | 4 | 56 | 0 | 30 | 0 | 107 | 15 | 105 | 1 | 57 | 0 |
| NPARA Group | 33 | 7 | 32 | 0 | 11 | 0 | 25 | 1 | 31 | 2 | 12 | 2 | 22 | 1 | 27 | 2 | 13 | 2 | 44 | 7 | 46 | 2 | 19 | 2 |
Solicited general symptoms included drowsiness, irritability, loss of appetite and fever [rectally, greater than or equal to (≥) 38 degrees Celsius (°C)]. Any= incidence of any symptom regardless of intensity grade or relationship to vaccination. Grade 3 drowsiness = drowsiness that interfered with normal activity. Grade 3 irritability = crying that could not be comforted/ prevented normal activity. Grade 3 loss of appetite = not eating at all. Grade 3 fever = fever above (>) 40.0°C. Related = symptom assessed by the investigator as related to the vaccination. (NCT01235949)
Timeframe: Within the 4-day (Days 0-3) period following booster vaccination
| Intervention | Participants (Count of Participants) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any Drowsiness | Grade 3 Drowsiness | Related Drowsiness | Any Irritability | Grade 3 Irritability | Related Irritability | Any Loss of appetite | Grade 3 Loss of appetite | Related Loss of appetite | Any Fever | Grade 3 Fever | Related Fever | |
| DIBU-DIBU Group | 9 | 0 | 9 | 26 | 0 | 20 | 15 | 1 | 15 | 19 | 1 | 18 |
| DIBU-IIBU Group | 19 | 1 | 13 | 22 | 3 | 13 | 12 | 1 | 9 | 19 | 0 | 17 |
| DIBU-NIBU Group | 21 | 0 | 17 | 27 | 3 | 23 | 19 | 0 | 17 | 20 | 0 | 18 |
| DPARA-IPARA Group | 16 | 0 | 13 | 22 | 3 | 20 | 10 | 1 | 6 | 14 | 0 | 13 |
| IIBU-DIBU Group | 18 | 1 | 13 | 27 | 3 | 18 | 16 | 0 | 11 | 21 | 0 | 17 |
| IIBU-IIBU Group | 18 | 1 | 15 | 33 | 1 | 22 | 14 | 0 | 11 | 22 | 0 | 20 |
| IIBU-NIBU Group | 17 | 0 | 13 | 23 | 1 | 13 | 9 | 0 | 4 | 15 | 0 | 12 |
| IPARA-NPARA Group | 12 | 1 | 10 | 26 | 2 | 18 | 9 | 0 | 8 | 21 | 0 | 18 |
| NIBU-DIBU Group | 24 | 0 | 18 | 33 | 0 | 26 | 24 | 0 | 19 | 23 | 0 | 19 |
| NIBU-IIBU Group | 22 | 0 | 17 | 36 | 3 | 27 | 21 | 3 | 19 | 20 | 0 | 18 |
| NIBU-NIBU Group | 24 | 2 | 21 | 32 | 3 | 27 | 14 | 1 | 12 | 28 | 0 | 24 |
| NPARA-IPARA Group | 19 | 0 | 16 | 27 | 0 | 16 | 17 | 0 | 13 | 18 | 0 | 16 |
Solicited general symptoms included drowsiness, irritability, loss of appetite and fever [rectally, greater than or equal to (≥) 38 degrees Celsius (°C)]. Any= incidence of any symptom regardless of intensity grade or relationship to vaccination. Grade 3 drowsiness = drowsiness that interfered with normal activity. Grade 3 irritability = crying that could not be comforted/ prevented normal activity. Grade 3 loss of appetite = not eating at all. Grade 3 fever = fever above (>) 40.0°C. Related = symptom assessed by the investigator as related to the vaccination. (NCT01235949)
Timeframe: Within the 4-day (Days 0-3) post-primary vaccination period following each dose and across doses
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any Drowsiness, Dose 1 | Grade 3 Drowsiness, Dose 1 | Related Drowsiness, Dose 1 | Any Irritability, Dose 1 | Grade 3 Irritability, Dose 1 | Related Irritability, Dose 1 | Any Loss appetite, Dose 1 | Grade 3 Loss appetite, Dose 1 | Related Loss appetite, Dose 1 | Any Fever, Dose 1 | Grade 3 Fever, Dose 1 | Related Fever, Dose 1 | Any Drowsiness, Dose 2 | Grade 3 Drowsiness, Dose 2 | Related Drowsiness, Dose 2 | Any Irritability, Dose 2 | Grade 3 Irritability, Dose 2 | Related Irritability, Dose 2 | Any Loss appetite, Dose 2 | Grade 3 Loss appetite, Dose 2 | Related Loss appetite, Dose 2 | Any Fever, Dose 2 | Grade 3 Fever, Dose 2 | Related Fever, Dose 2 | Any Drowsiness, Dose 3 | Grade 3 Drowsiness, Dose 3 | Related Drowsiness, Dose 3 | Any Irritability, Dose 3 | Grade 3 Irritability, Dose 3 | Related Irritability, Dose 3 | Any Loss appetite, Dose 3 | Grade 3 Loss appetite, Dose 3 | Related Loss appetite, Dose 3 | Any Fever, Dose 3 | Grade 3 Fever, Dose 3 | Related Fever, Dose 3 | Any Drowsiness, Across doses | Grade 3 Drowsiness, Across doses | Related Drowsiness, Across doses | Any Irritability, Across doses | Grade 3 Irritability, Across doses | Related Irritability, Across doses | Any Loss appetite, Across doses | Grade 3 Loss appetite, Across doses | Related Loss appetite, Across doses | Any Fever, Across doses | Grade 3 Fever, Across doses | Related Fever, Across doses | |
| DIBU Group | 78 | 3 | 47 | 83 | 3 | 49 | 54 | 0 | 35 | 73 | 0 | 56 | 66 | 0 | 41 | 88 | 5 | 58 | 55 | 0 | 41 | 55 | 0 | 49 | 50 | 0 | 35 | 68 | 5 | 48 | 41 | 1 | 30 | 31 | 0 | 27 | 111 | 3 | 72 | 121 | 12 | 82 | 98 | 1 | 68 | 101 | 0 | 84 |
| DPARA Group | 28 | 0 | 17 | 34 | 1 | 16 | 19 | 1 | 11 | 11 | 0 | 8 | 15 | 0 | 12 | 31 | 1 | 22 | 11 | 0 | 8 | 15 | 0 | 10 | 8 | 0 | 5 | 21 | 2 | 12 | 9 | 0 | 7 | 7 | 0 | 5 | 33 | 0 | 22 | 43 | 4 | 28 | 24 | 1 | 16 | 27 | 0 | 18 |
| IIBU Group | 71 | 3 | 42 | 91 | 4 | 61 | 51 | 0 | 32 | 81 | 0 | 58 | 64 | 2 | 40 | 79 | 3 | 56 | 52 | 0 | 37 | 76 | 0 | 61 | 62 | 1 | 40 | 74 | 3 | 48 | 42 | 0 | 26 | 46 | 0 | 38 | 115 | 6 | 77 | 120 | 10 | 86 | 84 | 0 | 56 | 121 | 0 | 90 |
| IPARA Group | 33 | 1 | 20 | 27 | 3 | 18 | 11 | 0 | 8 | 8 | 0 | 6 | 28 | 0 | 16 | 30 | 1 | 20 | 12 | 0 | 7 | 14 | 0 | 11 | 18 | 0 | 12 | 17 | 1 | 10 | 9 | 0 | 5 | 12 | 0 | 7 | 40 | 1 | 26 | 40 | 4 | 28 | 24 | 0 | 16 | 23 | 0 | 18 |
| NIBU Group | 101 | 3 | 65 | 109 | 6 | 76 | 71 | 0 | 43 | 85 | 0 | 68 | 63 | 2 | 43 | 89 | 5 | 64 | 47 | 1 | 28 | 69 | 0 | 55 | 45 | 0 | 30 | 77 | 2 | 57 | 42 | 3 | 26 | 42 | 0 | 35 | 123 | 4 | 87 | 138 | 12 | 104 | 100 | 3 | 64 | 122 | 0 | 101 |
| NPARA Group | 36 | 1 | 24 | 43 | 3 | 27 | 32 | 1 | 20 | 30 | 0 | 23 | 25 | 1 | 15 | 37 | 1 | 25 | 22 | 0 | 14 | 24 | 1 | 19 | 16 | 0 | 11 | 29 | 0 | 17 | 16 | 1 | 12 | 14 | 0 | 12 | 45 | 2 | 32 | 59 | 4 | 40 | 42 | 2 | 30 | 40 | 1 | 31 |
"OPA titers against pneumococcal serotypes (Opsono-1, -4, -5, -6A, -6B, -7F, -9V, -14, -18C, -19A, -19F and -23F) were presented as geometric mean titers (GMTs). The seropositivity cut-off for the assay was ≥ 8. When the number of subjects in a group for a specific category equals (=) 1, the lower limit and upper limit of the confidence interval that can't be calculated, are filled in with the GMT value (due to system constraint). Placeholder value 99999.9 has been entered when value to be entered in the system was greater than (>) 1.0 E10." (NCT01235949)
Timeframe: Prior to (Month 9) and one month after booster vaccination (Month 10)
| Intervention | Titers (Geometric Mean) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OPSONO-1, M9 | OPSONO-1, M10 | OPSONO-4, M9 | OPSONO-4, M10 | OPSONO-5, M9 | OPSONO-5, M10 | OPSONO-6B, M9 | OPSONO-6B, M10 | OPSONO-7F, M9 | OPSONO-7F, M10 | OPSONO-9V, M9 | OPSONO-9V, M10 | OPSONO-14, M9 | OPSONO-14, M10 | OPSONO-18C, M9 | OPSONO-18C, M10 | OPSONO-19F, M9 | OPSONO-19F, M10 | OPSONO-23F, M9 | OPSONO-23F, M10 | OPSONO-6A, M9 | OPSONO-6A, M10 | OPSONO-19A, M9 | OPSONO-19A, M10 | |
| IPARA-NPARA Group | 6 | 120.6 | 25.9 | 548.3 | 5.7 | 42.2 | 127.7 | 431.5 | 1290.9 | 11414.1 | 567.4 | 856.6 | 98.3 | 557.5 | 6.5 | 149.9 | 11 | 163.3 | 89.4 | 297 | 46.7 | 154 | 4 | 44.3 |
| NIBU-DIBU Group | 40.2 | 546.2 | 52.4 | 1149.8 | 12.7 | 128.9 | 13.7 | 173.1 | 1152 | 3565.8 | 282.1 | 2919.8 | 255.9 | 935.3 | 9.4 | 707.9 | 24.2 | 273.9 | 30.5 | 3682.7 | 34.1 | 106.9 | 4 | 253 |
| NIBU-IIBU Group | 7.3 | 388.2 | 98.1 | 1953.4 | 7.6 | 99.5 | 16.4 | 237.6 | 2563 | 14362.4 | 1075.2 | 4218.9 | 295 | 1498.1 | 31.9 | 428.6 | 15 | 572.7 | 499.7 | 4249.1 | 23.3 | 98.1 | 4 | 125.7 |
| NIBU-NIBU Group | 10.7 | 627 | 15.2 | 1414.1 | 9.8 | 184.6 | 182.5 | 1047.8 | 1263.5 | 5829.1 | 1571.3 | 8601.7 | 382.6 | 3817 | 5.5 | 481.3 | 53.2 | 250.6 | 15.6 | 1464.1 | 58.3 | 120 | 4 | 12.8 |
| NPARA-IPARA Group | 15.7 | 887.6 | 161.8 | 854.4 | 22.2 | 149.7 | 239 | 376.5 | 1744.7 | 7567.3 | 738.7 | 1340.1 | 195.4 | 587.5 | 14 | 242.7 | 48.4 | 511 | 37.7 | 875.2 | 24.5 | 78.5 | 4 | 541.6 |
| IIBU-NIBU Group | 4 | 316.4 | 4 | 2213.4 | 8.2 | 241.7 | 84.3 | 769.1 | 1762.5 | 12162.6 | 649.4 | 4756.1 | 47.2 | 4426.6 | 4 | 2394.7 | 88.5 | 2575.2 | 22.2 | 2792.9 | 13.4 | 318.4 | 4 | 21.2 |
| DIBU-DIBU Group | 50.6 | 248 | 407.6 | 1037.5 | 17.5 | 114.1 | 289.4 | 553.1 | 5343.2 | 9941.8 | 1423.6 | 3772.9 | 791.7 | 2002 | 21.9 | 650.6 | 17.7 | 1040.7 | 134 | 2096.1 | 224.8 | 74.5 | 7.4 | 29.8 |
| DIBU-IIBU Group | 50.3 | 158 | 9 | 2096.7 | 19 | 79 | 13.3 | 694.2 | 1729.9 | 11741 | 1302.7 | 4190.8 | 737.1 | 1507.6 | 11.5 | 397.3 | 9.7 | 637.1 | 29.7 | 2977.7 | 239.5 | 581.1 | 4 | 28 |
| DIBU-NIBU Group | 9.9 | 344.4 | 74.2 | 1096.7 | 10.8 | 165.8 | 208.9 | 1021.6 | 3522.8 | 5744.5 | 1081.9 | 4970.9 | 539.2 | 1312.4 | 10.9 | 298.1 | 67.8 | 1575 | 396.6 | 3530.1 | 99 | 169.2 | 4 | 325.4 |
| DPARA-IPARA Group | 12.2 | 736.3 | 56.3 | 1885.9 | 7.4 | 125.3 | 105.6 | 904.3 | 2256.2 | 21670 | 480.9 | 7262.2 | 260.7 | 2288 | 19.1 | 888.9 | 42.3 | 1215.3 | 274.5 | 1436.2 | 84 | 159.1 | 9.1 | 416.5 |
| IIBU-DIBU Group | 4 | 296.3 | 80.2 | 865.8 | 9.2 | 93.3 | 237.2 | 606.2 | 1777.3 | 4591.4 | 1283.8 | 7041.7 | 255.1 | 671.4 | 7.2 | 207.3 | 32.1 | 330.5 | 132.4 | 2381.5 | 45.1 | 125.4 | 4 | 4 |
| IIBU-IIBU Group | 5.8 | 346.2 | 34 | 928.1 | 12.9 | 131.8 | 96.1 | 745.6 | 2076 | 16259.9 | 830 | 4969 | 149.2 | 1592.9 | 7.2 | 912.9 | 63 | 1112.9 | 27.9 | 581 | 39.8 | 183.7 | 4 | 363.7 |
OPA titers against pneumococcal serotypes 1, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F (Opsono-1, -4, -5, -6A, -6B, -7F, -9V, -14, -18C, -19A, -19F and -23F) were presented as geometric mean titers (GMTs). The seropositivity cut-off for the assay was an antibody titer ≥ 8. (NCT01235949)
Timeframe: One month after primary immunization (Month 3)
| Intervention | Titers (Geometric Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OPSONO-1 | OPSONO-4 | OPSONO-5 | OPSONO-6B | OPSONO-7F | OPSONO-9V | OPSONO-14 | OPSONO-18C | OPSONO-19F | OPSONO-23F | OPSONO-6A | OPSONO-19A | |
| DIBU Group | 67.9 | 1172.3 | 52.4 | 882.4 | 4977.9 | 4040.4 | 1219.7 | 167.6 | 514.8 | 1105.5 | 151.1 | 46.1 |
| DPARA Group | 94 | 1712.4 | 70.7 | 140.3 | 7306.4 | 3777.1 | 1780.5 | 382.7 | 254.2 | 723 | 34.2 | 39.7 |
| IIBU Group | 69.4 | 1311 | 86.6 | 723 | 8827.7 | 3429.2 | 1346.3 | 186.9 | 536.2 | 989.8 | 79 | 16.6 |
| IPARA Group | 23 | 684.8 | 38.7 | 739.9 | 8362.7 | 5520.1 | 591.5 | 91.6 | 501.1 | 1188.4 | 100.7 | 11.2 |
| NIBU Group | 75.9 | 1027.7 | 74.3 | 361.3 | 6444.8 | 2744.2 | 1417.9 | 135.9 | 267.9 | 1296 | 26.4 | 20.4 |
| NPARA Group | 64.4 | 777.2 | 80.8 | 237.1 | 6286.1 | 2273.2 | 1460.1 | 106 | 272.1 | 838.4 | 44.5 | 11.4 |
Change in temperature in patients receiving intravenous ibuprofen and acetaminophen (APAP) after the first 30 minutes of treatment. (NCT01002573)
Timeframe: 30 minutes following treatment
| Intervention | Celsius (Mean) |
|---|---|
| Ibuprofen | -0.5 |
| Acetaminophen | -0.3 |
Change in temperature in patients receiving intravenous ibuprofen and APAP after the first 60 minutes of treatment. (NCT01002573)
Timeframe: 60 minutes following treatment
| Intervention | Celsius (Mean) |
|---|---|
| Ibuprofen | -0.9 |
| Acetaminophen | -0.5 |
Change in temperature during the first 4 hours of treatment by assessing the area under the change in temperature versus time curve during the first four hours of treatment (AUC0-4) (NCT01002573)
Timeframe: 0 to 4 hours post-dose
| Intervention | degree Celsius*Time (Mean) |
|---|---|
| Ibuprofen | -4.4 |
| Acetaminophen | -2.6 |
Change in temperature in patients receiving intravenous ibuprofen and APAP after the first 4 hours of treatment. (NCT01002573)
Timeframe: 4 hours following treatment
| Intervention | Celsius (Mean) |
|---|---|
| Ibuprofen | -1.5 |
| Acetaminophen | -0.9 |
Treatment of fever as measured by the area under the change in temperature versus time curve during the first two hours of treatment (AUC0-2) (NCT01002573)
Timeframe: 0 to 2 hours post-dose
| Intervention | degree Celsius*Time (Mean) |
|---|---|
| Ibuprofen | -1.5 |
| Acetaminophen | -0.9 |
Tme to afebrility (temperature less than 100.4 ºF [38 ºC]) in patients receiving intravenous ibuprofen and APAP. (NCT01002573)
Timeframe: 4 Hour post treatment
| Intervention | Hours (Mean) |
|---|---|
| Ibuprofen | 2.2 |
| Acetaminophen | 3.3 |
Number of Afebrile and Febrile Subject at 4 Hours Following Treatment (NCT01002573)
Timeframe: 4 Hours Post-Dose
| Intervention | participants (Number) | |
|---|---|---|
| Afebrile Subjects at 4 hours | Febrile at 4 Hours | |
| Acetaminophen | 40 | 11 |
| Ibuprofen | 43 | 3 |
Geometric LS mean concentrations (GMCs) and corresponding 2-sided 95% CIs were evaluated for Hib PRP antibody. (NCT01392378)
Timeframe: 1 month after the infant series
| Intervention | mcg/mL (Geometric Mean) |
|---|---|
| 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily | 0.54 |
| 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily | 0.59 |
| 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily | 0.49 |
| 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily | 0.51 |
| 13vPnC + INFANRIX Hexa | 0.58 |
Geometric LS mean concentration (GMCs) were measured in mcg/mL and corresponding 2-sided 95% CIs were evaluated for Hib PRP antibody. (NCT01392378)
Timeframe: 1 month after the toddler dose
| Intervention | mcg/mL (Geometric Mean) |
|---|---|
| 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily | 9.65 |
| 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily | 9.35 |
| 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily | 8.25 |
| 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily | 7.84 |
| 13vPnC + INFANRIX Hexa | 8.96 |
Geometric LS mean concentration (GMCs) were measured in milli international units/mL (mIU/mL) and corresponding 2-sided 95% CIs were evaluated for hepatitis B virus (HBV) antibody. (NCT01392378)
Timeframe: 1 month after the infant series
| Intervention | mIU/mL (Geometric Mean) |
|---|---|
| 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily | 756.42 |
| 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily | 770.93 |
| 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily | 689.34 |
| 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily | 599.12 |
| 13vPnC + INFANRIX Hexa | 733.29 |
Geometric LS mean concentration (GMCs) were measured in mIU/mL and corresponding 2-sided 95% CIs were evaluated for hepatitis B virus (HBV) antibody. (NCT01392378)
Timeframe: 1 month after the toddler dose
| Intervention | mIU/mL (Geometric Mean) |
|---|---|
| 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily | 4868.61 |
| 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily | 4148.04 |
| 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily | 4250.41 |
| 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily | 4263.28 |
| 13vPnC + INFANRIX Hexa | 3866.37 |
Geometric LS mean concentration (GMCs) were measured in EU/mL and corresponding 2-sided 95% CIs were evaluated for pertussis (pertussis toxin [PT], filamentous hemagglutinin [FHA] and pertactin [PRN]) antibodies. (NCT01392378)
Timeframe: 1 month after the toddler dose
| Intervention | EU/mL (Geometric Mean) | ||
|---|---|---|---|
| Pertussis PT | Pertussis FHA | Pertussis PRN | |
| 13vPnC + INFANRIX Hexa | 74.01 | 117.01 | 172.80 |
| 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily | 73.38 | 108.11 | 158.71 |
| 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily | 76.93 | 117.87 | 156.98 |
| 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily | 73.72 | 123.56 | 160.96 |
| 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily | 77.43 | 115.55 | 158.28 |
Geometric LS mean concentration (GMCs) were measured in Enzyme-linked Immunosorbent Assay (ELISA) units/mL (EU/mL) and corresponding 2-sided 95% CIs were evaluated for pertussis (pertussis toxin [PT], filamentous hemagglutinin [FHA] and pertactin [PRN]) antibodies. (NCT01392378)
Timeframe: 1 month after the infant series
| Intervention | EU/mL (Geometric Mean) | ||
|---|---|---|---|
| Pertussis PT | Pertussis FHA | Pertussis PRN | |
| 13vPnC + INFANRIX Hexa | 44.85 | 48.42 | 84.57 |
| 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily | 39.26 | 35.55 | 68.53 |
| 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily | 43.51 | 40.65 | 71.26 |
| 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily | 40.27 | 41.32 | 65.82 |
| 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily | 40.86 | 46.29 | 72.90 |
Geometric LS mean concentration (GMCs) were measured in IU/mL and corresponding 2-sided 95% CIs were evaluated for tetanus and diphtheria antibodies. (NCT01392378)
Timeframe: 1 month after the toddler dose
| Intervention | IU/mL (Geometric Mean) | |
|---|---|---|
| Tetanus | Diphtheria | |
| 13vPnC + INFANRIX Hexa | 2.66 | 1.90 |
| 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily | 2.29 | 1.87 |
| 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily | 2.50 | 1.94 |
| 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily | 2.60 | 1.69 |
| 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily | 2.54 | 1.64 |
Geometric LS mean concentration (GMCs) were measured in International Units/mL (IU/mL) and corresponding 2-sided 95% CIs were evaluated for tetanus and diphtheria antibodies. (NCT01392378)
Timeframe: 1 month after the infant series
| Intervention | IU/mL (Geometric Mean) | |
|---|---|---|
| Tetanus | Diphtheria | |
| 13vPnC + INFANRIX Hexa | 0.82 | 0.65 |
| 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily | 0.60 | 0.65 |
| 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily | 0.70 | 0.68 |
| 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily | 0.69 | 0.61 |
| 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily | 0.73 | 0.62 |
Antibody geometric least squares (LS) mean concentrations (GMCs) for 13 pneumococcal serotypes (4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95 percent (%) confidence interval (CI) were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw. Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies participants with a determinate IgG concentration to the given serotype for each arm, respectively. (NCT01392378)
Timeframe: 1 month after the infant series
| Intervention | microgram per milliliter (mcg/mL) (Geometric Mean) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 (n = 137, 155, 148, 146, 210) | 6B (n = 136, 155, 148, 146, 210) | 9V (n = 138, 155, 148, 147, 210) | 14 (n = 138, 155, 148, 147, 210) | 18C (n = 138, 155, 148, 147, 210) | 19F (n = 138, 155, 148, 147, 210) | 23F (n= 137, 155, 148, 146, 210) | 1 (n = 138, 155, 148, 147, 210) | 3 (n = 138, 155, 148, 147, 210) | 5 (n = 137, 155, 148, 146, 210) | 6A (n = 138, 155, 148, 146, 210) | 7F (n = 138, 155, 148, 146, 210) | 19A (n = 137, 155, 148, 146, 210) | |
| 13vPnC + INFANRIX Hexa | 2.02 | 0.81 | 1.31 | 5.38 | 1.54 | 1.99 | 1.04 | 1.25 | 0.88 | 0.81 | 1.10 | 2.15 | 3.02 |
| 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily | 2.07 | 0.90 | 1.40 | 5.26 | 1.75 | 2.04 | 1.07 | 1.29 | 0.84 | 0.90 | 1.22 | 2.28 | 3.14 |
| 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily | 1.99 | 0.91 | 1.45 | 4.73 | 1.73 | 2.30 | 1.19 | 1.50 | 0.83 | 0.98 | 1.25 | 2.22 | 3.39 |
| 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily | 1.48 | 0.56 | 1.17 | 4.75 | 1.25 | 1.59 | 0.73 | 1.02 | 0.57 | 0.63 | 0.85 | 1.83 | 2.53 |
| 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily | 1.64 | 0.68 | 1.13 | 4.45 | 1.47 | 1.78 | 0.85 | 1.12 | 0.71 | 0.79 | 0.97 | 1.94 | 2.70 |
Antibody geometric LS mean concentrations (GMCs) for 13 pneumococcal serotypes (4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% CI were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw. Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies participants with a determinate IgG concentration to the given serotype for each arm respectively. (NCT01392378)
Timeframe: 1 month after the toddler dose
| Intervention | mcg/mL (Geometric Mean) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 (n = 130, 144, 143, 139, 206) | 6B (n = 130, 144, 143, 139, 206) | 9V (n = 130, 144, 143, 139, 206) | 14 (n = 130, 144, 143, 139, 206) | 18C (n = 130, 144, 143, 139, 206) | 19F (n = 130, 144, 143, 139, 206) | 23F (n = 130, 144, 142, 139, 206) | 1 (n = 130, 144, 143, 139, 206) | 3 (n = 129, 144, 143, 138, 203) | 5 (n = 130, 144, 143, 139, 206) | 6A (n = 130, 144, 143, 139, 206) | 7F (n = 130, 144, 142, 139, 206) | 19A (n = 129, 144, 142, 139, 206) | |
| 13vPnC + INFANRIX Hexa | 3.10 | 7.08 | 2.16 | 9.10 | 1.59 | 7.95 | 2.75 | 3.04 | 0.54 | 2.84 | 5.52 | 3.98 | 7.71 |
| 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily | 3.43 | 7.30 | 2.12 | 9.12 | 1.63 | 8.02 | 2.86 | 3.12 | 0.49 | 2.62 | 5.36 | 3.97 | 7.35 |
| 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily | 3.43 | 8.01 | 2.23 | 8.40 | 1.68 | 8.99 | 2.96 | 3.22 | 0.54 | 2.75 | 5.73 | 3.89 | 7.99 |
| 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily | 2.97 | 6.38 | 2.17 | 7.95 | 1.36 | 7.53 | 2.37 | 2.66 | 0.46 | 2.40 | 5.27 | 3.56 | 7.31 |
| 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily | 3.07 | 6.70 | 2.15 | 8.10 | 1.35 | 8.41 | 2.34 | 2.80 | 0.46 | 2.33 | 5.12 | 3.79 | 7.11 |
Geometric LS mean concentrations (GMCs) were measured as titers and corresponding 2-sided 95% CIs were evaluated for poliomyelitis type 1, 2 and 3 antibodies. (NCT01392378)
Timeframe: 1 month after the infant series
| Intervention | titer (Geometric Mean) | ||
|---|---|---|---|
| Poliomyelitis Type 1 | Poliomyelitis Type 2 | Poliomyelitis Type 3 | |
| 13vPnC + INFANRIX Hexa | 72.02 | 67.37 | 231.02 |
| 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily | 70.66 | 55.17 | 218.85 |
| 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily | 66.59 | 73.52 | 184.03 |
| 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily | 67.43 | 62.12 | 257.92 |
| 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily | 68.11 | 79.60 | 246.22 |
Geometric LS mean concentration (GMCs) were measured as titers and corresponding 2-sided 95% CIs were evaluated for poliomyelitis type 1, 2 and 3 antibodies. (NCT01392378)
Timeframe: 1 month after the toddler dose
| Intervention | titer (Geometric Mean) | ||
|---|---|---|---|
| Poliomyelitis Type 1 | Poliomyelitis Type 2 | Poliomyelitis Type 3 | |
| 13vPnC + INFANRIX Hexa | 406.37 | 621.07 | 1237.86 |
| 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily | 415.45 | 605.78 | 1187.11 |
| 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily | 426.63 | 586.30 | 1045.57 |
| 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily | 443.97 | 587.56 | 1210.29 |
| 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily | 399.56 | 613.18 | 1205.80 |
Antibody-mediated serum OPA against the 13 pneumococcal serotypes (4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F and 19A) was measured centrally using a pneumococcal OPA assay. Results were expressed as OPA titers. OPA titers were logarithmically transformed for analysis; geometric means calculated and expressed as geometric mean titers (GMTs). (NCT01392378)
Timeframe: 1 month after the infant series
| Intervention | titer (Geometric Mean) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 (n = 37, 46, 42, 41, 61) | 6B (n = 36, 45, 43, 40, 62) | 9V (n = 37, 48, 42, 41, 65) | 14 (n = 38, 48, 41, 41, 64) | 18C (n = 37, 47, 41, 41, 62) | 19F (n = 37, 46, 41, 42, 63) | 23F (n = 38, 45, 42, 42, 63) | 1 (n = 42, 42, 43, 44, 74) | 3 (n = 41, 41, 39, 39, 69) | 5 (n = 42, 43, 44, 42, 73) | 6A (n = 46, 42, 39, 39, 76) | 7F (n = 46, 42, 40, 39, 76) | 19A (n = 42, 44, 41, 42, 74) | |
| 13vPnC + INFANRIX Hexa | 1086 | 748 | 241 | 951 | 1092 | 279 | 366 | 12 | 87 | 76 | 1462 | 2125 | 240 |
| 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily | 1361 | 663 | 285 | 991 | 1031 | 294 | 321 | 8 | 62 | 99 | 1281 | 1584 | 159 |
| 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily | 1135 | 655 | 166 | 622 | 853 | 221 | 441 | 11 | 76 | 96 | 1681 | 1907 | 257 |
| 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily | 1240 | 470 | 93 | 650 | 877 | 165 | 332 | 8 | 56 | 54 | 1228 | 1747 | 163 |
| 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily | 1269 | 794 | 120 | 435 | 1094 | 346 | 342 | 12 | 72 | 86 | 1060 | 1766 | 185 |
An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. SAE: an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent events after the infant series were events between 1 month (28 to 42 days) after infant series to toddler dose that were absent before treatment or that worsened relative to pre-treatment state. Reported non-SAEs included AEs other than SAEs spontaneously collected on case report form (non-systematic assessment). (NCT01392378)
Timeframe: 1 Month (28 to 42 days) after infant series Dose 3 up to toddler dose
| Intervention | participants (Number) | |
|---|---|---|
| Non-SAEs | SAEs | |
| 13vPnC + INFANRIX Hexa | 8 | 9 |
| 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily | 4 | 11 |
| 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily | 6 | 14 |
| 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily | 3 | 10 |
| 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily | 3 | 6 |
An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. SAE: an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent events for infant series were events between infant series Dose 1 and up to 1 month (28 to 42 days) after infant series that were absent before treatment or that worsened relative to pre-treatment state. Reported non-SAEs included AEs other than SAEs collected using electronic diary (fever, systematic assessment) and events spontaneously collected on case report form at each visit (non-systematic assessment). (NCT01392378)
Timeframe: Baseline up to 1 Month (28 to 42 days) after infant series
| Intervention | participants (Number) | |
|---|---|---|
| Non-SAEs | SAEs | |
| 13vPnC + INFANRIX Hexa | 80 | 10 |
| 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily | 72 | 8 |
| 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily | 71 | 3 |
| 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily | 67 | 11 |
| 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily | 57 | 7 |
An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. SAE: an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent events for toddler dose were events between toddler dose and up to 1 month (28 to 42 days) after toddler dose that were absent before treatment or that worsened relative to pre-treatment state. Reported non-SAEs included AEs other than SAEs collected using electronic diary (fever, systematic assessment) and events spontaneously collected on case report form at each visit (non-systematic assessment). (NCT01392378)
Timeframe: Toddler dose up to 1 Month (28 to 42 days) after toddler dose
| Intervention | participants (Number) | |
|---|---|---|
| Non-SAEs | SAEs | |
| 13vPnC + INFANRIX Hexa | 50 | 1 |
| 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily | 76 | 1 |
| 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily | 57 | 2 |
| 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily | 52 | 1 |
| 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily | 47 | 3 |
Percentage of participants achieving pre-specified criteria for concomitant antigens contained in INFANRIX hexa (Hib polyribosylribitol phosphate [PRP] >=0.15 mcg/mL; Hib PRP >=1 mcg/mL; Pertussis PT >=14.6 EU/mL, FHA >=16.1 EU/mL, PRN >=24.0 EU/mL; Tetanus >=0.1 IU/mL; Diphtheria >=0.1 IU/mL; HBV >=10 mIU/mL; Poliomyelitis Type 1, 2, 3 >=1:8 titer) along with the corresponding 95% CIs were presented. Exact 2-sided CI based on the observed proportion of participants. Pre-specified criteria for pertussis was the level that 95% of the participants achieved in 13vPnC + INFANRIX hexa group. (NCT01392378)
Timeframe: 1 month after the infant series
| Intervention | percentage of participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Hib PRP >=0.15 mcg/mL (n= 136, 146, 144, 139, 198) | Hib PRP >=1 mcg/mL (n = 136, 146, 144, 139, 198) | Pertussis PT >=14.6 EU/mL (n= 132,143,141,131,193) | Pertussis FHA >=16.1 EU/mL (n=132,143,141,131,193) | Pertussis PRN >=24.0 EU/mL (n=132,143,141,131,193) | Tetanus >=0.1 IU/mL (n = 132,143,141,131,193) | Diphtheria >=0.1 IU/mL (n = 132,143,141,131,193) | HBV >= 10mIU/mL (n = 105,116,120,112,156) | PoliomyelitisType1 >=1:8titer (n=89,105,93,84,135) | PoliomyelitisType2 >=1:8titer (n=89,105,93,84,135) | PoliomyelitisType3 >=1:8titer (n=89,105,93,84,135) | |
| 13vPnC + INFANRIX Hexa | 87.9 | 33.8 | 95.3 | 95.3 | 95.3 | 99.5 | 99.5 | 98.7 | 99.3 | 95.6 | 99.3 |
| 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily | 85.6 | 28.1 | 90.8 | 88.5 | 89.3 | 98.5 | 97.7 | 99.1 | 100.0 | 96.4 | 98.8 |
| 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily | 84.2 | 37.0 | 97.2 | 92.3 | 87.4 | 100.0 | 98.6 | 99.1 | 98.1 | 98.1 | 100.0 |
| 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily | 86.1 | 27.1 | 91.5 | 93.6 | 88.7 | 100.0 | 99.3 | 99.2 | 97.8 | 95.7 | 98.9 |
| 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily | 87.5 | 33.8 | 93.2 | 96.2 | 90.9 | 100.0 | 100.0 | 100.0 | 97.8 | 95.5 | 100.0 |
Percentage of participants achieving pre-specified criteria for concomitant antigens contained in INFANRIX hexa (Hib polyribosylribitol phosphate [PRP] >=0.15 mcg/mL; Hib PRP >=1 mcg/mL; Pertussis PT >=14.8 EU/mL, FHA >=46.5 EU/mL, PRN >=43.5 EU/mL; Tetanus >=0.1 IU/mL; Diphtheria >=0.1 IU/mL; HBV >=10 mIU/mL; Poliomyelitis Type 1, 2, 3 >=1:8 titer) along with the corresponding 95% CIs were presented. Exact 2-sided CI based on the observed proportion of participants. Pre-specified criteria for pertussis was the level that 95% of the participants achieved in 13vPnC + INFANRIX hexa group. (NCT01392378)
Timeframe: 1 month after the toddler dose
| Intervention | percentage of participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Hib PRP >=0.15 mcg/mL (n= 126, 135, 141, 138, 202) | Hib PRP >=1 mcg/mL (n = 126, 135, 141, 138, 202) | Pertussis PT >=14.8 EU/mL (n= 123,137,141,136,199) | Pertussis FHA >=46.5 EU/mL (n=123,137,141,136,199) | Pertussis PRN >=43.5 EU/mL (n=123,137,141,136,199) | Tetanus >=0.1 IU/mL (n = 123,137,141,136,199) | Diphtheria >=0.1 IU/mL (n = 123,137,141,136,199) | HBV >= 10 mIU/mL (n = 119,131,133,133,191) | Poliomyelitis 1 >=1:8titer (n=123,133,141,136,201) | Poliomyelitis 2 >=1:8titer (n=123,133,141,136,201) | Poliomyelitis 3 >=1:8titer (n=123,133,141,136,201) | |
| 13vPnC + INFANRIX Hexa | 100.0 | 95.0 | 95.5 | 95.5 | 95.5 | 100.0 | 100.0 | 99.5 | 99.5 | 100.0 | 100.0 |
| 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily | 100.0 | 95.7 | 100.0 | 92.6 | 94.1 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 |
| 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily | 99.3 | 96.3 | 99.3 | 94.9 | 94.9 | 100.0 | 100.0 | 98.5 | 100.0 | 100.0 | 100.0 |
| 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily | 100.0 | 95.7 | 98.6 | 93.6 | 94.3 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 |
| 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily | 100.0 | 95.2 | 97.6 | 91.1 | 91.9 | 100.0 | 100.0 | 100.0 | 99.2 | 100.0 | 100.0 |
Percentage of participants achieving predefined antibody threshold >=0.35 mcg/mL along with the corresponding 95% confidence interval (CI) for 13 pneumococcal serotypes (4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants. (NCT01392378)
Timeframe: 1 month after the infant series
| Intervention | percentage of participants (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 (n = 137, 155, 148, 146, 210) | 6B (n = 136, 155, 148, 146, 210) | 9V (n = 138, 155, 148, 147, 210) | 14 (n = 138, 155, 148, 147, 210) | 18C (n = 138, 155, 148, 147, 210) | 19F (n = 138, 155, 148, 147, 210) | 23F (n = 137, 155, 148, 146, 210) | 1 (n = 138, 155, 148, 147, 210) | 3 (n = 138, 155, 148, 147, 210) | 5 (n = 137, 155, 148, 146, 210) | 6A (n = 138, 155, 148, 146, 210) | 7F (n = 138, 155, 148, 146, 210) | 19A (n = 137, 155, 148, 146, 210) | |
| 13vPnC + INFANRIX Hexa | 98.1 | 77.6 | 96.2 | 99.5 | 96.7 | 97.6 | 88.1 | 94.3 | 91.0 | 84.3 | 91.9 | 99.5 | 100.0 |
| 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily | 97.3 | 79.5 | 95.9 | 98.6 | 95.9 | 96.6 | 88.4 | 94.6 | 88.4 | 89.7 | 91.8 | 100.0 | 99.3 |
| 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily | 97.4 | 80.0 | 99.4 | 98.7 | 97.4 | 99.4 | 90.3 | 97.4 | 89.7 | 91.0 | 92.3 | 99.4 | 99.4 |
| 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily | 96.6 | 61.5 | 95.9 | 99.3 | 95.3 | 95.3 | 74.3 | 90.5 | 81.1 | 76.4 | 83.1 | 97.3 | 98.0 |
| 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily | 96.4 | 72.8 | 94.2 | 100.0 | 96.4 | 97.1 | 86.1 | 94.2 | 83.3 | 84.7 | 86.2 | 100.0 | 98.5 |
Percentage of participants achieving serotype-specific pneumococcal OPA titer >= LLOQ, along with the corresponding 95% CIs for 13 pneumococcal serotypes (4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants. The OPA LLOQ in titers for each serotype: 1 = 1:18; 3 = 1:12; 4 = 1:21; 5 = 1:29; 6A = 1:37; 6B = 1:43; 7F = 1:210; 9V = 1:345; 14 = 1:35; 18C = 1:31; 19A = 1:18; 19F = 1:48; 23F = 1:13. (NCT01392378)
Timeframe: 1 month after the infant series
| Intervention | percentage of participants (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 (n = 37, 46, 42, 41, 61) | 6B (n = 36, 45, 43, 40, 62) | 9V (n = 37, 48, 42, 41, 65) | 14 (n = 38, 48, 41, 41, 64) | 18C (n = 37, 47, 41, 41, 62) | 19F (n = 37, 46, 41, 42, 63) | 23F (n = 38, 45, 42, 42, 63) | 1 (n = 42, 42, 43, 44, 74) | 3 (n = 41, 41, 39, 39, 69) | 5 (n = 42, 43, 44, 42, 73) | 6A (n = 46, 42, 39, 39, 76) | 7F (n = 46, 42, 40, 39, 76) | 19A (n = 42, 44, 41, 42, 74) | |
| 13vPnC + INFANRIX Hexa | 100.0 | 96.8 | 75.4 | 96.9 | 100.0 | 95.2 | 93.7 | 45.9 | 100.0 | 86.3 | 98.7 | 100.0 | 97.3 |
| 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily | 100.0 | 92.5 | 80.5 | 97.6 | 97.6 | 92.9 | 90.5 | 29.5 | 94.9 | 92.9 | 100.0 | 97.4 | 88.1 |
| 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily | 100.0 | 88.9 | 66.7 | 97.9 | 95.7 | 87.0 | 97.8 | 42.9 | 97.6 | 90.7 | 100.0 | 100.0 | 100.0 |
| 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily | 100.0 | 88.4 | 59.5 | 100.0 | 100.0 | 90.2 | 92.9 | 30.2 | 97.4 | 86.4 | 100.0 | 100.0 | 90.2 |
| 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily | 100.0 | 94.4 | 62.2 | 89.5 | 100.0 | 97.3 | 92.1 | 47.6 | 97.6 | 92.9 | 93.5 | 100.0 | 92.9 |
Participants' core (rectal) temperature was collected for 4 days after each vaccination using an electronic diary. Participants' temperature was collected at 6 to 8 hours after vaccination, 6 to 8 hours following that and coincidentally with antipyretic administration for groups receiving antipyretics. Temperature was recorded at bedtime daily for 3 following days (Day 2 to Day 4) and at any time during the 3 days when fever was suspected. The highest temperature for each day was recorded in the e-diary. Incidences of fever were presented in following categories: >=38 but <=39 degree Celsius (degree C), greater than (>) 39 but <=40 degree C and >40 degree C. (NCT01392378)
Timeframe: Within 4 days after infant series Dose 1
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Fever >=38, <=39 degree C (n= 149,157,147,155,187) | Fever >39, <=40 degree C (n = 138,145,137,146,170) | Fever >40 degree C (n = 138,145,137,146,170) | |
| 13vPnC + INFANRIX Hexa | 41.7 | 1.2 | 0.0 |
| 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily | 34.2 | 0.7 | 0.0 |
| 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily | 45.2 | 1.4 | 0.0 |
| 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily | 18.4 | 0.7 | 0.0 |
| 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily | 32.9 | 1.4 | 0.0 |
Participants' rectal temperature was collected for 4 days after each vaccination using an electronic diary. Participants' temperature was collected at 6 to 8 hours after vaccination, 6 to 8 hours following that and coincidentally with antipyretic administration for groups receiving antipyretics. Temperature was recorded at bedtime daily for 3 following days (Day 2 to Day 4) and at any time during the 3 days when fever was suspected. The highest temperature for each day was recorded in the e-diary. Incidences of fever were presented in following categories: >=38 but <=39 degree C, >39 but <=40 degree C and >40 degree C. (NCT01392378)
Timeframe: Within 4 days after infant series Dose 2
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Fever >=38, <=39 degree C (n= 141,152,140,159,181) | Fever >39, <=40 degree C (n = 133,140,134,145,164) | Fever >40 degree C (n = 131,140,133,144,164) | |
| 13vPnC + INFANRIX Hexa | 39.8 | 3.7 | 0.0 |
| 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily | 44.0 | 1.4 | 0.0 |
| 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily | 42.8 | 0.7 | 0.0 |
| 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily | 21.4 | 1.5 | 0.0 |
| 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily | 26.2 | 1.5 | 0.0 |
Participants' rectal temperature was collected for 4 days after each vaccination using an electronic diary. Participants' temperature was collected at 6 to 8 hours after vaccination, 6 to 8 hours following that and coincidentally with antipyretic administration for groups receiving antipyretics. Temperature was recorded at bedtime daily for 3 following days (Day 2 to Day 4) and at any time during the 3 days when fever was suspected. The highest temperature for each day was recorded in the e-diary. Incidences of fever were presented in following categories: >=38 but <=39 degree C, >39 but <=40 degree C and >40 degree C. Report of fever >40 degrees C after 13vPnC Infant Series Dose 3 was confirmed as data entry error. (NCT01392378)
Timeframe: Within 4 days after infant series Dose 3
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Fever >=38, <=39 degree C (n= 136,146,135,141,175) | Fever >39, <=40 degree C (n = 129,137,125,136,167) | Fever >40 degree C (n = 128,136,126,135,166) | |
| 13vPnC + INFANRIX Hexa | 29.7 | 1.8 | 0.0 |
| 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily | 33.3 | 1.5 | 0.0 |
| 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily | 30.8 | 2.9 | 0.0 |
| 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily | 17.0 | 0.8 | 0.8 |
| 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily | 22.1 | 1.6 | 0.0 |
Participants' rectal temperature was collected for 4 days after each vaccination using an electronic diary. Participants' temperature was collected at 6 to 8 hours after vaccination, 6 to 8 hours following that and coincidentally with antipyretic administration for groups receiving antipyretics. Temperature was recorded at bedtime daily for 3 following days (Day 2 to Day 4) and at any time during the 3 days when fever was suspected. The highest temperature for each day was recorded in the e-diary. Incidences of fever were presented in following categories: >=38 but <=39 degree C, >39 but <=40 degree C and >40 degree C. (NCT01392378)
Timeframe: Within 4 days after toddler dose
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Fever >=38, <=39 degree C (n= 133,140,134,144,162) | Fever >39, <=40 degree C (n = 128,127,118,123,150) | Fever >40 degree C (n = 123,125,117,122,150) | |
| 13vPnC + INFANRIX Hexa | 30.2 | 2.0 | 0.0 |
| 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily | 50.0 | 5.7 | 0.0 |
| 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily | 37.1 | 7.1 | 0.0 |
| 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily | 37.3 | 4.2 | 0.0 |
| 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily | 31.6 | 5.5 | 0.0 |
Clinically significant hypotension is defined as an acute drop in mean arterial pressure requiring treatment. Treatment is defined as either a 500 cc (or greater) fluid bolus and/or an increase in inotrope support of greater than 5 mcg/min over baseline. (NCT02280239)
Timeframe: 4 hours post acetaminophen administration
| Intervention | Participants (Count of Participants) |
|---|---|
| Control Group | 0 |
| Acetaminophen Group | 0 |
systolic blood pressure (SBP), diastolic blood pressure (DBP) and mean arterial pressures (MAP) will be monitored for 4 hours post intervention (NCT02280239)
Timeframe: 4 hours post intervention
| Intervention | mmHg (Mean) | |||||
|---|---|---|---|---|---|---|
| SBP: Pre-Intervention (2 hours) | SBP: Post-Intervention (4 hours) | DBP: Pre-Intervention (2 hours) | DBP: Post-Intervention (4 hours) | MAP: Pre-Intervention (2 hours) | MAP: Post-Intervention (4 hours) | |
| Acetaminophen Group | 122.6 | 119.5 | 66.2 | 65.4 | 84.1 | 82.4 |
| Control Group | 141.6 | 141.5 | 57.4 | 51.0 | 80.8 | 75.5 |
"Total dose of all vasoactive medications will be converted to total Equidose value (with the formula 10 mcg/min norepinephrine ≈ 5 mcg/kg/min dopamine ≈ 10 mcg/min epinephrine ≈ 1 mcg/min phenylephrine ≈ 0.02 u/min vasopressin as per Russell et al. (2008)) before comparing the treatment and control groups~Only 2 of the 6 participants were on low-dose vasoactive medications, (i.e., one was on norepinephrine and the other was on milrinone) therefore the pre-planned conversion calculation was not done." (NCT02280239)
Timeframe: 4 hours post intervention
| Intervention | mcg (Number) | |||
|---|---|---|---|---|
| Pre-Intervention (2 hours) TOTAL Norepinephrine | Pre-Intervention (2 hours) TOTAL Milrinone | Post-Intervention (4 hours) TOTAL Norepinephrine | Post-Intervention (4 hours) TOTAL Milrinone | |
| Acetaminophen Group | NA | 6000.0 | NA | 7000.0 |
| Control Group | 167.0 | NA | 576.0 | NA |
Total crystalloid and colloid fluid will be converted the the equi-volume dose (with the ratio 1.4:1 (as per Finfer et al.(2004) & Vincent and Weil (2006) before making comparisons between the treatment and control groups. (NCT02280239)
Timeframe: 4 hours post intervention
| Intervention | mL (Mean) | |||
|---|---|---|---|---|
| Pre-Intervention (2 hours) Total fluid INTAKE | Pre-Intervention (2 hours) Total fluid OUTPUT | Post-Intervention (4 hours) Total Fluid INTAKE | Post-Intervention (4 hours) Total Fluid OUTPUT | |
| Acetaminophen Group | 298 | 370 | 612 | 852 |
| Control Group | 235 | 80 | 734 | 245 |
"Continuous measurements of core body temperature will be recorded for 6 hours. Fever burden (FB) is defined as area between the 6 hour temperature curve and 38.3°C cut-off and it is reported in °C-hour.~PRE-INTERVENTION FB: is reported for a 2 hour period. POST-INTERVENTION FB: post-intervention fever burden is reported for a 6 hour period and average hourly fever burden.~Peak Temperature: is the highest recorded temperature for the study period in °C Minimum Temperature: is the lowest recorded temperature for the study period in °C" (NCT02280239)
Timeframe: 6 hours post intervention
| Intervention | °C*hours (Mean) | |
|---|---|---|
| Pre-Intervention FB (2 hours) | Post-Intervention FB (6 hours) | |
| Acetaminophen Group | 2.16 | 5.65 |
| Control Group | 0.97 | 0.74 |
change over time core temperature after study drug administration (adjusted to baseline core temperature) (NCT01869699)
Timeframe: 2 hours
| Intervention | degrees Celsius (Mean) |
|---|---|
| Normal Saline Placebo | -0.01 |
| Acetaminophen | -0.8 |
2-hour change over time heart rate from time of study drug administration (means adjusted to baseline HR) (NCT01869699)
Timeframe: Baseline to 2 hours
| Intervention | BPM (Mean) |
|---|---|
| Normal Saline Placebo | 2 |
| Acetaminophen | -6 |
2-hour change over time SBP from study drug administration (means adjusted to baseline SBP) (NCT01869699)
Timeframe: Baseline to 2 hours
| Intervention | mm Hg (Mean) |
|---|---|
| Normal Saline Placebo | -0.1 |
| Acetaminophen | -24 |
time-weighted average core body temperature over 4 hours. Core temperature was measured every 5 minutes times 4, and then every 15 minutes over the following 4 hours from the time of study drug administration. The sum of the core temperature values was divided by time in minutes. (NCT01869699)
Timeframe: Baseline to 4 hours post study drug administration
| Intervention | degrees Celsius (Mean) |
|---|---|
| Normal Saline Placebo | 38.4 |
| Acetaminophen | 37.9 |
time-weighted average heart rate over 4 hours. Heart rate was measured every 5 minutes times 4, and then every 15 minutes over the following 4 hours from the time of study drug administration. The sum of the heart rate values was divided by time in minutes. (NCT01869699)
Timeframe: Baseline to 4 hours post study drug administration
| Intervention | beats per minute (Mean) |
|---|---|
| Normal Saline Placebo | 92 |
| Acetaminophen | 87 |
time weighted average for respiratory rate over 4 hours. Respiratory rate was measured every 5 minutes times 4, and then every 15 minutes over the following 4 hours from the time of study drug administration. The sum of the respiratory rate values was divided by time in minutes. (NCT01869699)
Timeframe: Baseline to 4 hours post study drug administration
| Intervention | breaths per minute (Mean) |
|---|---|
| Normal Saline Placebo | 22 |
| Acetaminophen | 21 |
time-weighted average systolic blood pressure over 4 hours. Systolic blood pressure was measured every 5 minutes times 4, and then every 15 minutes over the following 4 hours from the time of study drug administration. The sum of the systolic blood pressure values was divided by time in minutes. (NCT01869699)
Timeframe: Baseline to 4 hours post study drug administration
| Intervention | mm Hg (Mean) |
|---|---|
| Normal Saline Placebo | 143 |
| Acetaminophen | 127 |
The seroprotection cut-off for the assay was ≥ 10 mIU/mL. (NCT00496015)
Timeframe: 1 month post-vaccination (M1)
| Intervention | mIU/mL (Geometric Mean) |
|---|---|
| Synflorix I Group | 1883.9 |
| Synflorix II Group | 1460.6 |
| Synflorix PRE Group | 2133 |
| Synflorix POST Group | 1818.5 |
| Mencevax + Infanrix Hexa Group | 20610 |
The seroprotection cut-off for the assay was ≥ 10 mIU/mL. (NCT00496015)
Timeframe: 12 month post-vaccination (M12)
| Intervention | mIU/mL (Geometric Mean) |
|---|---|
| Synflorix I Group | 219.3 |
| Synflorix II Group | 147.3 |
| Synflorix PRE Group | 231.2 |
| Synflorix POST Group | 139.2 |
| Mencevax + Infanrix Hexa Group | 535.1 |
The seroprotection cut-off for the assay was ≥ 10 milli international units per milliliter (mIU/mL). Results were only tabulated for subjects who received a vaccine including the respective antigens (Mencevax + Infanrix Hexa Group). Dummy lower limit (LL) (0.0) and upper limit UL (99999.9) were entered when number of subjects analysed = 1. (NCT00496015)
Timeframe: Prior to vaccination (Pre)
| Intervention | mIU/mL (Geometric Mean) |
|---|---|
| Mencevax + Infanrix Hexa Group | 1336.1 |
The seroprotection cut-off for the assay was ≥ 0.15 μg/mL. (NCT00496015)
Timeframe: 1 month post-vaccination (M1)
| Intervention | μg/mL (Geometric Mean) |
|---|---|
| Synflorix I Group | 23.066 |
| Synflorix II Group | 26.006 |
| Synflorix PRE Group | 27.373 |
| Synflorix POST Group | 22.011 |
| Mencevax + Infanrix Hexa Group | 20.985 |
The seroprotection cut-off for the assay was ≥ 0.1 international units per milliliter (IU/mL). (NCT00496015)
Timeframe: Prior to vaccination (Pre)
| Intervention | IU/mL (Geometric Mean) |
|---|---|
| Mencevax + Infanrix Hexa Group | 0.512 |
The cut-off value for core fever (rectal temperature) was 39.0ºC. (NCT00496015)
Timeframe: Within 4 days (Day 0-3) after primary vaccination dose
| Intervention | Participants (Count of Participants) |
|---|---|
| Synflorix I Group | 4 |
| Synflorix II Group | 0 |
| Synflorix PRE Group | 14 |
| Synflorix POST Group | 1 |
| Mencevax + Infanrix Hexa Group | 16 |
The cut-off for core fever was 38.0 degrees Celsius (ºC). (NCT00496015)
Timeframe: Within 4 days (Day 0-3) after primary vaccine dose.
| Intervention | Participants (Count of Participants) |
|---|---|
| Synflorix I Group | 64 |
| Synflorix II Group | 14 |
| Synflorix PRE Group | 100 |
| Synflorix POST Group | 16 |
| Mencevax + Infanrix Hexa Group | 146 |
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. (NCT00496015)
Timeframe: Throughout the entire study period (Month 0-Month 12)
| Intervention | Participants (Count of Participants) |
|---|---|
| Synflorix I Group | 13 |
| Synflorix II Group | 5 |
| Synflorix PRE Group | 13 |
| Synflorix POST Group | 4 |
| Mencevax + Infanrix Hexa Group | 30 |
"The outcome measure was not reporting statistics for all the arms in the baseline period. Results were tabulated on baseline groups except for the Synforix PRE and Synforix POST groups, for which results were presented for the Pooled Synforix PRE and POST Group.~An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination." (NCT00496015)
Timeframe: Within 31 days (Days 0-30) after primary vaccine dose.
| Intervention | Participants (Count of Participants) |
|---|---|
| Synflorix I Group | 22 |
| Synflorix II Group | 3 |
| Mencevax + Infanrix Hexa Group | 64 |
| Pooled Synflorix PRE and POST Group | 30 |
The seropositivity cut-off for the assay was ≥ 5 Enzyme-Linked ImmunoSorbent Assay (ELISA) units per millimiter (EL.U/mL). (NCT00496015)
Timeframe: 1 month post-vaccination (M1)
| Intervention | EL.U/mL (Number) | ||
|---|---|---|---|
| Anti-PT, M1 | Anti-FHA, M1 | Anti-PRN, M1 | |
| Mencevax + Infanrix Hexa Group | 163.1 | 580.8 | 350.7 |
| Synflorix I Group | 83.3 | 467.9 | 222.8 |
| Synflorix II Group | 81.6 | 431.1 | 153.4 |
| Synflorix POST Group | 76.7 | 400.4 | 220.4 |
| Synflorix PRE Group | 82 | 453.8 | 254.9 |
The seroprotection cut-off for the assay was ≥ 8. (NCT00496015)
Timeframe: 12 month post-vaccination (M12)
| Intervention | Titers (Geometric Mean) | ||
|---|---|---|---|
| Anti-Polio 1, M12 | Anti-Polio 2, M12 | Anti-Polio 3, M12 | |
| Mencevax + Infanrix Hexa Group | 335.4 | 322.7 | 203.3 |
| Synflorix I Group | 208.2 | 311.2 | 431.3 |
| Synflorix II Group | 150.4 | 212.4 | 301 |
| Synflorix POST Group | 220.8 | 400 | 672.2 |
| Synflorix PRE Group | 234.5 | 310.6 | 506.3 |
The seroprotection cut-off for the assay was ≥ 8. (NCT00496015)
Timeframe: 1 month post-vaccination (M1)
| Intervention | Titers (Geometric Mean) | ||
|---|---|---|---|
| Anti-Polio 1, M1 | Anti-Polio 2, M1 | Anti-Polio 3, M1 | |
| Mencevax + Infanrix Hexa Group | 4096 | 8192 | 8192 |
| Synflorix I Group | 1193 | 1354.1 | 2354.2 |
| Synflorix II Group | 1534.2 | 2047.9 | 2233.3 |
| Synflorix POST Group | 1208.6 | 2215.8 | 3576.5 |
| Synflorix PRE Group | 1058.7 | 1413.2 | 2647.5 |
"Certain pneumococcal serotypes included pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (Anti-1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F).~Anti-1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F antibody concentrations were measured by 22F-inhibition Enzyme-Linked ImmunoSorbent Assay (ELISA).~Seropositivity cut-off for the assay was ≥ 0.05 microgram per milliliter (μg/mL)." (NCT00496015)
Timeframe: Prior to booster vaccination (PRE), 1 month (M1) and 12 months (M12) post-booster vaccination
| Intervention | μg/mL (Geometric Mean) | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ANTI-1 PRE | ANTI-1 M1 | ANTI-1 M12 | ANTI-4 PRE | ANTI-4 M1 | ANTI-4 M12 | ANTI-5 PRE | ANTI-5 M1 | ANTI-5 M12 | ANTI-6B PRE | ANTI-6B M1 | ANTI-6B M12 | ANTI-7F PRE | ANTI-7F M1 | ANTI-7F M12 | ANTI-9V PRE | ANTI-9V M1 | ANTI-9V M12 | ANTI-14 PRE | ANTI-14 M1 | ANTI-14 M12 | ANTI-18C PRE | ANTI-18C M1 | ANTI-18C M12 | ANTI-19F PRE | ANTI-19F M1 | ANTI-19F M12 | ANTI-23F PRE | ANTI-23F M1 | ANTI-23F M12 | |
| Mencevax + Infanrix Hexa Group | 0.03 | 0.03 | 0.04 | 0.03 | 0.03 | 0.04 | 0.04 | 0.04 | 0.06 | 0.03 | 0.03 | 0.04 | 0.03 | 0.03 | 0.04 | 0.03 | 0.03 | 0.04 | 0.04 | 0.05 | 0.11 | 0.03 | 0.03 | 0.04 | 0.03 | 0.05 | 0.12 | 0.03 | 0.03 | 0.04 |
| Synflorix I Group | 0.22 | 1.67 | 0.26 | 0.4 | 3.01 | 0.34 | 0.36 | 2.3 | 0.42 | 0.35 | 1.35 | 0.4 | 0.74 | 2.9 | 0.68 | 0.61 | 2.86 | 0.67 | 0.82 | 4.58 | 0.89 | 0.47 | 4.96 | 0.56 | 0.98 | 6 | 1.46 | 0.38 | 1.99 | 0.46 |
| Synflorix II Group | 0.18 | 1.64 | 0.18 | 0.24 | 2.84 | 0.21 | 0.31 | 2 | 0.35 | 0.18 | 0.89 | 0.36 | 0.55 | 2.37 | 0.45 | 0.59 | 2.57 | 0.55 | 0.52 | 4.37 | 0.94 | 0.29 | 3.46 | 0.44 | 0.63 | 4.84 | 0.82 | 0.3 | 1.33 | 0.29 |
| Synflorix POST Group | 0.26 | 2.97 | 0.41 | 0.45 | 3.95 | 0.55 | 0.53 | 3.03 | 0.58 | 0.5 | 2.25 | 0.54 | 0.87 | 4.38 | 0.96 | 0.99 | 4.35 | 0.86 | 1.27 | 5.86 | 1.25 | 0.54 | 6.13 | 0.92 | 1.4 | 8.77 | 2.04 | 0.45 | 3.86 | 0.98 |
| Synflorix PRE Group | 0.31 | 2.62 | 0.39 | 0.6 | 4.21 | 0.5 | 0.59 | 3.68 | 0.72 | 0.55 | 2.45 | 0.56 | 1.05 | 4.13 | 0.91 | 1 | 4.39 | 0.97 | 1.57 | 5.95 | 1.54 | 0.78 | 7 | 1.05 | 1.48 | 7.55 | 1.8 | 0.54 | 2.92 | 0.8 |
Anti-6A and 19A antibody concentrations were measured by 22F-inhibition Enzyme-Linked ImmunoSorbent Assay (ELISA). (NCT00496015)
Timeframe: Prior to booster vaccination (PRE), 1 month (M1) and 12 months (M12) post-booster vaccination
| Intervention | μg/mL (Geometric Mean) | |||||
|---|---|---|---|---|---|---|
| Anti-6A-PRE | Anti-6A-M1 | Anti-6A-M12 | Anti-19A-PRE | Anti-19A-M1 | Anti-19A-M12 | |
| Mencevax + Infanrix Hexa Group | 0.03 | 0.03 | 0.04 | 0.03 | 0.04 | 0.06 |
| Synflorix I Group | 0.12 | 0.4 | 0.14 | 0.15 | 0.84 | 0.22 |
| Synflorix II Group | 0.08 | 0.29 | 0.1 | 0.12 | 0.56 | 0.13 |
| Synflorix POST Group | 0.19 | 0.75 | 0.2 | 0.2 | 1.54 | 0.41 |
| Synflorix PRE Group | 0.21 | 0.86 | 0.24 | 0.23 | 1.34 | 0.36 |
The seroprotection cut-off for the assay was ≥ 0.1 international units per milliliter (IU/mL). (NCT00496015)
Timeframe: 1 month post-vaccination (M1)
| Intervention | IU/mL (Geometric Mean) | |
|---|---|---|
| Anti-D, M1 | Anti-T, M1 | |
| Mencevax + Infanrix Hexa Group | 7.291 | 11.79 |
| Synflorix I Group | 10.112 | 7.382 |
| Synflorix II Group | 9.839 | 8.684 |
| Synflorix POST Group | 11 | 8.196 |
| Synflorix PRE Group | 12.285 | 9.583 |
The seropositivity cut-off for the assay was ≥ 100 Enzyme-Linked ImmunoSorbent Assay (ELISA) units per milliliter (EL.U/mL). (NCT00496015)
Timeframe: Prior to booster vaccination (PRE), 1 month (M1) and 12 months (M12) post-booster vaccination
| Intervention | EL.U/mL (Geometric Mean) | ||
|---|---|---|---|
| Anti-PD-PRE | Anti-PD-M1 | Anti-PD-M12 | |
| Mencevax + Infanrix Hexa Group | 65.6 | 64.6 | 74.4 |
| Synflorix I Group | 365.1 | 1654 | 468.1 |
| Synflorix II Group | 356.5 | 1813.5 | 418 |
| Synflorix POST Group | 584.3 | 2612.3 | 713.4 |
| Synflorix PRE Group | 685.5 | 3134.2 | 834.6 |
Anti-PS assessed were Anti-PSA, anti-PSC, anti-PSW-135 and anti-PSY. Results were only tabulated for subjects who received a vaccine including the respective antigens (Mencevax + Infanrix Hexa Group). (NCT00496015)
Timeframe: Prior to vaccination(PRE), 1 month (M1) and 12 months (M12) post- vaccination.
| Intervention | μg/mL (Geometric Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anti-PSA, Pre | Anti-PSA, M1 | Anti-PSA, M12 | Anti-PSC, Pre | Anti-PSC, M1 | Anti-PSC, M12 | Anti-PSW-135, Pre | Anti-PSW-135, M1 | Anti-PSW-135, M12 | Anti-PSY, Pre | Anti-PSY, M1 | Anti-PSY, M12 | |
| Mencevax + Infanrix Hexa Group | 0.16 | 36.28 | 0.99 | 0.15 | 14.12 | 0.42 | 0.15 | 6.11 | 1.21 | 0.15 | 8.03 | 1.81 |
Results were tabulated on Mencevax + Infanrix Hexa Group and on Pooled Synflorix Group. (NCT00496015)
Timeframe: Prior to vaccination(Pre), 1 month post-vaccination (M1), 3 months post-vaccination (M3), 7 months post-vaccination (M7), 12 months post-vaccination (M12) and across all time points (Overall)
| Intervention | Swabs (Number) | |||||
|---|---|---|---|---|---|---|
| Pre | M1 | M3 | M7 | M12 | Overall | |
| Mencevax + Infanrix Hexa Group | 41 | 39 | 34 | 49 | 57 | 124 |
| Pooled Synflorix Group | 48 | 56 | 62 | 64 | 46 | 160 |
Results were tabulated on Mencevax + Infanrix Hexa Group and on Pooled Synflorix Group. (NCT00496015)
Timeframe: Prior to vaccination(Pre), 1 month post-vaccination (M1), 3 months post-vaccination (M3), 7 months post-vaccination (M7), 12 months post-vaccination (M12) and across all time points (Overall)
| Intervention | Swabs (Number) | |||||
|---|---|---|---|---|---|---|
| Pre | M1 | M3 | M7 | M12 | Overall | |
| Mencevax + Infanrix Hexa Group | 19 | 20 | 17 | 22 | 22 | 61 |
| Pooled Synflorix Group | 21 | 30 | 31 | 28 | 19 | 86 |
Results were tabulated on Pooled Synflorix Group and on Mencevax + Infanrix Hexa Group. (NCT00496015)
Timeframe: Prior to vaccination(Pre), 1 month post-vaccination (M1), 3 months post-vaccination (M3), 7 months post-vaccination (M7), 12 months post-vaccination (M12) and across all time points (Overall)
| Intervention | Swabs (Number) | |||||
|---|---|---|---|---|---|---|
| Pre | M1 | M3 | M7 | M12 | Overall | |
| Mencevax + Infanrix Hexa Group | 13 | 19 | 21 | 19 | 19 | 55 |
| Pooled Synflorix Group | 15 | 22 | 27 | 21 | 18 | 59 |
Results were tabulated on Mencevax + Infanrix Hexa Group and on Pooled Synflorix Group. (NCT00496015)
Timeframe: Prior to vaccination(Pre), 1 month post-vaccination (M1), 3 months post-vaccination (M3), 7 months post-vaccination (M7), 12 months post-vaccination (M12) and across all time points (Overall)
| Intervention | Swabs (Number) | |||||
|---|---|---|---|---|---|---|
| Pre | M1 | M3 | M7 | M12 | Overall | |
| Mencevax + Infanrix Hexa Group | 26 | 30 | 32 | 29 | 22 | 82 |
| Pooled Synflorix Group | 27 | 42 | 45 | 42 | 39 | 111 |
Results were tabulated on Pooled Synflorix Group and on Mencevax + Infanrix Hexa Group. (NCT00496015)
Timeframe: Prior to vaccination(Pre), 1 month post-vaccination (M1), 3 months post-vaccination (M3), 7 months post-vaccination (M7), 12 months post-vaccination (M12) and across all time points (Overall)
| Intervention | Swabs (Number) | |||||
|---|---|---|---|---|---|---|
| Pre | M1 | M3 | M7 | M12 | Overall | |
| Mencevax + Infanrix Hexa Group | 53 | 47 | 55 | 50 | 43 | 115 |
| Pooled Synflorix Group | 43 | 45 | 49 | 42 | 34 | 111 |
Results were tabulated only on Mencevax + Infanrix Hexa Group, according to the outcome measure specification of the protocol. (NCT00496015)
Timeframe: Up to 6 months after vaccination with Mencevax™
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Subject(s) with any rash(es) | Subject(s) with any NOCI(s) | Subject(s) with any ER visit(s) | Subject(s) with any visit(s) at physician office | |
| Mencevax + Infanrix Hexa Group | 7 | 1 | 0 | 53 |
Solicited local symptoms assessed were pain, redness and swelling. Any was defined as any occurrence of the specified symptom regardless of intensity. Grade 3 pain was defined as cried when limb was moved/spontaneously painful. Grade 3 redness/swelling was defined as redness/swelling > 30 millimeters (mm) from injection site. (NCT00496015)
Timeframe: During the 4-day (Days 0-3) post-primary vaccination period
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| Any Pain | Grade 3 Pain | Any Redness | Grade 3 Redness | Any Swelling | Grade 3 Swelling | |
| Mencevax + Infanrix Hexa Group | 114 | 4 | 146 | 16 | 71 | 12 |
| Synflorix I Group | 54 | 2 | 89 | 7 | 52 | 2 |
| Synflorix II Group | 10 | 2 | 9 | 1 | 8 | 1 |
| Synflorix POST Group | 19 | 3 | 12 | 1 | 13 | 3 |
| Synflorix PRE Group | 79 | 10 | 74 | 14 | 50 | 9 |
Solicited general symptoms assessed were drowsiness, fever (rectal temperature ≥ 38.5°C), irritability and loss of appetite. Any was defined as any occurrence of the specified symptom regardless of intensity and relation to vaccination. Grade 3 drowsiness was defined as drowsiness that prevented normal activity. Grade 3 fever was defined as rectal temperature >40.0°C. Grade 3 irritability was defined as crying that could not be comforted/ prevented normal activity. Grade 3 loss of appetite was defined as not eating at all. Related was defined as solicited symptoms assessed by the investigator as causally related to the study vaccination. (NCT00496015)
Timeframe: During the 4-day (Day 0-3) post-vaccination period
| Intervention | Participants (Count of Participants) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any Drowsiness | Grade 3 Drowsiness | Related Drowsiness | Any Fever (rectal temperature ≥ 38.0°C) | Grade 3 Fever (rectal temperature > 40.0°C) | Related Fever (rectal temperature > 40.0°C) | Any Irritability | Grade 3 Irritability | Related Irritability | Any Loss of appetite | Grade 3 Loss of appetite | Related Loss of appetite | |
| Mencevax + Infanrix Hexa Group | 146 | 2 | 120 | 146 | 3 | 140 | 147 | 2 | 129 | 88 | 3 | 71 |
| Synflorix I Group | 91 | 0 | 84 | 64 | 1 | 62 | 86 | 1 | 80 | 47 | 0 | 42 |
| Synflorix II Group | 11 | 0 | 11 | 14 | 0 | 14 | 17 | 0 | 17 | 8 | 0 | 7 |
| Synflorix POST Group | 18 | 1 | 18 | 16 | 0 | 16 | 19 | 2 | 18 | 10 | 1 | 10 |
| Synflorix PRE Group | 84 | 1 | 79 | 100 | 1 | 99 | 105 | 2 | 98 | 46 | 4 | 41 |
Anti-PS assessed were anti-PS meningitidis serogroup A (anti-PSA), C (anti-PSC), W (anti-PSW-135) and Y (anti-PSY). The cut-offs for anti-PS concentrations were 0.3 μg/mL and 2.0 μg/mL, tabulated for subjects who received a vaccine including the respective antigens (Mencevax + Infanrix Hexa Group). (NCT00496015)
Timeframe: Prior to vaccination(PRE), 1 month (M1) and 12 months (M12) post-vaccination
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ANTI-PSA PRE ≥ 0.3 μg/mL | ANTI-PSA PRE ≥ 2.0 μg/mL | ANTI-PSA M1≥ 0.3 μg/mL | ANTI-PSA M1 ≥ 2.0 μg/mL | ANTI-PSA M12 ≥ 0.3 μg/mL | ANTI-PSA M12 ≥ 2.0 μg/mL | ANTI-PSC PRE ≥ 0.3 μg/mL | ANTI-PSC PRE ≥ 2.0 μg/mL | ANTI-PSC M1 ≥ 0.3 μg/mL | ANTI-PSC M1≥ 2.0 μg/mL | ANTI-PSC M12 ≥ 0.3 μg/mL | ANTI-PSC M12 ≥ 2.0 μg/mL | ANTI-PSW-135 PRE ≥ 0.3 μg/mL | ANTI-PSW-135 PRE ≥ 2.0 μg/mL | ANTI-PSW-135 M1 ≥ 0.3 μg/mL | ANTI-PSW-135 M1 ≥ 2.0 μg/mL | ANTI-PSW-135 M12 ≥ 0.3 μg/mL | ANTI-PSW-135 M12 ≥ 2.0 μg/mL | ANTI-PSY PRE ≥ 0.3 μg/mL | ANTI-PSY PRE ≥ 2.0 μg/mL | ANTI-PSY M1 ≥ 0.3 μg/mL | ANTI-PSY M1 ≥ 2.0 μg/mL | ANTI-PSY M12 ≥ 0.3 μg/mL | ANTI-PSY M12 ≥ 2.0 μg/mL | |
| Mencevax + Infanrix Hexa Group | 12 | 1 | 271 | 271 | 133 | 47 | 3 | 0 | 278 | 277 | 94 | 9 | 1 | 0 | 258 | 234 | 117 | 45 | 3 | 0 | 261 | 249 | 131 | 59 |
"Certain pneumococcal serotypes includes pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (Anti-1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F). Anti-1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F antibody concentrations were measured by 22F-inhibition Enzyme-Linked ImmunoSorbent Assay (ELISA).~The seroprotection cut-off for the assay was ≥ 0.2 microgram per milliliter (μg/mL)." (NCT00496015)
Timeframe: Prior to booster vaccination (PRE), 1 month (M1) and 12 months (M12) post-booster vaccination
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ANTI-1 PRE | ANTI-1 M1 | ANTI-1 M12 | ANTI-4 PRE | ANTI-4 M1 | ANTI-4 M12 | ANTI-5 PRE | ANTI-5 M1 | ANTI-5 M12 | ANTI-6B PRE | ANTI-6B M1 | ANTI-6B M12 | ANTI-7F PRE | ANTI-7F M1 | ANTI-7F M12 | ANTI-9V PRE | ANTI-9V M1 | ANTI-9V M12 | ANTI-14 PRE | ANTI-14 M1 | ANTI-14 M12 | ANTI-18C PRE | ANTI-18C M1 | ANTI-18C M12 | ANTI-19F PRE | ANTI-19F M1 | ANTI-19F M12 | ANTI-23F PRE | ANTI-23F M1 | ANTI-23F M12 | |
| Mencevax + Infanrix Hexa Group | 6 | 5 | 11 | 6 | 6 | 20 | 6 | 10 | 31 | 1 | 1 | 21 | 5 | 9 | 20 | 5 | 10 | 30 | 25 | 29 | 63 | 8 | 9 | 29 | 17 | 24 | 90 | 2 | 4 | 24 |
| Synflorix I Group | 74 | 140 | 89 | 123 | 141 | 103 | 102 | 140 | 113 | 110 | 134 | 97 | 130 | 140 | 132 | 117 | 141 | 129 | 131 | 140 | 131 | 118 | 141 | 113 | 128 | 138 | 135 | 103 | 135 | 115 |
| Synflorix II Group | 14 | 24 | 11 | 15 | 24 | 14 | 15 | 23 | 18 | 13 | 21 | 18 | 21 | 25 | 21 | 20 | 24 | 20 | 22 | 24 | 21 | 14 | 25 | 18 | 21 | 25 | 22 | 14 | 21 | 16 |
| Synflorix POST Group | 27 | 36 | 30 | 31 | 37 | 27 | 30 | 36 | 30 | 32 | 35 | 30 | 34 | 37 | 36 | 34 | 37 | 35 | 35 | 36 | 34 | 29 | 37 | 35 | 36 | 37 | 36 | 30 | 36 | 33 |
| Synflorix PRE Group | 115 | 167 | 122 | 147 | 167 | 147 | 142 | 167 | 159 | 143 | 166 | 148 | 156 | 167 | 165 | 152 | 167 | 166 | 159 | 166 | 166 | 154 | 167 | 157 | 163 | 165 | 165 | 132 | 163 | 154 |
Results were tabulated on Mencevax + Infanrix Hexa Group and on Pooled Synflorix Group. (NCT00496015)
Timeframe: 1 month post-vaccination (M1), 3 months post-vaccination (M3), 7 months post-vaccination (M7), 12 months post-vaccination (M12) and across all time points (Overall)
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| M1 | M3 | M7 | M12 | Overall | |
| Mencevax + Infanrix Hexa Group | 21 | 22 | 37 | 39 | 104 |
| Pooled Synflorix Group | 32 | 40 | 42 | 35 | 129 |
Results were tabulated on Mencevax + Infanrix Hexa Group and on Pooled Synflorix Group. (NCT00496015)
Timeframe: 1 month post-vaccination (M1), 3 months post-vaccination (M3), 7 months post-vaccination (M7), 12 months post-vaccination (M12) and across all time points (Overall)
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| M1 | M3 | M7 | M12 | Overall | |
| Mencevax + Infanrix Hexa Group | 43 | 63 | 70 | 65 | 161 |
| Pooled Synflorix Group | 56 | 76 | 73 | 70 | 195 |
"The cut-off values assessed were 1:8 and 1:128 for meningococcal polysaccharides A , C, W-135 and Y serum bactericidal antibodies, using baby rabbit complement for assay (rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY).~Results were only tabulated for subjects who received a vaccine including the respective antigens (Mencevax + Infanrix Hexa Group)." (NCT00496015)
Timeframe: Prior to vaccination (PRE), 1 month (M1) and 12 months (M12) post-vaccination
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| rSBA-MenA,Pre, ≥ 1:8 | rSBA-MenA, Pre, ≥ 1:128 | rSBA-MenA, M1, ≥ 1:8 | rSBA-MenA, M1, ≥ 1:128 | rSBA-MenA, M12, ≥ 1:8 | rSBA-MenA, M12, ≥ 1:128 | rSBA-MenC,Pre, ≥ 1:8 | rSBA-MenC, Pre, ≥ 1:128 | rSBA-MenC, M1, ≥ 1:8 | rSBA-MenC, M1, ≥ 1:128 | rSBA-MenC, M12, ≥ 1:8 | rSBA-MenC, M12, ≥ 1:128 | rSBA-MenW-135,Pre, ≥ 1:8 | rSBA-MenW-135, Pre, ≥ 1:128 | rSBA-MenW-135, M1, ≥ 1:8 | rSBA-MenW-135, M1, ≥ 1:128 | rSBA-MenW-135, M12, ≥ 1:8 | rSBA-MenW-135, M12, ≥ 1:128 | rSBA-MenY,Pre, ≥ 1:8 | rSBA-MenY, Pre, ≥ 1:128 | rSBA-MenY, M1, ≥ 1:8 | rSBA-MenY, M1, ≥ 1:128 | rSBA-MenY, M12, ≥ 1:8 | rSBA-MenY, M12, ≥ 1:128 | |
| Mencevax + Infanrix Hexa Group | 69 | 44 | 298 | 298 | 136 | 134 | 50 | 17 | 300 | 294 | 154 | 105 | 114 | 59 | 301 | 301 | 138 | 129 | 167 | 93 | 300 | 300 | 137 | 127 |
OPA titers against pneumococcal serotypes 6A and 19A (Opsono-6A and 19A) were calculated, expressed as geometric mean titers (GMTs) and tabulated. The seropositivity cut-off for the assay was ≥ 8. (NCT00496015)
Timeframe: Prior to booster vaccination (PRE), 1 month (M1) and 12 months (M12) post-booster vaccination
| Intervention | Titers (Geometric Mean) | |||||
|---|---|---|---|---|---|---|
| OPSONO-6A-PRE | OPSONO-6A-M1 | OPSONO-6A-M12 | OPSONO-19A-PRE | OPSONO-19A-M1 | OPSONO-19A-M12 | |
| Mencevax + Infanrix Hexa Group | 9.7 | 16.1 | 17.1 | 4 | 4 | 4.7 |
| Synflorix I Group | 72.4 | 251.5 | 59.4 | 5 | 39.2 | 7 |
| Synflorix II Group | 35.6 | 105.1 | 23 | 4.9 | 39.7 | 4.8 |
| Synflorix POST Group | 66 | 403.7 | 37.2 | 5 | 99.6 | 9.5 |
| Synflorix PRE Group | 65.4 | 401.7 | 52.1 | 4.8 | 89.7 | 8.9 |
OPA titers against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (Opsono-1, -4, -5, -6B, -7F, -9V, -14, -18C, -19F and -23F) were calculated, expressed as geometric mean titers (GMTs) and tabulated. The seropositivity cut-off for the assay was ≥ 8. (NCT00496015)
Timeframe: Prior to booster vaccination (PRE), 1 month (M1) and 12 months (M12) post-booster vaccination
| Intervention | Titers (Geometric Mean) | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OPSONO-1 PRE | OPSONO-1 M1 | OPSONO-1 M12 | OPSONO-4 PRE | OPSONO-4 M1 | OPSONO-4 M12 | OPSONO-5 PRE | OPSONO-5 M1 | OPSONO-5 M12 | OPSONO-6B PRE | OPSONO-6B M1 | OPSONO-6B M12 | OPSONO-7F PRE | OPSONO-7F M1 | OPSONO-7F M12 | OPSONO-9V PRE | OPSONO-9V M1 | OPSONO-9V M12 | OPSONO-14 PRE | OPSONO-14 M1 | OPSONO-14 M12 | OPSONO-18C PRE | OPSONO-18C M1 | OPSONO-18C M12 | OPSONO-19F PRE | OPSONO-19F M1 | OPSONO-19F M12 | OPSONO-23F PRE | OPSONO-23F M1 | OPSONO-23F M12 | |
| Mencevax + Infanrix Hexa Group | 4.9 | 5.1 | 4.7 | 5.9 | 7.8 | 6.8 | 4.2 | 4.3 | 4 | 9.9 | 20.9 | 19.1 | 90 | 267.3 | 681.1 | 69.2 | 87.4 | 127.2 | 11.5 | 158 | 287.8 | 4.5 | 4 | 4.6 | 5.3 | 4.5 | 6.4 | 20.2 | 261.8 | 147.1 |
| Synflorix I Group | 6.1 | 144.6 | 12.8 | 23.8 | 1547.9 | 19.9 | 8.5 | 134.3 | 10.3 | 32.5 | 496.7 | 46.9 | 413.6 | 4025.8 | 1503.3 | 420.7 | 2234.8 | 791.6 | 189.7 | 1581.7 | 434.5 | 6.1 | 652.9 | 11.9 | 21.2 | 629.4 | 64.3 | 288.7 | 2335.7 | 386.4 |
| Synflorix II Group | 5.6 | 193.4 | 12.5 | 8.8 | 971.6 | 14.9 | 10.4 | 105 | 10.5 | 15.9 | 148.3 | 97.7 | 221.4 | 1749 | 1606.4 | 472.9 | 752.9 | 552.2 | 150.2 | 1515 | 438.4 | 6 | 269.7 | 24.7 | 17.4 | 372.9 | 39.4 | 310.1 | 1223.1 | 433.8 |
| Synflorix POST Group | 6 | 325 | 20.5 | 29.7 | 1303.2 | 72.5 | 15.1 | 227.7 | 15.4 | 49.7 | 718.3 | 29.4 | 258.4 | 2212.2 | 1738.3 | 365.7 | 1155.5 | 716.8 | 227.4 | 1964.5 | 558 | 9.5 | 537.6 | 23.5 | 36.4 | 1198.8 | 121.3 | 305.3 | 1808.7 | 670.2 |
| Synflorix PRE Group | 8.1 | 417 | 23.1 | 44.9 | 2297 | 51.2 | 16.6 | 289.3 | 23.7 | 45.2 | 985.7 | 53.9 | 584.7 | 4674.7 | 1285.7 | 407.7 | 2403.7 | 906.7 | 293.2 | 1865.2 | 447.5 | 11.7 | 737.8 | 27.7 | 35.1 | 1062.2 | 101.3 | 408 | 3154 | 857.5 |
Results were only tabulated for subjects who received a vaccine including the respective antigens (Mencevax + Infanrix Hexa Group). (NCT00496015)
Timeframe: Prior to vaccination(PRE), 1 month (M1) and 12 months (M12) post- vaccination.
| Intervention | Titers (Geometric Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| rSBA-MenA,Pre | rSBA-MenA, M1 | rSBA-MenA, M12 | rSBA-MenC,Pre | rSBA-MenC, M1 | rSBA-MenC, M12 | rSBA-MenW-135,Pre | rSBA-MenW-135, M1 | rSBA-MenW-135, M12 | rSBA-MenY,Pre | rSBA-MenY, M1 | rSBA-MenY, M12 | |
| Mencevax + Infanrix Hexa Group | 11.5 | 2151.3 | 677.6 | 6.9 | 811.2 | 191.1 | 16.3 | 5393.6 | 573.1 | 30.2 | 2863.7 | 665.2 |
The fold-difference (defined as a ratio to describe the change from baseline to Day 28) in geometric mean serum HAI antibody titers against influenza B between non-AD and moderate to severe AD participants, following a single dose of the seasonal 2012-2013 Fluzone Intradermal vaccine. A fold-difference of greater than 1 indicated an increase in HAI antibody titers against influenza B as a result of vaccination; therefore, higher numbers indicate a greater probability of avoiding disease if infected with influenza B. Participants who achieved seroprotection (which is defined as having a sufficient antibody amount to avoid disease in half of the individuals infected with influenza B) prior to vaccination were excluded from the analysis. (NCT01737710)
Timeframe: Day 28 post vaccination
| Intervention | HAI antibody titers (Geometric Mean) |
|---|---|
| Moderate to Severe AD, Intradermal | 2.6 |
| Non-AD, Intradermal | 2.0 |
The fold-difference (defined as a ratio to describe the change from baseline to Day 28) in geometric mean serum HAI antibody titers against influenza H1N1 between non-AD and moderate to severe AD participants, following a single dose of the seasonal 2012-2013 Fluzone Intradermal vaccine. A fold-difference of greater than or equal to 1 indicated an increase in HAI antibody titers against influenza H1N1 as a result of vaccination; therefore, higher numbers indicate a greater probability of avoiding disease if infected with influenza H1N1. Participants who achieved seroprotection prior to vaccination were excluded from the analysis, which is defined as having a sufficient antibody amount to avoid disease in half of the individuals infected with influenza H1N1. (NCT01737710)
Timeframe: Day 28 post vaccination
| Intervention | HAI antibody titers (Geometric Mean) |
|---|---|
| Moderate to Severe AD, Intradermal | 22.4 |
| Non-AD, Intradermal | 37.7 |
The fold-difference (defined as a ratio to describe the change from baseline to Day 28) in geometric mean serum HAI antibody titers against influenza H3N2 between non-AD and moderate to severe AD participants, following a single dose of the seasonal 2012-2013 Fluzone Intradermal vaccine. A fold-difference of greater than or equal to 1 indicated an increase in HAI antibody titers against influenza H3N2 as a result of vaccination; therefore, higher numbers indicate a greater probability of avoiding disease if infected with influenza H3N2 Participants who achieved seroprotection prior to vaccination were excluded from the analysis, which is defined as having a sufficient antibody amount to avoid disease in half of the individuals infected with influenza H3N2. (NCT01737710)
Timeframe: Day 28 post vaccination
| Intervention | HAI antibody titers (Geometric Mean) |
|---|---|
| Moderate to Severe AD, Intradermal | 10.1 |
| Non-AD, Intradermal | 9.7 |
The difference in the percentage of moderate to severe AD participants that achieved seroconversion at Day 28 between those given a single dose (0.1mL) of the seasonal 2012 - 2013 Fluzone Intradermal vaccine and those given a single dose (0.1mL) of the seasonal 2012 - 2013 Fluzone (Intramuscular) vaccine. Seroconversion is defined as a 4-fold or greater increase in serum hemagglutination-inhibition [HAI] antibody titers against influenza B compared to baseline values, which represents the minimum intended effect of vaccination. Participants who achieved seroprotection, defined as having a sufficient antibody amount to avoid disease in half of the individuals infected with influenza B, prior to vaccination were excluded from the analysis. The goal was to examine whether there was a difference between the two groups in the percentage of participants who achieved seroconversion at Day 28 who were not seroprotected prior to vaccination. (NCT01737710)
Timeframe: Day 28 Post Vaccination
| Intervention | percentage of participants (Number) |
|---|---|
| Moderate to Severe AD, Intradermal | 40.6 |
| Moderate to Severe AD, Intramuscular | 47.8 |
The difference in the percentage of moderate to severe AD participants that achieved seroconversion at Day 28 between those given a single dose (0.1mL) of the seasonal 2012 - 2013 Fluzone Intradermal vaccine and those given a single dose (0.1mL) of the seasonal 2012 - 2013 Fluzone (Intramuscular) vaccine. Seroconversion is defined as a 4-fold or greater increase in serum hemagglutination-inhibition [HAI] antibody titers against influenza H1N1 compared to baseline values, which represents the minimum intended effect of vaccination. Participants who achieved seroprotection, defined as having a sufficient antibody amount to avoid disease in half of the individuals infected with influenza H1N1, prior to vaccination were excluded from the analysis. The goal was to examine whether there was a difference between the two groups in the percentage of participants who achieved seroconversion at Day 28 who were not seroprotected prior to vaccination. (NCT01737710)
Timeframe: Day 28 Post Vaccination
| Intervention | percentage of participants (Number) |
|---|---|
| Moderate to Severe AD, Intradermal | 85.7 |
| Moderate to Severe AD, Intramuscular | 88.7 |
The difference in the percentage of moderate to severe AD participants that achieved seroconversion at Day 28 between those given a single dose (0.1mL) of the seasonal 2012 - 2013 Fluzone Intradermal vaccine and those given a single dose (0.1mL) of the seasonal 2012 - 2013 Fluzone (Intramuscular) vaccine. Seroconversion is defined as a 4-fold or greater increase in serum hemagglutination-inhibition [HAI] antibody titers against influenza H3N2 compared to baseline values, which represents the minimum intended effect of vaccination. Participants who achieved seroprotection, defined as having a sufficient antibody amount to avoid disease in half of the individuals infected with influenza H3N2, prior to vaccination were excluded from the analysis. The goal was to examine whether there was a difference between the two groups in the percentage of participants who achieved seroconversion at Day 28 who were not seroprotected prior to vaccination. (NCT01737710)
Timeframe: Day 28 Post Vaccination
| Intervention | percentage of participants (Number) |
|---|---|
| Moderate to Severe AD, Intradermal | 76.3 |
| Moderate to Severe AD, Intramuscular | 87.8 |
The difference in the percentage of participants that achieved seroconversion at Day 28 between non-AD and moderate to severe AD participants, following a single dose (0.1mL) of the seasonal 2012 - 2013 Fluzone Intradermal vaccine. Seroconversion is defined as a 4-fold or greater increase in serum hemagglutination-inhibition [HAI] antibody titers against influenza H1N1 compared to baseline values, which represents the minimum intended effect of vaccination. Participants who achieved seroprotection, defined as having a sufficient antibody amount to avoid disease in half of the individuals infected with influenza H1N1, prior to vaccination were excluded from the analysis. The goal was to examine whether there was a difference between the two groups in the percentage of participants who achieved seroconversion at Day 28 who were not seroprotected prior to vaccination. (NCT01737710)
Timeframe: Day 28 Post Vaccination
| Intervention | percentage of participants (Number) |
|---|---|
| Moderate to Severe AD, Intradermal | 85.7 |
| Non-AD, Intradermal | 88.1 |
The difference in the percentage of participants that achieved seroconversion at Day 28 between non-AD and moderate to severe AD participants, following a single dose (0.1mL) of the seasonal 2012 - 2013 Fluzone Intradermal vaccine. Seroconversion is defined as a 4-fold or greater increase in serum hemagglutination-inhibition [HAI] antibody titers against influenza B compared to baseline values, which represents the minimum intended effect of vaccination. Participants who achieved seroprotection, defined as having a sufficient antibody amount to avoid disease in half of the individuals infected with influenza B, prior to vaccination were excluded from the analysis. The goal was to examine whether there was a difference between the two groups in the percentage of participants who achieved seroconversion at Day 28 who were not seroprotected prior to vaccination. (NCT01737710)
Timeframe: Day 28 Post Vaccination
| Intervention | percentage of participants (Number) |
|---|---|
| Moderate to Severe AD, Intradermal | 40.6 |
| Non-AD, Intradermal | 30.4 |
The difference in the percentage of participants that achieved seroconversion at Day 28 between non-AD and moderate to severe AD participants, following a single dose (0.1mL) of the seasonal 2012 - 2013 Fluzone Intradermal vaccine. Seroconversion is defined as a 4-fold or greater increase in serum hemagglutination-inhibition [HAI] antibody titers against influenza H3N2 compared to baseline values, which represents the minimum intended effect of vaccination. Participants who achieved seroprotection, defined as having a sufficient antibody amount to avoid disease in half of the individuals infected with influenza H3N2, prior to vaccination were excluded from the analysis. The goal was to examine whether there was a difference between the two groups in the percentage of participants who achieved seroconversion at Day 28 who were not seroprotected prior to vaccination. (NCT01737710)
Timeframe: Day 28 Post Vaccination
| Intervention | percentage of participants (Number) |
|---|---|
| Moderate to Severe AD, Intradermal | 76.3 |
| Non-AD, Intradermal | 73.3 |
The difference in the percentage of moderate to severe AD participants that achieved seroprotection against influenza B at Day 28 between those given a single dose (0.1mL) of the seasonal 2012 - 2013 Fluzone Intradermal vaccine and those given a single dose (0.1mL) of the seasonal 2012 - 2013 Fluzone (Intramuscular) vaccine. Seroprotection is defined as having a serum hemagglutination-inhibition (HAI) antibody titer of 1:40 or greater, which represents a sufficient antibody amount to avoid disease in half of the individuals infected with influenza B. Participants who achieved seroprotection prior to vaccination were excluded from the analysis. The goal was to examine whether there was a difference between the two groups in the percentage of participants who achieved seroprotection at Day 28 who were not seroprotected prior to vaccination. (NCT01737710)
Timeframe: Day 28 post vaccination
| Intervention | percentage of participants (Number) |
|---|---|
| Moderate to Severe AD, Intradermal | 34.4 |
| Moderate to Severe AD, Intramuscular | 33.7 |
The difference in the percentage of moderate to severe AD participants that achieved seroprotection against influenza H1N1 at Day 28 between those given a single dose (0.1mL) of the seasonal 2012 - 2013 Fluzone Intradermal vaccine and those given a single dose (0.1mL) of the seasonal 2012 - 2013 Fluzone (Intramuscular) vaccine. Seroprotection is defined as having a serum hemagglutination-inhibition (HAI) antibody titer of 1:40 or greater, which represents a sufficient antibody amount to avoid disease in half of the individuals infected with influenza H1N1. Participants who achieved seroprotection prior to vaccination were excluded from the analysis. The goal was to examine whether there was a difference between the two groups in the percentage of participants who achieved seroprotection at Day 28 who were not seroprotected prior to vaccination. (NCT01737710)
Timeframe: Day 28 Post Vaccination
| Intervention | percentage of participants (Number) |
|---|---|
| Moderate to Severe AD, Intradermal | 84.1 |
| Moderate to Severe AD, Intramuscular | 92.5 |
The difference in the percentage of moderate to severe AD participants that achieved seroprotection against influenza H3N2 at Day 28 between those given a single dose (0.1mL) of the seasonal 2012 - 2013 Fluzone Intradermal vaccine and those given a single dose (0.1mL) of the seasonal 2012 - 2013 Fluzone (Intramuscular) vaccine. Seroprotection is defined as having a serum hemagglutination-inhibition (HAI) antibody titer of 1:40 or greater, which represents a sufficient antibody amount to avoid disease in half of the individuals infected with influenza H3N2. Participants who achieved seroprotection prior to vaccination were excluded from the analysis. The goal was to examine whether there was a difference between the two groups in the percentage of participants who achieved seroprotection at Day 28 who were not seroprotected prior to vaccination. (NCT01737710)
Timeframe: Day 28 Post Vaccination
| Intervention | percentage of participants (Number) |
|---|---|
| Moderate to Severe AD, Intradermal | 84.7 |
| Moderate to Severe AD, Intramuscular | 93.9 |
The difference in the percent of participants that achieved seroprotection against influenza B at Day 28 between non-AD and moderate to severe AD participants, following a single dose (0.1mL) of the seasonal 2012 - 2013 Fluzone Intradermal vaccine. Seroprotection is defined as having a serum hemagglutination-inhibition (HAI) antibody titer of 1:40 or greater, which represents a sufficient antibody amount to avoid disease in half of the individuals infected with influenza B. Participants who achieved seroprotection prior to vaccination were excluded from the analysis. The goal was to examine whether there was a difference between the two groups in the percent of participants who achieved seroprotection at Day 28 who were not seroprotected prior to vaccination. (NCT01737710)
Timeframe: Day 28 post vaccination
| Intervention | percentage of participants (Number) |
|---|---|
| Moderate to Severe AD, Intradermal | 34.4 |
| Non-AD, Intradermal | 22.5 |
The difference in the percentage of participants that achieved seroprotection against influenza H1N1 at Day 28 between non-AD and moderate to severe AD participants, following a single dose (0.1mL) of the seasonal 2012 - 2013 Fluzone Intradermal vaccine. Seroprotection is defined as having a serum hemagglutination-inhibition (HAI) antibody titer of 1:40 or greater, which represents a sufficient antibody amount to avoid disease in half of the individuals infected with influenza H1N1. Participants who achieved seroprotection prior to vaccination were excluded from the analysis. The goal was to examine whether there was a difference between the two groups in the percentage of participants who achieved seroprotection at Day 28 who were not seroprotected prior to vaccination. (NCT01737710)
Timeframe: Day 28 Post Vaccination
| Intervention | percentage of participants (Number) |
|---|---|
| Moderate to Severe AD, Intradermal | 84.1 |
| Non-AD, Intradermal | 86.4 |
The difference in the percentage of participants that achieved seroprotection against influenza H3N2 at Day 28 between non-AD and moderate to severe AD participants, following a single dose (0.1mL) of the seasonal 2012 - 2013 Fluzone Intradermal vaccine. Seroprotection is defined as having a serum hemagglutination-inhibition (HAI) antibody titer of 1:40 or greater, which represents a sufficient antibody amount to avoid disease in half of the individuals infected with influenza H3N2. Participants who achieved seroprotection prior to vaccination were excluded from the analysis. The goal was to examine whether there was a difference between the two groups in the percentage of participants who achieved seroprotection at Day 28 who were not seroprotected prior to vaccination. (NCT01737710)
Timeframe: Day 28 Post Vaccination
| Intervention | percentage of participants (Number) |
|---|---|
| Moderate to Severe AD, Intradermal | 84.7 |
| Non-AD, Intradermal | 73.3 |
Temperature was measured hourly using a temporal thermometer to monitor the child's temperature in degrees C. Temperature of 38 degrees C or higher was considered febrile. (NCT00267293)
Timeframe: 6 hours
| Intervention | degrees Celcius (Mean) |
|---|---|
| Group A: Ibuprofen Alone | 38.5 |
| Group B: Ibuprofen and Acetaminophen | 37.2 |
| Group C: Ibuprofen Then Acetaminophen | 36.9 |
Fever, defined as rectal temperature >=38C within 32 hours of vaccination. (NCT00325819)
Timeframe: Fever within 32 hours following vaccination
| Intervention | percentage of participants (Number) |
|---|---|
| Acetaminophen | 14 |
| Placebo | 22 |
Fever, defined as rectal temperature >=39C within 32 hours of vaccination. (NCT00325819)
Timeframe: Fever within 32 hours following vaccination
| Intervention | percentage of participants (Number) |
|---|---|
| Acetaminophen | 0 |
| Placebo | 2 |
Telephone calls to the consulting nurse or the child's physician that were made due to concerns regarding an acute illness, fever, or possible vaccine reaction and outpatient, urgent care, and emergency room visits that were for evaluation of an acute illness, fever, or a possible vaccine reaction, within 32 hours of vaccination. (NCT00325819)
Timeframe: Within 32 hours of vaccination.
| Intervention | percentage of participants (Number) |
|---|---|
| Acetaminophen | 3 |
| Placebo | 6 |
Parents were asked to report whether they were scheduled to work on the day of the vaccination visit (but following that visit) or the next day and, if so, whether they had to miss work to care for their infant because of fever, fussiness, or possible vaccine reaction on those days. (NCT00325819)
Timeframe: Through the day after vaccination
| Intervention | percentage of participants (Number) |
|---|---|
| Acetaminophen | 4 |
| Placebo | 1 |
The need for unblinding at any time during the study (NCT00325819)
Timeframe: At any time during participation in the study
| Intervention | percentage of participants (Number) |
|---|---|
| Acetaminophen | 3 |
| Placebo | 9 |
Parents were asked to record level of fussiness (compared with the child's usual) within 32 hours of vaccination, using the categories much less than usual, less than usual, about usual, more than usual, and much more than usual. (NCT00325819)
Timeframe: Within 32 hours of vaccination
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Infant fussiness - About usual or less than usual | Infant fussiness-More than or much more than usual | Infant fussiness-Much more than usual | |
| Acetaminophen | 42 | 58 | 10 |
| Placebo | 38 | 62 | 24 |
Parents were asked about their infant's sleep on the night following the vaccinations. They were asked to report whether their infant slept much less than usual, less than usual, about the usual amount, more than usual, or much more than usual on that night. (NCT00325819)
Timeframe: On the night following vaccinations
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Infant sleep - About usual or more than usual | Infant sleep - Less than or much less than usual | Infant sleep - Much less than usual | |
| Acetaminophen | 78 | 22 | 2 |
| Placebo | 81 | 19 | 2 |
Parents were asked about their sleep on the night following the vaccinations. They were asked to report whether they slept much less than usual, less than usual, about the usual amount, more than usual, or much more than usual on that night. (NCT00325819)
Timeframe: On the night following vaccinations
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Parent sleep - About usual or more than usual | Parent sleep - Less than or much less than usual | Parent sleep - Much less than usual | |
| Acetaminophen | 73 | 27 | 3 |
| Placebo | 77 | 23 | 5 |
Postoperative hemorrhage is defined as any history of bleeding occurring within the 14 day postoperative period. Hemorrhage will be stratified into 3 levels of severity. Level 1: includes children with a history of postoperative bleeding evaluated and/or treated by a physician in the emergency room, inpatient unit or operating room; Level 2: children requiring inpatient admission for postoperative bleeding regardless of the need for operative intervention; Level 3: children requiring inpatient admission and return to the operating room for control of post-tonsillectomy hemorrhage. (NCT01605903)
Timeframe: Data about post-tonsillectomy bleeding will be obtained after the end of a 14-day postoperative period.
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment With Ibuprofen | 10 |
| Treatment With Acetaminophen | 4 |
Using the Faces Pain Scale, the pediatric patient will indicate his/her pain level at scheduled intervals (7 times per day) for 14 days post-surgery.The Faces Pain Scale Revised is a dimensionless 10 point likert scale used to assess self-reported pain intensity on a scale from 0 (no pain) to 10 (most pain you can imagine). Greater pain scores are indicative of more severe pain. For this analysis, participant pain scores were summed and the mean per group was calculated. Total summed scores could range from 0 to 980. (NCT02296840)
Timeframe: 2 weeks after surgery
| Intervention | units on a scale (Mean) |
|---|---|
| Ibuprofen | 158.95 |
| Hydrocodone-acetaminophen | 219.94 |
The occurrence of post-operative bleeding at the surgical site for each participant will be assessed by review of the participant's study records and clinical records and by questioning the caregiver in follow-up. If postoperative bleeding has occurred, details of the episode of bleeding will also be obtained (requirement for surgical intervention, observation at home, or observation at the hospital). (NCT02296840)
Timeframe: 2 weeks after surgery
| Intervention | Participants (Count of Participants) |
|---|---|
| Ibuprofen | 2 |
| Hydrocodone-acetaminophen | 0 |
102 reviews available for acetaminophen and Fever
| Article | Year |
|---|---|
Comparison between Ibuprofen and Acetaminophen in the Treatment of Infectious Fever in Children: A Meta-Analysis.
Topics: Acetaminophen; Child; Fever; Humans; Ibuprofen; Odds Ratio; Retrospective Studies | 2022 |
Antipyretic Effectiveness of Oral Acetaminophen Versus Rectal Acetaminophen in Pediatric Patients With Fever.
Topics: Acetaminophen; Administration, Rectal; Antipyretics; Case-Control Studies; Child; Fever; Humans; Ran | 2022 |
Clinical management of fever in children in Brazil: practical recommendations from an expert panel.
Topics: Acetaminophen; Antipyretics; Brazil; Child; Fever; Humans; Ibuprofen | 2022 |
Common Selfcare Indications of Pain Medications in Children.
Topics: Acetaminophen; Adolescent; Analgesics, Non-Narcotic; Child; COVID-19; Fever; Humans; Ibuprofen; Pain | 2023 |
Intravenous ibuprofen in postoperative pain and fever management in adults: A systematic review and meta-analysis of randomized controlled trials.
Topics: Acetaminophen; Adult; Antipyretics; Fever; Humans; Ibuprofen; Pain, Postoperative; Randomized Contro | 2023 |
Paracetamol (acetaminophen) or non-steroidal anti-inflammatory drugs, alone or combined, for pain relief in acute otitis media in children.
Topics: Acetaminophen; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Child; Fever; Humans; | 2023 |
Safety and immunogenicity of co-administered meningococcal serogroup B (4CMenB) vaccine: A literature review.
Topics: Acetaminophen; Child; Fever; Humans; Meningococcal Infections; Meningococcal Vaccines; Neisseria men | 2023 |
Comparison of Acetaminophen (Paracetamol) With Ibuprofen for Treatment of Fever or Pain in Children Younger Than 2 Years: A Systematic Review and Meta-analysis.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Child, Preschool; Female; Fever; Humans; Ibu | 2020 |
Ibuprofen Better than Acetaminophen for Reducing Fever, Pain in Young Children.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Fever; Humans; Ibuprofen; Incidence; Pediatr | 2021 |
Ibuprofen vs. Acetaminophen for Fever or Pain in Children Younger Than Two Years.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Fever; Humans; Ibuprofen; Infant; Pain; Patient Selection; | 2021 |
Acetaminophen and ibuprofen in the treatment of pediatric fever: a narrative review.
Topics: Acetaminophen; Administration, Intravenous; Analgesics, Non-Narcotic; Antipyretics; Child; Fever; Hu | 2021 |
A narrative review of paracetamol-induced hypotension: Keeping the patient safe.
Topics: Acetaminophen; Critical Illness; Fever; Humans; Hypotension; Hypotension, Controlled | 2022 |
Paracetamol: unconventional uses of a well-known drug.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Child; Child, Preschool; Fever; Humans; Illicit Drugs; Pain | 2021 |
[Revision of the Dutch College of General Practitioners practice guideline 'Children with fever'].
Topics: Acetaminophen; Child; Family Practice; Fever; General Practitioners; Humans; Ibuprofen; Netherlands; | 2017 |
[Antipyretics in intensive care patients].
Topics: Acetaminophen; Antipyretics; Critical Care; Critical Illness; Fever; Humans; Sepsis | 2017 |
Effectiveness of paracetamol versus ibuprofen administration in febrile children: A systematic literature review.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Antipyretics; Child; Child, Preschool; Fever; Humans; Ibupr | 2017 |
Faster recovery and reduced paracetamol use - a meta-analysis of EPs 7630 in children with acute respiratory tract infections.
Topics: Acetaminophen; Acute Disease; Analgesics, Non-Narcotic; Child; Fever; Humans; Recovery of Function; | 2019 |
Does combination treatment with ibuprofen and acetaminophen improve fever control?
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Antipyretics; Child; Child, Preschool; Drug | 2013 |
A review of dengue fever: a resurging tropical disease.
Topics: Acetaminophen; Aedes; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Viral; Asia; Car | 2013 |
Question 2: does a failure to respond to antipyretics predict serious illness in children with a fever?
Topics: Acetaminophen; Antipyretics; Child; Fever; Humans; Infant; Male; Treatment Failure | 2013 |
Dosing and antipyretic efficacy of oral acetaminophen in children.
Topics: Acetaminophen; Administration, Oral; Antipyretics; Child; Child, Preschool; Drug Dosage Calculations | 2013 |
Combined and alternating paracetamol and ibuprofen therapy for febrile children.
Topics: Acetaminophen; Antipyretics; Body Temperature; Child; Combined Modality Therapy; Fever; Humans; Ibup | 2013 |
Paracetamol: a focus for the general pediatrician.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Child; Drug Overdose; Fever; Humans; Pain; Risk Factors | 2014 |
[Risks and benefits of paracetamol in children with fever].
Topics: Acetaminophen; Analgesics, Non-Narcotic; Child; Child, Preschool; Fever; Humans; Pain; Risk Assessme | 2014 |
Effects of Leukoreduction and Premedication With Acetaminophen and Diphenhydramine in Minimizing Febrile Nonhemolytic Transfusion Reactions and Allergic Transfusion Reactions During and After Blood Product Administration: A Literature Review With Recommen
Topics: Acetaminophen; Diphenhydramine; Drug Administration Schedule; Erythrocyte Transfusion; Evidence-Base | 2014 |
A practical approach to the treatment of low-risk childhood fever.
Topics: Acetaminophen; Child; Fever; Humans; Ibuprofen | 2014 |
A practical approach to the treatment of low-risk childhood fever.
Topics: Acetaminophen; Child; Fever; Humans; Ibuprofen | 2014 |
A practical approach to the treatment of low-risk childhood fever.
Topics: Acetaminophen; Child; Fever; Humans; Ibuprofen | 2014 |
A practical approach to the treatment of low-risk childhood fever.
Topics: Acetaminophen; Child; Fever; Humans; Ibuprofen | 2014 |
A practical approach to the treatment of low-risk childhood fever.
Topics: Acetaminophen; Child; Fever; Humans; Ibuprofen | 2014 |
A practical approach to the treatment of low-risk childhood fever.
Topics: Acetaminophen; Child; Fever; Humans; Ibuprofen | 2014 |
A practical approach to the treatment of low-risk childhood fever.
Topics: Acetaminophen; Child; Fever; Humans; Ibuprofen | 2014 |
A practical approach to the treatment of low-risk childhood fever.
Topics: Acetaminophen; Child; Fever; Humans; Ibuprofen | 2014 |
A practical approach to the treatment of low-risk childhood fever.
Topics: Acetaminophen; Child; Fever; Humans; Ibuprofen | 2014 |
Does paracetamol help or hinder healing in bacterial infections?
Topics: Acetaminophen; Aged, 80 and over; Anti-Bacterial Agents; Antipyretics; Bacterial Infections; Evidenc | 2014 |
Combined and alternating paracetamol and ibuprofen therapy for febrile children.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Antipyretics; Child; Child, Preschool; Drug | 2014 |
Intravenous acetaminophen use in pediatrics.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Antipyretics; Bicycling; Body Weight; Chemic | 2015 |
Question 1: Does prophylactic paracetamol prevent fever after vaccination in infants?
Topics: Acetaminophen; Antipyretics; Evidence-Based Medicine; Fever; Humans; Infant; Male; Vaccination | 2015 |
Vaccines for the prevention of meningococcal capsular group B disease: What have we recently learned?
Topics: Acetaminophen; Adolescent; Antipyretics; Chemoprevention; Child; Child, Preschool; Fever; Humans; Im | 2016 |
Paracetamol (acetaminophen) or non-steroidal anti-inflammatory drugs, alone or combined, for pain relief in acute otitis media in children.
Topics: Acetaminophen; Acute Disease; Analgesics, Non-Narcotic; Anti-Bacterial Agents; Anti-Inflammatory Age | 2016 |
Paracetamol in fever in critically ill patients-an update.
Topics: Acetaminophen; Analgesics; Analgesics, Non-Narcotic; Antipyretics; Critical Illness; Cyclooxygenase | 2017 |
A clinical and safety review of paracetamol and ibuprofen in children.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Child; Drug Overdo | 2017 |
Acute Nonspecific Mesenteric Lymphadenitis: More Than "No Need for Surgery".
Topics: Abdomen; Acetaminophen; Acute Disease; Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Appendic | 2017 |
Effectiveness of oral vs rectal acetaminophen: a meta-analysis.
Topics: Acetaminophen; Administration, Oral; Administration, Rectal; Analgesics, Non-Narcotic; Child; Fever; | 2008 |
[Research advance on pediatric antipyretic].
Topics: Acetaminophen; Analgesics, Non-Narcotic; Aspirin; Fever; Humans; Ibuprofen; Sulfonamides | 2008 |
Intravenous paracetamol (acetaminophen).
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Child; Controlled Clinical Trials as Topic; Fever; H | 2009 |
Systematic review and meta-analysis of the clinical safety and tolerability of ibuprofen compared with paracetamol in paediatric pain and fever.
Topics: Acetaminophen; Algorithms; Analgesics, Non-Narcotic; Anaphylaxis; Child; Fever; Gastrointestinal Hem | 2009 |
Is combining or alternating antipyretic therapy more beneficial than monotherapy for febrile children?
Topics: Acetaminophen; Analgesics, Non-Narcotic; Child; Combined Modality Therapy; Fever; Humans; Ibuprofen | 2009 |
Clinical safety and tolerability of ibuprofen compared with paracetamol in pediatric pain and fever. A systematic review.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Child; Fever; Humans; Ibuprofen; Pain | 2009 |
Did acetaminophen provoke the autism epidemic?
Topics: Acetaminophen; Analgesics, Non-Narcotic; Aspirin; Autistic Disorder; Centers for Disease Control and | 2009 |
Efficacy and safety of ibuprofen and acetaminophen in children and adults: a meta-analysis and qualitative review.
Topics: Acetaminophen; Adult; Age Factors; Analgesics, Non-Narcotic; Child; Female; Fever; Humans; Ibuprofen | 2010 |
Fever management: evaluating the use of ibuprofen and paracetamol.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Child; Drug Administration Schedule; Emergency Nursing; Fem | 2010 |
Clinical inquiries. Does lowering a fever >101 degrees F in children improve clinical outcomes?
Topics: Acetaminophen; Analgesics, Non-Narcotic; Chickenpox; Cryotherapy; Fasciitis, Necrotizing; Fever; Hum | 2010 |
Pharmacological interventions for the prevention of allergic and febrile non-haemolytic transfusion reactions.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Diphenhydramine; Fever; Histamine H1 Antagon | 2010 |
Intravenous acetaminophen.
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Child; Clinical Trials as Topic; Fever; Humans; Inje | 2010 |
Fever without a localizing source.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Antipyretics; Bacteremia; Child, Preschool; Female; Fever; | 2011 |
[Efficacy and safety of ibuprofen and paracetamol in fever among children].
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Child; Drug Combin | 2011 |
Systematic review of studies comparing combined treatment with paracetamol and ibuprofen, with either drug alone.
Topics: Acetaminophen; Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Antipyretics; Child; Child, Pres | 2011 |
Short-term acetylsalicylic acid (aspirin) use for pain, fever, or colds - gastrointestinal adverse effects: a meta-analysis of randomized clinical trials.
Topics: Acetaminophen; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Common Cold; Double-Blind Me | 2011 |
Treatment of fever after stroke: conflicting evidence.
Topics: Acetaminophen; Animals; Antipyretics; Body Temperature; Fever; Humans; Severity of Illness Index; St | 2011 |
[Fever in non-neurological critically ill patients; friends or foe?].
Topics: Acetaminophen; Aged; Anti-Inflammatory Agents, Non-Steroidal; Body Temperature; Clinical Trials as T | 2011 |
Acetaminophen and Ibuprofen overdosage.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Antipyretics; Chemical and Drug Induced Live | 2012 |
Efficacy and gastrointestinal risk of aspirin used for the treatment of pain and cold.
Topics: Acetaminophen; Aspirin; Common Cold; Dyspepsia; Fever; Gastrointestinal Tract; Humans; Ibuprofen; No | 2012 |
Alternating antipyretics in the treatment of fever in children: a systematic review of randomized clinical trials.
Topics: Acetaminophen; Antipyretics; Child; Drug Substitution; Drug Therapy, Combination; Fever; Humans; Ibu | 2012 |
Optimising the management of fever and pain in children.
Topics: Acetaminophen; Analgesics; Child; Comparative Effectiveness Research; Dose-Response Relationship, Dr | 2013 |
Nursing management of fever in children: a systematic review.
Topics: Acetaminophen; Adolescent; Baths; Child; Child, Preschool; Evidence-Based Medicine; Fever; Humans; I | 2003 |
The safety of ibuprofen suspension in children.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Child; Fev | 2003 |
Physical methods for treating fever in children.
Topics: Acetaminophen; Adolescent; Analgesics, Non-Narcotic; Baths; Child; Child, Preschool; Cryotherapy; Fe | 2003 |
Nitric oxide releasing acetaminophen (nitroacetaminophen).
Topics: Acetaminophen; Analgesics, Non-Narcotic; Animals; Anti-Inflammatory Agents, Non-Steroidal; Disease M | 2003 |
Evidence on the use of paracetamol in febrile children.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Child; Clinical Trials as Topic; Drug Costs; Fever; Global | 2003 |
Antipyretic efficacy and safety of ibuprofen and acetaminophen in children.
Topics: Acetaminophen; Child; Child, Preschool; Drug Administration Schedule; Fever; Humans; Ibuprofen; Infa | 2004 |
Efficacy and safety of acetaminophen vs ibuprofen for treating children's pain or fever: a meta-analysis.
Topics: Acetaminophen; Adolescent; Analgesics, Non-Narcotic; Child; Child, Preschool; Fever; Humans; Ibuprof | 2004 |
Efficacy and safety of over-the-counter analgesics in the treatment of common cold and flu.
Topics: Acetaminophen; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Child; Child, Preschool; Com | 2006 |
Acetaminophen and diphenhydramine premedication for allergic and febrile nonhemolytic transfusion reactions: good prophylaxis or bad practice?
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Allergic Agents; Blood Component Transfusion; Diphenhy | 2007 |
Using paracetamol before immunisation--does it work?
Topics: Acetaminophen; Analgesics, Non-Narcotic; Evidence-Based Medicine; Fever; Humans; Pain; Practice Guid | 2007 |
Characterization and clinical management of clozapine-induced fever.
Topics: Acetaminophen; Animals; Clozapine; Disease Management; Fever; Humans | 2007 |
[Answers to the questions on application of ibuprofen and acetaminophen in children with fever].
Topics: Acetaminophen; Child; Fever; Humans; Ibuprofen; Neonatology | 2007 |
A review of ibuprofen and acetaminophen use in febrile children and the occurrence of asthma-related symptoms.
Topics: Acetaminophen; Algorithms; Analgesics, Non-Narcotic; Asthma; Child; Fever; Hospitalization; Humans; | 2007 |
[Using evidence-based nursing to explore the management of child fever].
Topics: Acetaminophen; Child; Evidence-Based Medicine; Fever; Humans; Ibuprofen | 2008 |
Treatment of fever in 1982: a review.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Body Temperature Regulation; Chemical and Dr | 1983 |
Use of antipyretic analgesics in the pediatric patient.
Topics: Acetaminophen; Adolescent; Agranulocytosis; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chemic | 1983 |
Review of comparative antipyretic activity in children.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Body Temperature Regulation; Child; | 1983 |
[Body temperature and fever--body temperature regulation, indications and possibilities of fever reducing therapy. II. Indications and effects of fever-lowering procedures and fever-reducing drug therapy].
Topics: Acetaminophen; Age Factors; Aminopyrine; Body Temperature Regulation; Child; Child, Preschool; Diclo | 1981 |
[Paracetamol: overdose and hepatic lesions].
Topics: Acetaminophen; Aspirin; Chemical and Drug Induced Liver Injury; Fever; Humans; Liver; Necrosis; Pain | 1981 |
[Amidazophen. Yes or no?].
Topics: Acetaminophen; Adult; Aminopyrine; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal | 1995 |
[Paracetamol and other antipyretic analgesics: optimal doses in pediatrics].
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Child; Dose-Response Relationship, Drug; Dru | 1994 |
Treatment of fever in childhood.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Child; Dipyrone; Fever; Humans | 1994 |
[Fever in children: what to do?].
Topics: Acetaminophen; Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Child; Fever; Humans | 1993 |
Antipyretic therapy.
Topics: Acetaminophen; Age of Onset; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Chil | 1997 |
Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. Paracetamol or ibuprofen in febrile children.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Child, Preschool; Emergency Medicine; Evidence-Based Medici | 1999 |
As compared to Paracetamol, does the Paracetamol and Methionine combinations have better efficacy and safety and can it be used safely in the management of pyrexia associated with liver diseases?
Topics: Acetaminophen; Analgesics, Non-Narcotic; Drug Therapy, Combination; Female; Fever; Humans; Liver Dis | 1999 |
[The controversy surrounding paracetamol therapy in childhood].
Topics: Acetaminophen; Analgesics, Non-Narcotic; Bacteremia; Child; Fever; Humans | 2000 |
Nonsteroidal anti-inflammatory drugs, acetaminophen, cyclooxygenase 2, and fever.
Topics: Acetaminophen; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 1; Cyclooxygenase 2; | 2000 |
Toxicities of drugs used in the management of fever.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2; | 2000 |
Treatment of pain or fever with paracetamol (acetaminophen) in the alcoholic patient: a systematic review.
Topics: Acetaminophen; Alcoholism; Analgesics, Non-Narcotic; Clinical Trials as Topic; Fever; Humans; Liver; | 2000 |
Paracetamol efficacy and safety in children: the first 40 years.
Topics: Acetaminophen; Child; Fever; Humans; Nonprescription Drugs; Pain | 2000 |
Paracetamol: past, present, and future.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Fever; Humans; Pain | 2000 |
Childhood fever revisited.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Body Temperature; Child; Fever; Humans; Ibuprofen; Thermome | 2002 |
Antipyretics in children.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Aspirin; Child; Cyclooxygenase Inhibitors; Fever; Humans; I | 2002 |
Antipyretics in the paediatric A&E setting: a review.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Child; Emergency Nursing; Evidence-Based Medicine; Fever; H | 2002 |
Management of the child with fever.
Topics: Acetaminophen; Adolescent; Analgesics, Non-Narcotic; Baths; Child; Child, Preschool; Fever; Humans; | 2002 |
Treating fever in children: paracetamol or ibuprofen?
Topics: Acetaminophen; Analgesics, Non-Narcotic; Child; Effect Modifier, Epidemiologic; Evidence-Based Medic | 2002 |
Paracetamol for treating fever in children.
Topics: Acetaminophen; Adolescent; Analgesics, Non-Narcotic; Child; Child, Preschool; Fever; Humans; Infant; | 2002 |
Acetaminophen.
Topics: Acetaminophen; Analgesia; Animals; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; | 1977 |
Aspirin and acetaminophen: a comparative view of their antipyretic and analgesic activity.
Topics: Acetaminophen; Aspirin; Body Temperature; Fever; Humans; Hypothalamus; Pain | 1978 |
Antipyretic therapy in the febrile child.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Child, Preschool; Drug Therapy, Com | 1992 |
[Treatment of fever in children. False problems or real debate?].
Topics: Acetaminophen; Aspirin; Child; Fever; Humans | 1991 |
Prophylactic paracetamol with childhood immunisation?
Topics: Acetaminophen; Child; Diphtheria-Tetanus-Pertussis Vaccine; Drug Combinations; Fever; Humans; Measle | 1990 |
How safe is acetaminophen? Some practical cautions with this widely used agent.
Topics: Acetaminophen; Analgesics; Animals; Aspirin; Chemical Phenomena; Chemistry; Child; Drug Synergism; F | 1973 |
Treatment of salicylate poisoning.
Topics: Acetaminophen; Acid-Base Equilibrium; Acidosis; Acute Kidney Injury; Alkalosis, Respiratory; Aspirin | 1971 |
177 trials available for acetaminophen and Fever
| Article | Year |
|---|---|
[Hyperthermia in children, efficacy of a drinkable solution of paracetamol].
Topics: Acetaminophen; Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Ascorbic Acid; Bacteri | 1984 |
Panic or peace - prioritising infant welfare when medicating feverish infants: a grounded theory study of adherence in a paediatric clinical trial.
Topics: Acetaminophen; Asthma; Fever; Grounded Theory; Humans; Ibuprofen; Infant; Infant Welfare | 2022 |
Aggressive antipyretics in central nervous system malaria: Study protocol of a randomized-controlled trial assessing antipyretic efficacy and parasite clearance effects (Malaria FEVER study).
Topics: Acetaminophen; Animals; Antipyretics; Central Nervous System; Child; Fever; Histidine; Humans; Ibupr | 2022 |
Comparing the effect of body wash with marshmallow plant and lukewarm water on reducing the temperature of febrile children: a randomized clinical trial.
Topics: Acetaminophen; Child; Fever; Humans; Ibuprofen; Iran; Temperature; Water | 2022 |
A Randomized Study on the Prophylactic Use of Acetaminophen to Prevent Fever after the Removal of Drainage Tubes for Lumbar Surgery.
Topics: Acetaminophen; Antipyretics; Device Removal; Drainage; Fever; Humans; Length of Stay; Lumbar Vertebr | 2023 |
A Randomized Study on the Prophylactic Use of Acetaminophen to Prevent Fever after the Removal of Drainage Tubes for Lumbar Surgery.
Topics: Acetaminophen; Antipyretics; Device Removal; Drainage; Fever; Humans; Length of Stay; Lumbar Vertebr | 2023 |
A Randomized Study on the Prophylactic Use of Acetaminophen to Prevent Fever after the Removal of Drainage Tubes for Lumbar Surgery.
Topics: Acetaminophen; Antipyretics; Device Removal; Drainage; Fever; Humans; Length of Stay; Lumbar Vertebr | 2023 |
A Randomized Study on the Prophylactic Use of Acetaminophen to Prevent Fever after the Removal of Drainage Tubes for Lumbar Surgery.
Topics: Acetaminophen; Antipyretics; Device Removal; Drainage; Fever; Humans; Length of Stay; Lumbar Vertebr | 2023 |
Randomised evaluation of active control of temperature versus ordinary temperature management (REACTOR) trial.
Topics: Acetaminophen; Adult; Aged; Antipyretics; Australia; Body Temperature; Brain Diseases; Chi-Square Di | 2019 |
Ibuprofen versus paracetamol for treating fever in preschool children in Nigeria: a randomized clinical trial of effectiveness and safety.
Topics: Acetaminophen; Antipyretics; Body Temperature; Child, Preschool; Female; Fever; Hospitals, Teaching; | 2020 |
Randomized control trial of intravenous acetaminophen for reduction of intrapartum maternal fever.
Topics: Acetaminophen; Female; Fever; Humans; Infant, Newborn; Interleukin-13; Interleukin-2; Placenta; Preg | 2021 |
Randomised comparative trial of the efficacy of paracetamol syrup and dispersible tablets for the treatment of fever in children.
Topics: Acetaminophen; Antipyretics; Child; Double-Blind Method; Fever; Humans; Tablets | 2021 |
Comparison of intravenous ibuprofen and paracetamol in the treatment of fever: A randomized double-blind study.
Topics: Acetaminophen; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antipyretics; Double-Blind Method; Em | 2021 |
Effects of IV Acetaminophen on Core Body Temperature and Hemodynamic Responses in Febrile Critically Ill Adults: A Randomized Controlled Trial.
Topics: Acetaminophen; Adult; Aged; Blood Pressure; Body Temperature; Critical Illness; Double-Blind Method; | 2017 |
Effect of prophylactic or therapeutic administration of paracetamol on immune response to DTwP-HepB-Hib combination vaccine in Indian infants.
Topics: Acetaminophen; Antibodies, Bacterial; Diphtheria; Diphtheria-Tetanus-Pertussis Vaccine; Female; Feve | 2017 |
Alternating Acetaminophen and Ibuprofen versus Monotherapies in Improvements of Distress and Reducing Refractory Fever in Febrile Children: A Randomized Controlled Trial.
Topics: Acetaminophen; Antipyretics; Child; Child, Preschool; Drug Administration Schedule; Drug Therapy, Co | 2017 |
Comparison of Antipyretic Efficacy of Intravenous (IV) Acetaminophen versus Oral (PO) Acetaminophen in the Management of Fever in Children.
Topics: Acetaminophen; Administration, Oral; Antipyretics; Child; Female; Fever; Humans; Injections, Intrave | 2018 |
Population pharmacokinetics of intravenous paracetamol in critically ill patients with traumatic brain injury.
Topics: Acetaminophen; Adult; Antipyretics; Area Under Curve; Brain Injuries, Traumatic; Critical Illness; D | 2018 |
The antipyretic efficacy and safety of propacetamol compared with dexibuprofen in febrile children: a multicenter, randomized, double-blind, comparative, phase 3 clinical trial.
Topics: Acetaminophen; Administration, Oral; Adolescent; Antipyretics; Child; Child, Preschool; Double-Blind | 2018 |
[In process].
Topics: Acetaminophen; Asthma; Child, Preschool; Disease Progression; Fever; Humans; Ibuprofen; Pain; Prospe | 2016 |
Effect of standard dose paracetamol versus placebo as antipyretic therapy on liver injury in adult dengue infection: a multicentre randomised controlled trial.
Topics: Acetaminophen; Adult; Alanine Transaminase; Antipyretics; Aspartate Aminotransferases; Dengue; Doubl | 2019 |
Paracetamol (Acetaminophen) in stroke 2 (PAIS 2): protocol for a randomized, placebo-controlled, double-blind clinical trial to assess the effect of high-dose paracetamol on functional outcome in patients with acute stroke and a body temperature of 36.5 °
Topics: Acetaminophen; Antipyretics; Body Temperature; Clinical Protocols; Dose-Response Relationship, Drug; | 2015 |
Temperature management in patients with acute neurological lesions: an Australian and New Zealand point prevalence study.
Topics: Acetaminophen; Antipyretics; Australia; Body Temperature; Brain Injuries; Dose-Response Relationship | 2013 |
Statistical analysis plan for the HEAT trial: a multicentre randomised placebo-controlled trial of intravenous paracetamol in intensive care unit patients with fever and infection.
Topics: Acetaminophen; Administration, Intravenous; Antipyretics; Clinical Trials, Phase II as Topic; Critic | 2013 |
Intravenous paracetamol as an antipyretic and analgesic medication: the significance of drug metabolism.
Topics: Abdominal Pain; Acetaminophen; Adolescent; Adult; Aged; Female; Fever; Humans; Infections; Infusions | 2014 |
Effects of prophylactic and therapeutic paracetamol treatment during vaccination on hepatitis B antibody levels in adults: two open-label, randomized controlled trials.
Topics: Acetaminophen; Adolescent; Adult; Female; Fever; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Va | 2014 |
Features and management of pyrexia with combined dabrafenib and trametinib in metastatic melanoma.
Topics: Acetaminophen; Adrenal Cortex Hormones; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antine | 2014 |
Acetaminophen for Fever in Critically Ill Patients with Suspected Infection.
Topics: Acetaminophen; Aged; Body Temperature; Critical Illness; Double-Blind Method; Female; Fever; Humans; | 2015 |
Acetaminophen for Fever in Critically Ill Patients with Suspected Infection.
Topics: Acetaminophen; Aged; Body Temperature; Critical Illness; Double-Blind Method; Female; Fever; Humans; | 2015 |
Acetaminophen for Fever in Critically Ill Patients with Suspected Infection.
Topics: Acetaminophen; Aged; Body Temperature; Critical Illness; Double-Blind Method; Female; Fever; Humans; | 2015 |
Acetaminophen for Fever in Critically Ill Patients with Suspected Infection.
Topics: Acetaminophen; Aged; Body Temperature; Critical Illness; Double-Blind Method; Female; Fever; Humans; | 2015 |
The Effect of Paracetamol on Core Body Temperature in Acute Traumatic Brain Injury: A Randomised, Controlled Clinical Trial.
Topics: Acetaminophen; Adult; Antipyretics; Body Temperature; Brain Injuries; Double-Blind Method; Female; F | 2015 |
Acetaminophen versus Ibuprofen in Young Children with Mild Persistent Asthma.
Topics: Acetaminophen; Asthma; Child, Preschool; Double-Blind Method; Female; Fever; Humans; Ibuprofen; Inci | 2016 |
Effects of prophylactic ibuprofen and paracetamol administration on the immunogenicity and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugated vaccine (PHiD-CV) co-administered with DTPa-combined vaccines
Topics: Acetaminophen; Antibodies, Bacterial; Antipyretics; Diphtheria-Tetanus-acellular Pertussis Vaccines; | 2017 |
Randomized, controlled, multicentre clinical trial of the antipyretic effect of intravenous paracetamol in patients admitted to hospital with infection.
Topics: Acetaminophen; Administration, Intravenous; Adult; Aged; Antipyretics; Double-Blind Method; Female; | 2017 |
Antipyretic Efficacy and Safety of Ibuprofen Versus Acetaminophen Suspension in Febrile Children: Results of 2 Randomized, Double-Blind, Single-Dose Studies.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Antipyretics; Chil | 2017 |
A multicenter, randomized, open-label, active-comparator trial to determine the efficacy, safety, and pharmacokinetics of intravenous ibuprofen for treatment of fever in hospitalized pediatric patients.
Topics: Acetaminophen; Administration, Oral; Adolescent; Antipyretics; Area Under Curve; Child; Child, Presc | 2017 |
A randomized study of fever prophylaxis and the immunogenicity of routine pediatric vaccinations.
Topics: Acetaminophen; Antibodies, Bacterial; Antipyretics; Chemoprevention; Diphtheria-Tetanus-Pertussis Va | 2017 |
PAIS 2 (Paracetamol [Acetaminophen] in Stroke 2): Results of a Randomized, Double-Blind Placebo-Controlled Clinical Trial.
Topics: Acetaminophen; Aged; Aged, 80 and over; Antipyretics; Brain Ischemia; Cerebral Hemorrhage; Double-Bl | 2017 |
Alternating antipyretics: antipyretic efficacy of acetaminophen versus acetaminophen alternated with ibuprofen in children.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Child; Child, Preschool; Double-Blind Method; Female; Fever | 2008 |
Prophylactic use of acetaminophen in children vaccinated with diphtheria-tetanus-pertussis.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anorexia; Chemoprevention; Diphtheria-Tetanus-Pertussis Vac | 2008 |
A prospective, randomized, double-blind controlled trial of acetaminophen and diphenhydramine pretransfusion medication versus placebo for the prevention of transfusion reactions.
Topics: Acetaminophen; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Diphenhydramine; Do | 2008 |
Paracetamol plus ibuprofen for the treatment of fever in children (PITCH): randomised controlled trial.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Body Temperature; Child; Child, Preschool; Drug Therapy, Co | 2008 |
Paracetamol plus ibuprofen for the treatment of fever in children (PITCH): economic evaluation of a randomised controlled trial.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Child; Child, Preschool; Cost-Benefit Analysis; Drug Therap | 2008 |
Correction: PAIS: paracetamol (acetaminophen) in stroke; protocol for a randomized, double blind clinical trial. [ISCRTN74418480].
Topics: Acetaminophen; Analgesics, Non-Narcotic; Clinical Protocols; Double-Blind Method; Fever; Humans; Log | 2008 |
Antipyretic effect of ketoprofen.
Topics: Acetaminophen; Adolescent; Analgesics, Non-Narcotic; Analysis of Variance; Anti-Inflammatory Agents, | 2009 |
Paracetamol and ibuprofen for the treatment of fever in children: the PITCH randomised controlled trial.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Child; Child, Preschool; Cost-Benefit Analysis; Double-Blin | 2009 |
Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Antibody Formation; Chemoprevention; Female; Fever; Humans; | 2009 |
Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Antibody Formation; Chemoprevention; Female; Fever; Humans; | 2009 |
Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Antibody Formation; Chemoprevention; Female; Fever; Humans; | 2009 |
Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Antibody Formation; Chemoprevention; Female; Fever; Humans; | 2009 |
Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Antibody Formation; Chemoprevention; Female; Fever; Humans; | 2009 |
Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Antibody Formation; Chemoprevention; Female; Fever; Humans; | 2009 |
Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Antibody Formation; Chemoprevention; Female; Fever; Humans; | 2009 |
Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Antibody Formation; Chemoprevention; Female; Fever; Humans; | 2009 |
Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Antibody Formation; Chemoprevention; Female; Fever; Humans; | 2009 |
Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Antibody Formation; Chemoprevention; Female; Fever; Humans; | 2009 |
Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Antibody Formation; Chemoprevention; Female; Fever; Humans; | 2009 |
Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Antibody Formation; Chemoprevention; Female; Fever; Humans; | 2009 |
Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Antibody Formation; Chemoprevention; Female; Fever; Humans; | 2009 |
Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Antibody Formation; Chemoprevention; Female; Fever; Humans; | 2009 |
Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Antibody Formation; Chemoprevention; Female; Fever; Humans; | 2009 |
Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Antibody Formation; Chemoprevention; Female; Fever; Humans; | 2009 |
Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Antibody Formation; Chemoprevention; Female; Fever; Humans; | 2009 |
Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Antibody Formation; Chemoprevention; Female; Fever; Humans; | 2009 |
Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Antibody Formation; Chemoprevention; Female; Fever; Humans; | 2009 |
Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Antibody Formation; Chemoprevention; Female; Fever; Humans; | 2009 |
Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Antibody Formation; Chemoprevention; Female; Fever; Humans; | 2009 |
Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Antibody Formation; Chemoprevention; Female; Fever; Humans; | 2009 |
Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Antibody Formation; Chemoprevention; Female; Fever; Humans; | 2009 |
Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Antibody Formation; Chemoprevention; Female; Fever; Humans; | 2009 |
Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Antibody Formation; Chemoprevention; Female; Fever; Humans; | 2009 |
Antibiotic prophylaxis in third molar surgery: A randomized double-blind placebo-controlled clinical trial using split-mouth technique.
Topics: Acetaminophen; Adult; Amoxicillin; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Bacterial Agen | 2010 |
Dose-finding studies of ketoprofen in the management of fever in children: report on two randomized, single-blind, comparator-controlled, single-dose, multicentre, phase II studies.
Topics: Acetaminophen; Administration, Oral; Age Factors; Analgesics, Non-Narcotic; Anti-Inflammatory Agents | 2010 |
Ketoprofen versus paracetamol (acetaminophen) or ibuprofen in the management of fever: results of two randomized, double-blind, double-dummy, parallel-group, repeated-dose, multicentre, phase III studies in children.
Topics: Acetaminophen; Administration, Oral; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroid | 2010 |
Effect of acetaminophen and fluvastatin on post-dose symptoms following infusion of zoledronic acid.
Topics: Acetaminophen; Acute-Phase Reaction; Aged; Antipyretics; Bone Density Conservation Agents; Diphospho | 2011 |
Safety of multiple-dose intravenous acetaminophen in adult inpatients.
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Fever; Humans; Injections, Intravenous; Pain; Prospe | 2010 |
Treatment with acetaminophen/paracetamol or ibuprofen alleviates post-dose symptoms related to intravenous infusion with zoledronic acid 5 mg.
Topics: Acetaminophen; Aged; Arthralgia; Body Temperature; Bone Density Conservation Agents; Diphosphonates; | 2012 |
Efficacy of standard doses of Ibuprofen alone, alternating, and combined with acetaminophen for the treatment of febrile children.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Antipyretics; Child; Child, Preschool; Dose- | 2010 |
Efficacy of standard doses of Ibuprofen alone, alternating, and combined with acetaminophen for the treatment of febrile children.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Antipyretics; Child; Child, Preschool; Dose- | 2010 |
Efficacy of standard doses of Ibuprofen alone, alternating, and combined with acetaminophen for the treatment of febrile children.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Antipyretics; Child; Child, Preschool; Dose- | 2010 |
Efficacy of standard doses of Ibuprofen alone, alternating, and combined with acetaminophen for the treatment of febrile children.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Antipyretics; Child; Child, Preschool; Dose- | 2010 |
A randomized study of the efficacy and safety of intravenous acetaminophen compared to oral acetaminophen for the treatment of fever.
Topics: Acetaminophen; Administration, Oral; Adult; Antipyretics; Double-Blind Method; Endotoxins; Fever; Hu | 2011 |
A prospective randomized study to evaluate the antipyretic effect of the combination of acetaminophen and ibuprofen in neurological ICU patients.
Topics: Academic Medical Centers; Acetaminophen; Antipyretics; Body Temperature; Drug Therapy, Combination; | 2011 |
A prospective randomized study to evaluate the antipyretic effect of the combination of acetaminophen and ibuprofen in neurological ICU patients.
Topics: Academic Medical Centers; Acetaminophen; Antipyretics; Body Temperature; Drug Therapy, Combination; | 2011 |
A prospective randomized study to evaluate the antipyretic effect of the combination of acetaminophen and ibuprofen in neurological ICU patients.
Topics: Academic Medical Centers; Acetaminophen; Antipyretics; Body Temperature; Drug Therapy, Combination; | 2011 |
A prospective randomized study to evaluate the antipyretic effect of the combination of acetaminophen and ibuprofen in neurological ICU patients.
Topics: Academic Medical Centers; Acetaminophen; Antipyretics; Body Temperature; Drug Therapy, Combination; | 2011 |
A randomized study of the efficacy and safety of intravenous acetaminophen vs. intravenous placebo for the treatment of fever.
Topics: Acetaminophen; Adult; Alanine Transaminase; Antipyretics; Aspartate Aminotransferases; Body Temperat | 2011 |
Fever and fever management among intensive care patients with known or suspected infection: a multicentre prospective cohort study.
Topics: Acetaminophen; Adolescent; Adult; Anti-Bacterial Agents; Antipyretics; Australia; Bacterial Infectio | 2011 |
Paracetamol versus placebo in treatment of non-severe malaria in children in Guinea-Bissau: a randomized controlled trial.
Topics: Acetaminophen; Adolescent; Antipyretics; Body Temperature; Child; Child, Preschool; Female; Fever; G | 2011 |
Comparison of the antipyretic efficacy of ketoprofen, acetylsalicylic acid, and paracetamol, orally administered to swine.
Topics: Acetaminophen; Administration, Oral; Animals; Antipyretics; Aspirin; Fever; Ketoprofen; Lipopolysacc | 2012 |
A randomized placebo-controlled trial of acetaminophen for prevention of post-vaccination fever in infants.
Topics: Acetaminophen; Fever; Humans; Infant; Pertussis Vaccine; Placebos; Sample Size | 2011 |
Comparison of acetaminophen and ketoprofen in febrile children: a single dose randomized clinical trial.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Antipyretics; Child; Child, Preschool; Femal | 2012 |
Immediate versus as-needed acetaminophen for post-immunisation pyrexia.
Topics: Acetaminophen; Antipyretics; Chemoprevention; Diphtheria-Tetanus-Pertussis Vaccine; Female; Fever; H | 2011 |
Acetaminophen pediatric dose selection: caregiver satisfaction regarding the antipyretic efficacy of acetaminophen in children.
Topics: Acetaminophen; Administration, Oral; Adult; Algorithms; Antipyretics; Caregivers; Child, Preschool; | 2012 |
Assessment of the safety and feasibility of administering antipyretic therapy in critically ill adults: a pilot randomized clinical trial.
Topics: Acetaminophen; Aged; Antipyretics; Chi-Square Distribution; Critical Illness; Feasibility Studies; F | 2013 |
A novel paracetamol 1,000 mg sustained release formulation vs conventional paracetamol 500 mg formulation in patients with fever and pain: a randomized noninferiority trial.
Topics: Acetaminophen; Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Antipyretics; Delayed-Action Prepa | 2013 |
Comparison of oral versus normal and high-dose rectal acetaminophen in the treatment of febrile children.
Topics: Acetaminophen; Administration, Oral; Administration, Rectal; Analgesics, Non-Narcotic; Child; Child, | 2002 |
Elevated maternal and fetal serum interleukin-6 levels are associated with epidural fever.
Topics: Acetaminophen; Analgesia, Epidural; Analgesia, Obstetrical; Analgesics, Non-Narcotic; Double-Blind M | 2002 |
[Metamizol versus propacetamol: comparative study of the hemodynamic and antipyretic effects in critically ill patients].
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Critical Illness; Dipyrone; Female; Fever; H | 2002 |
Symptomatic intravenous antipyretic therapy: efficacy of metamizol, diclofenac, and propacetamol.
Topics: Acetaminophen; Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Anti-Inflammato | 2002 |
Effect of paracetamol (acetaminophen) and ibuprofen on body temperature in acute ischemic stroke PISA, a phase II double-blind, randomized, placebo-controlled trial [ISRCTN98608690].
Topics: Acetaminophen; Acute Disease; Aged; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroida | 2003 |
Intravenous corticosteroids to reduce gemtuzumab ozogamicin infusion reactions.
Topics: Acetaminophen; Adult; Aminoglycosides; Analgesics, Non-Narcotic; Anti-Bacterial Agents; Anti-Inflamm | 2003 |
[Treatment of stroke by reducing the body temperature; 'Paracetamol (acetaminophen) in stroke' (PAIS): start of a clinical trial].
Topics: Acetaminophen; Acute Disease; Analgesics, Non-Narcotic; Body Temperature; Double-Blind Method; Fever | 2003 |
Acetylsalicylic acid and acetaminophen to combat elevated body temperature in acute ischemic stroke.
Topics: Acetaminophen; Acute Disease; Aged; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroida | 2004 |
Randomized trial of the effect of antipyresis by metamizol, propacetamol or external cooling on metabolism, hemodynamics and inflammatory response.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Analysis of Variance; Body Temperature; Cryotherapy; Cytoki | 2004 |
Randomized trial of the effect of antipyresis by metamizol, propacetamol or external cooling on metabolism, hemodynamics and inflammatory response.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Analysis of Variance; Body Temperature; Cryotherapy; Cytoki | 2004 |
Randomized trial of the effect of antipyresis by metamizol, propacetamol or external cooling on metabolism, hemodynamics and inflammatory response.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Analysis of Variance; Body Temperature; Cryotherapy; Cytoki | 2004 |
Randomized trial of the effect of antipyresis by metamizol, propacetamol or external cooling on metabolism, hemodynamics and inflammatory response.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Analysis of Variance; Body Temperature; Cryotherapy; Cytoki | 2004 |
The antipyretic effect of ibuprofen and acetaminophen in children.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Body Temperature; Child; Child, Preschool; Fever; Half-Life | 2004 |
Prophylactic acetaminophen does not prevent epidural fever in nulliparous women: a double-blind placebo-controlled trial.
Topics: Acetaminophen; Adult; Anesthesia, Epidural; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Me | 2004 |
Corticosteroids, ibuprofen, and acetaminophen for IFNbeta-1a flu symptoms in MS: a randomized trial.
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Asthenia; Chills; Double-Blind Method; Drug Administ | 2004 |
[Antipyretic effectiveness of ibuprofen and paracetamol].
Topics: Acetaminophen; Analgesics, Non-Narcotic; Child; Child, Preschool; Female; Fever; Humans; Ibuprofen; | 2005 |
When fever, paracetamol? Theory and practice in a paediatric outpatient clinic.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Body Temperature; Body Weight; Child, Preschool; Data Colle | 2005 |
Equal antipyretic effectiveness of oral and rectal acetaminophen: a randomized controlled trial [ISRCTN11886401].
Topics: Acetaminophen; Administration, Oral; Administration, Rectal; Adolescent; Analgesics, Non-Narcotic; B | 2005 |
Aspirin compared with acetaminophen in the treatment of fever and other symptoms of upper respiratory tract infection in adults: a multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group, single-dose, 6-hour dose-ranging st
Topics: Acetaminophen; Acute Disease; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspi | 2005 |
The effect of antipyretic therapy upon outcomes in critically ill patients: a randomized, prospective study.
Topics: Acetaminophen; Adult; Aged; Analgesics, Non-Narcotic; Body Temperature; Body Temperature Regulation; | 2005 |
Antipyretic treatment in young children with fever: acetaminophen, ibuprofen, or both alternating in a randomized, double-blind study.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Child, Preschool; Double-Blind Method; Drug Therapy, Combin | 2006 |
Randomised controlled trial of combined paracetamol and ibuprofen for fever.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Child; Child, Preschool; Drug Therapy, Combination; Emergen | 2006 |
Alternating ibuprofen and acetaminophen in the treatment of febrile children: a pilot study [ISRCTN30487061].
Topics: Acetaminophen; Administration, Oral; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroid | 2006 |
Antipyretic efficacy and tolerability of a single intravenous dose of the acetaminophen prodrug propacetamol in children: a randomized, double-blind, placebo-controlled trial.
Topics: Acetaminophen; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Child; Child, Preschool; Double- | 2006 |
Antipyretic efficacy and safety of a single intravenous administration of 15 mg/kg paracetamol versus 30 mg/kg propacetamol in children with acute fever due to infection.
Topics: Acetaminophen; Acute Disease; Analgesics, Non-Narcotic; Child; Child, Preschool; Double-Blind Method | 2007 |
The effect of acetaminophen (four grams a day for three consecutive days) on hepatic tests in alcoholic patients--a multicenter randomized study.
Topics: Acetaminophen; Adolescent; Adult; Alanine Transaminase; Alcoholism; Analgesics, Non-Narcotic; Aspart | 2007 |
Ibuprofen versus paracetamol in pediatric fever: objective and subjective findings from a randomized, blinded study.
Topics: Acetaminophen; Child; Child, Preschool; Double-Blind Method; Female; Fever; Humans; Ibuprofen; Infan | 2007 |
A prospective, observational clinical trial of fever reduction to reduce systemic oxygen consumption in the setting of acute brain injury.
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; APACHE; Body Temperature; Brain Injuries; Combined M | 2008 |
The association between acetaminophen concentrations in the cerebrospinal fluid and temperature decline in febrile infants.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Drug Monitoring; Female; Fever; Humans; Infant; Male; Time | 2007 |
Role of paracetamol in treatment of childhood Fever: a double-blind randomized placebo controlled trial.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Child; Child, Preschool; Female; Fever; Humans; Infant; Liv | 2007 |
The effects of remifentanil or acetaminophen with epidural ropivacaine on body temperature during labor.
Topics: Acetaminophen; Adult; Amides; Analgesics, Non-Narcotic; Analgesics, Opioid; Anesthesia, Obstetrical; | 2008 |
[Trial of oral paracetamol solution in febrile children].
Topics: Acetaminophen; Child, Preschool; Clinical Trials as Topic; Female; Fever; Humans; Male; Solutions | 1983 |
Acetaminophen accumulation in pediatric patients after repeated therapeutic doses.
Topics: Acetaminophen; Child; Child, Preschool; Female; Fever; Humans; Infant; Kidney Function Tests; Kineti | 1984 |
Primary care of hyperpyrexia. Evaluation of a simple physical method.
Topics: Acetaminophen; Baths; Child; Child, Preschool; Evaluation Studies as Topic; Fever; Humans; Infant | 1984 |
[Analgesic, antipyretic and anti-rheumatic activity of 2 preparations evaluated in a multicenter clinical trial].
Topics: Acetaminophen; Adolescent; Adult; Aged; Aspirin; Caffeine; Child; Child, Preschool; Clinical Trials | 1982 |
Comparative efficacy of aspirin and acetaminophen in the reduction of fever in children.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Child; Child, Preschool; Clinical T | 1981 |
A comparison of nimesulide vs paracetamol in the treatment of pyrexia in the elderly.
Topics: Acetaminophen; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method | 1993 |
A comparison of nimesulide and paracetamol in the treatment of fever due to inflammatory diseases of the upper respiratory tract in children.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Child; Child, Preschool; Female; Fever; Huma | 1993 |
Correcting respiratory rate for the presence of fever.
Topics: Acetaminophen; Child, Preschool; Double-Blind Method; Female; Fever; Humans; Infant; Male; Respirati | 1994 |
Pretreatment regimens for adverse events related to infusion of amphotericin B.
Topics: Acetaminophen; Adrenal Cortex Hormones; Amphotericin B; Diphenhydramine; Fever; Headache; Heparin; H | 1995 |
Risks of antipyretics in young children with fever due to infectious disease.
Topics: Acetaminophen; Adolescent; Analgesics, Non-Narcotic; Bacterial Infections; Child; Child, Preschool; | 1994 |
Evaluation of the antipyretic effect of ketorolac, acetaminophen, and placebo in endotoxin-induced fever.
Topics: Acetaminophen; Adolescent; Adult; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; | 1994 |
Antipyretic efficacy of indomethacin and acetaminophen in uncomplicated falciparum malaria.
Topics: Acetaminophen; Administration, Oral; Adolescent; Adult; Female; Fever; Humans; Indomethacin; Malaria | 1994 |
Tepid sponging to reduce temperature in febrile children in a tropical climate.
Topics: Acetaminophen; Administration, Oral; Administration, Topical; Body Temperature; Child, Preschool; Co | 1994 |
Efficacy and safety of aerosolized ribavirin in young children hospitalized with influenza: a double-blind, multicenter, placebo-controlled trial.
Topics: Acetaminophen; Administration, Inhalation; Antibodies, Viral; Child, Preschool; Double-Blind Method; | 1994 |
Comparative efficacy and tolerance of ibuprofen syrup and acetaminophen syrup in children with pyrexia associated with infectious diseases and treated with antibiotics.
Topics: Acetaminophen; Anti-Bacterial Agents; Child, Preschool; Double-Blind Method; Female; Fever; Humans; | 1994 |
Antipyretic effectiveness of acetaminophen in febrile seizures: ongoing prophylaxis versus sporadic usage.
Topics: Acetaminophen; Body Temperature; Child, Preschool; Drug Administration Schedule; Female; Fever; Huma | 1993 |
Primary immunization series for infants: comparison of two-component acellular and standard whole-cell pertussis vaccines combined with diphtheria-tetanus toxoids.
Topics: Academic Medical Centers; Acetaminophen; Antibody Formation; Diphtheria-Tetanus-Pertussis Vaccine; D | 1993 |
Nimesulide in the treatment of hyperpyrexia in the aged. Double-blind comparison with paracetamol.
Topics: Acetaminophen; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Bod | 1993 |
Reduction of the initial febrile response to OKT3 with indomethacin.
Topics: Acetaminophen; Adult; Creatinine; Diphenhydramine; Drug Administration Schedule; Female; Fever; Graf | 1993 |
Comparing efficacy and tolerability of ibuprofen and paracetamol in fever.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Body Temperature; Child; Child, Preschool; D | 1996 |
Choice of antipyretic in children.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Child; Child, Pres | 1995 |
Evaluation of ibuprofen versus aspirin and paracetamol on efficacy and comfort in children with fever.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Body Temp | 1997 |
Metabolic effects of i.v. propacetamol, metamizol or external cooling in critically ill febrile sedated patients.
Topics: Acetaminophen; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Critical Illness; Cross-Over St | 1997 |
The efficacy of tepid sponge bathing to reduce fever in young children.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Baths; Body Temperature; Child; Child, Preschool; Combined | 1997 |
Evaluation of sponging and antipyretic medication to reduce body temperature in febrile children.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Aspirin; Baths; Child, Preschool; Female; Fever; Humans; Ib | 1997 |
A comparison of ibuprofen versus acetaminophen with codeine in the young tonsillectomy patient.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal | 1997 |
A comparison of ibuprofen versus acetaminophen with codeine in the young tonsillectomy patient.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal | 1997 |
A comparison of ibuprofen versus acetaminophen with codeine in the young tonsillectomy patient.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal | 1997 |
A comparison of ibuprofen versus acetaminophen with codeine in the young tonsillectomy patient.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal | 1997 |
A comparison of ibuprofen versus acetaminophen with codeine in the young tonsillectomy patient.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal | 1997 |
A comparison of ibuprofen versus acetaminophen with codeine in the young tonsillectomy patient.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal | 1997 |
A comparison of ibuprofen versus acetaminophen with codeine in the young tonsillectomy patient.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal | 1997 |
A comparison of ibuprofen versus acetaminophen with codeine in the young tonsillectomy patient.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal | 1997 |
A comparison of ibuprofen versus acetaminophen with codeine in the young tonsillectomy patient.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal | 1997 |
Effect of paracetamol on parasite clearance time in Plasmodium falciparum malaria.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Animals; Child; Child, Preschool; Female; Fever; Humans; In | 1997 |
Renal function after short-term ibuprofen use in infants and children.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Blood Urea Nitroge | 1997 |
Equivalent antipyretic activity of ibuprofen and paracetamol in febrile children.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Child; Child, Pres | 1997 |
Efficacy of tepid sponging versus paracetamol in reducing temperature in febrile children.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Body Temperature Regulation; Child, Preschool; Female; Feve | 1997 |
Antipyretic effect of oral v. rectal paracetamol.
Topics: Acetaminophen; Administration, Oral; Administration, Rectal; Analgesics, Non-Narcotic; Child, Presch | 1997 |
[The experience with solpadeine -- a new analgesic].
Topics: Acetaminophen; Adolescent; Adult; Analgesics; Analgesics, Non-Narcotic; Caffeine; Codeine; Drug Comb | 1997 |
Amelioration of flulike symptoms at the onset of interferon beta-1b therapy in multiple sclerosis by low-dose oral steroids is related to a decrease in interleukin-6 induction.
Topics: Acetaminophen; Administration, Oral; Adult; Analgesics, Non-Narcotic; Dose-Response Relationship, Dr | 1998 |
Double blind randomized comparative evaluation of nimesulide and paracetamol as antipyretics.
Topics: Abdominal Pain; Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Ax | 1998 |
Acetaminophen has greater antipyretic efficacy than aspirin in endotoxemia: a randomized, double-blind, placebo-controlled trial.
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Aspirin; Body Temperature; Double-Blind Method; Endo | 1999 |
The safety of acetaminophen and ibuprofen among children younger than two years old.
Topics: Acetaminophen; Acute Disease; Analgesics, Non-Narcotic; Asthma; Bronchiolitis; Double-Blind Method; | 1999 |
Ketorolac versus acetaminophen for treatment of acute fever in the emergency department.
Topics: Acetaminophen; Acute Disease; Administration, Oral; Analgesics, Non-Narcotic; Body Temperature; Doub | 1999 |
Interferon treatment of chronic hepatitis C in patients cured of pediatric malignancies.
Topics: Acetaminophen; Adolescent; Adult; Alanine Transaminase; Alopecia; Asthenia; Chlorpheniramine; DNA, V | 2000 |
Assessment of the efficacy and safety of paracetamol, ibuprofen and nimesulide in children with upper respiratory tract infections.
Topics: Acetaminophen; Acute Disease; Adolescent; Analgesics, Non-Narcotic; Analysis of Variance; Anti-Infla | 1999 |
Acetaminophen controlled-release sprinkles versus acetaminophen immediate-release elixir in febrile children.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anxiety; Area Under Curve; Body Temperature; Child; Child, | 2000 |
Stroke severity determines body temperature in acute stroke.
Topics: Acetaminophen; Acute Disease; Aged; Aged, 80 and over; Anticoagulants; Body Temperature; Cerebral He | 2001 |
Antipyretic effects of nimesulide, paracetamol and ibuprofen-paracetamol.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Child, Preschool; Double-Blind Method; Drug | 2000 |
Early pregnancy termination with vaginal misoprostol combined with loperamide and acetaminophen prophylaxis.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Acetaminophen; Administration, Intravaginal; | 2001 |
Comparison of fever treatments in the critically ill: a pilot study.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Combined Modality Therapy; Critical Care; Critical Illness; | 2001 |
Effect of paracetamol (acetaminophen) on body temperature in acute ischemic stroke: a double-blind, randomized phase II clinical trial.
Topics: Acetaminophen; Acute Disease; Aged; Body Temperature; Brain Ischemia; Double-Blind Method; Female; F | 2001 |
Antipyretic efficacy of an initial 30-mg/kg loading dose of acetaminophen versus a 15-mg/kg maintenance dose.
Topics: Acetaminophen; Administration, Oral; Ambulatory Care; Analgesics, Non-Narcotic; Child; Child, Presch | 2001 |
Acetaminophen for altering body temperature in acute stroke: a randomized clinical trial.
Topics: Acetaminophen; Acute Disease; Aged; Body Temperature; Double-Blind Method; Female; Fever; Humans; Hy | 2002 |
Antipyretic effects of dipyrone versus ibuprofen versus acetaminophen in children: results of a multinational, randomized, modified double-blind study.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroid | 2001 |
Asthma morbidity after the short-term use of ibuprofen in children.
Topics: Acetaminophen; Age Factors; Ambulatory Care; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non | 2002 |
Both paracetamol and ibuprofen are equally effective in managing flu-like symptoms in relapsing-remitting multiple sclerosis patients during interferon beta-1a (AVONEX) therapy.
Topics: Acetaminophen; Adult; Chills; Female; Fever; Headache; Humans; Ibuprofen; Interferon beta-1a; Interf | 2002 |
Comparison of antipyretic effect of nimesulide and paracetamol in children attending a secondary level hospital.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Child; Child, Pres | 2002 |
Effectiveness and tolerability of ibuprofen-arginine versus paracetamol in children with fever of likely infectious origin.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Arginine; Child; Child, Preschool; Double-Blind Method; Dru | 2002 |
Sulfadoxine-pyrimethamine monotherapy in Tanzanian children gives rapid parasite clearance but slow fever clearance that is improved by chloroquine in combination therapy.
Topics: Acetaminophen; Antimalarials; Child, Preschool; Chloroquine; Drug Combinations; Drug Resistance; Dru | 2002 |
[On the antipyretic effect of paracetamol. Clinical investigation with two different forms of application (author's transl)].
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Child; Child, Preschool; Dosage Forms; Doxyl | 1978 |
Acetaminophen.
Topics: Acetaminophen; Analgesia; Animals; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; | 1977 |
Antipyretic therapy. Comparison of rectal and oral paracetamol.
Topics: Acetaminophen; Administration, Oral; Adult; Child; Child, Preschool; Clinical Trials as Topic; Fever | 1977 |
Rectal paracetamol in small children with fever.
Topics: Acetaminophen; Administration, Oral; Child; Child, Preschool; Fever; Humans; Infant; Random Allocati | 1979 |
The antipyretic effectiveness of acetaminophen suppositories versus tablets: a double-blind study.
Topics: Acetaminophen; Adult; Aged; Body Temperature; Clinical Trials as Topic; Female; Fever; Humans; Male; | 1976 |
Management of feverish children at home.
Topics: Acetaminophen; Baths; Child, Preschool; Clothing; Fever; Home Nursing; Humans; Infant; Random Alloca | 1992 |
Pharmacokinetics and pharmacodynamics of ibuprofen isomers and acetaminophen in febrile children.
Topics: Acetaminophen; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Fever; Humans; Ibu | 1992 |
Antipyretic efficacy of ibuprofen vs acetaminophen.
Topics: Acetaminophen; Body Temperature; Child; Child, Preschool; Double-Blind Method; Female; Fever; Humans | 1992 |
Comparison of multidose ibuprofen and acetaminophen therapy in febrile children.
Topics: Acetaminophen; Body Temperature; Child; Child, Preschool; Double-Blind Method; Drug Administration S | 1992 |
Pilot study of the antipyretic and analgesic activity of nimesulide paediatric suppositories.
Topics: Acetaminophen; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Child; Child, Preschoo | 1992 |
Risks and benefits of paracetamol antipyresis in young children with fever of presumed viral origin.
Topics: Acetaminophen; Acute Disease; Child; Child, Preschool; Double-Blind Method; Drug Administration Sche | 1991 |
Treatment of childhood fevers.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Child; Child, Preschool; Culture; Fever; Hum | 1991 |
Single-dose, placebo-controlled comparative study of ibuprofen and acetaminophen antipyresis in children.
Topics: Acetaminophen; Administration, Oral; Anti-Bacterial Agents; Body Temperature; Body Weight; Child; Ch | 1991 |
Ibuprofen versus paracetamol for the treatment of fever in children.
Topics: Acetaminophen; Child; Child, Preschool; Fever; Humans; Ibuprofen; Infant; Research Design | 1990 |
A double-blind comparison of ibuprofen and paracetamol in juvenile pyrexia.
Topics: Acetaminophen; Body Temperature; Child; Child, Preschool; Double-Blind Method; Drug Administration S | 1990 |
A comparison of three methods of managing fever in the neurologic patient.
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Baths; Evaluation Studies as Topic; Female; Fever; Hu | 1990 |
[Pharmacosurveillance of antipyretics. Evaluation of the risk-benefit ratio of a combination of paracetamol and sobrerol. Monitoring of 3501 ambulatory patients].
Topics: Acetaminophen; Adult; Ambulatory Care; Anti-Inflammatory Agents, Non-Steroidal; Drug Evaluation; Dru | 1990 |
Adverse effects of aspirin, acetaminophen, and ibuprofen on immune function, viral shedding, and clinical status in rhinovirus-infected volunteers.
Topics: Acetaminophen; Adult; Antibodies, Viral; Aspirin; Common Cold; Double-Blind Method; Female; Fever; H | 1990 |
Pharmacokinetics of paracetamol after cardiac surgery.
Topics: Acetaminophen; Administration, Rectal; Cardiac Surgical Procedures; Child; Child, Preschool; Fever; | 1990 |
Comparative evaluation of the antipyretic efficacy of ibuprofen and paracetamol.
Topics: Acetaminophen; Child; Child, Preschool; Female; Fever; Humans; Ibuprofen; Infant; Male | 1990 |
Longitudinal study of adverse reactions following diphtheria-tetanus-pertussis vaccine in infancy.
Topics: Acetaminophen; Age Factors; Antibody Formation; Diphtheria-Tetanus-Pertussis Vaccine; Erythema; Feve | 1990 |
Efficacy of sponging vs acetaminophen for reduction of fever. Sponging Study Group.
Topics: Acetaminophen; Baths; Body Temperature; Body Temperature Regulation; Child, Preschool; Combined Moda | 1990 |
[Comparison of the antipyretic effect of a single dose of dipyrone, paracetamol and diclofenac resinate. A multicenter clinical trial].
Topics: Acetaminophen; Body Temperature; Child; Child, Preschool; Diclofenac; Dipyrone; Female; Fever; Human | 1989 |
Ibuprofen, acetaminophen, and placebo treatment of febrile children.
Topics: Acetaminophen; Administration, Oral; Adolescent; Child; Child, Preschool; Clinical Trials as Topic; | 1989 |
Effect of prophylactic acetaminophen administration on reaction to DTP vaccination.
Topics: Acetaminophen; Clinical Trials as Topic; Diphtheria Toxoid; Double-Blind Method; Fever; Humans; Immu | 1988 |
Acetaminophen prophylaxis of adverse reactions following vaccination of infants with diphtheria-pertussis-tetanus toxoids-polio vaccine.
Topics: Acetaminophen; Body Temperature; Clinical Trials as Topic; Diphtheria Toxoid; Diphtheria-Tetanus-Per | 1987 |
Fever response to acetaminophen in viral vs. bacterial infections.
Topics: Acetaminophen; Adolescent; Bacterial Infections; Child; Child, Preschool; Clinical Trials as Topic; | 1987 |
Antipyretic activity of ibuprofen and paracetamol in children with pyrexia.
Topics: Acetaminophen; Child; Child, Preschool; Clinical Trials as Topic; Female; Fever; Humans; Ibuprofen; | 1985 |
Clinical experience and results of treatment with suprofen in pediatrics. 2nd communication: Use of suprofen suppositories as an antipyretic in children with fever due to acute infections/A single-blind controlled study of suprofen versus paracetamol.
Topics: Acetaminophen; Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Body Temperature; Child; Chil | 1985 |
Antipyretic effect of tenoxicam and paracetamol in febrile children.
Topics: Acetaminophen; Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Child, Preschool; Clinica | 1985 |
A comparison of the antipyretic effect of acetaminophen and aspirin. Another approach to poison prevention.
Topics: Acetaminophen; Age Factors; Aspirin; Body Temperature; Child, Preschool; Clinical Trials as Topic; F | 1972 |
[Use in the pediatric field of an antipyretic, hypno-sedative and analgesic combination].
Topics: Acetaminophen; Analgesics; Benzoates; Child, Preschool; Clinical Trials as Topic; Drug Combinations; | 1973 |
Study of antipyretic therapy in current use.
Topics: Acetaminophen; Aspirin; Body Temperature; Child, Preschool; Clinical Trials as Topic; Fever; Humans; | 1973 |
A comparative evaluation of indomethacin, acetaminophen and placebo as antipyretic agents in children.
Topics: Acetaminophen; Chemical Phenomena; Chemistry; Child; Clinical Trials as Topic; Fever; Humans; Indome | 1968 |
Evaluation of sponging and of oral antipyretic therapy to reduce fever.
Topics: 1-Propanol; Acetaminophen; Baths; Child, Preschool; Fever; Humans; Infant; Placebos; Temperature; Ti | 1970 |
426 other studies available for acetaminophen and Fever
| Article | Year |
|---|---|
Microsomal prostaglandin E2 synthase-1 (mPGES-1): a novel anti-inflammatory therapeutic target.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Atherosclerosis; Fever; Humans; Intramolecular Oxi | 2008 |
Synthesis, biological evaluation and docking studies of novel benzopyranone congeners for their expected activity as anti-inflammatory, analgesic and antipyretic agents.
Topics: Analgesics, Non-Narcotic; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzopyrans; Catalytic D | 2009 |
Syntheses, characterization and evaluation of novel 2,6-diarylpiperidin-4-ones as potential analgesic-antipyretic agents.
Topics: Acetic Acid; Analgesics; Animals; Antipyretics; Body Temperature; Dose-Response Relationship, Drug; | 2014 |
Synthesis, hepatotoxic evaluation and antipyretic activity of nitrate ester analogs of the acetaminophen derivative SCP-1.
Topics: Acetaminophen; Animals; Antipyretics; Chemical and Drug Induced Liver Injury; Crystallography, X-Ray | 2018 |
Intravenous Versus Oral Acetaminophen Use in Febrile Neurocritical Care Patients.
Topics: Acetaminophen; Administration, Intravenous; Fever; Humans; Hypothermia, Induced; Ischemic Stroke; Re | 2022 |
COVID Arm After Moderna Booster in Healthcare Worker: A Case Report.
Topics: 2019-nCoV Vaccine mRNA-1273; Acetaminophen; Analgesics, Non-Narcotic; Biopsy; COVID-19; COVID-19 Vac | 2021 |
Fever-Related Ventricular Fibrillation - Potential Adverse Effect of SARS-CoV-2 Vaccination in Patients With Brugada Syndrome.
Topics: Acetaminophen; Adult; Anti-Arrhythmia Agents; Antipyretics; Arrhythmias, Cardiac; Brugada Syndrome; | 2022 |
Does immunosuppressive property of non-steroidal anti-inflammatory drugs (NSAIDs) reduce COVID-19 vaccine-induced systemic side effects?
Topics: Acetaminophen; Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; COVID-19 Vaccines; Fati | 2021 |
Risk Factors for Intravenous Propacetamol-Induced Blood Pressure Drop in the Neurointensive Care Unit: A Retrospective Observational Study.
Topics: Acetaminophen; Blood Pressure; Fever; Humans; Hypotension; Retrospective Studies; Risk Factors | 2022 |
Investigations of the antipyretic effect and safety of Prasachandaeng, a traditional remedy from Thailand national list of essential medicines.
Topics: Acetaminophen; Animals; Antipyretics; Cytochrome P-450 CYP2E1; Disease Models, Animal; Dose-Response | 2022 |
Efficacy, safety, and economic impact of diazepam suppositories with as-needed acetaminophen for prevention of seizure recurrence during the same fever episode in children with suspected simple febrile seizures.
Topics: Acetaminophen; Child; Diazepam; Fever; Humans; Infant; Prospective Studies; Recurrence; Seizures, Fe | 2022 |
Recurrent vincristine-associated fever in a child with Wilms tumor.
Topics: Acetaminophen; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Dexamethason | 2022 |
The attitudes and expectation of caregivers of febrile child receiving medical services: a multicenter survey in Thailand.
Topics: Acetaminophen; Adolescent; Adult; Antipyretics; Attitude to Health; Caregivers; Child; Cross-Section | 2023 |
Acetaminophen Versus Ibuprofen for Fever Reduction in the Pediatric Emergency Department.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Child; Drug Therap | 2023 |
Acetaminophen Versus Ibuprofen for Fever Reduction in the Pediatric Emergency Department.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Child; Drug Therap | 2023 |
Acetaminophen Versus Ibuprofen for Fever Reduction in the Pediatric Emergency Department.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Child; Drug Therap | 2023 |
Acetaminophen Versus Ibuprofen for Fever Reduction in the Pediatric Emergency Department.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Child; Drug Therap | 2023 |
Current perceptions and use of paracetamol in dogs among veterinary surgeons working in the United Kingdom.
Topics: Acetaminophen; Analgesia; Animals; Anti-Inflammatory Agents, Non-Steroidal; Dogs; Fever; Humans; Uni | 2023 |
Antipyretic and antinociceptive effects of methanolic extract of C. iria L. tuber.
Topics: Acetaminophen; Acetic Acid; Analgesics; Animals; Antipyretics; Fever; Methanol; Mice; Plant Extracts | 2024 |
Lack of evidence for a beneficial effect of antipyretic drugs.
Topics: Acetaminophen; Antipyretics; Fever; Humans | 2023 |
Are we confident that we all share a common understanding of discomfort in febrile children?
Topics: Acetaminophen; Child; Fever; Humans | 2023 |
Treatment of fever and associated symptoms in the emergency department: which drug to choose?
Topics: Acetaminophen; Adult; Aged; Bacteriophages; Emergency Service, Hospital; Fever; Humans; Ibuprofen; M | 2023 |
Adverse events following immunization (AEFIs) with anti-meningococcus type B vaccine (4CMenB): Data of post-marketing active surveillance program. Apulia Region (Italy), 2019-2023.
Topics: Acetaminophen; Antibodies; Cross-Sectional Studies; Fever; Humans; Immunization; Infant; Italy; Meni | 2023 |
Antipyretic Efficacy of Acetaminophen and Ibuprofen in Critically Ill Pediatric Patients.
Topics: Acetaminophen; Antipyretics; Body Temperature; Child; Child, Preschool; Critical Illness; Female; Fe | 2019 |
Reply to Acetaminophen Use and Stroke Risk.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Fever; Humans; Stroke | 2019 |
Efficacy and safety of modified-release paracetamol for acute and chronic pain: a systematic review protocol.
Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Australia; Child; Child, Preschool; Chron | 2019 |
Prophylactic Paracetamol After Meningococcal B Vaccination Reduces Postvaccination Fever and Septic Screens in Hospitalized Preterm Infants.
Topics: Acetaminophen; Female; Fever; Hospitalization; Humans; Infant; Infant, Newborn; Infant, Premature; M | 2020 |
Antihyperthermic treatment decreases perihematomal hypodensity.
Topics: Acetaminophen; Aged; Aged, 80 and over; Antipyretics; Body Temperature; Cerebral Hemorrhage; Dipyron | 2020 |
Antipyretics might occupy a narrow temporal position in aetiology of type 1 diabetes: Immunological and intestinal studies required.
Topics: Acetaminophen; Antipyretics; Autoimmune Diseases; Child, Preschool; Diabetes Mellitus, Type 1; Fever | 2020 |
First case of focal epilepsy associated with SARS-coronavirus-2.
Topics: Acetaminophen; Acetylcysteine; Aged; Ambroxol; Anticonvulsants; Cough; COVID-19; COVID-19 Drug Treat | 2020 |
Treating COVID-19 with colchicine in community healthcare setting.
Topics: Acetaminophen; Anti-Inflammatory Agents; Azithromycin; Betacoronavirus; Cohort Studies; Colchicine; | 2020 |
The use of ibuprofen to treat fever in COVID-19: A possible indirect association with worse outcome?
Topics: Acetaminophen; Antipyretics; COVID-19 Drug Treatment; Fever; Humans; Ibuprofen; Models, Theoretical; | 2020 |
Ibuprofen use and clinical outcomes in COVID-19 patients.
Topics: Acetaminophen; Adult; Antipyretics; COVID-19; COVID-19 Drug Treatment; Female; Fever; Humans; Ibupro | 2020 |
Safety and Feasibility of a Novel Transnasal Cooling Device to Induce Normothermia in Febrile Cerebrovascular Patients.
Topics: Acetaminophen; Body Temperature; Cold Temperature; Feasibility Studies; Female; Fever; Humans; Hypot | 2021 |
[Acetaminophen induced delayed-type urticaria and angioedema in a child].
Topics: Acetaminophen; Angioedema; Anti-Inflammatory Agents, Non-Steroidal; Fever; Humans; Infant; Urticaria | 2020 |
An assessment of parents' knowledge and awareness regarding paracetamol use in children: a cross-sectional study from Palestine.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Child; Cross-Sectional Studies; Female; Fever; Health Knowl | 2021 |
Paracetamol or ibuprofen for fever or pain in children under 2 years old.
Topics: Acetaminophen; Antipyretics; Child; Fever; Humans; Ibuprofen; Infant; Pain | 2021 |
Appropriateness of Acetaminophen Dosing by Caregivers of Pediatric Patients Presenting to the Emergency Department at the University Pediatric Hospital in Puerto Rico.
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Caregivers; Child; Child, Preschool; Cross-Sectional | 2021 |
Community use of paracetamol and ibuprofen in children with fever.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Child; Fever; Humans; Ibuprofen; Prospective Studies | 2021 |
Comparative Analysis of Single and Combined Antipyretics Using Patient-Generated Health Data: Retrospective Observational Study.
Topics: Acetaminophen; Antipyretics; Child; Fever; Humans; Mobile Applications; Retrospective Studies | 2021 |
Initial experience of the safety and tolerability of the BNT162b2 (Pfizer-Bio-N-Tech) vaccine in extremely vulnerable children aged 12-15 years.
Topics: Acetaminophen; Adolescent; Adult; Age Factors; BNT162 Vaccine; Child; Comorbidity; COVID-19; Fever; | 2022 |
Severe polyarthralgia, high-grade fever, diffuse maculopapular rash on trunk and extremities · Dx?
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Ankle; Anti-Inflammatory Agents; Arthralgia; Caribbe | 2017 |
Haemodynamic changes with paracetamol in critically-ill children.
Topics: Acetaminophen; Adolescent; Adult; Analgesics, Non-Narcotic; Blood Pressure; Child; Child, Hospitaliz | 2017 |
UK parents' attitudes towards meningococcal group B (MenB) vaccination: a qualitative analysis.
Topics: Acetaminophen; Adult; Anxiety; Cross-Sectional Studies; England; Evaluation Studies as Topic; Female | 2017 |
Antipyretic potential of herbal coded formulation (Pyrexol).
Topics: Acetaminophen; Animals; Antipyretics; Body Temperature Regulation; Disease Models, Animal; Female; F | 2017 |
Hemodynamic changes in patients with influenza A after propacetamol infusion in the emergency department.
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Blood Pressure; Emergency Service, Hospital; Female; | 2018 |
Medicine use practices in management of symptoms of acute upper respiratory tract infections in children (≤12 years) in Kampala city, Uganda.
Topics: Acetaminophen; Acute Disease; Adult; Amoxicillin; Anti-Infective Agents; Artemether, Lumefantrine Dr | 2017 |
NBAS mutations cause acute liver failure: when acetaminophen is not a culprit.
Topics: Acetaminophen; Diagnosis, Differential; Disease Progression; Fever; Genetic Predisposition to Diseas | 2017 |
Antipyretic Medication Exposures Among Young Children Reported to US Poison Centers, 2000-2015.
Topics: Acetaminophen; Age Distribution; Antipyretics; Child; Child, Preschool; Confidence Intervals; Databa | 2018 |
The effect of antipyretics on immune response and fever following receipt of inactivated influenza vaccine in young children.
Topics: Acetaminophen; Antibodies, Viral; Antipyretics; Child, Preschool; Female; Fever; Hemagglutination In | 2017 |
Hemodynamic changes after propacetamol administration in patients with febrile UTI in the ED.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Dose-Response Relationship, Drug; Emergency | 2018 |
The Effect of Acetaminophen on Temperature in Critically Ill Children: A Retrospective Analysis of Over 50,000 Doses.
Topics: Acetaminophen; Antipyretics; Body Temperature; Child; Cohort Studies; Critical Illness; Fever; Human | 2018 |
Effect of early natal supplementation of paracetamol on attenuation of exotoxin/endotoxin induced pyrexia and precipitation of autistic like features in albino rats.
Topics: Acetaminophen; Animals; Animals, Newborn; Antipyretics; Autistic Disorder; Behavior, Animal; Diphthe | 2018 |
Complex analyses on clinical information systems using restricted natural language querying to resolve time-event dependencies.
Topics: Acetaminophen; Algorithms; Body Temperature; Brain Injuries, Traumatic; Data Collection; Data Scienc | 2018 |
Intravenous acetaminophen for the treatment of intrapartum fever and resolution of fetal tachycardia: a novel use for an old medication.
Topics: Acetaminophen; Antipyretics; Female; Fetal Diseases; Fever; Humans; Infant, Newborn; Infusions, Intr | 2017 |
Ibuprofen and Paracetamol: Acceptably Safe for All?
Topics: Acetaminophen; Analgesics, Non-Narcotic; Fever; Humans; Ibuprofen | 2018 |
A Survey on Fever Monitoring and Management in Patients With Acute Brain Injury: The SUMMA Study.
Topics: Acetaminophen; Acute Disease; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antipyretics; Body Tem | 2019 |
[Side Effects of Acetaminophen and their Management].
Topics: Acetaminophen; Aspirin; Chronic Pain; Cyclooxygenase 1; Fever; Humans; Pain Management; Reye Syndrom | 2016 |
Short-term safety of 4CMenB vaccine during a mass meningococcal B vaccination campaign in Quebec, Canada.
Topics: Acetaminophen; Adolescent; Child; Child, Preschool; Female; Fever; Humans; Immunization Programs; Im | 2018 |
Antipyretic effect of phytol, possibly via 5KIR-dependent COX-2 inhibition pathway.
Topics: Acetaminophen; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antipyretics; Cyclooxygenase 1; Cyc | 2019 |
Arthus Reaction.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Arthus Reaction; Child; Cyproheptadine; Diphtheria-Tetanus- | 2019 |
Feasibility and Safety of Transnasal High Flow Air to Reduce Core Body Temperature in Febrile Neurocritical Care Patients: A Pilot Study.
Topics: Acetaminophen; Adult; Aged; Antipyretics; Body Temperature; Cerebral Hemorrhage; Cerebral Intraventr | 2019 |
Paracetamol for dengue fever: no benefit and potential harm?
Topics: Acetaminophen; Adult; Antipyretics; Dengue; Fever; Humans; Liver | 2019 |
Phytochemical screening and antipyretic effects of hydroalcoholic extracts of selected medicinal plants of Rawalakot, Azad Jammu and Kashmir in albino rats.
Topics: Acetaminophen; Achillea; Animals; Antipyretics; Drug Evaluation, Preclinical; Female; Fever; Male; P | 2019 |
Maternal fever during pregnancy and offspring attention deficit hyperactivity disorder.
Topics: Acetaminophen; Adult; Attention Deficit Disorder with Hyperactivity; Child; Cohort Studies; Female; | 2019 |
The investigation of possible roles of central 5-HT
Topics: Acetaminophen; Animals; Antipyretics; Body Temperature; Disease Models, Animal; Fever; Interleukin-6 | 2019 |
Using health information technology to improve health care: emphasizing speed to value.
Topics: Acetaminophen; Female; Fever; Humans; Inpatients; Liver Failure, Acute; Male | 2012 |
Use of paracetamol in ischaemic stroke patients: evidence from VISTA.
Topics: Acetaminophen; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Brain Ischemia; Female; Fever; Hum | 2013 |
Acetaminophen reduces lipopolysaccharide-induced fever by inhibiting cyclooxygenase-2.
Topics: Acetaminophen; Animals; Antipyretics; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; D | 2013 |
The ability of a retrospective review of electronic health records to fully capture the frequency of supratherapeutic dosing of acetaminophen.
Topics: Acetaminophen; Female; Fever; Humans; Inpatients; Liver Failure, Acute; Male | 2013 |
The ability of a retrospective review of electronic health records to fully capture the frequency of supratherapeutic dosing of acetaminophen--reply.
Topics: Acetaminophen; Female; Fever; Humans; Inpatients; Liver Failure, Acute; Male | 2013 |
Temperature management in haematology patients with febrile neutropenia: a practice survey.
Topics: Acetaminophen; Antipyretics; Cryotherapy; Fever; Hematology; Humans; Meperidine; Neutropenia; New Ze | 2013 |
Management of children's fever by parents and caregivers: Practical measurement of functional health literacy.
Topics: Acetaminophen; Antipyretics; Australia; Caregivers; Child, Preschool; Female; Fever; Health Literacy | 2014 |
Statistical significance of paracetamol administration in fetal and maternal body temperatures.
Topics: Acetaminophen; Antipyretics; Body Temperature; Female; Fever; Humans; Obstetric Labor Complications; | 2013 |
Parental language and dosing errors after discharge from the pediatric emergency department.
Topics: Acetaminophen; Adult; Body Weight; Boston; Child; Child Health Services; Child, Preschool; Communica | 2013 |
Authors' response.
Topics: Acetaminophen; Antipyretics; Body Temperature; Female; Fever; Humans; Obstetric Labor Complications; | 2013 |
Is fever treated more promptly than pain in the pediatric emergency department?
Topics: Acetaminophen; Adolescent; Age Factors; Analgesics, Non-Narcotic; Antipyretics; Child; Child, Presch | 2014 |
Management of fever, hyperglycemia, and swallowing dysfunction following hospital admission for acute stroke in New South Wales, Australia.
Topics: Acetaminophen; Aged; Aged, 80 and over; Antipyretics; Cohort Studies; Deglutition Disorders; Female; | 2014 |
Diagnosis and management of temperature abnormality in ICUs: a EUROBACT investigators' survey.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Antipyretics; Bacteremia; Clinical Protocols | 2013 |
Adherence among Italian paediatricians to the Italian guidelines for the management of fever in children: a cross sectional survey.
Topics: Acetaminophen; Administration, Rectal; Antipyretics; Child; Cross-Sectional Studies; Fever; Guidelin | 2013 |
Arsenic reduces the antipyretic activity of paracetamol in rats: modulation of brain COX-2 activity and CB₁ receptor expression.
Topics: Acetaminophen; Animals; Antipyretics; Arsenic; Brain; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxyge | 2014 |
[How to treat pediatric fever in 2013 with little evidence-based?].
Topics: Acetaminophen; Child; Evidence-Based Practice; Fever; Humans; Ibuprofen; Seizures, Febrile | 2014 |
Paracetamol induced Stevens-Johnson syndrome--toxic epidermal necrolysis overlap syndrome.
Topics: Acetaminophen; Antipyretics; Child; Female; Fever; Humans; Stevens-Johnson Syndrome | 2014 |
Pyroglutamic acid-induced metabolic acidosis: a case report.
Topics: Acetaminophen; Acidosis; Anti-Bacterial Agents; Antipyretics; Female; Fever; Floxacillin; Humans; Mi | 2014 |
Acute inhalation exposure to titanium ethanolate as a possible cause of metal fume fever.
Topics: Acetaminophen; Adult; Aerosols; Analgesics, Non-Narcotic; Complex Mixtures; Dyspnea; Ethanol; Fever; | 2014 |
Intravenous paracetamol for fever control in acute brain injury patients: cerebral and hemodynamic effects.
Topics: Acetaminophen; Adult; Aged; Female; Fever; Hemodynamics; Humans; Injections, Intravenous; Intracrani | 2014 |
Acetaminophen-induced liver injury in a woman with febrile flare of systemic lupus erythematosus.
Topics: Acetaminophen; Acetylcysteine; Adult; Biopsy; Chemical and Drug Induced Liver Injury; Female; Fever; | 2014 |
Cochrane in context: Combined and alternating paracetamol and ibuprofen therapy for febrile children.
Topics: Acetaminophen; Antipyretics; Child; Child, Preschool; Drug Therapy, Combination; Fever; Humans; Ibup | 2014 |
Fever and the use of paracetamol during IL-2-based immunotherapy in metastatic melanoma.
Topics: Acetaminophen; Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Antineoplastic Combined Chemothera | 2015 |
Kikuchi-Fujimoto disease: an unusual cause of neck swelling in pregnancy.
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Anti-Bacterial Agents; Biopsy, Fine-Needle; Diagnosi | 2015 |
Acetaminophen & children. Why have pediatric dosage guidelines changed, and what does it mean in practice?
Topics: Acetaminophen; Age Factors; Analgesics, Non-Narcotic; Antipyretics; Child; Child, Preschool; Dose-Re | 2011 |
Severe intrinsic acute kidney injury associated with therapeutic doses of acetaminophen.
Topics: Acetaminophen; Acute Kidney Injury; Analgesics, Non-Narcotic; Child, Preschool; Female; Fever; Human | 2015 |
A few pointers for judicious pediatric practice.
Topics: Acetaminophen; Child; Fever; Humans; Infant, Newborn; Patient Safety; Pediatrics; Resuscitation; Suc | 2015 |
Non-Steroid Anti-Inflammatory Drugs Are Better than Acetaminophen on Fever Control at Acute Stage of Fracture.
Topics: Acetaminophen; Animals; Anti-Inflammatory Agents, Non-Steroidal; Disease Models, Animal; Female; Fev | 2015 |
Are Recommended Doses of Acetaminophen Effective for Children Aged 2 to 3 Years? A Pharmacokinetic Modeling Answer.
Topics: Acetaminophen; Age Factors; Antipyretics; Child, Preschool; Female; Fever; Humans; Male; Models, Bio | 2016 |
Acetaminophen administration in pediatric age: an observational prospective cross-sectional study.
Topics: Acetaminophen; Adolescent; Child; Child, Preschool; Cross-Sectional Studies; Emergency Service, Hosp | 2016 |
Acetaminophen for Fever in Critically Ill Patients with Suspected Infection.
Topics: Acetaminophen; Female; Fever; Humans; Infections; Male | 2016 |
Acetaminophen for Fever in Critically Ill Patients with Suspected Infection.
Topics: Acetaminophen; Female; Fever; Humans; Infections; Male | 2016 |
Acetaminophen for Fever in Critically Ill Patients with Suspected Infection.
Topics: Acetaminophen; Female; Fever; Humans; Infections; Male | 2016 |
Acetaminophen for Fever in Critically Ill Patients with Suspected Infection.
Topics: Acetaminophen; Female; Fever; Humans; Infections; Male | 2016 |
Clinically significant hemodynamic alterations after propacetamol injection in the emergency department: prevalence and risk factors.
Topics: Acetaminophen; Adult; Aged; Emergency Service, Hospital; Female; Fever; Hemodynamics; Humans; Hypote | 2017 |
Enduring large use of acetaminophen suppositories for fever management in children: a national survey of French parents and healthcare professionals' practices.
Topics: Acetaminophen; Administration, Rectal; Antipyretics; Child; Child, Preschool; Cross-Sectional Studie | 2016 |
Paracetamol: pharmacology, prescribing and controversies.
Topics: Acetaminophen; Adolescent; Analgesics, Non-Narcotic; Child; Child, Preschool; Female; Fever; Humans; | 2016 |
Paracetamol-induced fixed drug eruption in a patient with recurrent fever and rash.
Topics: Acetaminophen; Antipyretics; Autoimmunity; Child, Preschool; DNA Mutational Analysis; Drug Eruptions | 2016 |
The pharma-fever that almost got away.
Topics: Acetaminophen; Aged; Analgesics, Opioid; Antipyretics; Carcinoma, Non-Small-Cell Lung; Drug Overdose | 2016 |
Paracetamol is no more likely to exacerbate asthma in children than ibuprofen, shows study.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Child; Fev | 2016 |
National modulators of symptomatic fever management in children: comparative analysis of survey data.
Topics: Acetaminophen; Administration, Rectal; Antipyretics; Female; Fever; Humans; Ibuprofen; Infant; Italy | 2018 |
Association of Acetaminophen and Ibuprofen Use With Wheezing in Children With Acute Febrile Illness.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Antipyretics; Asthma; Child; Child, Preschool; Cross-Sectio | 2017 |
Parental Approach to the Prevention and Management of Fever and Pain Following Childhood Immunizations: A Survey Study.
Topics: Acetaminophen; Adult; Analgesics; Antipyretics; Caregivers; Cross-Sectional Studies; Culture; Female | 2017 |
Parental beliefs and practices regarding childhood fever in Turkish primary care.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Antipyretics; Body Temperature; Caregivers; Child; Child, P | 2017 |
Acetaminophen versus Ibuprofen in Mild Persistent Asthma.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Double-Blind Method; Fever; Humans; | 2016 |
Acetaminophen versus Ibuprofen in Mild Persistent Asthma.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Double-Blind Method; Fever; Humans; | 2016 |
Attitudes towards fever amongst UK paediatric intensive care staff.
Topics: Acetaminophen; Antipyretics; Attitude of Health Personnel; Child; Cross-Sectional Studies; Fever; Hu | 2017 |
Prenatal acetaminophen use and outcomes in children.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Child; Child, Preschool; Female; Fever; Humans; Neurodevelo | 2017 |
[Myocardial infarction-like electrocardiogram in acute Hantavirus infection. Suspected secondary peri-myocarditis].
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Antibodies, Viral; Back Pain; Diagnosis, Differentia | 2008 |
Antipyretic treatment for feverish young children in primary care.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Child; Child, Preschool; Fever; Humans; Ibuprofen; Infant; | 2008 |
Reactogenicity of infant whole cell pertussis combination vaccine compared with acellular pertussis vaccines with or without simultaneous pneumococcal vaccine in the Netherlands.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Crying; Data Collection; Data Interpretation, Statistical; | 2008 |
Combining paracetamol and ibuprofen for fever in children.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Child; Drug Therapy, Combination; Fever; Humans; Ibuprofen | 2008 |
Association between paracetamol use in infancy and childhood, and risk of asthma, rhinoconjunctivitis, and eczema in children aged 6-7 years: analysis from Phase Three of the ISAAC programme.
Topics: Acetaminophen; Adolescent; Analgesics, Non-Narcotic; Asthma; Child; Conjunctivitis; Cross-Sectional | 2008 |
Ibuprofen increases soft tissue infections in children.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Child; Fever; Humans; Ibuprofen; Soft Tissue Infections | 2008 |
Effect of intravenous propacetamol on blood pressure in febrile critically ill patients.
Topics: Acetaminophen; Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Blood Pressure; | 2008 |
Effect of intravenous propacetamol on blood pressure in febrile critically ill patients.
Topics: Acetaminophen; Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Blood Pressure; | 2008 |
Effect of intravenous propacetamol on blood pressure in febrile critically ill patients.
Topics: Acetaminophen; Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Blood Pressure; | 2008 |
Effect of intravenous propacetamol on blood pressure in febrile critically ill patients.
Topics: Acetaminophen; Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Blood Pressure; | 2008 |
Paracetamol with ibuprofen: Ibuprofen is a marker of soft tissue infection.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Chickenpox; Child; Fever; Humans; Ibuprofen; Soft Tissue In | 2008 |
. . . And which works better on fever--acetaminophen, ibuprofen, or both?
Topics: Acetaminophen; Age Factors; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Child | 2008 |
Prevention of febrile nonhemolytic and allergic transfusion reactions with pretransfusion medication: is this evidence-based medicine?
Topics: Acetaminophen; Anemia, Hemolytic; Diphenhydramine; Evidence-Based Medicine; Fever; Humans; Leukocyte | 2008 |
Paracetamol and fever management.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Evidence-Based Medicine; Fever; Humans; Patient Education a | 2008 |
Fever: to treat or not to treat?
Topics: Acetaminophen; Analgesics, Non-Narcotic; Drug Therapy, Combination; Fever; Humans; Ibuprofen; Treatm | 2008 |
Evaluation of the anti-pyretic potential of Orthosiphon stamineus Benth standardized extract.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Animals; Body Temperature; Chromatography, High Pressure Li | 2009 |
[The practice guideline 'Children with fever' (second revision) from the Dutch College of General Practitioners; a response from the perspective of general practice].
Topics: Acetaminophen; Child; Dehydration; Diagnosis, Differential; Family Practice; Fever; Humans; Netherla | 2008 |
Acute non-oliguric kidney failure and cholestatic hepatitis induced by ibuprofen and acetaminophen: a case report.
Topics: Acetaminophen; Acute Kidney Injury; Analgesics, Non-Narcotic; Chemical and Drug Induced Liver Injury | 2009 |
Is giving acetaminophen rectally as good as giving it orally?
Topics: Acetaminophen; Administration, Oral; Administration, Rectal; Child; Fever; Humans | 2009 |
Pyrexia after transcranial surgery for Pfeiffer syndrome.
Topics: Acetaminophen; Acrocephalosyndactylia; Age Factors; Analgesics, Non-Narcotic; Body Temperature; Chil | 2009 |
Characterization and pharmacological evaluation of febrile response on zymosan-induced arthritis in rats.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Animals; Arthritis, Experimental; Body Temperature; Celecox | 2009 |
Hyperthermic effects of Durio zibethinus and its interaction with paracetamol.
Topics: Acetaminophen; Alanine Transaminase; Analgesics, Non-Narcotic; Animals; Asia, Southeastern; Blood Pr | 2008 |
Acute, reversible nonoliguric renal failure in two children associated with analgesic-antipyretic drugs.
Topics: Abdominal Pain; Acetaminophen; Acute Kidney Injury; Adolescent; Analgesics, Non-Narcotic; Child; Deh | 2009 |
Ethnic differences in parental perceptions and management of childhood fever.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Black or African American; Body Temperature; Child; Child, | 2010 |
Anti-inflammatory, analgesic and antipyretic activity of aqueous extract of fresh leaves of Coccinia indica.
Topics: Acetaminophen; Analgesics; Analgesics, Non-Narcotic; Animals; Anti-Inflammatory Agents; Cucurbitacea | 2009 |
Potential benefit of paracetamol administration in adult-onset Still's disease.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Drug Therapy, Combination; Fever; Humans; Immunosuppressive | 2009 |
Acetaminophen has limited antipyretic activity in critically ill patients.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Body Temperature; Critical Care; Critical Illness; Female; | 2010 |
Management of fever in children: summary of the Italian Pediatric Society guidelines.
Topics: Acetaminophen; Age Factors; Analgesics, Non-Narcotic; Axilla; Body Temperature; Body Weight; Child; | 2009 |
The yin and yang of paracetamol and paediatric immunisations.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Child; Fever; Humans; Immunity, Active; Mass Vaccination | 2009 |
Renal colic in adults: NSAIDs and morphine are effective for pain relief.
Topics: Acetaminophen; Adult; Analgesia; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Clinic | 2009 |
A/H1N1 flu pandemic. Fever as nature's engine?
Topics: Acetaminophen; Analgesics, Non-Narcotic; Body Temperature; Fever; Humans; Influenza A Virus, H1N1 Su | 2009 |
[44 year old gardener with lower back pain, myalgia and fever].
Topics: Acetaminophen; Adolescent; Adult; Age Factors; Analgesics, Non-Narcotic; Child; Clinical Trials as T | 2010 |
Adolescents with asthma or atopic eczema have more febrile days in early childhood: a possible explanation for the connection between paracetamol and asthma?
Topics: Acetaminophen; Adolescent; Analgesics, Non-Narcotic; Asthma; Child; Dermatitis, Atopic; Fever; Human | 2010 |
Antipyretic and antinociceptive properties of Mentha longifolia Huds. (Lamiaceae) leaf aqueous extract in rats and mice.
Topics: Acetaminophen; Analgesics; Analgesics, Non-Narcotic; Animals; Disease Models, Animal; Dose-Response | 2009 |
Paracetamol for feverish children: parental motives and experiences.
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Child; Cross-Sectional Studies; Drug Utilization; Ed | 2010 |
Can autism be triggered by acetaminophen activation of the endocannabinoid system?
Topics: Acetaminophen; Autistic Disorder; Cannabinoid Receptor Modulators; Child; Child, Preschool; Endocann | 2010 |
Paracetamol induced skin blood flow and blood pressure changes in febrile intensive care patients: An observational study.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Analysis of Variance; APACHE; Blood Flow Velocity; Blood Pr | 2010 |
Paracetamol induced skin blood flow and blood pressure changes in febrile intensive care patients: An observational study.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Analysis of Variance; APACHE; Blood Flow Velocity; Blood Pr | 2010 |
Paracetamol induced skin blood flow and blood pressure changes in febrile intensive care patients: An observational study.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Analysis of Variance; APACHE; Blood Flow Velocity; Blood Pr | 2010 |
Paracetamol induced skin blood flow and blood pressure changes in febrile intensive care patients: An observational study.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Analysis of Variance; APACHE; Blood Flow Velocity; Blood Pr | 2010 |
Treatment of pediatric fever: Are acetaminophen and ibuprofen equivalent?
Topics: Acetaminophen; Antipyretics; Child; Child, Preschool; Family Practice; Fever; Humans; Ibuprofen; Inf | 2010 |
An early rise in body temperature is related to unfavorable outcome after stroke: data from the PAIS study.
Topics: Acetaminophen; Aged; Antipyretics; Female; Fever; Humans; Male; Multicenter Studies as Topic; Random | 2011 |
Respiratory tract infections and not paracetamol medication during infancy are associated with asthma development in childhood.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Asthma; Child; Child, Preschool; Fever; Humans; Infant; Inf | 2010 |
Clinical management of fever by nurses: doing what works.
Topics: Acetaminophen; Acute Disease; Adult; Child; Clinical Competence; Decision Making; Evidence-Based Nur | 2011 |
Pediatric rash and joint pain: a case review.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Ankle Joint; Anti-Bacterial Agents; Arthralgia; Ceftriaxone | 2010 |
Does intravenous paracetamol administration affect body temperature in neonates?
Topics: Acetaminophen; Analgesics, Non-Narcotic; Birth Weight; Body Temperature; Cohort Studies; Drug Admini | 2011 |
Standardized antipyretic treatment in stroke: a pilot study.
Topics: Acetaminophen; Aged; Aged, 80 and over; Antipyretics; Body Temperature Regulation; Case-Control Stud | 2011 |
Effective fever control in acute stroke: still wanted!
Topics: Acetaminophen; Antipyretics; Body Temperature Regulation; Combined Modality Therapy; Dipyrone; Fever | 2011 |
Parental administration of antipyretics to children with upper respiratory tract infections without consultation with a physician.
Topics: Acetaminophen; Adolescent; Adult; Antipyretics; Child; Child Care; Child Day Care Centers; Child, Pr | 2011 |
The persistence of drug-induced fever by teicoplanin--a case report.
Topics: Acetaminophen; Anti-Bacterial Agents; Antipyretics; Cardiomyopathy, Dilated; Fever; Half-Life; Heart | 2011 |
Knowledge of using acetaminophen syrup and comprehension of written medication instruction among caregivers with febrile children.
Topics: Acetaminophen; Administration, Oral; Adult; Caregivers; Child; Child, Preschool; Cross-Sectional Stu | 2012 |
Hypotension with acetaminophen--maybe there is a different mechanism.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Blood Flow Velocity; Blood Pressure; Female; Fever; Humans; | 2011 |
Effects of high-dose paracetamol on blood pressure in acute stroke.
Topics: Acetaminophen; Aged; Aged, 80 and over; Antipyretics; Blood Pressure; Blood Pressure Determination; | 2012 |
A survey of teething beliefs and related practices among child healthcare workers in Ile-Ife, Nigeria.
Topics: Acetaminophen; Antipyretics; Attitude of Health Personnel; Child Health Services; Cross-Sectional St | 2011 |
OFIRMEV: a recently introduced drug.
Topics: Acetaminophen; Acute Pain; Analgesics; Antipyretics; Clinical Trials as Topic; Drug Approval; Fever; | 2011 |
Clinical and demographic factors associated with antipyretic use in gram-negative severe sepsis and septic shock.
Topics: Academic Medical Centers; Acetaminophen; Adult; Aged; Antipyretics; Bacteremia; Cohort Studies; Fema | 2011 |
Antipyretic therapy for influenza infection--benefit or harm?
Topics: Acetaminophen; Adult; Animals; Antipyretics; Child; Fever; Humans; Ibuprofen; Influenza, Human; Mice | 2011 |
Fever and antipyresis in infection.
Topics: Acetaminophen; Antipyretics; Fever; Humans; Immunity, Innate; Infections | 2011 |
Fever control in the NICU: is there still a simpler and cheaper solution?
Topics: Acetaminophen; Antipyretics; Fever; Humans; Ibuprofen; Intensive Care Units; Intracranial Hemorrhage | 2011 |
[Does paracetamol improve recovery after stroke?].
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Dose-Response Relationship, Drug; Fever; Hum | 2011 |
A survey of fever management for febrile intensive care patients without neurological injury.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Attitude of Health Personnel; Critical Illness; Fever; Heal | 2011 |
Assessment of the safety and feasibility of administering anti-pyretic therapy in critically ill adults: study protocol of a randomized trial.
Topics: Acetaminophen; Adolescent; Adult; Aged; Alberta; Antipyretics; Body Temperature; Critical Illness; D | 2012 |
[Hemodynamic and antipyretic effects of paracetamol, metamizol and dexketoprofen in critical patients].
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Antipyretics | 2012 |
Analgesic and antipyretic activities of ethanol extract of Stereospermum suaveolens.
Topics: Acetaminophen; Acetic Acid; Analgesics; Animals; Antipyretics; Behavior, Animal; Bignoniaceae; Disea | 2010 |
AAP reports on the use of antipyretics for fever in children.
Topics: Acetaminophen; Antipyretics; Child; Drug Therapy, Combination; Fever; Humans; Ibuprofen; Practice Gu | 2012 |
[Paracetamol or NSAID for relief treatment in febrile children].
Topics: Acetaminophen; Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Antipyretics; Child; D | 2012 |
[Ibuprofen is more effective than paracetamol in lowering the temperature in febrile children].
Topics: Acetaminophen; Analgesics, Non-Narcotic; Antipyretics; Child; Drug Therapy, Combination; Fever; Huma | 2012 |
Antipyretic, analgesic and anti-inflammatory activity of Viola betonicifolia whole plant.
Topics: Acetaminophen; Acetic Acid; Analgesics; Animals; Anti-Inflammatory Agents; Antipyretics; Behavior, A | 2012 |
Alternating acetaminophen and ibuprofen for pain in children.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Child; Child, Pres | 2012 |
Update of the 2009 Italian Pediatric Society Guidelines about management of fever in children.
Topics: Acetaminophen; Age Factors; Antipyretics; Axilla; Body Temperature; Child; Child, Preschool; Fever; | 2012 |
Knowledge of Iranian general practitioners for acetaminophen dosing in children.
Topics: Acetaminophen; Adult; Antipyretics; Child, Preschool; Cross-Sectional Studies; Female; Fever; Genera | 2012 |
Paracetamol use (and/or misuse) in children in Enugu, South-East, Nigeria.
Topics: Acetaminophen; Adolescent; Adult; Analgesics, Non-Narcotic; Caregivers; Child; Child, Preschool; Dru | 2012 |
Early antipyretic exposure does not increase mortality in patients with gram-negative severe sepsis: a retrospective cohort study.
Topics: Acetaminophen; Adult; Aged; Antipyretics; Female; Fever; Gram-Negative Bacterial Infections; Hospita | 2012 |
The HEAT trial: a protocol for a multicentre randomised placebo-controlled trial of IV paracetamol in ICU patients with fever and infection.
Topics: Acetaminophen; Administration, Intravenous; Adult; Antipyretics; Clinical Trials, Phase II as Topic; | 2012 |
Symptom to door interval in febrile neutropenia: perspective in India.
Topics: Acetaminophen; Antipyretics; Bacterial Infections; Child; Child, Preschool; Female; Fever; Hospitali | 2013 |
The majority of sick children receive paracetamol during the winter.
Topics: Acetaminophen; Antipyretics; Cohort Studies; Cold Temperature; Denmark; Female; Fever; Follow-Up Stu | 2012 |
Non-prescription medicines for pain and fever--a comparison of recommendations and counseling from staff in pharmacy and general sales stores.
Topics: Acetaminophen; Analgesics; Antipyretics; Aspirin; Child; Commerce; Contraindications; Counseling; Fe | 2013 |
Effects on fetal and maternal temperatures of paracetamol administration during labour: a case-control study.
Topics: Acetaminophen; Adult; Algorithms; Antipyretics; Axilla; Body Temperature; Case-Control Studies; Coho | 2013 |
Supratherapeutic dosing of acetaminophen among hospitalized patients.
Topics: Acetaminophen; Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Child; Confiden | 2012 |
Intramuscular injection of propacetamol in a neonate.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Fever; Humans; Infant, Newborn; Injections, Intramuscular | 2002 |
Body temperature in acute stroke.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Animals; Body Temperature; Disease Progression; Fever; Huma | 2002 |
Short report: parental knowledge of rectal acetaminophen.
Topics: Acetaminophen; Administration, Rectal; Adolescent; Adult; Child; Child, Preschool; Female; Fever; He | 2002 |
Antipyretic effect of nimesulide and paracetamol in children.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Child; Fever; Huma | 2002 |
Prehospital use of paracetamol among children attending the accident and emergency department.
Topics: Acetaminophen; Adolescent; Analgesics, Non-Narcotic; Child; Child, Preschool; Cohort Studies; Emerge | 2003 |
Evaluation of antipyretic activity of leaf extracts of Mallotus peltatus (Geist) Muell. arg. var acuminatus: a folk medicine.
Topics: Acetaminophen; Administration, Oral; Analgesics, Non-Narcotic; Animals; Body Temperature; Dose-Respo | 2002 |
Evaluation of anti-pyretic potential of Ficus racemosa bark.
Topics: Acetaminophen; Administration, Oral; Analgesics, Non-Narcotic; Animals; Body Temperature; Dose-Respo | 2002 |
Nimesulide vs. paracetamol: this trial needs to stand trial.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Child; Fever; Hosp | 2003 |
Evaluation of antipyretic potential of Cleome viscosa Linn. (Capparidaceae) extract in rats.
Topics: Acetaminophen; Administration, Oral; Analgesics, Non-Narcotic; Animals; Body Temperature; Cleome; Do | 2003 |
Paracetamol is the drug of choice for childhood pain and fever.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Child; Child, Preschool; Fever; Humans; Infant; Pain | 2003 |
[RECTAL USE OF NAPA AS ANTIPYRETIC IN PEDIATRICS].
Topics: Acetaminophen; Antipyretics; Bronchitis; Child; Drug Therapy; Fever; Gastroenteritis; Humans; Infant | 1964 |
Paracetamol for injection: new formulation. New formulation: why so widely used?
Topics: Acetaminophen; Adult; Child; Clinical Trials as Topic; Drug Approval; Fever; France; Humans; Infusio | 2003 |
Time to counter 'fever phobia'!
Topics: Acetaminophen; Analgesics, Non-Narcotic; Attitude to Health; Child; Fear; Fever; Humans; Parents | 2003 |
Childhood illnesses and the use of paracetamol (acetaminophen): a qualitative study of parents' management of common childhood illnesses.
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Attitude to Health; Child, Preschool; Family; Female | 2003 |
Fever phobia revisited.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Child, Preschool; Drug Therapy, Combination; Fever; Humans; | 2004 |
Antipyretic effect of acetaminophen by inhibition of glutamate release after staphylococcal enterotoxin A fever in rabbits.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Animals; Body Temperature; Disease Models, Animal; Dose-Res | 2004 |
Underdosing of acetaminophen by parents and emergency department utilization.
Topics: Acetaminophen; Adolescent; Analgesics, Non-Narcotic; Child; Child, Preschool; Cross-Sectional Studie | 2004 |
Severe traumatic head injury in adults: which patients are at risk of early hyperthermia?
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Body Temperature; Brain Injuries; Female; Fever; Hum | 2004 |
Acetaminophen dose accuracy and pediatric emergency care.
Topics: Acetaminophen; Administration, Oral; Administration, Rectal; Analgesics, Non-Narcotic; Anti-Inflamma | 2004 |
[The use of paracetamol and antibiotics among preschool children].
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Infective Agents; Bacterial Infections; Child, Prescho | 2004 |
[Paracetamol to preschool children--indications and cultural background].
Topics: Acetaminophen; Analgesics, Non-Narcotic; Attitude to Health; Child, Preschool; Cultural Characterist | 2004 |
Febrile nonhemolytic transfusion reactions. Management by premedication and cost implications in adult patients.
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Blood Transfusion; Costs and Cost Analysis; Fever; H | 2004 |
Ibuprofen or acetaminophen in children? As the debate continues, the evidence may favor ibuprofen.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Child; Fever; Huma | 2004 |
Reduction of body temperature with paracetamol in patients with acute stroke: randomised clinical trials are needed.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Fever; Hu | 2004 |
Hypothermia following fever.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Female; Fever; Humans; Hypothermia; Ibuprofen; Infant | 2004 |
Fever management: paediatric nurses' knowledge, attitudes and influencing factors.
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Attitude of Health Personnel; Child; Cross-Sectional | 2005 |
The use of folk remedies among children in an urban black community: remedies for fever, colic, and teething.
Topics: 2-Propanol; Acetaminophen; Adolescent; Adult; Age Factors; Anesthetics, Local; Baths; Benzocaine; Bl | 2005 |
[New solution of simultaneous equations in spectrophotometry for the determination of aspirin and acetaminophen in xiaoer tuishao pian].
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Fever; Spectrophotometry | 1999 |
Fever control in septic shock: beneficial or harmful?
Topics: Acetaminophen; Animals; Body Temperature; Body Weight; Female; Fever; HSP70 Heat-Shock Proteins; Iso | 2005 |
Paracetamol/acetaminophen-induced fever and malaise in a juvenile patient.
Topics: Acetaminophen; Adolescent; Analgesics, Non-Narcotic; Arthralgia; Female; Fever; Humans; Knee Joint | 2005 |
[Aspirin, paracetamol, ibuprofen: analgesics in the family medicine cabinet].
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Contraind | 2005 |
Fever in term labour.
Topics: Acetaminophen; Amniotic Fluid; Analgesia, Epidural; Female; Fever; Humans; Intensive Care, Neonatal; | 2005 |
Acetaminophen-induced anion gap metabolic acidosis and 5-oxoprolinuria (pyroglutamic aciduria) acquired in hospital.
Topics: Acetaminophen; Acid-Base Equilibrium; Acidosis; Adult; Analgesics, Non-Narcotic; Antineoplastic Comb | 2005 |
[Familial use of ibuprofen in febrile children: a prospective study in the emergency room of an hospital in Lille].
Topics: Acetaminophen; Adolescent; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Child; | 2005 |
PAIS: paracetamol (acetaminophen) in stroke; protocol for a randomized, double blind clinical trial [ISCRTN 74418480].
Topics: Acetaminophen; Analgesics, Non-Narcotic; Body Temperature; Clinical Protocols; Double-Blind Method; | 2005 |
Premedication with acetaminophen or diphenhydramine for transfusion with leucoreduced blood products in children.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Allergic Agents; Blood Component Removal; Blood Compon | 2005 |
Antipyretics and delirious behavior during febrile illness.
Topics: Acetaminophen; Adolescent; Analgesics, Non-Narcotic; Child; Child, Preschool; Delirium; Diclofenac; | 2006 |
Use and misuse of aspirin in rural Ethiopia.
Topics: Acetaminophen; Adolescent; Adult; Aged; Aspirin; Child; Cross-Sectional Studies; Ethiopia; Female; F | 2006 |
A Friday afternoon case of apparent anti-glomerular basement nephritis.
Topics: Acetaminophen; Acute Kidney Injury; Analgesics; Animals; Anti-Glomerular Basement Membrane Disease; | 2006 |
Immunizations. Can fever-reducers prevent redness from DTP shots?
Topics: Acetaminophen; Anti-Inflammatory Agents; Child; Diphtheria-Tetanus-Pertussis Vaccine; Drug Eruptions | 2006 |
[Change in habits among the population in the management of childhood fever].
Topics: Acetaminophen; Child; Child, Preschool; Fever; Habits; Humans; Ibuprofen; Infant | 2006 |
The effects of a complex homeopathic medicine compared with acetaminophen in the symptomatic treatment of acute febrile infections in children: an observational study.
Topics: Acetaminophen; Acute Disease; Analgesics, Non-Narcotic; Analysis of Variance; Body Temperature; Chil | 2005 |
Antipyretic drugs for children.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Child; Drug Combinations; Fever; Humans; Ibuprofen | 2006 |
Alternating acetaminophen and ibuprofen in children may cause parental confusion and is dangerous.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Child; Child, Preschool; Confusion; Drug Administration Sch | 2006 |
Concerns over alternating acetaminophen and ibuprofen for fever.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Child; Confusion; Drug Therapy, Combination; Fever; Humans; | 2006 |
Determinants of antipyretic misuse in children up to 5 years of age: a cross-sectional study.
Topics: Acetaminophen; Administration, Oral; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroid | 2006 |
Synthesis of new chemical entities from paracetamol and NSAIDs with improved pharmacodynamic profile.
Topics: Acetaminophen; Analgesics; Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroida | 2006 |
Relationship between antipyretic effects and cytokine levels in uncomplicated falciparum malaria during different treatment regimes.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Animals; Antimalarials; Child, Preschool; Chloroquine; Cyto | 2006 |
Severity of illness and the use of paracetamol in febrile preschool children; a case simulation study of parents' assessments.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Appetite; Body Temperature; Child, Preschool; Decision Maki | 2006 |
Fulminant hepatic failure and paracetamol overuse with therapeutic intent in febrile children.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Case-Control Studies; Child; Child, Preschool; Drug Overdos | 2006 |
Natural course of fever during influenza virus infection in children.
Topics: Acetaminophen; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Child; Female; Fever; | 2007 |
Tramadol infusion for the pain management in sickle cell disease: a case report.
Topics: Abdominal Pain; Acetaminophen; Analgesics, Non-Narcotic; Analgesics, Opioid; Anemia, Sickle Cell; Ch | 2007 |
Fever after subarachnoid hemorrhage: risk factors and impact on outcome.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Body Temperature; Brain; Cerebral Hemorrhage; Cognition Dis | 2007 |
Alternating antipyretics for fever reduction in children: an unfounded practice passed down to parents from pediatricians.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Child, Preschool; Drug Administration Schedule; Fever; Heal | 2007 |
Dipyrone and acetaminophen: correct dosing by parents?
Topics: Acetaminophen; Adult; Age Distribution; Anti-Inflammatory Agents, Non-Steroidal; Brazil; Dipyrone; D | 2007 |
The time course and determinants of temperature within the first 48 h after ischaemic stroke.
Topics: Acetaminophen; Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Bacterial Infec | 2007 |
Antipyretic drug use in children in French office based medical practice.
Topics: Acetaminophen; Age Factors; Analgesics, Non-Narcotic; Aspirin; Child; Child, Preschool; Drug Therapy | 2007 |
Preoptic nitric oxide attenuates endotoxic fever in guinea pigs by inhibiting the POA release of norepinephrine.
Topics: Acetaminophen; Adrenergic alpha-Antagonists; Animals; Body Temperature; Catheterization; Cyclooxygen | 2007 |
Preoptic norepinephrine mediates the febrile response of guinea pigs to lipopolysaccharide.
Topics: Acetaminophen; Adrenergic alpha-Antagonists; Animals; Body Temperature; Catheterization; Cyclooxygen | 2007 |
Over-the-counter medication use for childhood fever: a cross-sectional study of Australian parents.
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Child, Preschool; Cross-Sectional Studies; Female; F | 2007 |
Simultaneous sudden infant death syndrome.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Brain; Diphtheria-Tetanus-Pertussis Vaccine; Female; Fever; | 2007 |
Alternating acetaminophen with ibuprofen for fever: is this a problem?
Topics: Acetaminophen; Analgesics, Non-Narcotic; Child, Preschool; Drug Therapy, Combination; Fever; Humans; | 2007 |
Acetaminophen for temperature reduction in acute stroke: potential but unproven benefits.
Topics: Acetaminophen; Acute Disease; Analgesics, Non-Narcotic; Body Temperature; Clinical Trials as Topic; | 2007 |
Question from the clinician: alternating acetaminophen and ibuprofen in the treatment of fever.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Child; Drug Administration Schedule; Drug Therapy, Combinat | 2007 |
Antipyretic treatment of noninfectious fever in children with severe traumatic brain injury.
Topics: Acetaminophen; Age Factors; Analgesics, Non-Narcotic; Brain Injuries; Child; Child, Preschool; Dose- | 2008 |
[Chikungunya: fever and joint pains after vacation in a tropical area].
Topics: Acetaminophen; Adult; Alphavirus Infections; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Infl | 2008 |
A 2-year-old boy with fever and altered mental status.
Topics: Acetaminophen; Child, Preschool; Contraindications; Diagnosis, Differential; Fever; Humans; Intensiv | 2008 |
When the child has a fever.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Child; Diagnosis, Differential; Fever; Humans; Ibuprofen; P | 2008 |
Recurrent fever, chills, and arthralgia with local anesthetics containing epinephrine-metabisulfite.
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Anesthetics, Local; Arthralgia; Carticaine; Chills; | 2008 |
Clinical comparison of three antipyretic agents.
Topics: Acetaminophen; Aspirin; Body Temperature; Child, Preschool; Female; Fever; Humans; Infant; Male; Sal | 1967 |
Hyperpyrexia, allergic-type response and death occurring with low-dose bleomycin administration.
Topics: Acetaminophen; Aged; Bleomycin; Dexamethasone; Dose-Response Relationship, Drug; Drug Hypersensitivi | 1980 |
Parents' conception of their use of over-the-counter medicines.
Topics: Acetaminophen; Aspirin; Child, Preschool; Fever; Humans; Infant; Infant, Newborn; Nasal Decongestant | 1982 |
[Paracetamol in oral solution: effectiveness against fever and tolerance in children with measles (author's transl)].
Topics: Acetaminophen; Administration, Oral; Child; Child, Preschool; Female; Fever; Humans; Male; Measles; | 1982 |
Cold comfort for hot children.
Topics: Acetaminophen; Aspirin; Child; Child, Preschool; Fever; Humans; Infant; Reye Syndrome | 1983 |
Comparative study of the antipyretic effect of ibuprofen (oral suspension) and paracetamol (suppositories) in paediatrics.
Topics: Acetaminophen; Administration, Oral; Body Temperature; Child; Child, Preschool; Female; Fever; Human | 1984 |
Fever therapy failure.
Topics: Acetaminophen; Child; Fever; Humans | 1984 |
Pediatric dosing of acetaminophen.
Topics: Acetaminophen; Child; Child, Preschool; Fever; Humans | 1984 |
Antipyretic potency of centrally administered alpha-melanocyte stimulating hormone.
Topics: Acetaminophen; Animals; Anti-Inflammatory Agents, Non-Steroidal; Body Temperature; Dose-Response Rel | 1983 |
[Problems with fever in children].
Topics: Acetaminophen; Aspirin; Child; Child, Preschool; Fever; Humans; Infant | 1983 |
House officer management of the febrile child. A survey.
Topics: Acetaminophen; Aspirin; Brain Damage, Chronic; Fever; Humans; Infant; Seizures; Surveys and Question | 1983 |
[Acetaminophen poisoning in children: a serious error in medical prescription].
Topics: Acetaminophen; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Fever; Humans; Iatro | 1983 |
[Antipyretic effect of an oral solution of paracetamol in children].
Topics: Acetaminophen; Administration, Oral; Age Factors; Child; Fever; Humans; Solutions | 1983 |
Pediatric dosing of acetaminophen.
Topics: Acetaminophen; Age Factors; Body Weight; Child; Child, Preschool; Dose-Response Relationship, Drug; | 1983 |
Acetaminophen: a practical pharmacologic overview.
Topics: Acetaminophen; Adolescent; Adult; Child; Child, Preschool; Fever; Humans; Infant; Kidney; Liver; Met | 1984 |
[Antipyretic effect of the oral paracetamol solution in children].
Topics: Acetaminophen; Administration, Oral; Child, Preschool; Female; Fever; Humans; Infant; Male | 1984 |
The treatment of fever.
Topics: Acetaminophen; Adult; Animals; Anti-Inflammatory Agents, Non-Steroidal; Child; Fever; Humans; Salicy | 1981 |
Efficacy, disposition and pharmacodynamics of aspirin, acetaminophen and choline salicylate in young febrile children.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Child; Child, Preschool; Choline; D | 1982 |
Why not use acetaminophen for fever?
Topics: Acetaminophen; Child; Fever; Humans; Reye Syndrome | 1982 |
Acetaminophen and aspirin. Prescription, use, and accidental ingestion among children.
Topics: Acetaminophen; Adolescent; Aspirin; Child; Child, Preschool; Drug Prescriptions; Drug Utilization; F | 1982 |
[Control of hyperthermia in young children with paracetamol oral solution].
Topics: Acetaminophen; Administration, Oral; Child; Child, Preschool; Female; Fever; Humans; Male | 1982 |
[Paracetamol, pharmacodynamic, clinical toxicology and pharmacokinetic].
Topics: Acetaminophen; Dose-Response Relationship, Drug; Fever; Half-Life; Humans; Intestinal Absorption; Ki | 1982 |
Febrile children and antipyretic drugs.
Topics: Acetaminophen; Child; Fever; Home Nursing; Humans | 1982 |
[Comparative study of the antipyretic effect of paracetamol and aminophenazone administered by the rectal route].
Topics: Acetaminophen; Adult; Aminopyrine; Fever; Humans; Rectum; Suppositories | 1980 |
Incorrect dosage of acetaminophen.
Topics: Acetaminophen; Child, Preschool; Fever; Humans; Infant | 1980 |
Risk factors for a first febrile seizure: a matched case-control study.
Topics: Acetaminophen; Acute Disease; Case-Control Studies; Comorbidity; Female; Fever; Gastroenteritis; Hum | 1995 |
Paracetamol in childhood illness.
Topics: Acetaminophen; Adolescent; Child; Child, Preschool; Fever; Humans; Infant; Surveys and Questionnaire | 1995 |
[Reduction of antipyretics. A gentler way to reduce fever with lemon compresses along with administration of paracetamol].
Topics: Acetaminophen; Bandages; Citrus; Fever; Humans | 1995 |
Effect of a standardized rewarming protocol and acetaminophen on core temperature after coronary artery bypass.
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Body Temperature; Clinical Protocols; Coronary Artery | 1995 |
Fever response to acetaminophen.
Topics: Acetaminophen; Bacteremia; Child; Cohort Studies; Fever; Humans; Research Design | 1995 |
[Acetaminophen-containing suppositories in vitro and in vivo].
Topics: Acetaminophen; Animals; Diffusion; Fever; Male; Rats; Rats, Wistar; Suppositories | 1994 |
[Paracetamol].
Topics: Acetaminophen; Fever; Humans; Pain | 1994 |
Diagnostic tests for occult bacteremia: temperature response to acetaminophen versus WBC count.
Topics: Acetaminophen; Bacteremia; Body Temperature; Child; Child, Preschool; Cohort Studies; Emergency Serv | 1994 |
Preischemic hyperglycemia leads to delayed postischemic hyperthermia.
Topics: Acetaminophen; Animals; Body Temperature Regulation; Brain Ischemia; Fever; Glucose; Hypercapnia; Hy | 1994 |
[Reduced erythrocyte glutathione and urinary thioethers in children undergoing treatment with paracetamol].
Topics: Acetaminophen; Child; Child, Preschool; Erythrocytes; Female; Fever; Glutathione; Humans; Infant; Ma | 1993 |
Vasopressin release within the ventral septal area of the rat brain during drug-induced antipyresis.
Topics: Acetaminophen; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arginine Vasopressin; Fever; Indome | 1993 |
Correlating changes in body temperature with infectious outcome in febrile children who receive acetaminophen.
Topics: Acetaminophen; Administration, Oral; Age Factors; Bacteremia; Body Temperature; Child, Preschool; Fe | 1993 |
Effect of malaria infection and endotoxin-induced fever on phenacetin O-deethylation by rat liver microsomes.
Topics: Acetaminophen; Animals; Cytochrome P-450 CYP1A2; Cytochrome P-450 Enzyme System; Disease Models, Ani | 1993 |
Is prescribing paracetamol 'pro re nata' acceptable?
Topics: Acetaminophen; Child; Child, Preschool; Drug Administration Schedule; Drug Utilization; Fever; Human | 1993 |
Fulminant hepatitis associated with centrilobular hepatic necrosis in young children.
Topics: Acetaminophen; Child, Preschool; Female; Fever; Hepatic Encephalopathy; Humans; Infant; Liver; Male; | 1995 |
Antipyretics induced erythema multiforme.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Child; Child, Preschool; Dipyrone; Erythema Multiforme; Fem | 1995 |
Supportive care during aldesleukin therapy for patients infected with human immunodeficiency virus.
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Antiemetics; Female; Fever; HIV Infections; Humans; | 1997 |
Managing measles. Giving paracetamol for fever is unnecessary.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Fever; Humans; Measles | 1997 |
[The physiological properties of the action of a new analgesic and antipyretic preparation].
Topics: Acetaminophen; Acetic Acid; Analgesics, Non-Narcotic; Animals; Anti-Inflammatory Agents, Non-Steroid | 1997 |
Over-the-counter medications. Do parents give what they intend to give?
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Child; Female; Fever; Health Education; Humans; Male | 1997 |
Ibuprofen and/or acetaminophen: what price for "euthermia"?
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Body Temperature; | 1997 |
Ibuprofen and/or acetaminophen: what price for "euthermia"?
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Chemistry, Pharmac | 1997 |
Rectal paracetamol dosing regimens: determination by computer simulation.
Topics: Acetaminophen; Administration, Rectal; Adolescent; Analgesics, Non-Narcotic; Biological Availability | 1997 |
[The use of the preparation Solpadeine in dental practice].
Topics: Acetaminophen; Adolescent; Adult; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Caff | 1997 |
Protection against hepatotoxicity by a single dose of amphetamine: the potential role of heat shock protein induction.
Topics: Acetaminophen; Amphetamine; Animals; Bromobenzenes; Carbon Tetrachloride; Chemical and Drug Induced | 1997 |
[Fatal acute liver damage caused by a therapeutic dose of paracetamol].
Topics: Acetaminophen; Adolescent; Chemical and Drug Induced Liver Injury; Child, Preschool; Dose-Response R | 1998 |
Variability of concentrations after rectal paracetamol.
Topics: Acetaminophen; Administration, Oral; Administration, Rectal; Adult; Analgesics, Non-Narcotic; Child; | 1998 |
Acetaminophen: a clarification.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Child; Fever; Huma | 1998 |
Combined antipyretic therapy: another potential source of chronic acetaminophen toxicity.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Child; Chronic Disease; Drug Interactions; Drug Therapy, Co | 1998 |
Reducing temperature in febrile children.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Child, Preschool; Fever; Humans | 1998 |
Paracetamol for fever in children: high time for systematic reviews of the evidence.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Chemical and Drug Induced Liver Injury; Child; Evidence-Bas | 1999 |
What we should know about paracetamol.
Topics: Acetaminophen; Administration, Oral; Administration, Rectal; Analgesics, Non-Narcotic; Blood-Brain B | 1999 |
Parental guidance suggested. Pediatric fever and pain relief require expert input.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Child; Child, Preschool; Education; Fever; Humans; Ibuprofe | 1999 |
Antipyretic efficacy of aspirin or acetaminophen.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Aspirin; Drug Storage; Fever; Humans; Lipopolysaccharides; | 2000 |
Toxic epidermal necrolysis associated with acetaminophen ingestion.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Child; Female; Fever; Humans; Stevens-Johnson Syndrome | 2000 |
Physical treatment of fever.
Topics: Acetaminophen; Adolescent; Analgesics, Non-Narcotic; Child; Child, Preschool; Combined Modality Ther | 2000 |
Parental knowledge of the treatment of fever in children.
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Child; Child, Preschool; Cross-Sectional Studies; Di | 1999 |
[Acetaminophen should remain the first choice drug for the treatment of fever in children].
Topics: Acetaminophen; Analgesics, Non-Narcotic; Child; Fever; Humans; Practice Guidelines as Topic | 2000 |
Ibuprofen treatment versus gradual introduction of interferon beta-1b in patients with MS.
Topics: Acetaminophen; Drug Administration Schedule; Fever; Humans; Hypothalamus; Ibuprofen; Interferon beta | 2000 |
Effect of antipyretic therapy on the duration of illness in experimental influenza A, Shigella sonnei, and Rickettsia rickettsii infections.
Topics: Acetaminophen; Adolescent; Adult; Analgesics, Non-Narcotic; Aspirin; Dysentery, Bacillary; Female; F | 2000 |
Invasive group A streptococcal infection and nonsteroidal antiinflammatory drug use among children with primary varicella.
Topics: Acetaminophen; Adolescent; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Case-C | 2001 |
Toxicity of over-the-counter cough and cold medications.
Topics: Acetaminophen; Antitussive Agents; Bradycardia; Brompheniramine; Cardiovascular Diseases; Child, Pre | 2001 |
Alternating antipyretics: is this an alternative?
Topics: Acetaminophen; Acute Kidney Injury; Analgesics, Non-Narcotic; Cyclooxygenase Inhibitors; Drug Synerg | 2001 |
[Use of alternating antipyretics in the treatment of fever in Spain].
Topics: Acetaminophen; Analgesics, Non-Narcotic; Child; Child, Preschool; Fever; Humans; Ibuprofen; Infant; | 2001 |
Programmable microchip monitoring of post-stroke pyrexia: effects of aspirin and paracetamol on temperature and infarct size in the rat.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; | 2002 |
Modification of body temperature after acute stroke: a new concept needed?
Topics: Acetaminophen; Acute Disease; Body Temperature; Double-Blind Method; Fever; Humans; Hypothermia; Str | 2002 |
Fever phobia.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Attitude to Health; Child; Fever; Humans; Infant; Parents; | 2002 |
PISA. The effect of paracetamol (acetaminophen) and ibuprofen on body temperature in acute stroke: protocol for a phase II double-blind randomised placebo-controlled trial [ISRCTN98608690].
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Body Temperature; Clinical Trials, Phase II | 2002 |
A prospective study of multiple supratherapeutic acetaminophen doses in febrile children.
Topics: Acetaminophen; Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Child; Child, Preschool; Cohort | 2002 |
Tepid sponging and paracetamol for reduction of body temperature in febrile children.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Baths; Child; Evidence-Based Medicine; Fever; Humans; Treat | 2002 |
Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
Topics: Acetaminophen; Administration, Oral; Albumins; Analgesics, Non-Narcotic; Aspirin; Canada; Case-Contr | 2002 |
[Severe Reye syndrome: report of 14 cases managed in a pediatric intensive care unit over 11 years].
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Edema; Child; Child, Preschoo | 2002 |
Oral antipyretic therapy: evaluation of benorylate, an ester of acetylsalicylic acid and paracetamol.
Topics: Acetaminophen; Aspirin; Body Temperature; Child; Child, Preschool; Fever; Humans; Infant; Salicylate | 1975 |
Fever and antipyresis in the bluegill sunfish, Lepomis macrochirus.
Topics: Acetaminophen; Aeromonas; Animals; Body Temperature; Body Temperature Regulation; Fever; Fishes | 1977 |
Fever produced in the squirrel monkey by human leukocytic pyrogen.
Topics: Acetaminophen; Animals; Fever; Haplorhini; Humans; Injections, Intravenous; Leukocytes; Male; Pyroge | 1979 |
Cyclic adenosine-3',5'-monophosphate in cerebrospinal fluid during fever and antipyresis.
Topics: Acetaminophen; Animals; Antigens, Bacterial; Cats; Cyclic AMP; Fever; Shigella dysenteriae | 1975 |
Evidence for the involvement of adenosine 3',5'-cyclic monophosphate in fever genesis.
Topics: Acetaminophen; Animals; Brain; Cyclic AMP; Female; Fever; Hypothalamus; Injections, Intraventricular | 1976 |
Cyclic adenosine 3', 5'-monophosphate in cerebrospinal fluid during thermoregulation and fever.
Topics: Acetaminophen; Animals; Body Temperature Regulation; Cats; Cold Temperature; Cyclic AMP; Female; Fev | 1976 |
Hyperthermia, antipyretics and function of polymorphonuclear leukocytes.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Bacterial Infections; Chemotaxis, Leukocyte; | 1978 |
Antipyretic effect of acetaminophen suppositories in rats.
Topics: Acetaminophen; Animals; Anti-Inflammatory Agents, Non-Steroidal; Fever; Male; Rats; Rectum; Supposit | 1979 |
[The antipyretic effect of Lonarid N in children].
Topics: Acetaminophen; Amobarbital; Caffeine; Child; Child, Preschool; Codeine; Drug Combinations; Drug Eval | 1979 |
Hyperthermia and rhabdomyolysis in self-poisoning with paracetamol and salicylates. Report of a case.
Topics: Acetaminophen; Adult; Female; Fever; Humans; Muscles; Muscular Diseases; Myoglobinuria; Necrosis; Sa | 1979 |
Antipyretic effect and plasma concentrations of rectal acetaminophen and diazepam in children.
Topics: Acetaminophen; Body Temperature; Child; Child, Preschool; Diazepam; Drug Therapy, Combination; Fever | 1979 |
Increase in body temperature during carrageenin-induced paw oedema in the rat. Effect of non-steroid anti-inflammatory substances and essential fatty acid deficiency.
Topics: Acetaminophen; Aging; Animals; Anti-Inflammatory Agents; Brain Chemistry; Carrageenan; Edema; Fatty | 1979 |
Oral antipyretic therapy. Evaluation of mefenamic acid (short communication).
Topics: Acetaminophen; Adolescent; Aminopyrine; Aspirin; Child; Child, Preschool; Drug Evaluation; Fever; Hu | 1977 |
[Investigations concerning temperature and serum concentrations of paracetamol in febrile infants following rectal application of paracetamol (author's transl)].
Topics: Acetaminophen; Body Temperature; Child, Preschool; Fever; Humans; Infant; Rectum; Suppositories; Tim | 1978 |
Effects of hyperbaric helium-oxygen on the antipyretic actions of aspirin and acetaminophen in rats.
Topics: Acetaminophen; Animals; Aspirin; Atmospheric Pressure; Fever; Helium; Hyperbaric Oxygenation; Oxygen | 1978 |
[Symptomatic antipyretic and analgesic treatment with Verlapyrin in children].
Topics: Acetaminophen; Child; Child, Preschool; Diphenhydramine; Drug Combinations; Drug Evaluation; Fever; | 1978 |
[Clinical effect of rectal application of paracetamol in childhood (author's transl)].
Topics: Acetaminophen; Body Temperature; Child; Child, Preschool; Fever; Humans; Infant; Suppositories | 1977 |
Oral antipyretic therapy.
Topics: Acetaminophen; Administration, Oral; Aminopyrine; Aspirin; Child; Child, Preschool; Drug Evaluation; | 1976 |
Antagonism by antipyretics of the hyperthermic effect of a prostaglandin precursor, sodium arachidonate, in the cat.
Topics: Acetaminophen; Analgesics; Animals; Arachidonic Acids; Body Temperature; Cats; Fever; Indomethacin; | 1976 |
[Investigations concerning serum concentration and temperature following oral application of a new paracetamol preparation (author's transl)].
Topics: Acetaminophen; Body Temperature; Child; Child, Preschool; Fever; Humans; Infant | 1976 |
Acetaminophen toxicosis in the cat.
Topics: Acetaminophen; Administration, Oral; Anemia; Animals; Bilirubin; Blood Urea Nitrogen; Cat Diseases; | 1975 |
Prostaglandins, endotoxin and lipid A on body temperature in rats.
Topics: Acetaminophen; Animals; Body Temperature; Cerebral Ventricles; Endotoxins; Female; Fever; Indomethac | 1975 |
Fever in childhood.
Topics: Acetaminophen; Aspirin; Child; Fever; Humans | 1976 |
Diencephalic efflux of 22Na+ and 45Ca2+ ions in the febrile cat: effect of an antipyretic.
Topics: Acetaminophen; Animals; Calcium; Cats; Diencephalon; Female; Fever; Hypothermia; Male; Pyrogens; Sal | 1976 |
[Monotherapy and treatment of fever in children].
Topics: Acetaminophen; Aspirin; Child; Drug Administration Schedule; Fever; Humans | 1992 |
Drugs for childhood fever.
Topics: Acetaminophen; Child; Contraindications; Fever; Humans; Ibuprofen | 1992 |
[Is the use of antipyretics justified in lowering fever and preventing febrile convulsions in children?].
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Child; Fever; Humans; Seizures, Febrile | 1992 |
[A combination of two antipyretic agents, is it adequate for the treatment of hyperthermia in pediatric patients?].
Topics: Acetaminophen; Age Factors; Aspirin; Child; Drug Therapy, Combination; Fever; Humans | 1992 |
Single-dose pharmacokinetics of ibuprofen and acetaminophen in febrile children.
Topics: Acetaminophen; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration Schedu | 1992 |
Antipyretics in febrile children.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Child; Fever; Humans | 1991 |
Management of childhood fever.
Topics: Acetaminophen; Child; Fever; Humans; Ibuprofen | 1991 |
Management of childhood fever.
Topics: Acetaminophen; Aspirin; Child; Fever; Humans; Ibuprofen | 1991 |
[The treatment of a high fever in young children at the prehospital stage].
Topics: Acetaminophen; Acute Disease; Combined Modality Therapy; Communicable Diseases; Cryotherapy; Dipyron | 1991 |
Appropriate dosage of acetominophen for infants.
Topics: Acetaminophen; Body Weight; Fever; Humans; Infant; Infant, Newborn; Reference Books, Medical | 1991 |
Guidelines for the care of children and adolescents with HIV infection. Management of the HIV-positive child with fever.
Topics: Acetaminophen; Acquired Immunodeficiency Syndrome; Child; Fever; HIV Infections; HIV Seropositivity; | 1991 |
[Antipyretic therapy in pediatrics].
Topics: Acetaminophen; Aspirin; Child; Child, Preschool; Fever; Humans; Infant | 1990 |
[Antipyretic action of aniline derivatives in rats during different parts of the day].
Topics: Acetaminophen; Animals; Circadian Rhythm; Fever; Male; Phenacetin; Phenetidine; Rats; Rats, Inbred S | 1990 |
[Paralen suppositories for children--a new therapeutic form of antipyretic].
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Child; Fever; Humans; Suppositories | 1990 |
Efficacy of sponging vs. acetaminophen for reduction of fever.
Topics: Acetaminophen; Baths; Child; Fever; Humans | 1990 |
Antipyretic orders in a university hospital.
Topics: Acetaminophen; Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Child; Child, Preschool; | 1990 |
[Use of acetaminophen in the community].
Topics: Acetaminophen; Child, Preschool; Dosage Forms; Drug Administration Schedule; Fever; Health Education | 1990 |
Central vasopressin V1-blockade prevents salicylate but not acetaminophen antipyresis.
Topics: Acetaminophen; Animals; Arginine Vasopressin; Brain; Endotoxins; Fever; Male; Rats; Rats, Inbred Str | 1990 |
Efficacy of sponging vs. acetaminophen for reduction of fever.
Topics: Acetaminophen; Baths; Child; Fever; Humans | 1990 |
Dangers from use of paracetamol.
Topics: Acetaminophen; Child; Fever; Humans | 1990 |
Using acetaminophen in infants.
Topics: Acetaminophen; Bacterial Infections; Fever; Humans; Infant | 1990 |
Trends in the incidence of Reye's syndrome and the use of aspirin.
Topics: Acetaminophen; Aspirin; Child; Child, Preschool; Female; Fever; Humans; Incidence; Infant; Male; Rey | 1990 |
Antipyretic effect of central alpha-MSH summates with that of acetaminophen or ibuprofen.
Topics: Acetaminophen; alpha-MSH; Animals; Anti-Inflammatory Agents, Non-Steroidal; Drug Combinations; Femal | 1989 |
Ibuprofen vs acetaminophen in children.
Topics: Acetaminophen; Child; Drug Overdose; Fever; Humans; Ibuprofen; Pain; Suspensions | 1989 |
[Paracetamol].
Topics: Acetaminophen; Fever; Humans; Pain | 1989 |
Severity of disease correlated with fever reduction in febrile infants.
Topics: Acetaminophen; Body Temperature; Fever; Haemophilus Infections; Haemophilus influenzae; Humans; Infa | 1989 |
Ibuprofen: an alternative for children's fevers.
Topics: Acetaminophen; Child; Child, Preschool; Fever; Humans; Ibuprofen | 1989 |
Paracetamol suppositories: a comparative study.
Topics: Acetaminophen; Adolescent; Child; Child, Preschool; Fever; Humans; Infant; Postoperative Complicatio | 1989 |
Fever. What to do and what not to do.
Topics: Acetaminophen; Acute-Phase Reaction; Aspirin; Body Temperature Regulation; Cold Temperature; Fever; | 1988 |
Paracetamol for fever in children.
Topics: Acetaminophen; Drug Administration Schedule; Fever; Humans | 1988 |
Are we sweeping DTP contraindications under the rug?
Topics: Acetaminophen; Child; Diphtheria Toxoid; Diphtheria-Tetanus-Pertussis Vaccine; Drug Combinations; Fe | 1988 |
FS 205-397: a new antipyretic analgesic with a paracetamol-like profile of activity but lack of acute hepatotoxicity in mice.
Topics: Acetaminophen; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Infectious; Disease Mode | 1988 |
Influence of ascorbic acid esters on acetaminophen-induced hepatotoxicity in mice.
Topics: Acetaminophen; Animals; Anti-Inflammatory Agents, Non-Steroidal; Ascorbic Acid; Body Weight; Drug Th | 1988 |
Acetaminophen (paracetamol) in the management of burned children with fever.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Burns; Child, Preschool; Female; Fever; Huma | 1988 |
Preadmission antipyretics in Reye's syndrome.
Topics: Acetaminophen; Adolescent; Aspirin; Child; Child, Preschool; Fever; Hospitalization; Humans; Infant; | 1988 |
Eugenol: antipyretic activity in rabbits.
Topics: Acetaminophen; Animals; Anti-Inflammatory Agents, Non-Steroidal; Dose-Response Relationship, Drug; E | 1987 |
Childhood fever: correlation of diagnosis with temperature response to acetaminophen.
Topics: Acetaminophen; Bacterial Infections; Body Temperature; Child; Child, Preschool; Drug Evaluation; Fem | 1987 |
Underdosing of acetaminophen by parents.
Topics: Acetaminophen; Age Factors; Body Weight; Child, Preschool; Fever; Humans; Infant; Medication Errors; | 1987 |
Effect of febrile illness and its treatment on anticonvulsant levels in children.
Topics: Acetaminophen; Anti-Bacterial Agents; Anticonvulsants; Child; Drug Interactions; Fever; Humans; Kine | 1986 |
Use of aspirin and Reye's syndrome.
Topics: Acetaminophen; Aspirin; Child; Fever; Humans; Reye Syndrome | 1987 |
Temperature response to antipyretic therapy in children: relationship to occult bacteremia.
Topics: Acetaminophen; Aspirin; Body Temperature; Child, Preschool; Fever; Haemophilus Infections; Haemophil | 1985 |
Fever: to treat or not to treat.
Topics: Acetaminophen; Aspirin; Child; Fever; Humans; Ibuprofen; Interleukin-1; Reye Syndrome | 1985 |
Decreasing trends in Reye syndrome and aspirin use in Michigan, 1979 to 1984.
Topics: Acetaminophen; Aspirin; Child; Common Cold; Fever; Humans; Michigan; Reye Syndrome | 1986 |
Kawasaki disease: review of risk factors for coronary aneurysms.
Topics: Acetaminophen; Age Factors; Aneurysm; Child; Child, Preschool; Coronary Disease; Female; Fever; Huma | 1986 |
Evaluation of sponging to reduce body temperature in febrile children.
Topics: Acetaminophen; Aspirin; Baths; Child, Preschool; Fever; Humans; Infant; Male | 1985 |
Antipyretic use among children during the 1983 influenza season.
Topics: Acetaminophen; Adolescent; Adult; Aspirin; Chickenpox; Child; Child, Preschool; Female; Fever; Healt | 1985 |
[Fever in the infant].
Topics: Acetaminophen; Aspirin; Body Temperature; Body Temperature Regulation; Drug Therapy, Combination; Fe | 1985 |
Absence of a pharmacokinetic interaction between chloramphenicol and acetaminophen in children.
Topics: Acetaminophen; Age Factors; Body Temperature; Child, Preschool; Chloramphenicol; Chromatography, Hig | 1985 |
Treatment of fever in burned children. A therapeutic program.
Topics: Acetaminophen; Adrenergic alpha-Antagonists; Burns; Child; Child, Preschool; Chlorpromazine; Fever; | 1973 |
Further studies on the role of prostaglandin in fever.
Topics: Acetaminophen; Animals; Body Temperature; Calcium; Cats; Cerebral Ventricles; Cerebrospinal Fluid; C | 1974 |
The hyperthermic effect of intracerebroventricular cholera enterotoxin in the unanaesthetized cat.
Topics: Acetaminophen; Animals; Body Temperature; Bucladesine; Cats; Cerebral Ventricles; Consciousness; Cyc | 1974 |
[Paidipyrin--a phenacetin free antipyretic for children].
Topics: Acetaminophen; Analgesics; Child; Child, Preschool; Fever; Humans; Infant; Urea | 1967 |
[Antipyresis in pediatrics].
Topics: Acetaminophen; Analgesics; Child, Preschool; Diphenylacetic Acids; Drug Combinations; Fever; Humans; | 1972 |
Proceedings: Lipid A and prostaglandin.
Topics: Acetaminophen; Animals; Aspirin; Cats; Endotoxins; Fever; Indomethacin; Lipids; Prostaglandins | 1974 |
Pyrogen fever and prostaglandin-like activity in cerebrospinal fluid.
Topics: Acetaminophen; Animals; Antigens, Bacterial; Biological Assay; Body Temperature; Cats; Fever; Lyserg | 1973 |
Effect of pyrogen and antipyretics on prostaglandin acitvity in cisternal c.s.f. of unanaesthetized cats.
Topics: Acetaminophen; Animals; Aspirin; Body Temperature; Cats; Cerebral Ventricles; Chromatography, Thin L | 1973 |
[Clinical experiences with a new analgetic-antipyretic drug combination in pediatrics].
Topics: Acetaminophen; Child; Child, Preschool; Dextropropoxyphene; Drug Combinations; Fever; Humans; Infant | 1973 |
Q fever.
Topics: Acetaminophen; Animals; Aspirin; Cattle; Coxiella; Disease Reservoirs; Feces; Fever; Headache; Human | 1973 |
Arthralgia and myalgia in mumps.
Topics: Acetaminophen; Adult; Arthritis; Blood Cell Count; Fever; Hematocrit; Hemoglobins; Humans; Male; Mum | 1973 |
[Clinical evaluation of the antipyretic activity of 4-prenyl-1,2-diphenyl-3,5-pyrazolidindione in pediatrics].
Topics: Acetaminophen; Analgesics; Child; Child, Preschool; Female; Fever; Gastroenteritis; Humans; Infant; | 1974 |
ORAL ANTIPYRETIC THERAPY. Evaluation of aspirin-acetaminophen combination.
Topics: Acetaminophen; Administration, Oral; Aspirin; Child, Preschool; Drug Combinations; Female; Fever; Hu | 1972 |
Inhibition of leukocytic pyrogen-induced fever by intracerebroventricular administration of salicylate and acetaminophen in the cat.
Topics: Acetaminophen; Animals; Ascitic Fluid; Cats; Cerebral Ventricles; Fever; Injections; Leukocytes; Met | 1972 |
Oral antipyretic therapy.
Topics: Acetaminophen; Administration, Oral; Aspirin; Drug Synergism; Fever; Humans; Time Factors | 1972 |
The effect of different environmental temperatures on the hyperpyrexia produced by the intraventricular injection of pyrogen, 5-hydroxytryptamine and prostaglandin E 1 in the conscious cat.
Topics: Acetaminophen; Animals; Body Temperature Regulation; Cats; Fever; Prostaglandins; Pyrogens; Serotoni | 1971 |
Fever responses to bacterial pyrogens in guinea pigs and application for screening of antipyretic agents.
Topics: Acetaminophen; Aminopyrine; Analgesics; Animals; Aspirin; Body Temperature; Female; Fever; Flufenami | 1968 |
The antipyretic effects of acetaminophen and sodium salicylate on endotoxin-induced fevers in cats.
Topics: Acetaminophen; Animals; Cats; Endotoxins; Fever; Injections, Intravenous; Salmonella typhi; Sodium S | 1970 |
[Antipyretic effect of togal suppositories for children].
Topics: Acetaminophen; Analgesics; Child; Child, Preschool; Fever; Humans; Quinine; Salicylamides; Supposito | 1970 |
Pyrexial reactions during haemodialysis.
Topics: Acetaminophen; Albumins; Blood; Codeine; Diazepam; Female; Fever; Humans; Kidneys, Artificial; Male; | 1971 |
Seizures and fever.
Topics: Acetaminophen; Acidosis, Respiratory; Age Factors; Alkalosis, Respiratory; Aspirin; Brain Diseases; | 1971 |
The assay of anti-pyretic drugs in mice, using intracerebral injection of pyretogenins.
Topics: Acetaminophen; Analgesics; Animals; Antipyrine; Aspirin; Biological Assay; Body Temperature; Cerebra | 1968 |
The effect of 4-acetamidophenol in reducing fever produced by the intracerebral injection of 5-hydroxytryptamine and pyrogen in the conscious cat.
Topics: Acetaminophen; Analgesics; Animals; Cats; Cerebral Ventricles; Fever; Injections; Injections, Intrap | 1968 |
[Report of experimentation with febrectol].
Topics: Acetaminophen; Adult; Aged; Female; Fever; Humans; Male; Middle Aged; Phenobarbital; Respiratory Tra | 1965 |